{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "ccf2c016-5445-42e7-9f0f-5ce3cfbe0da8",
   "metadata": {},
   "source": [
    "# Mistake analysis\n",
    "This notebook gives a quick look into the predications the model makes that are wrong according to the reference evaluation data. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "30446cb9-44dc-4b1f-8afd-423f530500f6",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/lgrootde/.conda/envs/llm_gen_re/lib/python3.10/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from transformers import (\n",
    "    T5Tokenizer,\n",
    "    AutoTokenizer,\n",
    "    T5ForConditionalGeneration,\n",
    "    Seq2SeqTrainingArguments,\n",
    "    Seq2SeqTrainer,\n",
    "    DataCollatorForSeq2Seq\n",
    ")\n",
    "import torch\n",
    "from datasets import load_dataset, concatenate_datasets\n",
    "from wasabi import msg\n",
    "import yaml\n",
    "import re\n",
    "import pandas as pd\n",
    "from pathlib import Path\n",
    "from os.path import abspath\n",
    "from tqdm import tqdm\n",
    "from typing import Set, Dict, Tuple, Union\n",
    "from helper_functions import *"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "41b36a1f-736c-4f00-9a9a-de0e44b7c052",
   "metadata": {},
   "source": [
    "## Setting home directory"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "aea61d60-6ae8-4f91-889a-8329d5d1ea68",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;4mℹ Home directory: /home/lgrootde/Generative-re-tests\u001b[0m\n",
      "\u001b[38;5;4mℹ Selected config:\n",
      "/home/lgrootde/Generative-re-tests/config/config_T5-11b_cdr_ds.yaml\u001b[0m\n",
      "\u001b[38;5;4mℹ Selected model:\n",
      "/home/lgrootde/data/generative_re_model_storage_azure/ds_runs/T5-11b_cdr_17_05_24/checkpoint-100\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "home_dir = Path(abspath(\"\")).parent\n",
    "config_path = home_dir.joinpath(\"config/config_T5-11b_cdr_ds.yaml\")\n",
    "trained_model_path = home_dir.parent.joinpath(\"data/generative_re_model_storage_azure/ds_runs/T5-11b_cdr_17_05_24/checkpoint-100\")\n",
    "predictions_dataset_dir = home_dir.joinpath(\"data/evaluate_trained_model\")\n",
    "\n",
    "msg.info(f\"Home directory: {home_dir}\")\n",
    "msg.info(f\"Selected config: {config_path}\")\n",
    "msg.info(f\"Selected model: {trained_model_path}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "473b11ad-6e32-4421-aad2-2c35a5fcb7af",
   "metadata": {},
   "source": [
    "## Load Config & Dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "5ee923f6-dca8-4afa-be9a-16bb513a3fe0",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load the config\n",
    "with open(config_path) as f:\n",
    "    config = yaml.load(f, Loader=yaml.FullLoader)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "13ad9288-daf4-4801-bcbe-448e71ad114c",
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset = load_dataset(\n",
    "    'csv',\n",
    "    data_files={\"validation\":home_dir.joinpath(config['validation_file']).__str__()}\n",
    ") \n",
    "dataset_eval = dataset[\"validation\"]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2616f3ae-11a9-4ae2-a192-9e47b9d1fe6e",
   "metadata": {},
   "source": [
    "## Load trained model and tokenizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "a0b48f98-164f-44e7-b41e-2ff803848be8",
   "metadata": {},
   "outputs": [],
   "source": [
    "use_model = True"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "aed39acd-7fa3-4c1a-81f5-9a09398eff39",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/lgrootde/.conda/envs/llm_gen_re/lib/python3.10/site-packages/transformers/models/t5/tokenization_t5_fast.py:171: FutureWarning: This tokenizer was incorrectly instantiated with a model max length of 512 which will be corrected in Transformers v5.\n",
      "For now, this behavior is kept to avoid breaking backwards compatibility when padding/encoding with `truncation is True`.\n",
      "- Be aware that you SHOULD NOT rely on google-t5/t5-11b automatically truncating your input to 512 when padding/encoding.\n",
      "- If you want to encode/pad to sequences longer than 512 you can either instantiate this tokenizer with `model_max_length` or pass `max_length` when encoding/padding.\n",
      "- To avoid this warning, please instantiate this tokenizer with `model_max_length` set to your preferred value.\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "if use_model:\n",
    "    model_name = config['model_name_or_path']\n",
    "    device_map = {\"\": 0}\n",
    "    \n",
    "    # Load tokenizer\n",
    "    tokenizer = AutoTokenizer.from_pretrained(model_name, trust_remote_code=True, legacy=False)\n",
    "    \n",
    "    # Load model after training\n",
    "    model = T5ForConditionalGeneration.from_pretrained(\n",
    "        trained_model_path,\n",
    "        device_map=device_map\n",
    "    )"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "49ca2f40-340e-4e6b-8bdf-512aebc57afb",
   "metadata": {},
   "source": [
    "## Run model over evaluation dataset \n",
    "And note where the model makes mistakes and where the model prediction match the reference."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "697f30ab-d1ae-4fdf-b448-09a9dd17cae1",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/1 [00:00<?, ?it/s]\n"
     ]
    },
    {
     "ename": "TypeError",
     "evalue": "string indices must be integers",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[7], line 12\u001b[0m\n\u001b[1;32m      3\u001b[0m data \u001b[38;5;241m=\u001b[39m {\n\u001b[1;32m      4\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124minput\u001b[39m\u001b[38;5;124m\"\u001b[39m:[],\n\u001b[1;32m      5\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mexpected output\u001b[39m\u001b[38;5;124m\"\u001b[39m:[],\n\u001b[1;32m      6\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpredicted output\u001b[39m\u001b[38;5;124m\"\u001b[39m:[],\n\u001b[1;32m      7\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmatch\u001b[39m\u001b[38;5;124m\"\u001b[39m:[]\n\u001b[1;32m      8\u001b[0m }\n\u001b[1;32m     10\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m row \u001b[38;5;129;01min\u001b[39;00m tqdm(dataset_eval):\n\u001b[1;32m     11\u001b[0m     \u001b[38;5;66;03m# Generate prediction\u001b[39;00m\n\u001b[0;32m---> 12\u001b[0m     input_ids \u001b[38;5;241m=\u001b[39m tokenizer(\u001b[43mrow\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43minput\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m]\u001b[49m, return_tensors\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpt\u001b[39m\u001b[38;5;124m\"\u001b[39m)\u001b[38;5;241m.\u001b[39minput_ids\u001b[38;5;241m.\u001b[39mto(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mcuda\u001b[39m\u001b[38;5;124m'\u001b[39m) \n\u001b[1;32m     13\u001b[0m     output \u001b[38;5;241m=\u001b[39m model\u001b[38;5;241m.\u001b[39mgenerate(input_ids, max_new_tokens\u001b[38;5;241m=\u001b[39mconfig[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgeneration_max_length\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[1;32m     14\u001b[0m     predicted \u001b[38;5;241m=\u001b[39m tokenizer\u001b[38;5;241m.\u001b[39mdecode(output[\u001b[38;5;241m0\u001b[39m], skip_special_tokens\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m)\n",
      "\u001b[0;31mTypeError\u001b[0m: string indices must be integers"
     ]
    }
   ],
   "source": [
    "if use_model:\n",
    "    # run model over dataset\n",
    "    data = {\n",
    "        \"input\":[],\n",
    "        \"expected output\":[],\n",
    "        \"predicted output\":[],\n",
    "        \"match\":[]\n",
    "    }\n",
    "    \n",
    "    for row in tqdm(dataset_eval):\n",
    "        # Generate prediction\n",
    "        input_ids = tokenizer(row['input'], return_tensors=\"pt\").input_ids.to('cuda') \n",
    "        output = model.generate(input_ids, max_new_tokens=config[\"generation_max_length\"])\n",
    "        predicted = tokenizer.decode(output[0], skip_special_tokens=True)\n",
    "    \n",
    "        # check for match\n",
    "        if row[\"relations\"].strip() == predicted.strip():\n",
    "            match = True\n",
    "        else:\n",
    "            match = False\n",
    "    \n",
    "        # Save all information\n",
    "        data[\"input\"].append(row[\"input\"])\n",
    "        data[\"expected output\"].append(row[\"relations\"])\n",
    "        data[\"predicted output\"].append(predicted)\n",
    "        data[\"match\"].append(match)\n",
    "        \n",
    "    dataframe = pd.DataFrame.from_dict(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "0bb0a1ed-b90d-43d7-b7a2-b44e792dfb85",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;4mℹ dataset name: ds_runs_T5-11b_cdr_17_05_24_checkpoint-100.csv\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "# Save dataframe   \n",
    "dataset_name = (trained_model_path.parts[-3]+\n",
    "                \"_\"+\n",
    "                trained_model_path.parts[-2]+\n",
    "                \"_\"+\n",
    "                trained_model_path.parts[-1]+\n",
    "                \".csv\")\n",
    "    \n",
    "msg.info(f\"dataset name: {dataset_name}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "c1594ae3-9da1-4a77-a5ec-54cca94ed22c",
   "metadata": {},
   "outputs": [],
   "source": [
    "if use_model:\n",
    "    # Save dataframe\n",
    "    dataframe.to_csv(predictions_dataset_dir.joinpath(dataset_name))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c82d2abc-601f-4764-8e73-9519ab2c8eab",
   "metadata": {},
   "source": [
    "## Show data for manual inspection"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "363054c7-463f-4db1-87eb-cb31d78630b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load dataset:\n",
    "dataset_path = predictions_dataset_dir.joinpath(dataset_name)\n",
    "dataframe = pd.read_csv(dataset_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "ada96cdf-047f-4f3e-b0d7-664d2a54a0d3",
   "metadata": {},
   "outputs": [],
   "source": [
    "def highlight_entities(input_text: str, rels_expected: Set[Dict], rels_predicted: Set[Dict]) -> str:\n",
    "    # Create a set to store all entity texts for predicted relationships\n",
    "    entity_texts_predicted = set()\n",
    "    \n",
    "    # Extract all entity texts from the predicted relationships data\n",
    "    for rel in rels_predicted:\n",
    "        head_ent_text = rel['head_ent']['text']\n",
    "        if isinstance(head_ent_text, tuple):\n",
    "            for text in head_ent_text:\n",
    "                entity_texts_predicted.add(text)\n",
    "        else:\n",
    "            entity_texts_predicted.add(head_ent_text)\n",
    "        \n",
    "        tail_ent_text = rel['tail_ent']['text']\n",
    "        if isinstance(tail_ent_text, tuple):\n",
    "            for text in tail_ent_text:\n",
    "                entity_texts_predicted.add(text)\n",
    "        else:\n",
    "            entity_texts_predicted.add(tail_ent_text)\n",
    "\n",
    "    # Highlight the entity texts for predicted relationships in the input text with pastel blue color\n",
    "    highlighted_text = input_text\n",
    "    for entity_text in entity_texts_predicted:\n",
    "        highlighted_text = re.sub(r'\\b{}\\b'.format(re.escape(entity_text)),\n",
    "                                  '\\033[48;2;173;216;230;38;2;0;0;0m{}\\033[00m'.format(entity_text),\n",
    "                                  highlighted_text, flags=re.IGNORECASE)\n",
    "    \n",
    "    # Create a set to store all entity texts for expected relationships\n",
    "    entity_texts_expected = set()\n",
    "    \n",
    "    # Extract all entity texts from the expected relationships data\n",
    "    for rel in rels_expected:\n",
    "        head_ent_text = rel['head_ent']['text']\n",
    "        if isinstance(head_ent_text, tuple):\n",
    "            for text in head_ent_text:\n",
    "                entity_texts_expected.add(text)\n",
    "        else:\n",
    "            entity_texts_expected.add(head_ent_text)\n",
    "        \n",
    "        tail_ent_text = rel['tail_ent']['text']\n",
    "        if isinstance(tail_ent_text, tuple):\n",
    "            for text in tail_ent_text:\n",
    "                entity_texts_expected.add(text)\n",
    "        else:\n",
    "            entity_texts_expected.add(tail_ent_text)\n",
    "\n",
    "    \n",
    "\n",
    "    # Highlight the entity texts for expected relationships in the input text with pastel green color\n",
    "    for entity_text in entity_texts_expected:\n",
    "        highlighted_text = re.sub(r'\\b{}\\b'.format(re.escape(entity_text)),\n",
    "                                  '\\033[48;2;144;238;144;38;2;0;0;0m{}\\033[00m'.format(entity_text),\n",
    "                                  highlighted_text, flags=re.IGNORECASE)\n",
    "\n",
    "    return highlighted_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "a058f804-2d34-482f-b22f-5d40cbc8e929",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities of expected output colored \u001b[48;2;144;238;144;38;2;0;0;0mgreen\u001b[00m, of predicted \u001b[48;2;173;216;230;38;2;0;0;0mblue\u001b[00m\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mtricuspid valve regurgitation\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mlithium carbonate\u001b[00m toxicity in a newborn infant. A newborn with massive tricuspid regurgitation, \u001b[48;2;173;216;230;38;2;0;0;0matrial flutter\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcongestive heart failure\u001b[00m, and a high serum lithium level is described. This is the first patient to initially manifest tricuspid regurgitation and \u001b[48;2;173;216;230;38;2;0;0;0matrial flutter\u001b[00m, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy. Sixty-three percent of these infants had tricuspid valve involvement. \u001b[48;2;173;216;230;38;2;0;0;0mlithium carbonate\u001b[00m may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes \u001b[48;2;144;238;144;38;2;0;0;0mneurologic depression\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcyanosis\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mcardiac arrhythmia\u001b[00m when consumed prior to delivery.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium carbonate @CHEMICAL@ neurologic depression @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ cyanosis @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ cardiac arrhythmia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium carbonate @CHEMICAL@ tricuspid valve regurgitation @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ atrial flutter @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ congestive heart failure @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ cyanosis @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ cardiac arrhythmia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Acute changes of blood \u001b[48;2;144;238;144;38;2;0;0;0mammonia\u001b[00m may predict short-term adverse effects of \u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs. A standardized loading dose of \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours. \u001b[48;2;144;238;144;38;2;0;0;0mammonia\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mnh3\u001b[00m) was higher in patients who, during continuous therapy, complained of \u001b[48;2;173;216;230;38;2;0;0;0mdrowsiness\u001b[00m (7 patients) than in those who were symptom-free (17 patients), although \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m plasma levels were similar in both groups. By measuring \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m-induced changes of blood \u001b[48;2;144;238;144;38;2;0;0;0mnh3\u001b[00m content, it may be possible to identify patients at higher risk of \u001b[48;2;173;216;230;38;2;0;0;0mobtundation\u001b[00m when \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m is given chronically.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ammonia ; nh3 @CHEMICAL@ drowsiness @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ drowsiness @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "valproic acid ; vpa @CHEMICAL@ drowsiness @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ obtundation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of \u001b[48;2;173;216;230;38;2;0;0;0mcalcitonin\u001b[00m on rat extrapyramidal motor system: behavioral and biochemical data. The effects of i.v.c. injection of human and salmon \u001b[48;2;173;216;230;38;2;0;0;0mcalcitonin\u001b[00m on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats. \u001b[48;2;173;216;230;38;2;0;0;0mcalcitonin\u001b[00m injection resulted in a potentiation of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m and a partial prevention of \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperactivity\u001b[00m. Moreover \u001b[48;2;173;216;230;38;2;0;0;0mcalcitonin\u001b[00m induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity. The results are discussed in view of a primary action of \u001b[48;2;173;216;230;38;2;0;0;0mcalcitonin\u001b[00m on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@ apomorphine @CHEMICAL@ hyperactivity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "calcitonin @CHEMICAL@ catalepsy @DISEASE@ @CID@ calcitonin @CHEMICAL@ hyperactivity @DISEASE@ @CID@ haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@ apomorphine @CHEMICAL@ hyperactivity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Development of \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiac hypertrophy\u001b[00m. The development of \u001b[48;2;173;216;230;38;2;0;0;0mcardiac hypertrophy\u001b[00m was studied in adult female Wistar rats following daily subcutaneous injections of \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0miso\u001b[00m) (0.3 mg/kg body weight). A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content. Heart weight increased 44% after 8 days of treatment with a half time of 3.4 days. Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy. The half time for RNA accumulation was 2.0 days. The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy. Ventricular DNA content was unchanged during the early stage (1-4 days) of \u001b[48;2;173;216;230;38;2;0;0;0mhypertrophic growth\u001b[00m but increased to a new steady-state level 19% above the controls after 8 days of treatment. Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy. However, dP/dt in the \u001b[48;2;173;216;230;38;2;0;0;0miso\u001b[00m-treated hearts was slightly but significantly (P less than 0.05) elevated. These data indicate that the adaptive response to \u001b[48;2;173;216;230;38;2;0;0;0miso\u001b[00m shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA. However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and \u001b[48;2;144;238;144;38;2;0;0;0mhyperplasia\u001b[00m within the heart.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "isoproterenol ; iso @CHEMICAL@ cardiac hypertrophy @DISEASE@ @CID@ isoproterenol ; iso @CHEMICAL@ hyperplasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "isoproterenol ; iso @CHEMICAL@ cardiac hypertrophy ; hypertrophic growth @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Co-carcinogenic effect of retinyl acetate on \u001b[48;2;173;216;230;38;2;0;0;0mforestomach carcinogenesis\u001b[00m of male F344 rats induced with \u001b[48;2;173;216;230;38;2;0;0;0mbutylated hydroxyanisole\u001b[00m. The potential modifying effect of retinyl acetate (RA) on \u001b[48;2;173;216;230;38;2;0;0;0mbutylated hydroxyanisole\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m)-induced rat \u001b[48;2;144;238;144;38;2;0;0;0mforestomach tumorigenesis\u001b[00m was examined. Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks. In groups given 2% \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mforestomach tumors\u001b[00m (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water. In rats given 1% \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m-induced epithelial hyperplasia. Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration. RA alone did not induce hyperplastic changes in the forestomach. These findings indicate that RA acted as a co-carcinogen in the \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mforestomach carcinogenesis\u001b[00m of the rat.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "butylated hydroxyanisole ; bha @CHEMICAL@ forestomach carcinogenesis ; forestomach tumorigenesis ; forestomach tumors @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "butylated hydroxyanisole ; bha @CHEMICAL@ forestomach carcinogenesis ; forestomach tumors ; forestomach papillomas @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Ketanserin pretreatment reverses \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m. Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m produced in rats by the potent short-acting opiate agonist \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m. Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m was assessed by analyzing root-mean-square electromyographic activity. Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m-induced increase in electromyographic activity compared with animals pretreated with saline. Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m produced by \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m. Despite the absence of \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m were motionless, flaccid, and less responsive to external stimuli than were animals receiving \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m alone. Rats that received ketanserin and \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone. These results, in combination with previous work, suggest that \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "alfentanil @CHEMICAL@ muscle rigidity ; rigidity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "alfentanil @CHEMICAL@ muscle rigidity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcerebral sinus thrombosis\u001b[00m as a potential hazard of antifibrinolytic treatment in menorrhagia. We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-aminocaproic acid\u001b[00m therapy for menorrhagia. This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss. Although increased risk of \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolic disease\u001b[00m has been reported during treatment with \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-aminocaproic acid\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcerebral sinus thrombosis\u001b[00m has not been previously described. Careful use of \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-aminocaproic acid\u001b[00m therapy is recommended.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "epsilon-aminocaproic acid @CHEMICAL@ sagittal sinus thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "epsilon-aminocaproic acid @CHEMICAL@ cerebral sinus thrombosis @DISEASE@ @CID@ epsilon-aminocaproic acid @CHEMICAL@ thromboembolic disease @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcystitis\u001b[00m complicating bone marrow transplantation. \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcystitis\u001b[00m is a potentially serious complication of high-dose \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m therapy administered before bone marrow transplantation. As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation. In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m that causes \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcystitis\u001b[00m. Of 97 patients who received standard prophylaxis, 4 had symptomatic \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcystitis\u001b[00m. In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcystitis\u001b[00m for at least 2 weeks. Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcystitis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ cystitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ hemorrhagic ; hemorrhagic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhepatic \u001b[48;2;144;238;144;38;2;0;0;0madenomas\u001b[00m\u001b[00m and focal nodular \u001b[48;2;173;216;230;38;2;0;0;0mhyperplasia of the liver\u001b[00m in young women on \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m: case reports. Two cases of \u001b[48;2;173;216;230;38;2;0;0;0mhepatic \u001b[48;2;144;238;144;38;2;0;0;0madenoma\u001b[00m\u001b[00m and one of \u001b[48;2;144;238;144;38;2;0;0;0mfocal nodular hyperplasia\u001b[00m presumably associated with the use of \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m, are reported. Special reference is made to their clinical presentation, which may be totally asymptomatic. Liver-function tests are of little diagnostic value, but valuable information may be obtained from both liver scanning and hepatic angiography. Histologic differences and clinical similarities between \u001b[48;2;173;216;230;38;2;0;0;0mhepatic \u001b[48;2;144;238;144;38;2;0;0;0madenoma\u001b[00m\u001b[00m and focal nodular \u001b[48;2;173;216;230;38;2;0;0;0mhyperplasia of the liver\u001b[00m are discussed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptives @CHEMICAL@ adenomas ; adenoma @DISEASE@ @CID@ oral contraceptives @CHEMICAL@ focal nodular hyperplasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oral contraceptives @CHEMICAL@ hepatic adenomas ; hepatic adenoma @DISEASE@ @CID@ oral contraceptives @CHEMICAL@ hyperplasia of the liver @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Arterial \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolism\u001b[00m in patients receiving systemic \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy: a complication associated with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m. Arterial \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolism\u001b[00m is a recognized complication of systemic \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy. Characteristic of the entity is \u001b[48;2;144;238;144;38;2;0;0;0marterial occlusion\u001b[00m by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy, preceded by profound \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The clinically apparent occlusion may be preceded by gastrointestinal and \u001b[48;2;173;216;230;38;2;0;0;0mmusculoskeletal symptoms\u001b[00m that appear to be ischemic in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m are reviewed. The common factor relating \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolism\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m is \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced platelet aggregation. Appropriate treatment consists of discontinuation of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, and anticoagulation with sodium warfarin if necessary. Vascular procedures are performed as indicated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ heparin @CHEMICAL@ arterial occlusion @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ thromboembolism @DISEASE@ @CID@ heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ heparin @CHEMICAL@ gastrointestinal symptoms @DISEASE@ @CID@ heparin @CHEMICAL@ musculoskeletal symptoms @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Serotonin 6 receptor gene is associated with \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m in a Japanese population. BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for \u001b[48;2;144;238;144;38;2;0;0;0mpsychotic disorders\u001b[00m such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of \u001b[48;2;144;238;144;38;2;0;0;0mpsychotic disorders\u001b[00m. The symptoms of \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m)-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m are similar to those of \u001b[48;2;173;216;230;38;2;0;0;0mparanoid type schizophrenia\u001b[00m. Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m. METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m patients and 337 controls) in the Japanese population. The age and sex of the control subjects did not differ from those of the \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m dependence patients. RESULTS: rs6693503 was associated with \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m patients in the allele/genotype-wise analysis. Moreover, this association remained significant after Bonferroni correction. In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m patients, respectively. CONCLUSION: HTR6 may play an important role in the pathophysiology of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m in the Japanese population.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ psychosis ; psychotic disorders @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ paranoid type schizophrenia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of increasing intraperitoneal infusion rates on \u001b[48;2;173;216;230;38;2;0;0;0mbupropion hydrochloride\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m in mice. BACKGROUND: It is not known if there is a relationship between input rate and incidence of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m. This is important, since different controlled release formulations of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m release the active drug at different rates. METHODS: We investigated the effect of varying the intraperitoneal infusion rates of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhcl\u001b[00m 120 mg/kg, a known \u001b[48;2;144;238;144;38;2;0;0;0mconvulsive\u001b[00m dose 50 (CD50), on the incidence and severity of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in the Swiss albino mice. A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhcl\u001b[00m 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group). \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhcl\u001b[00m was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min. The number, time of onset, duration and the intensity of the \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m or absence of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m were recorded. RESULTS: The results showed that IP administration of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhcl\u001b[00m 120 mg/kg by bolus injection induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in 6 out of 10 mice (60% of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsing\u001b[00m mice) in group 1. Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhcl\u001b[00m 120 mg/kg was associated with a 91% reduced odds of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m at infusion times of 15 to 90 min compared to bolus injection. Further increase in infusion time resulted in further reduction in the odds of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m to 99.8% reduction at 240 min. CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and \u001b[48;2;144;238;144;38;2;0;0;0mconvulsive\u001b[00m dose of \u001b[48;2;144;238;144;38;2;0;0;0mbupropion\u001b[00m and the risk of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in a prospective study is novel.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupropion hydrochloride ; bupropion ; bupropion hcl @CHEMICAL@ seizures ; convulsive ; convulsions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupropion hydrochloride ; hcl @CHEMICAL@ convulsions ; convulsion ; convulsing @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Detailed spectral profile analysis of \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mepileptiform activity\u001b[00m in anesthetized rats. \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m model is a widely used experimental model for \u001b[48;2;144;238;144;38;2;0;0;0mepilepsy\u001b[00m research. In the present study we aimed to portray a detailed spectral analysis of \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mepileptiform activity\u001b[00m in comparison with basal brain activity in anesthetized Wistar rats. Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup. After a short period of basal activity recording, \u001b[48;2;173;216;230;38;2;0;0;0mepileptic focus\u001b[00m was induced by injecting 400IU/2 microl \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-G potassium into the left lateral ventricle while the cortical activity was continuously recorded. Basal activity, latent period and the \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mepileptiform activity\u001b[00m periods were then analyzed using both conventional methods and spectral analysis. Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands. Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the \u001b[48;2;144;238;144;38;2;0;0;0mepileptiform activity\u001b[00m and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and \u001b[48;2;144;238;144;38;2;0;0;0mepileptiform activity\u001b[00m). Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental \u001b[48;2;144;238;144;38;2;0;0;0mepilepsies\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "penicillin-g potassium @CHEMICAL@ epileptiform activity ; epilepsy ; epileptic ; epilepsies @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "penicillin @CHEMICAL@ epileptic ; epileptic focus @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m causes alterations in the MAP kinase-related pathways in the brains of mice that display increased \u001b[48;2;173;216;230;38;2;0;0;0maggressiveness\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0maggressive behaviors\u001b[00m have been reported in patients who suffer from some \u001b[48;2;144;238;144;38;2;0;0;0mpsychiatric disorders\u001b[00m, and are common in \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m) abusers. Herein, we report that multiple (but not single) injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m significantly increased \u001b[48;2;173;216;230;38;2;0;0;0maggressiveness\u001b[00m in male CD-1 mice. This increase in \u001b[48;2;173;216;230;38;2;0;0;0maggressiveness\u001b[00m was not secondary to \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperactivity\u001b[00m. Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m injections. There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m. MEK1 was significantly decreased also after a single injection of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m, but to a much lesser degree than after multiple injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m. In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m. These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of \u001b[48;2;173;216;230;38;2;0;0;0maggressive behaviors\u001b[00m in mice.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ aggressiveness ; aggressive behaviors ; psychiatric disorders @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ aggressiveness ; aggressive behaviors ; aggressiveness @DISEASE@ @CID@ methamphetamine ; meth @CHEMICAL@ hyperactivity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mlamotrigine\u001b[00m associated with exacerbation or de novo \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonus\u001b[00m in idiopathic generalized epilepsies. Five patients with idiopathic generalized epilepsies (IGE) treated with \u001b[48;2;173;216;230;38;2;0;0;0mlamotrigine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m) experienced exacerbation or de novo appearance of \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonic jerks\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmj\u001b[00m). In three patients, \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m exacerbated \u001b[48;2;173;216;230;38;2;0;0;0mmj\u001b[00m in a dose-dependent manner with early aggravation during titration. \u001b[48;2;173;216;230;38;2;0;0;0mmj\u001b[00m disappeared when \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m dose was decreased by 25 to 50%. In two patients, \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m exacerbated \u001b[48;2;173;216;230;38;2;0;0;0mmj\u001b[00m in a delayed but more severe manner, with \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonic status\u001b[00m that only ceased after \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m withdrawal.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lamotrigine ; ltg @CHEMICAL@ myoclonus ; myoclonic jerks ; mj ; myoclonic status @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lamotrigine ; ltg @CHEMICAL@ myoclonus ; myoclonic jerks ; mj @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "rTMS of supplementary motor area modulates therapy-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m in Parkinson disease. The neural mechanisms and circuitry involved in \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m are unclear. Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a \u001b[48;2;173;216;230;38;2;0;0;0mdyskinetic\u001b[00m state induced by continuous \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m infusion. rTMS at 1 Hz was observed to markedly reduce drug-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m, whereas 5-Hz rTMS induced a slight but not significant increase.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; dyskinesia ; dyskinetic ; drug-induced dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "apomorphine @CHEMICAL@ dyskinesias ; dyskinetic ; drug-induced dyskinesias @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Assessment of the onset and persistence of \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m during procedural sedation with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m. OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring. METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m between December 28, 2002, and October 31, 2003. BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status. At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator. The BIS score at the time the word was read and the patient's ability to repeat the word were recorded. After the procedure, the patient was asked to state all of the words from the list that he or she could recall, and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed. RESULTS: Seventy-five consenting patients were enrolled; one patient was excluded from data analysis for a protocol violation. No serious adverse events were noted during the procedural sedations. The mean (+/-standard deviation) time of data collection was 16.4 minutes (+/-7.1; range 5 to 34 minutes). The mean initial (preprocedure) BIS score was 97.1 (+/-2.3; range 92 to 99). The mean lowest BIS score occurring during these procedural sedations was 66.9 (+/-14.4; range 33 to 91). The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77.1 (95% CI = 74.3 to 80.0). The mean highest BIS score corresponding to the \u001b[48;2;144;238;144;38;2;0;0;0minability to repeat words\u001b[00m was 81.5 (95% CI = 78.1 to 84.8). The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96.7 (+/-2.4; range 84 to 98). The mean BIS score corresponding to the first word recalled after the procedure was completed was 91.2 (95% CI = 88.1 to 94.3). All patients recalled at least one word that had been read to them during the protocol. The mean lowest BIS score for any recalled word was 91.5 (+/-11.1; range 79 to 98), and no words were recalled when the corresponding BIS score was less than 90. CONCLUSIONS: There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words. Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "propofol @CHEMICAL@ amnesia ; inability to repeat words @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "propofol @CHEMICAL@ amnesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Mitochondrial DNA and its respiratory chain products are defective in \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrosis\u001b[00m. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m induces a self-perpetuating nephropathy characterized by early glomerular and late-onset \u001b[48;2;173;216;230;38;2;0;0;0mtubular lesions\u001b[00m in rats. We investigated the potential role of mitochondrial injury in the onset of these lesions. METHODS: Rats were treated with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose. Additional rats received a single dose either 6 days or 2 h prior to euthanasia. All rats were killed at 48 weeks of age. Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components. Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion. RESULTS: The 'long-term' group had significant glomerular and \u001b[48;2;173;216;230;38;2;0;0;0mtubular lesions\u001b[00m, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity. In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased. In 'short-term' rats, there were fewer \u001b[48;2;173;216;230;38;2;0;0;0mtubular lesions\u001b[00m, but similar numbers of glomerular lesions activity. Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes. Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups. CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mrenal lesions\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "doxorubicin @CHEMICAL@ nephrosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin @CHEMICAL@ nephrosis ; nephrotic @DISEASE@ @CID@ doxorubicin @CHEMICAL@ tubular lesions ; renal lesions ; tubular lesions @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m in a patient with AIDS. OBJECTIVE: To report a case of multiple episodes of \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m activity in an AIDS patent following \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m infusion. CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m during intravenous infusion of \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m, then petit mal \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included \u001b[48;2;173;216;230;38;2;0;0;0mdidanosine\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mhydroxyzine\u001b[00m, promethazine, \u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m, and prochlorperazine. Despite administration of phenytoin and lorazepam, the \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m persisted and occurred only during \u001b[48;2;144;238;144;38;2;0;0;0mamphotercin b\u001b[00m administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mdidanosine\u001b[00m also has a potential for inducing \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. However, these other potential causes of \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m were ruled out. The time course of events suggested that \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m was the cause of the \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m in this AIDS patient. CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m seems to be the probable cause of the \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. To date, only three cases of \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amphotericin b ; amphotercin b @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amphotericin b @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ didanosine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ hydroxyzine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ hydrocortisone @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Therapeutic drug monitoring of \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m: once-daily versus twice-daily dosage schedules. OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of \u001b[48;2;144;238;144;38;2;0;0;0mtobramicyn\u001b[00m on steady-state serum concentrations and toxicity. MATERIALS AND METHODS: Patients undergoing treatment with i.v. \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m (4 mg/kg/day) were randomised to two groups. Group OD (n = 22) received a once-daily dose of \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m and group TD (n = 21) received the same dose divided into two doses daily. \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m serum concentrations (peak and trough) were measured by enzyme multiplied immunoassay. The renal and auditory functions of the patients were monitored before, during and immediately after treatment. RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function. No statistically significant differences were found in mean daily dose, duration of treatment, or cumulative dose. Trough concentrations were < 2 g/ml in the two groups (100%). Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01). Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01). The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD). Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity. In TD group, three patients developed \u001b[48;2;173;216;230;38;2;0;0;0mdecreased auditory function\u001b[00m, of which one presented with an \u001b[48;2;144;238;144;38;2;0;0;0mauditory loss\u001b[00m of -30 dB, whereas in the OD group only one patient presented \u001b[48;2;173;216;230;38;2;0;0;0mdecreased auditory function\u001b[00m. CONCLUSION: This small study suggests that a once-daily dosing regimen of \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m is at least as effective as and is no more and possibly less toxic than the twice-daily regimen. Using a single-dose therapy, peak concentration determination is not necessary, only trough samples should be monitored to ensure levels below 2 microg/ml.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tobramycin ; tobramicyn @CHEMICAL@ decreased auditory function ; auditory loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tobramycin @CHEMICAL@ decreased auditory function @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Posteroventral medial pallidotomy in advanced Parkinson's disease. BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up. METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (\"off\" period) and while taking their optimal medical regimens (\"on\" period). All patients were examined preoperatively and 39 were examined at six months; 27 of the patients were also examined at one year, and 11 at two years. RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m, 44 percent (95 percent confidence interval, 29 to 59 percent). The improvements in \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years. The improvement in ipsilateral \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m was lost after one year, and the improvements in postural stability and gait lasted only three to six months. Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery. The complications of surgery were generally well tolerated, and there were no significant changes in the use of medication. CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m and off-period disability. Much of the benefit is sustained at two years, although some improvements, such as those on the ipsilateral side and in axial symptoms, wane within the first year. The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; dyskinesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Neuropeptide-Y immunoreactivity in the \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m model of \u001b[48;2;173;216;230;38;2;0;0;0mtemporal lobe epilepsy\u001b[00m. Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental \u001b[48;2;173;216;230;38;2;0;0;0mtemporal lobe epilepsy\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtle\u001b[00m). This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices. The \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mpilo\u001b[00m) model of epilepsy is characterized by an acute period of \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m followed by spontaneous recurrent \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m and related brain damage. We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model. \u001b[48;2;173;216;230;38;2;0;0;0mpilo\u001b[00m-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells. NPY immunoreactivity was also dramatically changed in the entorhinal cortex, amygdala and sensorimotor areas. In addition, \u001b[48;2;173;216;230;38;2;0;0;0mpilo\u001b[00m injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls. The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the \u001b[48;2;173;216;230;38;2;0;0;0mpilo\u001b[00m model of \u001b[48;2;173;216;230;38;2;0;0;0mtle\u001b[00m. However, the significance of this changed synthesis of NPY remains to be determined.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pilocarpine ; pilo @CHEMICAL@ temporal lobe epilepsy ; tle @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pilocarpine ; pilo @CHEMICAL@ temporal lobe epilepsy ; tle @DISEASE@ @CID@ pilocarpine ; pilo @CHEMICAL@ status epilepticus @DISEASE@ @CID@ pilocarpine ; pilo @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve. PURPOSE: To assess by electrophysiologic testing the effect of photorefractive keratectomy (PRK) on the retina and optic nerve. SETTING: Eye Clinic, S. Salvatore Hospital, L'Aquila University, Italy. METHODS: Standard pattern electroretinograms (P-ERGs) and standard pattern visual evoked potentials (P-VEPs) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5.00 and 15.00 diopters (D) (mean 8.00 D). Testing was done preoperatively and 3, 6, 12, and 18 months postoperatively. The contralateral eyes served as controls. During the follow-up, 3 patients (12%) developed \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0melevated intraocular pressure\u001b[00m (IOP) that resolved after \u001b[48;2;144;238;144;38;2;0;0;0mcorticosteroid\u001b[00m therapy was discontinued. RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively. CONCLUSION: Myopic excimer laser PRK did not seem to affect the posterior segment. The transient \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0miop rise\u001b[00m did not seem to cause functional impairment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "corticosteroid @CHEMICAL@ elevated intraocular pressure ; iop rise @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "steroid @CHEMICAL@ elevated intraocular pressure ; iop rise @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Liposomal \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m in advanced Kaposi's sarcoma: a phase II study. We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdaunoxome\u001b[00m) in the treatment of AIDS related Kaposi's sarcoma. Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial. Changes in size, colour and associated oedema of selected 'target' lesions were measured. Clinical, biochemical and haematological toxicities were assessed. Ten subjects were evaluated. A partial response was achieved in four, of whom two subsequently relapsed. Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four. The drug was generally well tolerated, with few mild symptoms of toxicity. The main problem encountered was haematological toxicity, with three subjects experiencing severe \u001b[48;2;173;216;230;38;2;0;0;0mneutropenia\u001b[00m (neutrophil count < 0.5 x 10(9)/l). There was no evidence of cardiotoxicity. In this small patient sample, liposomal \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "daunorubicin @CHEMICAL@ neutropenia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "daunorubicin ; daunoxome @CHEMICAL@ neutropenia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Failure of ancrod in the treatment of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0marterial \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m\u001b[00m. The morbidity and mortality associated with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m remain high despite numerous empirical therapies. Ancrod has been used successfully for prophylaxis against development of \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m in patients with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m induced platelet aggregation who require brief reexposure to \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, but its success in patients who have developed the \u001b[48;2;173;216;230;38;2;0;0;0mthrombosis syndrome\u001b[00m is not well defined. The authors present a case of failure of ancrod treatment in a patient with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ arterial thrombosis ; thrombosis syndrome @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m administration in a pediatric patient. \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines. \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m and cardiac arrhythmias have complicated its use in adult patients. Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications. Little information exists concerning adverse effects of \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m in children. We report the occurrence of a generalized tonic-clonic \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m in a pediatric patient following the administration of \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "flumazenil @CHEMICAL@ seizure ; seizures ; tonic-clonic seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "flumazenil @CHEMICAL@ seizure ; tonic-clonic seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Remodelling of nerve structure in experimental \u001b[48;2;173;216;230;38;2;0;0;0misoniazid \u001b[48;2;144;238;144;38;2;0;0;0mneuropathy\u001b[00m\u001b[00m in the rat. The \u001b[48;2;144;238;144;38;2;0;0;0mneuropathy\u001b[00m caused by a single dose of \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m in rats was studied with a computer-assisted morphometric method. Scatter diagrams of the g ratio (quotient fibre diameter/axon diameter) define regenerating fibres as a distinct population, distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre. There was also evidence of a subtle direct toxic effect on the entire fibre population, causing axon shrinkage masked by readjustment of the myelin sheath.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "isoniazid @CHEMICAL@ neuropathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "isoniazid @CHEMICAL@ isoniazid neuropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Selective injection of \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m into the left coronary artery of the dog. Induction of \u001b[48;2;173;216;230;38;2;0;0;0mventricular fibrillation\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdecrease of aortic pressure\u001b[00m. In twenty beagle dogs selective injections were made into the left coronary artery with \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m in doses of 4 ml, 8 ml and 16 ml. Thirty-six \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m injections, 35 \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m injections and 37 \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m injections were made. Frequencies of \u001b[48;2;173;216;230;38;2;0;0;0mventricular fibrillation\u001b[00m were significantly lower (p less than 0.05) after \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m (0%) and \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m (3%) than after \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m (22%). \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m also produced significantly less \u001b[48;2;173;216;230;38;2;0;0;0mdecrease in aortic blood pressure\u001b[00m than \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m at the different doses.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "metrizoate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "iopentol @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ iohexol @CHEMICAL@ decrease of aortic pressure ; decrease in aortic blood pressure @DISEASE@ @CID@ metrizoate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ metrizoate @CHEMICAL@ decrease of aortic pressure ; decrease in aortic blood pressure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Magnetic resonance imaging of \u001b[48;2;173;216;230;38;2;0;0;0mcerebral \u001b[48;2;144;238;144;38;2;0;0;0mvenous thrombosis\u001b[00m\u001b[00m secondary to \"low-dose\" \u001b[48;2;173;216;230;38;2;0;0;0mbirth control pills\u001b[00m. The clinical and radiographic features of cerebral \u001b[48;2;144;238;144;38;2;0;0;0mdeep \u001b[48;2;144;238;144;38;2;0;0;0mvenous thrombosis\u001b[00m\u001b[00m in a 21-year-old white woman are presented. This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes. The only known risk factor was \"low-dose\" \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive pills\u001b[00m. The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus. The diagnosis was confirmed by arterial angiography.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptive @CHEMICAL@ venous thrombosis ; deep venous thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "birth control pills ; oral contraceptive pills @CHEMICAL@ cerebral venous thrombosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography. It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of \u001b[48;2;144;238;144;38;2;0;0;0mhyperemic\u001b[00m stimulation. The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis. The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT). During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced. The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002). During \u001b[48;2;173;216;230;38;2;0;0;0mdipyridamole\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperemia\u001b[00m, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography. The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in \u001b[48;2;173;216;230;38;2;0;0;0mdipyridamole\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperemia\u001b[00m. The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02). Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during \u001b[48;2;173;216;230;38;2;0;0;0mdipyridamole\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperemia\u001b[00m; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03). Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis. The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium-201 SPECT.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dipyridamole @CHEMICAL@ hyperemic ; hyperemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dipyridamole @CHEMICAL@ hyperemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Potential deleterious effect of \u001b[48;2;144;238;144;38;2;0;0;0mfurosemide\u001b[00m in radiocontrast \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m. The purpose of the study was to determine the efficacy of \u001b[48;2;144;238;144;38;2;0;0;0mfurosemide\u001b[00m in addition to intravenous fluids in the prevention of radiocontrast \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m. 18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital. In addition to fluids, the treatment group received \u001b[48;2;144;238;144;38;2;0;0;0mfurosemide\u001b[00m (mean dose 110 mg) intravenously 30 min prior to the injection of \u001b[48;2;173;216;230;38;2;0;0;0mcontrast\u001b[00m material. The control group received fluids (mean 3 liters). Radiological studies were mostly angiographies performed with both ionic and non-ionic \u001b[48;2;173;216;230;38;2;0;0;0mcontrast\u001b[00m material, at an average dose of 245 ml. \u001b[48;2;144;238;144;38;2;0;0;0mrenal function significantly deteriorated\u001b[00m in the group pretreated with \u001b[48;2;144;238;144;38;2;0;0;0mfurosemide\u001b[00m (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l). Renal failure was associated with \u001b[48;2;173;216;230;38;2;0;0;0mweight loss\u001b[00m in the \u001b[48;2;144;238;144;38;2;0;0;0mfurosemide\u001b[00m-treated group. \u001b[48;2;144;238;144;38;2;0;0;0mfurosemide\u001b[00m may be deleterious in the prevention of radiocontrast \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "furosemide @CHEMICAL@ renal function significantly deteriorated @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "contrast @CHEMICAL@ nephropathy @DISEASE@ @CID@ contrast @CHEMICAL@ weight loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Etiologic factors in the pathogenesis of \u001b[48;2;173;216;230;38;2;0;0;0mliver tumors\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m. Within the last several years, previously rare \u001b[48;2;173;216;230;38;2;0;0;0mliver tumors\u001b[00m have been seen in young women using \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive steroids\u001b[00m. The Registry for \u001b[48;2;173;216;230;38;2;0;0;0mliver tumors\u001b[00m Associated with \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m at the University of California, Irvine, has clearly identified 27 cases. The recent literature contains 44 case reports. Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive steroids\u001b[00m. Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptives ; oral contraceptive @CHEMICAL@ liver tumors @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oral contraceptives ; oral contraceptive steroids @CHEMICAL@ liver tumors ; liver tumor @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Graft-versus-host disease prophylaxis with \u001b[48;2;173;216;230;38;2;0;0;0meverolimus\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mtacrolimus\u001b[00m is associated with a high incidence of \u001b[48;2;173;216;230;38;2;0;0;0msinusoidal obstruction syndrome\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmicroangiopathy\u001b[00m: results of the EVTAC trial. A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). \u001b[48;2;173;216;230;38;2;0;0;0meverolimus\u001b[00m, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of \u001b[48;2;173;216;230;38;2;0;0;0meverolimus\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mtacrolimus\u001b[00m in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated \u001b[48;2;173;216;230;38;2;0;0;0mmicroangiopathy\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtma\u001b[00m) occurred in 7 patients (29%), with 2 cases of \u001b[48;2;173;216;230;38;2;0;0;0macute renal failure\u001b[00m. The study was terminated prematurely because an additional 6 patients (25%) developed \u001b[48;2;173;216;230;38;2;0;0;0msinusoidal obstruction syndrome\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0msos\u001b[00m), which was fatal in 2 cases. With a median follow-up of 26 months, the 2-year overall survival rate was 47%. Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mtma\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0msos\u001b[00m is considerably higher than seen with other regimens.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "everolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@ everolimus @CHEMICAL@ microangiopathy ; transplantation-associated microangiopathy ; tma @DISEASE@ @CID@ everolimus @CHEMICAL@ acute renal failure @DISEASE@ @CID@ tacrolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@ tacrolimus @CHEMICAL@ microangiopathy ; transplantation-associated microangiopathy ; tma @DISEASE@ @CID@ tacrolimus @CHEMICAL@ acute renal failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "everolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@ everolimus @CHEMICAL@ microangiopathy ; tma @DISEASE@ @CID@ everolimus @CHEMICAL@ acute renal failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of some convulsants on the protective activity of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m and its combinations with \u001b[48;2;173;216;230;38;2;0;0;0mvalproate\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mclonazepam\u001b[00m in amygdala-kindled rats. \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m and afterdischarge durations. The combinations of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m (2.5 mg/kg) with \u001b[48;2;173;216;230;38;2;0;0;0mvalproate\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mclonazepam\u001b[00m, or \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, \u001b[48;2;173;216;230;38;2;0;0;0mbicuculline\u001b[00m, N-methyl-D-aspartic acid and \u001b[48;2;144;238;144;38;2;0;0;0mbay k-8644\u001b[00m (the opener of L-type calcium channels) reversed the protective activity of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m alone and its combination with \u001b[48;2;173;216;230;38;2;0;0;0mvalproate\u001b[00m. On the other hand, \u001b[48;2;173;216;230;38;2;0;0;0mbicuculline\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0maminophylline\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mbay k-8644\u001b[00m inhibited the anticonvulsive action of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m combined with \u001b[48;2;173;216;230;38;2;0;0;0mclonazepam\u001b[00m. The results support the hypothesis that the protective activity of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bicuculline @CHEMICAL@ seizure @DISEASE@ @CID@ bay k-8644 @CHEMICAL@ seizure @DISEASE@ @CID@ aminophylline @CHEMICAL@ seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "loreclezole @CHEMICAL@ seizure ; seizure @DISEASE@ @CID@ valproate @CHEMICAL@ seizure ; seizure @DISEASE@ @CID@ clonazepam @CHEMICAL@ seizure ; seizure @DISEASE@ @CID@ carbamazepine @CHEMICAL@ seizure ; seizure @DISEASE@ @CID@ bicuculline @CHEMICAL@ seizure ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0macute liver failure\u001b[00m with concurrent \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m therapy. OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m. CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m and propranolol for the past 5 years. He received a 10-day course of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m as an aid for smoking cessation 10 weeks prior to presentation. He developed \u001b[48;2;173;216;230;38;2;0;0;0macute liver failure\u001b[00m with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific drug-induced \u001b[48;2;173;216;230;38;2;0;0;0macute liver injury\u001b[00m. His condition was further complicated by sepsis and coagulopathy. Death resulted 19 days after the onset of symptoms. The likelihood that \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m induced \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m in our patient was possible, based on the Naranjo probability scale. DISCUSSION: Although there is increasing evidence of \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m, this is the first case of fatality that could have resulted from \u001b[48;2;173;216;230;38;2;0;0;0macute liver failure\u001b[00m in a patient receiving \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m while on concomitant treatment with \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m. CONCLUSIONS: Clinicians should be aware of the possibility of \u001b[48;2;144;238;144;38;2;0;0;0macute liver insult\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m given concurrently with other \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxic\u001b[00m drugs.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupropion @CHEMICAL@ acute liver failure ; acute liver insult @DISEASE@ @CID@ bupropion @CHEMICAL@ drug-induced acute liver injury ; hepatotoxicity ; hepatotoxic @DISEASE@ @CID@ carbimazole @CHEMICAL@ acute liver failure ; acute liver insult @DISEASE@ @CID@ carbimazole @CHEMICAL@ drug-induced acute liver injury ; hepatotoxicity ; hepatotoxic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupropion @CHEMICAL@ acute liver failure ; acute liver injury @DISEASE@ @CID@ carbimazole @CHEMICAL@ acute liver failure ; acute liver injury @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Long term hormone therapy for perimenopausal and postmenopausal women. BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m, osteoporosis and \u001b[48;2;173;216;230;38;2;0;0;0mdementia\u001b[00m in older women. This is an updated version of the original Cochrane review first published in 2005. OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, \u001b[48;2;173;216;230;38;2;0;0;0mgallbladder disease\u001b[00m, cognition, fractures and quality of life. SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included \u001b[48;2;173;216;230;38;2;0;0;0moestrogens\u001b[00m, with or without \u001b[48;2;173;216;230;38;2;0;0;0mprogestogens\u001b[00m, via oral, transdermal, subcutaneous or transnasal routes. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of \u001b[48;2;173;216;230;38;2;0;0;0mvenous thrombo-embolism\u001b[00m or coronary event (after one year's use), \u001b[48;2;173;216;230;38;2;0;0;0mstroke\u001b[00m (after three years), \u001b[48;2;173;216;230;38;2;0;0;0mbreast cancer\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mgallbladder disease\u001b[00m. Long-term \u001b[48;2;173;216;230;38;2;0;0;0moestrogen\u001b[00m-only HT significantly increased the risk of \u001b[48;2;173;216;230;38;2;0;0;0mvenous thrombo-embolism\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mstroke\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mgallbladder disease\u001b[00m (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of \u001b[48;2;173;216;230;38;2;0;0;0mbreast cancer\u001b[00m. The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use. Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mdementia\u001b[00m. Among women with \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m, long-term use of combined continuous HT significantly increased the risk of \u001b[48;2;173;216;230;38;2;0;0;0mvenous thrombo-embolism\u001b[00m.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking \u001b[48;2;173;216;230;38;2;0;0;0moestrogen\u001b[00m-only HT, versus similar-sized placebo groups. The only significantly increased risk reported was for \u001b[48;2;173;216;230;38;2;0;0;0mvenous thrombo-embolism\u001b[00m in women taking combined continuous HT: their absolute risk remained low, at less than 1/500. However, this study was not powered to detect differences between groups of younger women. AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease. We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oestrogens ; oestrogen @CHEMICAL@ dementia @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ gallbladder disease @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ dementia @DISEASE@ @CID@ progestogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oestrogens ; oestrogen @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ stroke @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ breast cancer @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ gallbladder disease @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ cardiovascular disease @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ breast cancer @DISEASE@ @CID@ oestrogens ; oestrogen @CHEMICAL@ gallbladder disease @DISEASE@ @CID@ oestrogens @CHEMICAL@ dementia @DISEASE@ @CID@ oestrogens @CHEMICAL@ cardiovascular disease @DISEASE@ @CID@ oestrogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ oestrogens @CHEMICAL@ gallbladder disease @DISEASE@ @CID@ progestogens @CHEMICAL@ gallbladder disease @DISEASE@ @CID@ progestogens @CHEMICAL@ dementia @DISEASE@ @CID@ progestogens @CHEMICAL@ gallbladder disease @DISEASE@ @CID@ progestogens @CHEMICAL@ gallbladder disease @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Passage of \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m into the brain around gliomas: a potential cause of \u001b[48;2;173;216;230;38;2;0;0;0mrebound phenomenon\u001b[00m. A study on 21 patients. AIM: Widespread use of \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m to reduce brain edema and lower \u001b[48;2;144;238;144;38;2;0;0;0melevated icp\u001b[00m in brain tumor patients continues to be afflicted by the so-called \u001b[48;2;173;216;230;38;2;0;0;0mrebound phenomenon\u001b[00m. Leakage of \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound . This has only been demonstrated experimentally in animals. As a contribution to this issue we decided to research the possible passage of \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m into the brain after administration to 21 brain tumor patients. METHODS: \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy. During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample. \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times). In meningioma and metastases patients plasma concentrations of \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m were higher than white matter concentrations except in three cases with infiltration by neoplastic cells. CONCLUSIONS: The results of our study show that even after a single bolus, \u001b[48;2;173;216;230;38;2;0;0;0mmannitol\u001b[00m may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting \u001b[48;2;173;216;230;38;2;0;0;0mrebound of icp\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "mannitol @CHEMICAL@ elevated icp @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "mannitol @CHEMICAL@ rebound phenomenon ; rebound of icp @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Can lidocaine reduce \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m induced postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m? This study was undertaken to determine the effect of lidocaine pretreatment on reduction of \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m in patients undergoing general anesthesia for gynecological surgery. One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner. Group PS, the control group, received normal saline and \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1). Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry. Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m (Group PS, LS) or rocuronium (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of \u001b[48;2;144;238;144;38;2;0;0;0mfasciculation\u001b[00m were assessed visually on a four point scale by one investigator who was blinded to the drug administered. The blood pressure and heart rate of each patient were monitored on nine occasions. Twenty-four hours later, any \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management. The results indicate that \u001b[48;2;144;238;144;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mfasciculation\u001b[00m\u001b[00m was not found in Group PR while the patients in Group LS had a lower incidence of \u001b[48;2;144;238;144;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mfasciculation\u001b[00m\u001b[00m than those in Group PS (p < 0.001). At 24 h, the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m was higher in Group PS than in Group LS and PR (p < 0.05). A correlation was not found between the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m and the occurrence of \u001b[48;2;144;238;144;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mfasciculation\u001b[00m\u001b[00m. The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups. In conclusion, where \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "succinylcholine @CHEMICAL@ postoperative myalgia @DISEASE@ @CID@ succinylcholine @CHEMICAL@ fasciculation ; muscle fasciculation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "succinylcholine @CHEMICAL@ myalgia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Clinical evaluation on combined administration of oral prostacyclin analogue \u001b[48;2;144;238;144;38;2;0;0;0mberaprost\u001b[00m and phosphodiesterase inhibitor \u001b[48;2;173;216;230;38;2;0;0;0mcilostazol\u001b[00m. Among various oral antiplatelets, a combination of a novel prostacyclin analogue \u001b[48;2;144;238;144;38;2;0;0;0mberaprost\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mbpt\u001b[00m) and a potent phosphodiesterase inhibitor \u001b[48;2;173;216;230;38;2;0;0;0mcilostazol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mclz\u001b[00m) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate). Thereby, a clinical study of the combined administration of the two agents was attempted. Twelve healthy volunteers were assigned to take \u001b[48;2;144;238;144;38;2;0;0;0mbpt\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mclz\u001b[00m in the following schedule; \u001b[48;2;144;238;144;38;2;0;0;0mbpt\u001b[00m: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, \u001b[48;2;173;216;230;38;2;0;0;0mclz\u001b[00m: 200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed. Throughout the observation period, no significant alteration in vital signs was observed. Seven out of 12 subjects experienced \u001b[48;2;173;216;230;38;2;0;0;0mheadache\u001b[00m of a short duration accompanying facial \u001b[48;2;173;216;230;38;2;0;0;0mflush\u001b[00m in one and \u001b[48;2;173;216;230;38;2;0;0;0mnausea\u001b[00m in one, especially after ingestion of \u001b[48;2;173;216;230;38;2;0;0;0mclz\u001b[00m. All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required. Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol). The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted. In conclusion, the combined administration of \u001b[48;2;144;238;144;38;2;0;0;0mbpt\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mclz\u001b[00m is safe at doses used in the study, though the beneficial clinical effect of the combined administration has yet to be elucidated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "beraprost ; bpt @CHEMICAL@ headache @DISEASE@ @CID@ beraprost ; bpt @CHEMICAL@ facial flush @DISEASE@ @CID@ beraprost ; bpt @CHEMICAL@ nausea @DISEASE@ @CID@ cilostazol ; clz @CHEMICAL@ headache @DISEASE@ @CID@ cilostazol ; clz @CHEMICAL@ facial flush @DISEASE@ @CID@ cilostazol ; clz @CHEMICAL@ nausea @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cilostazol ; clz @CHEMICAL@ headache @DISEASE@ @CID@ cilostazol ; clz @CHEMICAL@ flush @DISEASE@ @CID@ cilostazol ; clz @CHEMICAL@ nausea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Gastrointestinal tolerability of \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m in rheumatoid arthritis patients: results of the \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m vs \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m in patients with rheumatoid arthritis (RA). PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m 90 mg daily (n = 2032) or \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m 75 mg twice daily (n = 2054). Use of gastroprotective agents and low-dose aspirin was allowed. The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (\u001b[48;2;173;216;230;38;2;0;0;0maes\u001b[00m). General safety was also assessed, including adjudicated thrombotic cardiovascular event data. Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale). RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m groups, respectively. The cumulative discontinuation rate due to GI \u001b[48;2;173;216;230;38;2;0;0;0maes\u001b[00m was significantly lower with \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m than \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)). The incidence of discontinuations for \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m-related and \u001b[48;2;173;216;230;38;2;0;0;0moedema\u001b[00m-related \u001b[48;2;173;216;230;38;2;0;0;0maes\u001b[00m were significantly higher with \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m (2.5% and 1.1% respectively) compared with \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m (1.5% and 0.4% respectively; p<0.001 for \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m and p<0.01 for \u001b[48;2;173;216;230;38;2;0;0;0moedema\u001b[00m). \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively). CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI \u001b[48;2;173;216;230;38;2;0;0;0maes\u001b[00m compared with \u001b[48;2;144;238;144;38;2;0;0;0mdiclofenac\u001b[00m 150 mg. Discontinuations from renovascular \u001b[48;2;173;216;230;38;2;0;0;0maes\u001b[00m, although less common than discontinuations from GI \u001b[48;2;173;216;230;38;2;0;0;0maes\u001b[00m, were significantly higher with \u001b[48;2;173;216;230;38;2;0;0;0metoricoxib\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "etoricoxib @CHEMICAL@ hypertension @DISEASE@ @CID@ etoricoxib @CHEMICAL@ oedema @DISEASE@ @CID@ diclofenac sodium ; diclofenac @CHEMICAL@ gi aes @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "etoricoxib @CHEMICAL@ gastrointestinal (gi) adverse experiences ; aes @DISEASE@ @CID@ etoricoxib @CHEMICAL@ hypertension @DISEASE@ @CID@ etoricoxib @CHEMICAL@ oedema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Placebo-level incidence of \u001b[48;2;173;216;230;38;2;0;0;0mextrapyramidal symptoms\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m) with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m in controlled studies of patients with bipolar mania. OBJECTIVES: To evaluate \u001b[48;2;173;216;230;38;2;0;0;0mextrapyramidal symptoms\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m), including \u001b[48;2;144;238;144;38;2;0;0;0makathisia\u001b[00m, with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m in patients with bipolar mania. METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies. Two studies evaluated \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with \u001b[48;2;144;238;144;38;2;0;0;0mlithium\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m monotherapy as respective active controls. Two studies evaluated \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m (up to 800 mg/day) in combination with a mood stabilizer (\u001b[48;2;144;238;144;38;2;0;0;0mlithium\u001b[00m or divalproex, QTP + \u001b[48;2;144;238;144;38;2;0;0;0mli\u001b[00m/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + \u001b[48;2;144;238;144;38;2;0;0;0mli\u001b[00m/DVP) (n = 203). \u001b[48;2;173;216;230;38;2;0;0;0mextrapyramidal symptoms\u001b[00m were evaluated using the Simpson-Angus Scale (SAS), the Barnes \u001b[48;2;144;238;144;38;2;0;0;0makathisia\u001b[00m Rating Scale (BARS), adverse event reports and anticholinergic drug usage. RESULTS: The incidence of \u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m-related adverse events, including \u001b[48;2;144;238;144;38;2;0;0;0makathisia\u001b[00m, was no different with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m monotherapy (12.9%) than with placebo (13.1%). Similarly, \u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m-related adverse events with QTP + \u001b[48;2;144;238;144;38;2;0;0;0mli\u001b[00m/DVP (21.4%) were no different than with PBO + \u001b[48;2;144;238;144;38;2;0;0;0mli\u001b[00m/DVP (19.2%). Adverse events related to \u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m occurred in 59.6% of patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m (n = 99) monotherapy, whereas 26.5% of patients treated with \u001b[48;2;144;238;144;38;2;0;0;0mlithium\u001b[00m (n = 98) monotherapy experienced adverse events related to \u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m. The incidence of \u001b[48;2;144;238;144;38;2;0;0;0makathisia\u001b[00m was low and similar with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m monotherapy (3.3%) and placebo (6.1%), and with QTP + \u001b[48;2;144;238;144;38;2;0;0;0mli\u001b[00m/DVP (3.6%) and PBO + \u001b[48;2;144;238;144;38;2;0;0;0mli\u001b[00m/DVP (4.9%). \u001b[48;2;144;238;144;38;2;0;0;0mlithium\u001b[00m was associated with a significantly higher incidence (p < 0.05) of \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m (18.4%) than \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m (5.6%); cerebellar \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m, which is a known adverse effect of \u001b[48;2;144;238;144;38;2;0;0;0mlithium\u001b[00m, may have contributed to the elevated rate of \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m in patients receiving \u001b[48;2;144;238;144;38;2;0;0;0mlithium\u001b[00m therapy. \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m induced a significantly higher incidence (p < 0.001) of \u001b[48;2;144;238;144;38;2;0;0;0makathisia\u001b[00m (33.3% versus 5.9%), \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m (30.3% versus 7.8%), and \u001b[48;2;173;216;230;38;2;0;0;0mextrapyramidal syndrome\u001b[00m (35.4% versus 5.9%) than \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m. No significant differences were observed between \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m and placebo on SAS and BARS scores. Anticholinergic use was low and similar with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m or placebo. CONCLUSIONS: In bipolar mania, the incidence of \u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m, including \u001b[48;2;144;238;144;38;2;0;0;0makathisia\u001b[00m, with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m therapy is similar to that with placebo.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium ; li @CHEMICAL@ extrapyramidal symptoms ; eps ; extrapyramidal syndrome @DISEASE@ @CID@ lithium ; li @CHEMICAL@ tremor @DISEASE@ @CID@ haloperidol @CHEMICAL@ extrapyramidal symptoms ; eps ; extrapyramidal syndrome @DISEASE@ @CID@ haloperidol @CHEMICAL@ akathisia @DISEASE@ @CID@ haloperidol @CHEMICAL@ tremor @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "quetiapine @CHEMICAL@ extrapyramidal symptoms ; eps ; extrapyramidal syndrome @DISEASE@ @CID@ haloperidol @CHEMICAL@ extrapyramidal symptoms ; eps ; extrapyramidal syndrome @DISEASE@ @CID@ haloperidol @CHEMICAL@ tremor @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m-treated spontaneously \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m rats. OBJECTIVE: To test the hypothesis that, in lifetime \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m-treated spontaneously \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m rats (SHR), the sympathetic nervous system contributes importantly to the \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m effect of dietary \u001b[48;2;173;216;230;38;2;0;0;0msodium chloride\u001b[00m supplementation. METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m or vehicle remained on a basal \u001b[48;2;173;216;230;38;2;0;0;0msodium chloride\u001b[00m diet or were fed a high \u001b[48;2;173;216;230;38;2;0;0;0msodium chloride\u001b[00m diet. After 2 weeks, the rats were subjected to ganglionic blockade and 2 days later, an infusion of clonidine. RESULTS: Lifetime \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m treatment significantly lowered mean arterial pressure in both groups. Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary \u001b[48;2;173;216;230;38;2;0;0;0msodium chloride\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mincrease in map\u001b[00m in both groups. Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) \u001b[48;2;173;216;230;38;2;0;0;0msodium chloride\u001b[00m diet. CONCLUSIONS: In both lifetime \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high \u001b[48;2;173;216;230;38;2;0;0;0msodium chloride\u001b[00m diet.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dietary sodium chloride @CHEMICAL@ hypertensive ; increase in map @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "captopril @CHEMICAL@ hypertensive ; hypertension @DISEASE@ @CID@ sodium chloride @CHEMICAL@ hypertensive ; hypertension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced \u001b[48;2;173;216;230;38;2;0;0;0mdelayed \u001b[48;2;144;238;144;38;2;0;0;0mneuropathy\u001b[00m\u001b[00m in chickens. \u001b[48;2;144;238;144;38;2;0;0;0mtri-ortho-tolyl phosphate\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtotp\u001b[00m), 360 mg/kg, po, and 0,0'-\u001b[48;2;173;216;230;38;2;0;0;0mdiisopropyl phosphorofluoridate\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdfp\u001b[00m), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone. Supplemented diets were continued until clinical signs and lesions of \u001b[48;2;173;216;230;38;2;0;0;0mdelayed \u001b[48;2;144;238;144;38;2;0;0;0mneuropathy\u001b[00m\u001b[00m appeared. Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on \u001b[48;2;173;216;230;38;2;0;0;0mtotp\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mneuropathy\u001b[00m, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either \u001b[48;2;173;216;230;38;2;0;0;0mtotp\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mdfp\u001b[00m. Neurotoxic esterase activities 24 hr after \u001b[48;2;173;216;230;38;2;0;0;0mtotp\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mdfp\u001b[00m were less than 20% of values measured in chickens not given organophosphorous compounds. Chickens given 200 ppm corticosterone without \u001b[48;2;173;216;230;38;2;0;0;0mtotp\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mdfp\u001b[00m had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase. \u001b[48;2;144;238;144;38;2;0;0;0mdegenerating myelinated fibers\u001b[00m were also evident in distal levels of the peripheral nerves of chickens given \u001b[48;2;173;216;230;38;2;0;0;0mtotp\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mdfp\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tri-ortho-tolyl phosphate ; totp @CHEMICAL@ neuropathy @DISEASE@ @CID@ tri-ortho-tolyl phosphate ; totp @CHEMICAL@ degenerating myelinated fibers @DISEASE@ @CID@ 0,0'-diisopropyl phosphorofluoridate ; dfp @CHEMICAL@ neuropathy @DISEASE@ @CID@ 0,0'-diisopropyl phosphorofluoridate ; dfp @CHEMICAL@ degenerating myelinated fibers @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "totp @CHEMICAL@ delayed neuropathy ; delayed neurotoxic @DISEASE@ @CID@ diisopropyl phosphorofluoridate ; dfp @CHEMICAL@ delayed neuropathy ; delayed neurotoxic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%. Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m, mouse model of \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0makinesia\u001b[00m, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced \u001b[48;2;173;216;230;38;2;0;0;0mrotation\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mmptp\u001b[00m-treated non-human primate model.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@ reserpine @CHEMICAL@ akinesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@ reserpine @CHEMICAL@ akinesia @DISEASE@ @CID@ mptp @CHEMICAL@ rotation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "An extremely rare case of \u001b[48;2;173;216;230;38;2;0;0;0mdelusional parasitosis\u001b[00m in a chronic hepatitis C patient during \u001b[48;2;173;216;230;38;2;0;0;0mpegylated interferon alpha-2b\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m treatment. During treatment of chronic hepatitis C patients with interferon and \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m, a lot of side effects are described. Twenty-three percent to 44% of patients develop \u001b[48;2;173;216;230;38;2;0;0;0mdepression\u001b[00m. A minority of patients evolve to \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m. To the best of our knowledge, no cases of \u001b[48;2;173;216;230;38;2;0;0;0mpsychogenic parasitosis\u001b[00m occurring during interferon therapy have been described in the literature. We present a 49-year-old woman who developed a \u001b[48;2;173;216;230;38;2;0;0;0mdelusional parasitosis\u001b[00m during treatment with \u001b[48;2;173;216;230;38;2;0;0;0mpegylated interferon alpha-2b\u001b[00m weekly and \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m. She complained of seeing parasites and the larvae of fleas in her stools. This could not be confirmed by any technical examination. All the complaints disappeared after stopping \u001b[48;2;173;216;230;38;2;0;0;0mpegylated interferon alpha-2b\u001b[00m and reappeared after restarting it. She had a complete sustained viral response.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pegylated interferon alpha-2b @CHEMICAL@ delusional parasitosis ; psychogenic parasitosis @DISEASE@ @CID@ ribavirin @CHEMICAL@ delusional parasitosis ; psychogenic parasitosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pegylated interferon alpha-2b @CHEMICAL@ delusional parasitosis ; psychogenic parasitosis @DISEASE@ @CID@ pegylated interferon alpha-2b @CHEMICAL@ depression @DISEASE@ @CID@ pegylated interferon alpha-2b @CHEMICAL@ psychosis @DISEASE@ @CID@ ribavirin @CHEMICAL@ delusional parasitosis ; psychogenic parasitosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m seizures cause age-dependent \u001b[48;2;144;238;144;38;2;0;0;0mimpairment in auditory location discrimination\u001b[00m. Children who have \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior. The extent to which \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m causes \u001b[48;2;144;238;144;38;2;0;0;0mdeficits in auditory discrimination\u001b[00m is unknown. A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m. Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m on P20 or P45. \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m on either day induced \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m; \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m at P45 resulted in CA3 \u001b[48;2;173;216;230;38;2;0;0;0mcell loss\u001b[00m and spontaneous seizures, whereas P20 rats had no \u001b[48;2;173;216;230;38;2;0;0;0mcell loss\u001b[00m or spontaneous seizures. Mature rats were trained with sound-source location and sound-silence discriminations. Control (saline P20) rats acquired both discriminations immediately. In \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m (P20) rats, acquisition of the sound-source location discrimination was moderately impaired. \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m (P45) rats failed to acquire either sound-source location or sound-silence discriminations. \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m in rat causes an age-dependent, long-term \u001b[48;2;144;238;144;38;2;0;0;0mimpairment in auditory discrimination\u001b[00m. This impairment may explain one cause of \u001b[48;2;144;238;144;38;2;0;0;0mimpaired auditory location discrimination\u001b[00m in humans.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ impairment in auditory location discrimination ; deficits in auditory discrimination ; impairment in auditory discrimination ; impaired auditory location discrimination @DISEASE@ @CID@ pilocarpine @CHEMICAL@ status epilepticus @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ status epilepticus @DISEASE@ @CID@ pilocarpine @CHEMICAL@ cell loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Cardiovascular risk with \u001b[48;2;173;216;230;38;2;0;0;0mcyclooxygenase inhibitors\u001b[00m: general problem with substance specific differences? Randomised clinical trials and observational studies have shown an increased risk of \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mstroke\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mheart failure\u001b[00m during treatment with \u001b[48;2;173;216;230;38;2;0;0;0mcyclooxygenase inhibitors\u001b[00m. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. \u001b[48;2;173;216;230;38;2;0;0;0mcyclooxygenase inhibitors\u001b[00m cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective \u001b[48;2;173;216;230;38;2;0;0;0mcyclooxygenase inhibitors\u001b[00m suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclooxygenase inhibitors @CHEMICAL@ myocardial infarction @DISEASE@ @CID@ cyclooxygenase inhibitors @CHEMICAL@ stroke @DISEASE@ @CID@ cyclooxygenase inhibitors @CHEMICAL@ hypertension @DISEASE@ @CID@ cyclooxygenase inhibitors @CHEMICAL@ heart failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclooxygenase inhibitors ; cyclooxygenase inhibitor @CHEMICAL@ myocardial infarction @DISEASE@ @CID@ cyclooxygenase inhibitors ; cyclooxygenase inhibitor @CHEMICAL@ stroke @DISEASE@ @CID@ cyclooxygenase inhibitors ; cyclooxygenase inhibitor @CHEMICAL@ hypertension @DISEASE@ @CID@ cyclooxygenase inhibitors ; cyclooxygenase inhibitor @CHEMICAL@ heart failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Predictors of \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m. Little information is available to predict which patients are at highest risk for this complication. OBJECTIVE: To quantify specific clinical predictors of \u001b[48;2;144;238;144;38;2;0;0;0mreduction in renal function\u001b[00m in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy. METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m for the treatment of CHF. There were 3379 patients randomly assigned to \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days. \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline. We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, \u001b[48;2;144;238;144;38;2;0;0;0mdiuretic\u001b[00m, and beta-blocker therapy. RESULTS: Patients randomly assigned to \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m had a 33% greater likelihood of \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m than controls (P =.003). By multivariate analysis, in both the placebo and \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m groups older age, \u001b[48;2;144;238;144;38;2;0;0;0mdiuretic\u001b[00m therapy, and diabetes were associated with \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m, whereas beta-blocker therapy and higher ejection fraction were renoprotective. Older age was associated with a greater risk of developing \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m in both groups, but significantly more so in the \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m group (\u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m; placebo: RR 1.18, 95% CI 1.12-1.25). \u001b[48;2;144;238;144;38;2;0;0;0mdiuretic\u001b[00m therapy was likewise associated with a greater risk of \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m in the \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66). Conversely, \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes. A lower risk of \u001b[48;2;173;216;230;38;2;0;0;0mrenal impairment\u001b[00m was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96). CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m use caused a 33% increase in the risk of \u001b[48;2;173;216;230;38;2;0;0;0mdecreased renal function\u001b[00m in patients with CHF. \u001b[48;2;144;238;144;38;2;0;0;0mdiuretic\u001b[00m use and advanced age increased this risk. Diabetes was associated with an increased risk of \u001b[48;2;173;216;230;38;2;0;0;0mrenal impairment\u001b[00m in all patients with CHF, but this risk was reduced in the \u001b[48;2;173;216;230;38;2;0;0;0menalapril\u001b[00m group compared with the placebo group. beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "enalapril @CHEMICAL@ decreased renal function ; reduction in renal function ; renal impairment @DISEASE@ @CID@ diuretic @CHEMICAL@ decreased renal function ; reduction in renal function ; renal impairment @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "enalapril @CHEMICAL@ decreased renal function ; renal impairment ; decreased renal function @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m induced acute \u001b[48;2;173;216;230;38;2;0;0;0mchoreoathetosis\u001b[00m: case report and review of the literature. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder. \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m has not been commonly associated in the literature as a cause of acute movement disorders. The following case describes two children acutely poisoned with \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m who experienced profound \u001b[48;2;173;216;230;38;2;0;0;0mchoreoathetosis\u001b[00m. CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m originally containing 59 tablets. The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success. This was their first day of \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m therapy. The \u001b[48;2;173;216;230;38;2;0;0;0mchoreoathetoid movements\u001b[00m began 45 min to 1 h after ingestion. The children gave no history of prior movement disorders and there was no family history of movement disorders. The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the \u001b[48;2;173;216;230;38;2;0;0;0mchoreoathetoid movements\u001b[00m. Despite treatment, the children continued to have \u001b[48;2;173;216;230;38;2;0;0;0mchoreoathetosis\u001b[00m for approximately 24 hours. Forty-eight hours after admission, the children appeared to be at their baseline and were discharged home. CONCLUSION: \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m associated movement disorder has been rarely reported in the acute toxicology literature. The possibility of \u001b[48;2;173;216;230;38;2;0;0;0mchoreoathetoid movements\u001b[00m should be considered in patients presenting after \u001b[48;2;173;216;230;38;2;0;0;0mpemoline\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pemoline @CHEMICAL@ choreoathetosis ; choreoathetoid @DISEASE@ @CID@ pemoline @CHEMICAL@ overdose @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pemoline @CHEMICAL@ choreoathetosis ; choreoathetoid movements @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Continuous subcutaneous administration of \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m to prevent \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mcystitis\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mcystitis\u001b[00m is a major potential toxicity of \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m that can be prevented by administering \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m along with the cytotoxic agent. \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m is generally administered by the intravenous route, although experience with oral delivery of the drug has increased. The continuous subcutaneous administration of \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m has the advantage of not requiring intravenous access. In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m concentrations, such as in a patient taking oral \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m who experiences severe \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0memesis\u001b[00m and is unable to absorb the drug. Limited clinical experience with continuous subcutaneous \u001b[48;2;144;238;144;38;2;0;0;0mmesna\u001b[00m administration suggests it is a safe, practical, and economic method of drug delivery that permits \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m to be administered successfully in the outpatient setting.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "mesna @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ mesna @CHEMICAL@ cystitis @DISEASE@ @CID@ ifosfamide @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ ifosfamide @CHEMICAL@ cystitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ifosfamide @CHEMICAL@ hemorrhagic ; hemorrhage @DISEASE@ @CID@ ifosfamide @CHEMICAL@ cystitis @DISEASE@ @CID@ ifosfamide @CHEMICAL@ emesis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Modification of drug action by hyperammonemia. Pretreatment with \u001b[48;2;144;238;144;38;2;0;0;0mammonium acetate\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m) (6 mmol/kg s.c.) approximately doubled the time \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-treated mice remained on a hot surface and similarly increased \u001b[48;2;173;216;230;38;2;0;0;0mmuscular \u001b[48;2;144;238;144;38;2;0;0;0mincoordination\u001b[00m\u001b[00m by \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m, but \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m treatment alone had no effect. Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mkcl\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcontractions of guinea-pig ileum\u001b[00m were inhibited 20% by 5 mM \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m. These results suggested that ammonia blocks calcium channels. Parallels in the actions of \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m pretreatment enhanced \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m analgesia- and \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmuscular \u001b[48;2;144;238;144;38;2;0;0;0mincoordination\u001b[00m\u001b[00m and antagonized amphetamine-induced motor activity, and neither verapamil nor \u001b[48;2;144;238;144;38;2;0;0;0mnh4ac\u001b[00m affected the convulsant action of metrazol. The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ammonium acetate ; nh4ac @CHEMICAL@ incoordination @DISEASE@ @CID@ diazepam @CHEMICAL@ incoordination @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "morphine @CHEMICAL@ muscular incoordination @DISEASE@ @CID@ diazepam @CHEMICAL@ muscular incoordination @DISEASE@ @CID@ kcl @CHEMICAL@ contractions of guinea-pig ileum @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Risk of \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m after consumption of nonionic \u001b[48;2;173;216;230;38;2;0;0;0mcontrast media\u001b[00m by children undergoing cardiac angiography: a prospective study. Despite increasing reports on nonionic \u001b[48;2;173;216;230;38;2;0;0;0mcontrast media\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography. This prospective study determined the incidence of \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m for two nonionic \u001b[48;2;173;216;230;38;2;0;0;0mcontrast media\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m), \u001b[48;2;144;238;144;38;2;0;0;0miopromide\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0miohexol\u001b[00m, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of \u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m and the presence of cyanosis. The 80 patients in the study consecutively received either \u001b[48;2;144;238;144;38;2;0;0;0miopromide\u001b[00m (group A, n = 40) or \u001b[48;2;144;238;144;38;2;0;0;0miohexol\u001b[00m (group B, n = 40). Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after \u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m use. Urine samples for Na and Cr also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage \u001b[48;2;144;238;144;38;2;0;0;0mrenal damage\u001b[00m (RIFLE criteria) were used to define \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m and its incidence in the study population. Accordingly, among the 15 \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had \u001b[48;2;173;216;230;38;2;0;0;0mrenal injury\u001b[00m, whereas 5% of group B had increased risk and 2.5% had \u001b[48;2;173;216;230;38;2;0;0;0mrenal injury\u001b[00m. Whereas 33.3% of the patients with \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m were among those who received the proper dosage of \u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m related to the different dosages of \u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m (p = 0.014). Among the 15 patients with \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243). Although clinically silent, \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m is not rare in pediatrics. The incidence depends on dosage but not on the type of consumed nonionic \u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m, nor on the presence of cyanosis, and although \u001b[48;2;144;238;144;38;2;0;0;0mcin\u001b[00m usually is reversible, more concern is needed for the prevention of such a complication in children.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "contrast media ; cm @CHEMICAL@ nephropathy ; cin ; renal damage @DISEASE@ @CID@ iopromide @CHEMICAL@ nephropathy ; cin ; renal damage @DISEASE@ @CID@ iohexol @CHEMICAL@ nephropathy ; cin ; renal damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "contrast media ; cm @CHEMICAL@ nephropathy ; renal injury ; kidney function loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A case of \u001b[48;2;173;216;230;38;2;0;0;0mventricular tachycardia\u001b[00m related to \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m pretreatment. Suboptimal \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m duration is commonly encountered in electroconvulsive therapy practice, especially in older patients with higher \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m thresholds. Intravenous \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m is commonly used to improve \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign \u001b[48;2;173;216;230;38;2;0;0;0mventricular ectopy\u001b[00m. We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained \u001b[48;2;173;216;230;38;2;0;0;0mbigeminy\u001b[00m and 2 brief runs of \u001b[48;2;173;216;230;38;2;0;0;0mventricular tachycardia\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m administration. Although intravenous \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "caffeine @CHEMICAL@ ventricular tachycardia @DISEASE@ @CID@ caffeine @CHEMICAL@ seizure @DISEASE@ @CID@ caffeine @CHEMICAL@ ventricular ectopy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "caffeine @CHEMICAL@ ventricular tachycardia ; ventricular ectopy @DISEASE@ @CID@ caffeine @CHEMICAL@ bigeminy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Optical coherence tomography can measure axonal loss in patients with \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m. PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m using optical coherence tomography (OCT). \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m is an antimycobacterial agent often used to treat tuberculosis. A serious complication of \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m is an \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m that impairs visual acuity, contrast sensitivity, and color vision. However, early on, when the toxic \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m is mild and partly reversible, the funduscopic findings are often subtle and easy to miss. METHODS: Three subjects with a history of \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0memb\u001b[00m)-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m of short-, intermediate-, and long-term \u001b[48;2;144;238;144;38;2;0;0;0mvisual deficits\u001b[00m were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination. In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol. OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL. RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661. In all subjects with history of \u001b[48;2;173;216;230;38;2;0;0;0memb\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate \u001b[48;2;144;238;144;38;2;0;0;0mvisual deficits\u001b[00m, 68% loss; patient C, with chronic \u001b[48;2;144;238;144;38;2;0;0;0mvisual deficits\u001b[00m, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm. There was a combined mean loss of 46% of fibers from the superior, inferior, and nasal quadrants in the (six) eyes of all three subjects (mean average thickness of 55+/-29 microm). In both sets (four) of eyes of the subjects with persistent \u001b[48;2;144;238;144;38;2;0;0;0mvisual deficits\u001b[00m (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant. CONCLUSIONS: The OCT results in these patients with \u001b[48;2;173;216;230;38;2;0;0;0memb\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m show considerable loss especially of the temporal fibers. This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary \u001b[48;2;144;238;144;38;2;0;0;0moptic neuropathies\u001b[00m. OCT can be a valuable tool in the quantitative analysis of \u001b[48;2;144;238;144;38;2;0;0;0moptic neuropathies\u001b[00m. Additionally, in terms of management of \u001b[48;2;173;216;230;38;2;0;0;0memb\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m, it is important to properly manage \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ethambutol ; emb @CHEMICAL@ optic neuropathy ; optic neuropathies @DISEASE@ @CID@ ethambutol ; emb @CHEMICAL@ visual deficits @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ethambutol ; emb @CHEMICAL@ optic neuropathy ; toxic optic neuropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of the cyclooxygenase-2 specific inhibitor \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m versus nonsteroidal antiinflammatory agents and placebo on \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m events\u001b[00m in patients with arthritis. There have been concerns that the risk of \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m events\u001b[00m may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We evaluated cardiovascular event data for \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m events\u001b[00m (cardiac, cerebrovascular and peripheral vascular, or arterial \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m) was determined by analyzing pooled \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m (10-80 mg daily), nonselective NSAID (\u001b[48;2;173;216;230;38;2;0;0;0mdiclofenac\u001b[00m 75 mg bid, \u001b[48;2;173;216;230;38;2;0;0;0mibuprofen\u001b[00m 800 mg tid, or \u001b[48;2;173;216;230;38;2;0;0;0mnaproxen\u001b[00m 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration. The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) \u001b[48;2;144;238;144;38;2;0;0;0maspirin\u001b[00m (n = 1051) and nonusers of \u001b[48;2;144;238;144;38;2;0;0;0maspirin\u001b[00m (n = 6883). Crude and exposure-adjusted incidences of \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m events were similar for \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m, NSAIDs, and placebo. The risk of serious \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m events was also similar for each \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m dose. \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m risk was consistently higher for users of \u001b[48;2;144;238;144;38;2;0;0;0maspirin\u001b[00m users than nonusers of \u001b[48;2;144;238;144;38;2;0;0;0maspirin\u001b[00m (placebo, 1.4% vs. 0%; \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%). The rates of events in users of \u001b[48;2;144;238;144;38;2;0;0;0maspirin\u001b[00m were similar for all 3 treatment groups and across \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m doses. Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) \u001b[48;2;173;216;230;38;2;0;0;0mvaldecoxib\u001b[00m doses was not associated with an increased incidence of \u001b[48;2;144;238;144;38;2;0;0;0mthrombotic\u001b[00m events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "aspirin @CHEMICAL@ thrombotic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "valdecoxib @CHEMICAL@ cardiovascular thrombotic events ; cardiovascular thrombotic @DISEASE@ @CID@ diclofenac @CHEMICAL@ cardiovascular thrombotic events ; cardiovascular thrombotic @DISEASE@ @CID@ ibuprofen @CHEMICAL@ cardiovascular thrombotic events ; cardiovascular thrombotic @DISEASE@ @CID@ naproxen @CHEMICAL@ cardiovascular thrombotic events ; cardiovascular thrombotic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A randomized, placebo-controlled, crossover study of \u001b[48;2;173;216;230;38;2;0;0;0mephedrine\u001b[00m for SSRI-induced female \u001b[48;2;173;216;230;38;2;0;0;0msexual dysfunction\u001b[00m. The objective of this study was to determine whether \u001b[48;2;173;216;230;38;2;0;0;0mephedrine\u001b[00m, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced \u001b[48;2;173;216;230;38;2;0;0;0msexual dysfunction\u001b[00m. Nineteen \u001b[48;2;173;216;230;38;2;0;0;0msexually dysfunctional\u001b[00m women receiving either \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0msertraline\u001b[00m, or \u001b[48;2;173;216;230;38;2;0;0;0mparoxetine\u001b[00m participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of \u001b[48;2;173;216;230;38;2;0;0;0mephedrine\u001b[00m (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction. Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg \u001b[48;2;173;216;230;38;2;0;0;0mephedrine\u001b[00m 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo. These findings highlight the importance of conducting placebo-controlled trials for this condition.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluoxetine @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@ sertraline @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@ paroxetine @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ephedrine @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@ fluoxetine @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@ sertraline @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@ paroxetine @CHEMICAL@ sexual dysfunction ; sexually dysfunctional @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0merectile dysfunction\u001b[00m occurs following substantia nigra lesions in the rat. Erectile function was assessed 6 weeks following uni- and bilateral injections of \u001b[48;2;144;238;144;38;2;0;0;0m6-hydroxydopamine\u001b[00m in the substantia nigra nucleus of the brain. Behavioral \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpenile erections\u001b[00m were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals. Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals. Lesions of the substantia nigra were confirmed by histology. Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats. Lesions of the substantia nigra are therefore associated with \u001b[48;2;144;238;144;38;2;0;0;0merectile dysfunction\u001b[00m in rats and may serve as a model to study \u001b[48;2;144;238;144;38;2;0;0;0merectile dysfunction\u001b[00m in Parkinson's disease.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "6-hydroxydopamine @CHEMICAL@ erectile dysfunction @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "apomorphine @CHEMICAL@ penile erections @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Potential therapeutic use of the selective dopamine D1 receptor agonist, \u001b[48;2;173;216;230;38;2;0;0;0ma-86929\u001b[00m: an acute study in \u001b[48;2;144;238;144;38;2;0;0;0mparkinsonian\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m-primed monkeys. The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear. The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance). We therefore conducted the present acute dose-response study in four \u001b[48;2;144;238;144;38;2;0;0;0m1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmptp\u001b[00m)-exposed cynomolgus monkeys primed to exhibit \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m to evaluate the locomotor and \u001b[48;2;144;238;144;38;2;0;0;0mdyskinetic\u001b[00m effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of \u001b[48;2;173;216;230;38;2;0;0;0ma-86929\u001b[00m ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action. \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison. Acute administration of \u001b[48;2;173;216;230;38;2;0;0;0ma-86929\u001b[00m was as efficacious in alleviating \u001b[48;2;173;216;230;38;2;0;0;0mmptp\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonism\u001b[00m as \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m and LY-171555, but was less likely to reproduce the \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m in these animals than with either LY-171555 or subsequent challenge of \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m. Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m and selective DA D2 receptor agonist. Potent DA D1 receptor agents with an intermediate duration of efficacy such as \u001b[48;2;173;216;230;38;2;0;0;0ma-86929\u001b[00m (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; dyskinetic @DISEASE@ @CID@ 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; mptp @CHEMICAL@ parkinsonian ; parkinsonism @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "a-86929 ; [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1-ena[c]phenathrene-9-10-diol @CHEMICAL@ dyskinesias @DISEASE@ @CID@ mptp @CHEMICAL@ parkinsonism @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmyoclonic\u001b[00m, atonic, and \u001b[48;2;173;216;230;38;2;0;0;0mabsence seizures\u001b[00m following institution of \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m therapy in children. Five children, aged 3 to 11 years, treated with \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m for epilepsy, had an acute aberrant reaction characterized by the onset of \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonic\u001b[00m, atypical absence and/or \u001b[48;2;173;216;230;38;2;0;0;0matonic (minor motor) seizures\u001b[00m within a few days. When the \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist. The child in whom the seizures persisted was later found to have ceroid lipofuscinosis. The other children are doing well on other anticonvulsants.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "carbamazepine @CHEMICAL@ myoclonic seizures @DISEASE@ @CID@ carbamazepine @CHEMICAL@ absence seizures ; atypical absence seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "carbamazepine @CHEMICAL@ myoclonic @DISEASE@ @CID@ carbamazepine @CHEMICAL@ atonic (minor motor) seizures @DISEASE@ @CID@ carbamazepine @CHEMICAL@ absence seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Naloxone reversal of \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m. The hemodynamic effects of \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m and other \u001b[48;2;144;238;144;38;2;0;0;0mangiotensin-converting enzyme inhibitors\u001b[00m may be mediated by the endogenous opioid system. The opioid antagonist naloxone has been shown to block or reverse the \u001b[48;2;173;216;230;38;2;0;0;0mhypotensive\u001b[00m actions of \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m. We report a case of an intentional \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m, manifested by marked \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m, that resolved promptly with the administration of naloxone. To our knowledge, this is the first reported case of \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m treated with naloxone. Our experience demonstrates a possible role of naloxone in the reversal of \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m resulting from \u001b[48;2;173;216;230;38;2;0;0;0mcaptopril\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "angiotensin-converting enzyme inhibitors @CHEMICAL@ hypotension ; hypotensive @DISEASE@ @CID@ angiotensin-converting enzyme inhibitors @CHEMICAL@ overdose @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "captopril @CHEMICAL@ hypotension ; hypotensive @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. A patient with \u001b[48;2;173;216;230;38;2;0;0;0msinus \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0matrioventricular block\u001b[00m, induced by \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m, prompted an extensive literature review of all previously reported cases. From the analysis of these cases, two distinct forms of \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m-associated cardiac dysfunction emerged. One patient group developed sinus \u001b[48;2;173;216;230;38;2;0;0;0mtachycardias\u001b[00m in the setting of a massive \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m overdose. The second group consisted almost exclusively of elderly women who developed potentially life-threatening \u001b[48;2;173;216;230;38;2;0;0;0mbradyarrhythmias\u001b[00m or \u001b[48;2;144;238;144;38;2;0;0;0matrioventricular conduction delay\u001b[00m, associated with either therapeutic or modestly elevated \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m serum levels. Because \u001b[48;2;173;216;230;38;2;0;0;0mcarbamazepine\u001b[00m is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "carbamazepine @CHEMICAL@ bradycardia ; bradyarrhythmias @DISEASE@ @CID@ carbamazepine @CHEMICAL@ atrioventricular block ; atrioventricular conduction delay @DISEASE@ @CID@ carbamazepine @CHEMICAL@ sinus tachycardias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "carbamazepine @CHEMICAL@ bradycardia ; bradyarrhythmias @DISEASE@ @CID@ carbamazepine @CHEMICAL@ atrioventricular block @DISEASE@ @CID@ carbamazepine @CHEMICAL@ sinus bradycardia ; bradyarrhythmias @DISEASE@ @CID@ carbamazepine @CHEMICAL@ tachycardias @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD). Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known. The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD. Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m in rats. AMN082 (2.5 and 5 mg/kg) reduces \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats. In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats. In addition, AMN082 reduces the duration of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice. Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD. Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity. Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@ apomorphine @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Nimodipine prevents \u001b[48;2;144;238;144;38;2;0;0;0mmemory impairment\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0mnitroglycerin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m in adult mice. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction. We tested the hypothesis that nimodipine (NIMO) administered at the onset of \u001b[48;2;173;216;230;38;2;0;0;0mnitroglycerin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m)-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m would preserve long-term associative memory. METHODS: The passive avoidance (PA) paradigm was used to assess memory retention. For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered. Latencies were recorded 48 h later for a testing trial. Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m immediately after learning, 3) \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m 3 h after learning, 4) \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m and NIMO, 5) vehicle, and 6) NIMO alone. The extent of \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and changes in brain tissue oxygenation (PbtO(2)) and in cerebral blood flow were studied in a separate group of animals. RESULTS: All groups exhibited similar training latencies (17.0 +/- 4.6 s). Mice subjected to \u001b[48;2;173;216;230;38;2;0;0;0mhypotensive\u001b[00m episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m + NIMO, or delayed \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively). A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001). In a separate group of mice not subjected to behavioral studies, the same dose of \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m (n = 3) and \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively. Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg. The intergroup difference was statistically significant (P < 0.05). PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m + NIMO groups, respectively. There were no significant differences among groups. CONCLUSION: In a PA retention paradigm, the injection of \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by \u001b[48;2;173;216;230;38;2;0;0;0mntg\u001b[00m but did not improve latency in the absence of \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m. The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m, because there were no differences in the PbtO(2) indices among groups.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nitroglycerin ; ntg @CHEMICAL@ memory impairment @DISEASE@ @CID@ nitroglycerin ; ntg @CHEMICAL@ hypotension ; hypotensive @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "nitroglycerin ; ntg @CHEMICAL@ hypotension ; hypotensive @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Fatal \u001b[48;2;173;216;230;38;2;0;0;0mhaemopericardium\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mgastrointestinal haemorrhage\u001b[00m due to possible interaction of \u001b[48;2;173;216;230;38;2;0;0;0mcranberry juice\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m. We report a case of fatal \u001b[48;2;173;216;230;38;2;0;0;0minternal haemorrhage\u001b[00m in an elderly man who consumed only \u001b[48;2;173;216;230;38;2;0;0;0mcranberry juice\u001b[00m for two weeks while maintaining his usual dosage of \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m. We propose that naturally occurring compounds such as \u001b[48;2;144;238;144;38;2;0;0;0mflavonoids\u001b[00m, which are present in fruit juices, may increase the potency of \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m by competing for the enzymes that normally inactivate \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m. While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "warfarin @CHEMICAL@ gastrointestinal haemorrhage @DISEASE@ @CID@ flavonoids @CHEMICAL@ gastrointestinal haemorrhage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cranberry juice @CHEMICAL@ haemopericardium @DISEASE@ @CID@ cranberry juice @CHEMICAL@ gastrointestinal haemorrhage @DISEASE@ @CID@ warfarin @CHEMICAL@ haemopericardium @DISEASE@ @CID@ warfarin @CHEMICAL@ internal haemorrhage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m induces primary loss of dystrophin in rat hearts: correlation with \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial injury\u001b[00m. The mechanism of \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial damage\u001b[00m is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and \u001b[48;2;144;238;144;38;2;0;0;0mmyocardial hyperactivity\u001b[00m is the best explanation for the complex morphological alterations observed. Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m. Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m affects sarcolemmal stability through changes in the DGC and integrins. We found different sensitivity of the DGC and integrin to \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m subcutaneous administration. Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix. The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin. Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process. In conclusion, administration of \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte. These changes, related to \u001b[48;2;144;238;144;38;2;0;0;0mischaemic injury\u001b[00m, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "isoproterenol @CHEMICAL@ myocardial injury ; myocardial damage ; myocardial hyperactivity @DISEASE@ @CID@ isoproterenol @CHEMICAL@ ischaemic injury @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "isoproterenol @CHEMICAL@ myocardial injury ; myocardial damage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "High \u001b[48;2;144;238;144;38;2;0;0;0mfat\u001b[00m diet-fed \u001b[48;2;144;238;144;38;2;0;0;0mobese\u001b[00m rats are highly sensitive to \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m. Often, chemotherapy by \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m) is limited due to life threatening \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m in patients during and posttherapy. Recently, we have shown that moderate diet restriction remarkably protects against \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m. This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high \u001b[48;2;144;238;144;38;2;0;0;0mfat\u001b[00m diet (HFD), which induces \u001b[48;2;144;238;144;38;2;0;0;0mobesity\u001b[00m in male Sprague-Dawley rats (250-275 g), sensitizes to \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m. A LD(10) dose (8 mg \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m/kg, ip) administered on day 43 of the HFD feeding regimen led to higher \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mcardiac dysfunction\u001b[00m, lipid peroxidation, and 80% mortality in the \u001b[48;2;144;238;144;38;2;0;0;0mobese\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mob\u001b[00m) rats in the absence of any significant renal or hepatic toxicity. \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m toxicokinetics studies revealed no change in accumulation of \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and \u001b[48;2;144;238;144;38;2;0;0;0mob\u001b[00m hearts. Mechanistic studies revealed that \u001b[48;2;144;238;144;38;2;0;0;0mob\u001b[00m rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in \u001b[48;2;144;238;144;38;2;0;0;0mob\u001b[00m), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m administration. Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway. In conclusion, HFD-induced \u001b[48;2;144;238;144;38;2;0;0;0mobese\u001b[00m rats are highly sensitized to \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fat @CHEMICAL@ obese ; obesity ; ob @DISEASE@ @CID@ doxorubicin ; adriamycin @CHEMICAL@ cardiac dysfunction @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin ; adriamycin @CHEMICAL@ cardiotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Complete \u001b[48;2;173;216;230;38;2;0;0;0matrioventricular block\u001b[00m secondary to \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy. \u001b[48;2;144;238;144;38;2;0;0;0msinus node dysfunction\u001b[00m has been reported most frequently among the adverse cardiovascular effects of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m. In the present case, complete \u001b[48;2;144;238;144;38;2;0;0;0matrioventricular (av) block\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0msyncopal attacks\u001b[00m developed secondary to \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy, necessitating permanent pacemaker implantation. Serum \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m levels remained under or within the therapeutic range during the \u001b[48;2;173;216;230;38;2;0;0;0msyncopal attacks\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m should be used with extreme caution, especially in patients with mild disturbance of AV conduction.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium @CHEMICAL@ atrioventricular block ; atrioventricular (av) block @DISEASE@ @CID@ lithium @CHEMICAL@ sinus node dysfunction @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium @CHEMICAL@ atrioventricular block ; av block @DISEASE@ @CID@ lithium @CHEMICAL@ syncopal attacks @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Possible \u001b[48;2;173;216;230;38;2;0;0;0mazithromycin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m. OBJECTIVE: To report a case of persistent \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m associated by \u001b[48;2;173;216;230;38;2;0;0;0mazithromycin\u001b[00m therapy. CASE SUMMARY: A 76-year-old man presented with persistent \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m after beginning \u001b[48;2;173;216;230;38;2;0;0;0mazithromycin\u001b[00m for the treatment of pharyngitis. \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m were persistent and exhausting. Discontinuation of \u001b[48;2;173;216;230;38;2;0;0;0mazithromycin\u001b[00m and therapy with \u001b[48;2;144;238;144;38;2;0;0;0mbaclofen\u001b[00m finally resolved \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m. No organic cause of \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m was identified despite extensive investigation. DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m. Few cases of drug-induced \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m have been reported related to macrolide antimicrobials. Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m. Our hypothesis is that a vagal mechanism mediated by \u001b[48;2;173;216;230;38;2;0;0;0mazithromycin\u001b[00m could be the pathogenesis of \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m in our patient. CONCLUSIONS: Diagnosis of drug-induced \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m is difficult and often achieved only by a process of elimination. However, macrolide antimicrobials have been reported to be associated with \u001b[48;2;173;216;230;38;2;0;0;0mhiccups\u001b[00m and vagal mechanism could explain the development of this side-effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "azithromycin @CHEMICAL@ hiccups @DISEASE@ @CID@ baclofen @CHEMICAL@ hiccups @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "azithromycin @CHEMICAL@ hiccups @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Time trends in \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhage\u001b[00m. The annual incidence of \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m-related \u001b[48;2;173;216;230;38;2;0;0;0mbleeding\u001b[00m at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study. The proportion of patients with major and intracranial \u001b[48;2;173;216;230;38;2;0;0;0mbleeding\u001b[00m increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "warfarin @CHEMICAL@ hemorrhage ; bleeding @DISEASE@ @CID@ warfarin @CHEMICAL@ intracranial bleeding @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "warfarin @CHEMICAL@ hemorrhage ; bleeding ; hemorrhage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Fatal \u001b[48;2;173;216;230;38;2;0;0;0mhaemorrhagic\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mmyocarditis\u001b[00m secondary to \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m therapy. \u001b[48;2;173;216;230;38;2;0;0;0mhaemorrhagic\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mmyocarditis\u001b[00m is a rare but important complication of \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m therapy. Echocardiographic identification of the disorder can be made. We believe that the ultrasound features of this disorder have not been previously reported.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ haemorrhagic @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ myocarditis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ haemorrhagic ; haemorrhage @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ myocarditis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mglyceryl trinitrate\u001b[00m induces attacks of \u001b[48;2;144;238;144;38;2;0;0;0mmigraine without aura\u001b[00m in sufferers of migraine with aura. Migraine with aura and \u001b[48;2;144;238;144;38;2;0;0;0mmigraine without aura\u001b[00m have the same pain phase, thus indicating that migraine with aura and \u001b[48;2;144;238;144;38;2;0;0;0mmigraine without aura\u001b[00m share a common pathway of nociception. In recent years, increasing evidence has suggested that the messenger molecule \u001b[48;2;144;238;144;38;2;0;0;0mnitric oxide\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mno\u001b[00m) is involved in pain mechanisms of \u001b[48;2;144;238;144;38;2;0;0;0mmigraine without aura\u001b[00m. In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of \u001b[48;2;173;216;230;38;2;0;0;0mglyceryl trinitrate\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mgtn\u001b[00m) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura. The specific aim was to elucidate whether an aura and/or an attack of \u001b[48;2;144;238;144;38;2;0;0;0mmigraine without aura\u001b[00m could be induced. Fourteen healthy subjects served as controls. Aura symptoms were not elicited in any subject. Headache was more severe in \u001b[48;2;173;216;230;38;2;0;0;0mmigraineurs\u001b[00m than in the controls during and immediately after \u001b[48;2;173;216;230;38;2;0;0;0mgtn\u001b[00m infusion (p=0.037) as well as during the following 11 h (p = 0.008). In the controls, the \u001b[48;2;173;216;230;38;2;0;0;0mgtn\u001b[00m-induced headache gradually disappeared, whereas in \u001b[48;2;173;216;230;38;2;0;0;0mmigraineurs\u001b[00m peak headache intensity occurred at a mean time of 240 min post-infusion. At this time the induced headache in 6 of 12 \u001b[48;2;173;216;230;38;2;0;0;0mmigraineurs\u001b[00m fulfilled the diagnostic criteria for \u001b[48;2;144;238;144;38;2;0;0;0mmigraine without aura\u001b[00m of the International Headache Society. The results therefore suggest that \u001b[48;2;144;238;144;38;2;0;0;0mno\u001b[00m is involved in the pain mechanisms of migraine with aura. Since cortical spreading depression has been shown to liberate \u001b[48;2;144;238;144;38;2;0;0;0mno\u001b[00m in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "glyceryl trinitrate ; gtn @CHEMICAL@ migraine without aura @DISEASE@ @CID@ nitric oxide ; no @CHEMICAL@ migraine without aura @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "glyceryl trinitrate ; gtn @CHEMICAL@ migraineurs @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m use. The association of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m use with \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mischemic \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m\u001b[00m is based almost solely on data from case series. The limited number of epidemiologic studies of \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m and use of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and/or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m have been done in settings that serve mostly the poor and/or minorities. This case-control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California. We attempted to identify all incident \u001b[48;2;144;238;144;38;2;0;0;0mstrokes\u001b[00m in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations. We selected controls, matched on age and facility of usual care, at random from healthy members of the health plan. We obtained information in face-to-face interviews. There were 347 confirmed \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m cases and 1,021 controls. The univariate matched odds ratio for \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m in women who admitted to using \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and/or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m was 8.5 (95% confidence interval = 3.6-20.0). After further adjustment for potential confounders, the odds ratio in women who reported using \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and/or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m was 7.0 (95% confidence interval = 2.8-17.9). The use of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and/or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m is a strong risk factor for \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m in this socioeconomically heterogeneous, insured urban population.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ stroke ; strokes @DISEASE@ @CID@ amphetamine @CHEMICAL@ stroke ; strokes @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ cocaine @CHEMICAL@ ischemic stroke @DISEASE@ @CID@ amphetamine @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ amphetamine @CHEMICAL@ ischemic stroke @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Prevention of breast cancer with \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m: preliminary findings from the Italian randomised trial among hysterectomised women. Italian \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m Prevention Study. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of \u001b[48;2;173;216;230;38;2;0;0;0mendometrial cancer\u001b[00m. Therefore we did a trial in hysterectomised women of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m as a chemopreventive. METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy. Women were randomised to receive \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m 20 mg per day or placebo, both orally for 5 years. The original plan was to follow the intervention phase by 5 years' follow-up. In June, 1997, the trialists and the data-monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study. Recruitment ended on July 11, 1997, and the study will continue as planned. The primary endpoints are the occurrence of and deaths from breast cancer. This preliminary interim analysis is based on intention-to-treat. FINDINGS: 5408 women were randomised; participating women have a median follow-up of 46 months for major endpoints. 41 cases of breast cancer occurred so far; there have been no deaths from breast cancer. There is no difference in breast-cancer frequency between the placebo (22 cases) and \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m (19) arms. There is a statistically significant reduction of breast cancer among women receiving \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m. Compared with the placebo group, there was a significantly increased risk of \u001b[48;2;144;238;144;38;2;0;0;0mvascular events\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhypertriglyceridaemia\u001b[00m among women on \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m. INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m are not yet apparent. Women using hormone-replacement therapy appear to have benefited from use of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m. There were no deaths from breast cancer recorded in women in the study. It is essential to continue follow-up to quantify the long-term risks and benefits of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tamoxifen @CHEMICAL@ vascular events @DISEASE@ @CID@ tamoxifen @CHEMICAL@ hypertriglyceridaemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tamoxifen @CHEMICAL@ endometrial cancer @DISEASE@ @CID@ tamoxifen @CHEMICAL@ hypertriglyceridaemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A measure of \u001b[48;2;144;238;144;38;2;0;0;0mpupillary oscillation\u001b[00m as a marker of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mparanoia\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mparanoia\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mcip\u001b[00m) remains an important drug-induced model of idiopathic \u001b[48;2;173;216;230;38;2;0;0;0mparanoia\u001b[00m for which no psychophysiologic marker has yet emerged. Measures of \u001b[48;2;144;238;144;38;2;0;0;0mpupillary oscillation\u001b[00m were able to significantly distinguish a group of abstinent crack \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m abusers endorsing past \u001b[48;2;144;238;144;38;2;0;0;0mcip\u001b[00m (n = 32) from another group of crack addicts who denied past \u001b[48;2;144;238;144;38;2;0;0;0mcip\u001b[00m (n = 29).\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ pupillary oscillation @DISEASE@ @CID@ cocaine @CHEMICAL@ paranoia ; cip @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ paranoia ; paranoi @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m induced by combined \u001b[48;2;173;216;230;38;2;0;0;0mlevomepromazine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m treatment. We report a case of combined \u001b[48;2;173;216;230;38;2;0;0;0mlevomepromazine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m treatment-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. It seems that combined treatment of \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m with phenothiazines may possess proconvulsive activity.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levomepromazine @CHEMICAL@ seizures @DISEASE@ @CID@ fluvoxamine @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levomepromazine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ fluvoxamine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Why may \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-aminocaproic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0meaca\u001b[00m) induce \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m in man? Report of a case and literature review. A case of \u001b[48;2;144;238;144;38;2;0;0;0mnecrotizing\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m due to a short \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-aminocaproic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0meaca\u001b[00m) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described. Pathogenetic hypotheses are discussed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "epsilon-aminocaproic acid ; eaca @CHEMICAL@ myopathy @DISEASE@ @CID@ epsilon-aminocaproic acid ; eaca @CHEMICAL@ necrotizing @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "epsilon-aminocaproic acid ; eaca @CHEMICAL@ myopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Comparison of the effectiveness of ranitidine and \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m in inhibiting acid secretion in patients with gastric hypersecretory states. The H2-histamine receptor antagonists ranitidine and \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states. Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion. The rates of onset of the action of \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m and ranitidine were the same. The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion. However, ranitidine was threefold more potent than \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m). Sixty percent of the males developed \u001b[48;2;173;216;230;38;2;0;0;0mbreast changes\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mimpotence\u001b[00m while taking \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m and in all cases these changes disappeared when \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m was replaced by ranitidine. Treatment with high doses of \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m therapy. The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states. Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of \u001b[48;2;173;216;230;38;2;0;0;0mcimetidine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cimetidine @CHEMICAL@ impotence @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cimetidine @CHEMICAL@ breast changes @DISEASE@ @CID@ cimetidine @CHEMICAL@ impotence @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A catch in the \u001b[48;2;144;238;144;38;2;0;0;0mreye\u001b[00m. Twenty-six cases of \u001b[48;2;173;216;230;38;2;0;0;0mreye syndrome\u001b[00m from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed. Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of \u001b[48;2;173;216;230;38;2;0;0;0mreye syndrome\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0maspirin\u001b[00m or salicylate ingestion had occurred in only one of the 20 cases (5%), and \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m) had been administered in only six of the cases (30%). Pathologic confirmation of the diagnosis of \u001b[48;2;173;216;230;38;2;0;0;0mreye syndrome\u001b[00m was accomplished in 90% of the cases. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mreye syndrome\u001b[00m in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain. The mortality for these \u001b[48;2;173;216;230;38;2;0;0;0mreye syndrome\u001b[00m cases in Australia was 45% as compared with a 32% case-fatality rate in the United States. In Australia, the pediatric usage of \u001b[48;2;173;216;230;38;2;0;0;0maspirin\u001b[00m has been extremely low for the past 25 years (less than 1% of total dosage units sold), with \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m) dominating the pediatric analgesic and antipyretic market. \u001b[48;2;173;216;230;38;2;0;0;0mreye syndrome\u001b[00m may be disappearing from Australia despite a total lack of association with salicylates or \u001b[48;2;173;216;230;38;2;0;0;0maspirin\u001b[00m ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "aspirin @CHEMICAL@ reye ; reye syndrome @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "aspirin @CHEMICAL@ reye syndrome @DISEASE@ @CID@ paracetamol ; acetaminophen @CHEMICAL@ reye syndrome @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "St. Anthony's fire, then and now: a case report and historical review. A rare case of morbid \u001b[48;2;173;216;230;38;2;0;0;0mvasospasm\u001b[00m, together with striking angiographic findings, is described secondary to the ingestion of \u001b[48;2;173;216;230;38;2;0;0;0mmethysergide\u001b[00m by a 48-year-old woman. A brief review of the literature on similar cases is presented. A discussion of the history of \u001b[48;2;144;238;144;38;2;0;0;0mergot\u001b[00m includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of \u001b[48;2;144;238;144;38;2;0;0;0mmigraine headache\u001b[00m. Despite the advent of calcium channel blockers and beta-adrenergic antagonists, \u001b[48;2;144;238;144;38;2;0;0;0mergot\u001b[00m preparations continue to play a major role in \u001b[48;2;144;238;144;38;2;0;0;0mmigraine\u001b[00m therapy, so that the danger of St. Anthony's fire persists.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methysergide @CHEMICAL@ vasospasm @DISEASE@ @CID@ ergot @CHEMICAL@ migraine headache ; migraine @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methysergide @CHEMICAL@ vasospasm @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m treatment of \u001b[48;2;144;238;144;38;2;0;0;0msexual side effects\u001b[00m induced by serotonin reuptake blockers. BACKGROUND: Preclinical and clinical studies suggest that \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m facilitates sexual behavior and may be helpful in the treatment of male impotence. A single case report suggests that \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m may be used to treat the \u001b[48;2;144;238;144;38;2;0;0;0msexual side effects\u001b[00m of \u001b[48;2;144;238;144;38;2;0;0;0mclomipramine\u001b[00m. This study evaluated \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m as a treatment for the \u001b[48;2;144;238;144;38;2;0;0;0msexual side effects\u001b[00m caused by serotonin reuptake blockers. METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, \u001b[48;2;173;216;230;38;2;0;0;0manxiety\u001b[00m, or affective disorders who suffered \u001b[48;2;144;238;144;38;2;0;0;0msexual side effects\u001b[00m after treatment with serotonin reuptake blockers were given \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m on a p.r.n. basis in an open clinical trial. Various doses of \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m were used to determine the ideal dose for each patient. RESULTS: Five of the six patients experienced improved sexual functioning after taking \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m. One patient who failed to comply with \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m treatment had no therapeutic effects. Side effects of \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m included \u001b[48;2;173;216;230;38;2;0;0;0mexcessive sweating\u001b[00m, increased \u001b[48;2;173;216;230;38;2;0;0;0manxiety\u001b[00m, and a \u001b[48;2;173;216;230;38;2;0;0;0mwound-up feeling\u001b[00m in some patients. CONCLUSION: The results of this study indicate that \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m may be an effective treatment for the \u001b[48;2;144;238;144;38;2;0;0;0msexual side effects\u001b[00m caused by serotonin reuptake blockers. Future controlled studies are needed to further investigate the effectiveness and safety of \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m for this indication.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "clomipramine @CHEMICAL@ sexual side effects @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "yohimbine @CHEMICAL@ excessive sweating @DISEASE@ @CID@ yohimbine @CHEMICAL@ anxiety @DISEASE@ @CID@ yohimbine @CHEMICAL@ wound-up feeling @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m immune reaction as a mechanism for \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m. OBJECTIVE: To assess lymphocyte reactivity to \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m and to serum containing putative ex vivo \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m antigens or metabolites in a case of \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mliver injury\u001b[00m. PATIENT: A 58-year-old woman with a clinical diagnosis of \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mliver injury\u001b[00m. METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m and also with sera collected from a volunteer before and after \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m intake. A similar protocol was performed with lymphocytes from a healthy subject. RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m solutions. A significant proliferative response to serum collected after \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake. No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions. CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m antigens, suggesting the involvement of an immunologic mechanism in \u001b[48;2;173;216;230;38;2;0;0;0mdilevalol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mliver injury\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dilevalol @CHEMICAL@ hypersensitivity @DISEASE@ @CID@ dilevalol @CHEMICAL@ hepatitis ; liver injury @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dilevalol @CHEMICAL@ hypersensitivity immune reaction ; hypersensitivity @DISEASE@ @CID@ dilevalol @CHEMICAL@ hepatitis @DISEASE@ @CID@ dilevalol @CHEMICAL@ liver injury @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Reversible \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial hypertrophy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m in a pediatric heart transplant recipient: case report. \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m is a potent immunosuppressant that is frequently used in organ transplantation. However, adverse effects include cardiac toxicity. Herein we describe transient \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial hypertrophy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m after heart transplantation. The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography. Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial hypertrophy\u001b[00m; neither cellular nor humoral rejection was detected. The blood \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m concentration was higher than usual at that time; thus, \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m dosage was reduced. \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial hypertrophy\u001b[00m completely resolved upon reducing the target concentration of \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m and did not recur, as confirmed at echocardiography and myocardial biopsy. Thus, we conclude that \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m induces reversible \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial hypertrophy\u001b[00m. In patients receiving \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tacrolimus @CHEMICAL@ myocardial hypertrophy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tacrolimus @CHEMICAL@ myocardial hypertrophy ; myocardial hypertrophy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease. A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed. Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m were selected. All patients had bilateral symptoms and their \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m equivalent dosing were analysed. Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN). Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery. There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months. \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m equivalent daily intake was significantly reduced in the STN group. Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups. Cognitive functions were unchanged in both groups. Complications were observed in two patients: one had a left homonymous \u001b[48;2;173;216;230;38;2;0;0;0mhemianopsia\u001b[00m after pallidotomy and another one developed left \u001b[48;2;173;216;230;38;2;0;0;0mhemiballistic movements\u001b[00m 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day. The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias @DISEASE@ @CID@ levodopa @CHEMICAL@ hemianopsia @DISEASE@ @CID@ levodopa @CHEMICAL@ hemiballistic movements @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Protective effects of antithrombin on \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrosis\u001b[00m in rats. We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrosis\u001b[00m, which is an experimental model of human nephrotic syndrome. Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m (50 mg/kg/i.v.). Treatment with antithrombin attenuated the \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhematological abnormalities\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mrenal dysfunction\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhyperlipidemia\u001b[00m were also suppressed. Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats. In addition, antithrombin treatment markedly suppressed \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced apoptosis of renal tubular epithelial cells. Furthermore, \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced increases in renal cytokine content were also decreased. These findings suggest that thrombin plays an important role in the pathogenesis of \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced nephrotic syndrome. Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "puromycin aminonucleoside @CHEMICAL@ nephrosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "puromycin aminonucleoside @CHEMICAL@ nephrosis ; neprotic syndrome @DISEASE@ @CID@ puromycin aminonucleoside @CHEMICAL@ hematological abnormalities @DISEASE@ @CID@ puromycin aminonucleoside @CHEMICAL@ renal dysfunction ; renal tubular expansion @DISEASE@ @CID@ puromycin aminonucleoside @CHEMICAL@ hyperlipidemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mreverse or inverted \u001b[48;2;144;238;144;38;2;0;0;0mleft ventricular \u001b[48;2;144;238;144;38;2;0;0;0mapical ballooning\u001b[00m syndrome\u001b[00m\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mreverse \u001b[48;2;144;238;144;38;2;0;0;0mtakotsubo cardiomyopathy\u001b[00m\u001b[00m) in a young woman in the setting of \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m use. Transient \u001b[48;2;144;238;144;38;2;0;0;0mleft ventricular \u001b[48;2;144;238;144;38;2;0;0;0mapical ballooning\u001b[00m syndrome\u001b[00m was first described in Japan as \"\u001b[48;2;144;238;144;38;2;0;0;0mtakotsubo cardiomyopathy\u001b[00m.\" This syndrome has been identified in many other countries. Many variations of this syndrome have been recently described in the literature. One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic \u001b[48;2;144;238;144;38;2;0;0;0mapical ballooning\u001b[00m). In this article, we report an interesting case of a young woman who presented with this rare type of reverse \u001b[48;2;144;238;144;38;2;0;0;0mapical ballooning\u001b[00m syndrome occurring after \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m use. This report is followed by review of the literature.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amphetamine @CHEMICAL@ left ventricular apical ballooning syndrome ; takotsubo cardiomyopathy ; apical ballooning ; apical ballooning syndrome @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amphetamine @CHEMICAL@ reverse or inverted left ventricular apical ballooning syndrome ; reverse takotsubo cardiomyopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Attenuated \u001b[48;2;173;216;230;38;2;0;0;0mdisruption of prepulse inhibition\u001b[00m by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats. The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease. We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats. Acute treatment with \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m caused \u001b[48;2;173;216;230;38;2;0;0;0mdisruption of prepulse inhibition\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mppi\u001b[00m) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress. \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m treatment significantly disrupted \u001b[48;2;173;216;230;38;2;0;0;0mppi\u001b[00m in both non-deprived groups, but was absent in both maternally deprived groups. The serotonin-1A receptor agonist, \u001b[48;2;173;216;230;38;2;0;0;0m8-oh-dpat\u001b[00m, induced a significant disruption of \u001b[48;2;173;216;230;38;2;0;0;0mppi\u001b[00m in all groups. \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mlocomotor hyperactivity\u001b[00m was similar in all groups. These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of \u001b[48;2;173;216;230;38;2;0;0;0mppi\u001b[00m. The altered effects of \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amphetamine @CHEMICAL@ locomotor hyperactivity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "apomorphine @CHEMICAL@ disruption of prepulse inhibition ; ppi @DISEASE@ @CID@ amphetamine @CHEMICAL@ disruption of prepulse inhibition ; ppi @DISEASE@ @CID@ 8-oh-dpat @CHEMICAL@ locomotor hyperactivity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Peripheral \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m induced \u001b[48;2;173;216;230;38;2;0;0;0mdegeneration of dopaminergic neurons\u001b[00m in rat substantia nigra. Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease. To demonstrate the relationship between peripheral iron overload and \u001b[48;2;173;216;230;38;2;0;0;0mdopaminergic neuron loss\u001b[00m in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the \u001b[48;2;173;216;230;38;2;0;0;0mdegeneration of dopaminergic neurons\u001b[00m and increased iron content in the SN of \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m overloaded animals. The findings showed that peripheral \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN. As a result, dopamine release and content, as well as its metabolites contents were decreased in caudate putamen. Even more dramatic changes were found in chronic overload group. These results suggest that peripheral \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m can increase the iron level in the SN, where excessive iron causes the \u001b[48;2;173;216;230;38;2;0;0;0mdegeneration of dopaminergic neurons\u001b[00m. The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "iron dextran @CHEMICAL@ degeneration of dopaminergic neurons @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "iron dextran @CHEMICAL@ degeneration of dopaminergic neurons ; dopaminergic neuron loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mleukocytoclastic vasculitis\u001b[00m. Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence. \u001b[48;2;173;216;230;38;2;0;0;0mleukocytoclastic vasculitis\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mlv\u001b[00m) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered. We report 4 patients with late-onset \u001b[48;2;173;216;230;38;2;0;0;0mlv\u001b[00m probably due to \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m. All 4 patients presented with skin eruptions that developed after receiving \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m for several years. The results of skin lesion biopsies were available in 3 patients, confirming \u001b[48;2;173;216;230;38;2;0;0;0mlv\u001b[00m Cutaneous lesions resolved in all patients after \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m was discontinued. In 2 of the 4 patients, rechallenge with \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m led to recurrence of the lesions. \u001b[48;2;173;216;230;38;2;0;0;0mlv\u001b[00m may be a late-onset adverse reaction associated with \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "warfarin @CHEMICAL@ lv cutaneous lesions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "warfarin @CHEMICAL@ leukocytoclastic vasculitis ; lv @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Screening for stimulant use in adult emergency department \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m patients. OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m in adult emergency department \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m patients. METHODS: This prospective study evaluated consecutive eligible \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m patients who had a plasma sample collected as part of their clinical evaluation. Plasma was tested for \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m and the \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m metabolite \u001b[48;2;173;216;230;38;2;0;0;0mbenzoylecgonine\u001b[00m using enzyme-mediated immunoassay methodology. Plasma samples with \u001b[48;2;173;216;230;38;2;0;0;0mbenzoylecgonine\u001b[00m greater than 150 ng/mL or an \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m greater than 500 ng/mL were defined as positive. Patient demographics, history of underlying drug or alcohol-related \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m disorder, estimated time from \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m to sample collection, history or suspicion of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers. RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for \u001b[48;2;173;216;230;38;2;0;0;0mbenzoylecgonine\u001b[00m and no samples (0%, 95% CI 0-1.2%) were positive for \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m. Positive test results were more common in patient visits where there was a history or suspicion of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m abuse (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and amphetamines in adult \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m patients had a low yield. As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "benzoylecgonine @CHEMICAL@ seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ seizure ; seizure disorder @DISEASE@ @CID@ amphetamine @CHEMICAL@ seizure ; seizure disorder @DISEASE@ @CID@ benzoylecgonine @CHEMICAL@ seizure ; seizure disorder @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m responses in \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m-maintained opioid abusers. Providing \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m management for known opioid abusers is a challenging clinical task, in part because little is known about their \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m experience and analgesic requirements. This study was designed to describe \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m tolerance and analgesic response in a sample of opioid addicts stabilized in \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60). By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m was examined, both before and after oral administration of therapeutic doses of common opioid (\u001b[48;2;173;216;230;38;2;0;0;0mhydromorphone\u001b[00m 2 mg) and nonsteroidal anti-inflammatory (\u001b[48;2;173;216;230;38;2;0;0;0mketorolac\u001b[00m 10 mg) analgesic agents. Results showed that MM individuals were significantly less tolerant of CP \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m than control subjects, replicating previous work. Analgesic effects were significant neither for medication nor group. These data indicate that MM opioid abusers represent a \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m-intolerant subset of clinical patients. Their complaints of \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m should be evaluated seriously and managed aggressively.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methadone @CHEMICAL@ pain-intolerant @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methadone @CHEMICAL@ pain @DISEASE@ @CID@ hydromorphone @CHEMICAL@ pain @DISEASE@ @CID@ ketorolac @CHEMICAL@ pain @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat \u001b[48;2;173;216;230;38;2;0;0;0mpituitary tumors\u001b[00m may mediate estrogen-initiated tumor angiogenesis. Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats. The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown. To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis. The expression of VEGF receptor (VEGFR-2/Flk-1/KDR) was also examined by immunohistochemistry. The results demonstrated that \u001b[48;2;173;216;230;38;2;0;0;0m17beta-estradiol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0me2\u001b[00m) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure. The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the \u001b[48;2;173;216;230;38;2;0;0;0me2\u001b[00m exposed pituitary of ovariectomized (OVEX) rats. VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells. After 15 days of \u001b[48;2;173;216;230;38;2;0;0;0me2\u001b[00m exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels. The function of non-endothelial-derived VEGF is not clear. Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of \u001b[48;2;173;216;230;38;2;0;0;0me2\u001b[00m exposure. These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "17beta-estradiol ; e2 @CHEMICAL@ pituitary tumors @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "17beta-estradiol ; e2 @CHEMICAL@ pituitary tumors ; pituitary tumor @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpravastatin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m. Report of a case. A case of acute inflammatory \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m associated with the use of \u001b[48;2;173;216;230;38;2;0;0;0mpravastatin\u001b[00m, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported. The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension. He assumed \u001b[48;2;173;216;230;38;2;0;0;0mpravastatin\u001b[00m (20 mg/day) because of \u001b[48;2;173;216;230;38;2;0;0;0mhypercholesterolemia\u001b[00m. He was admitted with acute \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy of the lower limbs\u001b[00m which resolved in a few days after \u001b[48;2;173;216;230;38;2;0;0;0mpravastatin\u001b[00m discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While lovastatin and simvastatin have been associated with toxic \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mpravastatin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m could represent a distinct, inflammatory entity.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pravastatin @CHEMICAL@ inflammatory myopathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pravastatin @CHEMICAL@ myopathy @DISEASE@ @CID@ pravastatin @CHEMICAL@ hypercholesterolemia @DISEASE@ @CID@ pravastatin @CHEMICAL@ myopathy of the lower limbs @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dose-effect and structure-function relationships in \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m) produced by the anticancer drug \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdxr\u001b[00m) (\u001b[48;2;144;238;144;38;2;0;0;0madriamycin\u001b[00m) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of \u001b[48;2;144;238;144;38;2;0;0;0mmyocardial disease\u001b[00m. We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving \u001b[48;2;173;216;230;38;2;0;0;0mdxr\u001b[00m. Morphologic damage was variable but was proportional to the total cumulative \u001b[48;2;173;216;230;38;2;0;0;0mdxr\u001b[00m dose between 100 and 600 mg/m2. Performance abnormalities correlated weakly with dose, exhibited a curvilinear relationship, and had a \"threshold\" for expression. Catheterization abnormalities correlated well with morphologic damage (r = 0.57 to 0.78) in a subgroup of patients in whom exercise hemodynamics were measured, and this relationship also exhibited a curvilinear, threshold configuration. In \u001b[48;2;173;216;230;38;2;0;0;0mdxr\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mcm\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mmyocardial damage\u001b[00m is proportional to the degree of cytotoxic insult (\u001b[48;2;173;216;230;38;2;0;0;0mdxr\u001b[00m dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "doxorubicin ; dxr ; adriamycin @CHEMICAL@ cardiomyopathy ; cm ; myocardial disease ; myocardial damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin ; dxr @CHEMICAL@ cardiomyopathy ; cm @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Fatal \u001b[48;2;173;216;230;38;2;0;0;0maplastic anemia\u001b[00m following topical administration of ophthalmic \u001b[48;2;173;216;230;38;2;0;0;0mchloramphenicol\u001b[00m. A 73-year-old woman died of \u001b[48;2;173;216;230;38;2;0;0;0maplastic anemia\u001b[00m less than two months after undergoing cataract extraction and beginning topical therapy with \u001b[48;2;173;216;230;38;2;0;0;0mchloramphenicol\u001b[00m. The first signs of \u001b[48;2;173;216;230;38;2;0;0;0mpancytopenia\u001b[00m began within one month of the surgery. The pattern of the \u001b[48;2;173;216;230;38;2;0;0;0maplastic anemia\u001b[00m was associated with an idiosyncratic response to \u001b[48;2;173;216;230;38;2;0;0;0mchloramphenicol\u001b[00m. This was the second report of fatal \u001b[48;2;173;216;230;38;2;0;0;0maplastic anemia\u001b[00m after topical treatment with \u001b[48;2;173;216;230;38;2;0;0;0mchloramphenicol\u001b[00m for ocular conditions, although two cases of reversible \u001b[48;2;173;216;230;38;2;0;0;0mbone marrow hypoplasia\u001b[00m have also been reported. Any other suspected cases of ocular toxicity associated with topically applied \u001b[48;2;173;216;230;38;2;0;0;0mchloramphenicol\u001b[00m should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "chloramphenicol @CHEMICAL@ aplastic anemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "chloramphenicol @CHEMICAL@ aplastic anemia @DISEASE@ @CID@ chloramphenicol @CHEMICAL@ pancytopenia @DISEASE@ @CID@ chloramphenicol @CHEMICAL@ bone marrow hypoplasia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl hydrochloride\u001b[00m. A chronic schizophrenic patient was treated with an anticholinergic drug, \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl hydrochloride\u001b[00m. The patient developed, paradoxically, sinus \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m. The reaction was specific to \u001b[48;2;144;238;144;38;2;0;0;0mtrihexyphenidyl\u001b[00m and not to other anticholinergic drugs. This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "trihexyphenidyl hydrochloride ; trihexyphenidyl @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "trihexyphenidyl hydrochloride @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Experimental \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m: risk of concomitant chemotherapy. The role of \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m) alone or in combination with various chemotherapeutics in the development of \u001b[48;2;173;216;230;38;2;0;0;0mrenal toxicity\u001b[00m was evaluated in rats. Administration of 20 mg/kg/day \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m for 4 weeks caused renal functional and structural changes similar to those reported in man. The combined administration of \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m and various chemotherapeutic drugs with a \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxic\u001b[00m potential, such as \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m (at therapeutic doses), amphothericin B and \u001b[48;2;173;216;230;38;2;0;0;0mketoconazole\u001b[00m, which are frequently used in immunosuppressed patients, did not aggravate the \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m induced toxicity in the rat model. \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m at toxic doses, however, increased \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m. Thus, the \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m has a different pathogenetic mechanism.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclosporine ; csa @CHEMICAL@ nephrotoxicity ; renal toxicity ; nephrotoxic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclosporine ; csa @CHEMICAL@ nephrotoxicity ; renal toxicity ; nephrotoxic @DISEASE@ @CID@ gentamicin @CHEMICAL@ nephrotoxicity ; renal toxicity ; nephrotoxic @DISEASE@ @CID@ ketoconazole @CHEMICAL@ nephrotoxicity ; renal toxicity ; nephrotoxic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Receptor mechanisms of \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mlocomotor hyperactivity\u001b[00m in chronic \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m-treated rats. Rats were pretreated with saline or \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m (1.5 mg/kg per day) by subcutaneously implanting each animal with an Alzet osmotic mini-pump which continuously released saline or \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m for 1, 5 and 14 days. At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]\u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m and [3H]spiperone binding sites in the striatum. We observed no changes in \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m-induced locomotor response, striatal L-[3H]\u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m and [3H]spiperone binding in the animals pretreated with \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m for 1 day. In rats which were pretreated with \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m for 5 days, there was a significant increase in the \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m-stimulated locomotor response which was associated with an increase in the number of L-[3H]\u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m binding sites and also with an elevated dopamine (DA) level in the striatum. The number of striatal [3H]spiperone binding sites was not affected. In animals pretreated with \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m for 14 days, the \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m-induced locomotor response remained to be potentiated. However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]\u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m binding sites and the striatal DA level were normal. These results suggest that chronic \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m-treated rats develop \u001b[48;2;173;216;230;38;2;0;0;0mlocomotor hyperactivity\u001b[00m in response to \u001b[48;2;173;216;230;38;2;0;0;0mnicotine\u001b[00m initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nicotine @CHEMICAL@ locomotor hyperactivity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "nicotine @CHEMICAL@ locomotor hyperactivity ; locomotor hyperactivity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m in humans: pressor responsiveness and sympathetic function. Oral \u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m increases blood pressure and enhances pressor responsiveness in normal human subjects. We studied the effects of 1 week of oral \u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers. Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01). Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05). Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025). The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after \u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after \u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m (SED +/- 6.0, p less than 0.05). A shift to the left in the dose-response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment. Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased. The \u001b[48;2;144;238;144;38;2;0;0;0mrise in resting blood pressure\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mhydrocortisone\u001b[00m is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hydrocortisone @CHEMICAL@ hypertension ; rise in resting blood pressure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "hydrocortisone @CHEMICAL@ hypertension ; hypertension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m on the isolated perfused rat kidney. Although \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m has been associated with the development of \u001b[48;2;173;216;230;38;2;0;0;0macute renal failure\u001b[00m in greater than 100 subjects, the mechanism of damage remains unclear. The direct nephrotoxic effects of a single dose of 15 mg of \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid. There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m compared with the drug-free control groups. In contrast, a significant decline in glomerular filtration rate was found after the introduction of \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m to the kidney perfused with uric acid; no changes were found with \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m in the absence of uric acid. A significant decrease in the baseline excretion rate of uric acid was found in rats given \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m, compared with drug-free controls. However, the fractional excretion of uric acid was unchanged between the groups over the experimental period. In summary, \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m causes \u001b[48;2;144;238;144;38;2;0;0;0macute declines in renal function\u001b[00m, most likely by directly altering the intrarenal distribution of uric acid.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "suprofen @CHEMICAL@ acute renal failure ; acute declines in renal function @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "suprofen @CHEMICAL@ acute renal failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced brainstem \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m and behavior. A variety of \u001b[48;2;173;216;230;38;2;0;0;0mabnormal sensory/motor behaviors\u001b[00m associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m. The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations. \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m (40 mg/kg) was injected subcutaneously for an acute experiment and subsequent 20 mg/kg doses twice daily for 3 days in a chronic study. \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects. The abnormal behaviors were yawning, retrocollis, \u001b[48;2;173;216;230;38;2;0;0;0mhyperactivity\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m, \"beating drum\" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching. Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states. \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation. These findings suggest that the brainstem generates and propagates \u001b[48;2;173;216;230;38;2;0;0;0mpathological discharges\u001b[00m that can be elicited by mechanical and DC electrical perturbation. \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates. Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ seizures ; abnormal sensory/motor behaviors ; abnormal discharges ; pathological discharges @DISEASE@ @CID@ cocaine @CHEMICAL@ hyperactivity @DISEASE@ @CID@ cocaine @CHEMICAL@ hypersensitivity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m on myocardial oxygen supply and demand in patients with chronic coronary artery disease. A hemodynamic, volumetric, and metabolic study in patients without heart failure. The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man. We assessed the effects of \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical \u001b[48;2;173;216;230;38;2;0;0;0mcongestive heart failure\u001b[00m. Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m administration was omitted. Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m, even though they were initially elevated in only two patients. Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m infusion was completed. The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility. No significant change in these parameters occurred in the control patients. No significant change in myocardial oxygen consumption occurred after \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m administration but this may be related to a greater decrease in mean arterial pressure in the \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m patients than in the control patients. We conclude that in patients with chronic coronary artery disease who are not in clinical \u001b[48;2;173;216;230;38;2;0;0;0mcongestive heart failure\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mleft ventricular end-diastolic volume falls\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m administration even when it is initially normal. Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption. Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ouabain @CHEMICAL@ left ventricular end-diastolic volume falls @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ouabain @CHEMICAL@ congestive heart failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mprolongation of the qt interval\u001b[00m related to \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m interaction. \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders. \u001b[48;2;144;238;144;38;2;0;0;0mprolongation of qt interval\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtorsades de pointes\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0msudden cardiac death\u001b[00m have been reported after concomitant administration with \u001b[48;2;144;238;144;38;2;0;0;0merythromycin\u001b[00m or \u001b[48;2;144;238;144;38;2;0;0;0mazole\u001b[00m antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m for gastroesophageal reflux disorder and \u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m, an agent that has inhibitory effect on CYP3A4, for hypertension. The patient was in near syncope and had \u001b[48;2;144;238;144;38;2;0;0;0mqt-interval prolongation\u001b[00m. After discontinuing \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m, the QT interval returned to normal and symptoms did not recur. We suggest that caution be taken when \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m is prescribed with any potent inhibitor of CYP3A4, including \u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cisapride @CHEMICAL@ prolongation of the qt interval ; prolongation of qt interval ; qt-interval prolongation @DISEASE@ @CID@ cisapride @CHEMICAL@ torsades de pointes @DISEASE@ @CID@ cisapride @CHEMICAL@ sudden cardiac death @DISEASE@ @CID@ diltiazem @CHEMICAL@ prolongation of the qt interval ; prolongation of qt interval ; qt-interval prolongation @DISEASE@ @CID@ erythromycin @CHEMICAL@ prolongation of the qt interval ; prolongation of qt interval ; qt-interval prolongation @DISEASE@ @CID@ erythromycin @CHEMICAL@ torsades de pointes @DISEASE@ @CID@ erythromycin @CHEMICAL@ sudden cardiac death @DISEASE@ @CID@ azole @CHEMICAL@ prolongation of the qt interval ; prolongation of qt interval ; qt-interval prolongation @DISEASE@ @CID@ azole @CHEMICAL@ torsades de pointes @DISEASE@ @CID@ azole @CHEMICAL@ sudden cardiac death @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cisapride @CHEMICAL@ prolongation of the qt interval ; qt interval prolongation @DISEASE@ @CID@ cisapride @CHEMICAL@ torsades de pointes @DISEASE@ @CID@ cisapride @CHEMICAL@ sudden cardiac death @DISEASE@ @CID@ diltiazem @CHEMICAL@ prolongation of the qt interval ; qt interval prolongation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m combined with \u001b[48;2;144;238;144;38;2;0;0;0mcarboplatin\u001b[00m in the first-line treatment of advanced ovarian cancer. In a phase I study to determine the maximum tolerated dose of \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtaxol\u001b[00m; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with \u001b[48;2;144;238;144;38;2;0;0;0mcarboplatin\u001b[00m administered every 21 days to women with advanced ovarian cancer, \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2. The fixed dose of \u001b[48;2;144;238;144;38;2;0;0;0mcarboplatin\u001b[00m at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula. In levels 5 and 6 the \u001b[48;2;144;238;144;38;2;0;0;0mcarboplatin\u001b[00m dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was \u001b[48;2;173;216;230;38;2;0;0;0mmyelosuppression\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mleukopenia\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mgranulocytopenia\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m). \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m was largely moderate. So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients. No patient had disease progression. We conclude that the combination of \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of \u001b[48;2;144;238;144;38;2;0;0;0mcarboplatin\u001b[00m at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting. The recommended dose for phase III studies is \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m 185 mg/m2 and \u001b[48;2;144;238;144;38;2;0;0;0mcarboplatin\u001b[00m AUC 6.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "paclitaxel ; taxol @CHEMICAL@ leukopenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ granulocytopenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ neurotoxicity @DISEASE@ @CID@ carboplatin @CHEMICAL@ leukopenia @DISEASE@ @CID@ carboplatin @CHEMICAL@ granulocytopenia @DISEASE@ @CID@ carboplatin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ carboplatin @CHEMICAL@ neurotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "paclitaxel ; taxol @CHEMICAL@ myelosuppression ; leukopenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ granulocytopenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ neurotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Treatment of \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m-related adverse effects by conversion to cyclosporine in liver transplant recipients. When \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary. We characterized \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m (20), (insulin-dependent) diabetes mellitus (\u001b[48;2;144;238;144;38;2;0;0;0middm\u001b[00m) (5), \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxicity\u001b[00m (3), \u001b[48;2;144;238;144;38;2;0;0;0mgastrointestinal (gi) toxicity\u001b[00m (6), and \u001b[48;2;144;238;144;38;2;0;0;0mcardiomyopathy\u001b[00m (1), and for late conversion were \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m (15), \u001b[48;2;144;238;144;38;2;0;0;0middm\u001b[00m (12), \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxicity\u001b[00m (3), \u001b[48;2;144;238;144;38;2;0;0;0mgi toxicity\u001b[00m (5), \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m (6), \u001b[48;2;144;238;144;38;2;0;0;0mpost-transplant lmphoproliferate disease\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mptld\u001b[00m) (2), \u001b[48;2;144;238;144;38;2;0;0;0mcardiomyopathy\u001b[00m (1), \u001b[48;2;144;238;144;38;2;0;0;0mhemolytic anemia\u001b[00m (1), and \u001b[48;2;144;238;144;38;2;0;0;0mpruritus\u001b[00m (1). All early-conversion patients showed improvement/resolution of symptoms. Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted. The overall rejection rate was 30%. Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion. When \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tacrolimus @CHEMICAL@ neurotoxicity @DISEASE@ @CID@ tacrolimus @CHEMICAL@ (insulin-dependent) diabetes mellitus ; iddm @DISEASE@ @CID@ tacrolimus @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ tacrolimus @CHEMICAL@ gastrointestinal (gi) toxicity ; gi toxicity @DISEASE@ @CID@ tacrolimus @CHEMICAL@ cardiomyopathy @DISEASE@ @CID@ tacrolimus @CHEMICAL@ hepatotoxicity @DISEASE@ @CID@ tacrolimus @CHEMICAL@ post-transplant lmphoproliferate disease ; ptld @DISEASE@ @CID@ tacrolimus @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@ tacrolimus @CHEMICAL@ pruritus @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tacrolimus @CHEMICAL@ neurotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Relative efficacy and toxicity of \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m in oncology patients. We prospectively compared the efficacy and safety of \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m sulfate or \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m sulfate in conjunction with \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m sodium in 118 immunocompromised patients with presumed severe infections. The two treatment regimens were equally efficacious. \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m occurred in a similar proportion in patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m (17% vs 11%). \u001b[48;2;173;216;230;38;2;0;0;0mototoxicity\u001b[00m occurred in four (9.5%) of 42 \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m and in 12 (22%) of 54 \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m-treated patients. Of those evaluated with posttherapy audiograms, three of four \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m-treated patients had auditory thresholds return to baseline compared with one of nine \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m-treated patients. The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m- vs \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mpiperacillin\u001b[00m-treated patients (18 of 78 vs 67 of 115). We conclude that aminoglycoside-associated \u001b[48;2;173;216;230;38;2;0;0;0mototoxicity\u001b[00m was less severe and more often reversible with \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m than with \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "netilmicin ; netilmicin sulfate @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ netilmicin ; netilmicin sulfate @CHEMICAL@ ototoxicity @DISEASE@ @CID@ tobramycin ; tobramycin sulfate @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ tobramycin ; tobramycin sulfate @CHEMICAL@ ototoxicity @DISEASE@ @CID@ piperacillin sodium ; piperacillin @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ piperacillin sodium ; piperacillin @CHEMICAL@ ototoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "netilmicin ; netilmicin sulfate @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ netilmicin ; netilmicin sulfate @CHEMICAL@ ototoxicity @DISEASE@ @CID@ tobramycin ; tobramycin sulfate @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ tobramycin ; tobramycin sulfate @CHEMICAL@ ototoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of prostaglandin synthetase inhibitors on experimentally induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in rats. To investigate the relationship of prostaglandins (PGs) to \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m induction, the effects of six PG synthetase inhibitors on \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mflurothyl\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mpicrotoxin\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mpentetrazol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mptz\u001b[00m), electroshock or \u001b[48;2;173;216;230;38;2;0;0;0mbicuculline\u001b[00m were evaluated. Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the \u001b[48;2;173;216;230;38;2;0;0;0mflurothyl\u001b[00m and/or \u001b[48;2;173;216;230;38;2;0;0;0mptz\u001b[00m models; the electroshock, \u001b[48;2;173;216;230;38;2;0;0;0mpicrotoxin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mbicuculline\u001b[00m models were not significantly affected by any of the pretreatment agents. These results suggest that PGs are involved in the mechanism(s) underlying \u001b[48;2;144;238;144;38;2;0;0;0mfluorthyl\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mptz\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m, but not \u001b[48;2;173;216;230;38;2;0;0;0mpicrotoxin\u001b[00m-, electroshock-, or \u001b[48;2;173;216;230;38;2;0;0;0mbicuculline\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "flurothyl ; fluorthyl @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@ picrotoxin @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@ pentetrazol ; ptz @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@ bicuculline @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "flurothyl @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@ picrotoxin @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@ pentetrazol ; ptz @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@ bicuculline @CHEMICAL@ convulsions ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Angiotensin-converting enzyme (ACE) inhibitor-associated \u001b[48;2;144;238;144;38;2;0;0;0mangioedema\u001b[00m of the stomach and small intestine: a case report. This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m/\u001b[48;2;144;238;144;38;2;0;0;0mbenazapril\u001b[00m 10/5 mg. The very next day, she presented at the emergency room (ER) with \u001b[48;2;173;216;230;38;2;0;0;0mabdominal pain\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mnausea\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mvomiting\u001b[00m. Physical exam, complete metabolic panel, and hemogram were in the normal range. She was discharged from the ER after a few hours of treatment with fluid and analgesics. However, she returned to the ER the next day with the same complaints. This time the physical exam was significant for a distended abdomen with dullness to percussion. CT scan of the abdomen revealed markedly thickened antrum of the stomach, duodenum and jejunum, along with fluid in the abdominal and pelvic cavity. Angiotensin-converting enzyme inhibitor (ACEI)-induced \u001b[48;2;144;238;144;38;2;0;0;0mangioedema\u001b[00m was suspected, and anti-hypertensive medications were discontinued. Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of \u001b[48;2;173;216;230;38;2;0;0;0mascites\u001b[00m. The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) \u001b[48;2;144;238;144;38;2;0;0;0mintestinal\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mangioedema\u001b[00m constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amlodipine @CHEMICAL@ angioedema @DISEASE@ @CID@ amlodipine @CHEMICAL@ intestinal @DISEASE@ @CID@ benazapril @CHEMICAL@ angioedema @DISEASE@ @CID@ benazapril @CHEMICAL@ intestinal @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amlodipine @CHEMICAL@ abdominal pain @DISEASE@ @CID@ amlodipine @CHEMICAL@ nausea @DISEASE@ @CID@ amlodipine @CHEMICAL@ vomiting @DISEASE@ @CID@ amlodipine @CHEMICAL@ ascites @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m I: time course of lipid peroxidation biomarkers, \u001b[48;2;144;238;144;38;2;0;0;0mliver toxicity\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m metabolite levels in rats. A single dose of \u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of \u001b[48;2;144;238;144;38;2;0;0;0m15-f(2t)-isoprostane\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0m15-f(2t)-isop\u001b[00m). To determine whether there was a temporal relationship between \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m-associated oxidative stress and \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m, adult male Sprague-Dawley rats were treated ip with \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days. Oxidative stress was assessed by determining plasma and liver levels of \u001b[48;2;144;238;144;38;2;0;0;0m15-f(2t)-isop\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mlipid hydroperoxides\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mlpo\u001b[00m), and \u001b[48;2;144;238;144;38;2;0;0;0mthiobarbituric acid reactive substances\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mtbars\u001b[00m). Plasma and liver \u001b[48;2;144;238;144;38;2;0;0;0m15-f(2t)-isop\u001b[00m were elevated and reached a plateau after day 2 of \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m treatment compared to control. Liver \u001b[48;2;144;238;144;38;2;0;0;0mlpo\u001b[00m levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05). Liver and plasma \u001b[48;2;144;238;144;38;2;0;0;0mtbars\u001b[00m were not increased until 14 days (2-fold vs. control, p < 0.05). \u001b[48;2;144;238;144;38;2;0;0;0mliver toxicity\u001b[00m was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m as shown by the increasing incidence of \u001b[48;2;173;216;230;38;2;0;0;0minflammation of the liver capsule\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mnecrosis\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0msteatosis\u001b[00m throughout the study. The liver levels of beta-oxidation metabolites of \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m were decreased by day 14, while the levels of 4-ene-\u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m and (E)-2,4-diene-\u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m were not elevated throughout the study. Overall, these findings indicate that \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m treatment results in oxidative stress, as measured by levels of \u001b[48;2;144;238;144;38;2;0;0;0m15-f(2t)-isop\u001b[00m, which precedes the onset of \u001b[48;2;173;216;230;38;2;0;0;0mnecrosis\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0msteatosis\u001b[00m, and elevated levels of serum alpha-GST.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "valproic acid ; vpa @CHEMICAL@ liver toxicity ; hepatotoxicity @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ necrosis @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ steatosis @DISEASE@ @CID@ 15-f(2t)-isoprostane ; 15-f(2t)-isop @CHEMICAL@ liver toxicity ; hepatotoxicity @DISEASE@ @CID@ lipid hydroperoxides ; lpo @CHEMICAL@ liver toxicity ; hepatotoxicity @DISEASE@ @CID@ thiobarbituric acid reactive substances ; tbars @CHEMICAL@ liver toxicity ; hepatotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "valproic acid ; vpa @CHEMICAL@ inflammation of the liver capsule @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ necrosis @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ steatosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Pheochromocytoma unmasked by \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtiapride\u001b[00m. OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtiapride\u001b[00m. CASE SUMMARY: A 42-year-old white man developed acute \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m with severe \u001b[48;2;173;216;230;38;2;0;0;0mheadache\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mvomiting\u001b[00m 2 hours after the first doses of \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m 100 mg and \u001b[48;2;173;216;230;38;2;0;0;0mtiapride\u001b[00m 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment. Abdominal ultrasound showed an \u001b[48;2;173;216;230;38;2;0;0;0madrenal mass\u001b[00m, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma. DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown. In our case, use of the Naranjo probability scale indicated a possible relationship between the \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m crisis and \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtiapride\u001b[00m therapy. CONCLUSIONS: As of March 24, 2005, this is the first reported case of \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mtiapride\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m crisis in a patient with pheochromocytoma. Physicians and other healthcare professionals should be aware of this potential adverse effect of \u001b[48;2;173;216;230;38;2;0;0;0mtiapride\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amisulpride @CHEMICAL@ hypertension ; hypertensive @DISEASE@ @CID@ amisulpride @CHEMICAL@ headache @DISEASE@ @CID@ amisulpride @CHEMICAL@ vomiting @DISEASE@ @CID@ tiapride @CHEMICAL@ hypertension ; hypertensive @DISEASE@ @CID@ tiapride @CHEMICAL@ headache @DISEASE@ @CID@ tiapride @CHEMICAL@ vomiting @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amisulpride @CHEMICAL@ hypertension ; hypertensive @DISEASE@ @CID@ amisulpride @CHEMICAL@ headache @DISEASE@ @CID@ amisulpride @CHEMICAL@ vomiting @DISEASE@ @CID@ tiapride @CHEMICAL@ hypertension ; hypertensive @DISEASE@ @CID@ tiapride @CHEMICAL@ adrenal mass @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Quantitative drug levels in \u001b[48;2;173;216;230;38;2;0;0;0mstimulant\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m: relationship to symptom severity, catecholamines and \u001b[48;2;173;216;230;38;2;0;0;0mhyperkinesia\u001b[00m. To examine the relationship between quantitative \u001b[48;2;173;216;230;38;2;0;0;0mstimulant\u001b[00m drug levels, catecholamines, and \u001b[48;2;173;216;230;38;2;0;0;0mpsychotic symptoms\u001b[00m, nineteen patients in a psychiatric emergency service with a diagnosis of \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m- or \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m were interviewed, and plasma and urine were collected for quantitative assays of \u001b[48;2;173;216;230;38;2;0;0;0mstimulant\u001b[00m drug and catecholamine metabolite levels. \u001b[48;2;144;238;144;38;2;0;0;0mmethamphetamine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m levels were related to several psychopathology scores and the global \u001b[48;2;173;216;230;38;2;0;0;0mhyperkinesia\u001b[00m rating. HVA levels were related to global \u001b[48;2;173;216;230;38;2;0;0;0mhyperkinesia\u001b[00m but not to psychopathology ratings. Although many other factors such as sensitization may play a role, intensity of \u001b[48;2;173;216;230;38;2;0;0;0mstimulant\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychotic symptoms\u001b[00m and stereotypies appears to be at least in part dose-related.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amphetamine @CHEMICAL@ psychosis ; psychotic symptoms @DISEASE@ @CID@ amphetamine @CHEMICAL@ hyperkinesia @DISEASE@ @CID@ cocaine @CHEMICAL@ psychosis ; psychotic symptoms @DISEASE@ @CID@ cocaine @CHEMICAL@ hyperkinesia @DISEASE@ @CID@ methamphetamine @CHEMICAL@ psychosis ; psychotic symptoms @DISEASE@ @CID@ methamphetamine @CHEMICAL@ hyperkinesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "stimulant ; stimulant drugs @CHEMICAL@ hyperkinesia @DISEASE@ @CID@ amphetamine @CHEMICAL@ psychosis ; psychotic symptoms @DISEASE@ @CID@ cocaine @CHEMICAL@ psychosis ; psychotic symptoms @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Delayed \u001b[48;2;173;216;230;38;2;0;0;0masystolic \u001b[48;2;144;238;144;38;2;0;0;0mcardiac arrest\u001b[00m\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m; resuscitation with high dose intravenous calcium. A 51 year old man took a mixed \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m including 1.8-3.6 g of \u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m, paracetamol, aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and was treated with activated charcoal and intravenous fluids. Eighteen hours after the \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m he had two generalised \u001b[48;2;173;216;230;38;2;0;0;0mtonic-clonic seizures\u001b[00m. The patient remained unresponsive with junctional \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m, unrecordable blood pressure, and then became \u001b[48;2;144;238;144;38;2;0;0;0masystolic\u001b[00m. He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine). He required inotropic support and temporary pacing over the next 48 hours. This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe \u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m, particularly with the onset of \u001b[48;2;144;238;144;38;2;0;0;0masystole\u001b[00m. It should be considered early in cases of \u001b[48;2;144;238;144;38;2;0;0;0mcardiac arrest\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mdiltiazem\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m. The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "diltiazem @CHEMICAL@ asystolic ; cardiac arrest ; asystole @DISEASE@ @CID@ diltiazem @CHEMICAL@ overdose @DISEASE@ @CID@ diltiazem @CHEMICAL@ hypotension @DISEASE@ @CID@ diltiazem @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "diltiazem @CHEMICAL@ asystolic cardiac arrest @DISEASE@ @CID@ diltiazem @CHEMICAL@ hypotension @DISEASE@ @CID@ diltiazem @CHEMICAL@ tonic-clonic seizures @DISEASE@ @CID@ diltiazem @CHEMICAL@ bradycardia @DISEASE@ @CID@ diltiazem @CHEMICAL@ asystolic cardiac arrest @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Adverse interaction between \u001b[48;2;144;238;144;38;2;0;0;0mbeta-adrenergic blocking drugs\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mverapamil\u001b[00m--report of three cases. Three patients with ischaemic heart disease developed profound \u001b[48;2;173;216;230;38;2;0;0;0mcardiac failure\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m during combined therapy with \u001b[48;2;173;216;230;38;2;0;0;0mverapamil\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mbeta-adrenergic blocking drugs\u001b[00m. This clinical picture resolved completely with cessation of the combined therapy. Baseline left ventricular function, assessed by cardiac catheterisation or nuclear angiography, was normal in two patients and only mildly reduced in the other. Simultaneously administration of \u001b[48;2;144;238;144;38;2;0;0;0mbeta-adrenergic blocking drugs\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mverapamil\u001b[00m may result in profound adverse interactions and should only be administered with great caution.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "beta-adrenergic blocking drugs @CHEMICAL@ cardiac failure @DISEASE@ @CID@ beta-adrenergic blocking drugs @CHEMICAL@ hypotension @DISEASE@ @CID@ beta-adrenergic blocking drugs @CHEMICAL@ bradycardia @DISEASE@ @CID@ verapamil @CHEMICAL@ cardiac failure @DISEASE@ @CID@ verapamil @CHEMICAL@ hypotension @DISEASE@ @CID@ verapamil @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "verapamil @CHEMICAL@ cardiac failure @DISEASE@ @CID@ verapamil @CHEMICAL@ hypotension @DISEASE@ @CID@ verapamil @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Adverse reactions to \u001b[48;2;173;216;230;38;2;0;0;0mbendrofluazide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: \u001b[48;2;173;216;230;38;2;0;0;0mbendrofluazide\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m, or a placebo for either of these drugs. The trial is single-blind. 23 582 patient-years of observation have been completed so far, 10 684 on active drugs and 12 898 on placebos. The results show an association between \u001b[48;2;173;216;230;38;2;0;0;0mbendrofluazide\u001b[00m treatment and \u001b[48;2;173;216;230;38;2;0;0;0mimpotence\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mimpotence\u001b[00m also occurred more frequently in patients taking \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m than in those taking placebos. Other adverse reactions significantly linked with active drugs include \u001b[48;2;173;216;230;38;2;0;0;0mimpaired glucose tolerance\u001b[00m in men and women and \u001b[48;2;173;216;230;38;2;0;0;0mgout\u001b[00m in men, associated with \u001b[48;2;173;216;230;38;2;0;0;0mbendrofluazide\u001b[00m treatment, and \u001b[48;2;144;238;144;38;2;0;0;0mraynaud's phenomenon\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdyspnoea\u001b[00m in men and women taking \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m. No corneal disease is known to have occurred in the \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m group. Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking \u001b[48;2;173;216;230;38;2;0;0;0mbendrofluazide\u001b[00m. In the \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bendrofluazide @CHEMICAL@ impotence @DISEASE@ @CID@ bendrofluazide @CHEMICAL@ impaired glucose tolerance @DISEASE@ @CID@ bendrofluazide @CHEMICAL@ gout @DISEASE@ @CID@ propranolol @CHEMICAL@ impotence @DISEASE@ @CID@ propranolol @CHEMICAL@ raynaud's phenomenon @DISEASE@ @CID@ propranolol @CHEMICAL@ dyspnoea @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bendrofluazide @CHEMICAL@ impotence @DISEASE@ @CID@ bendrofluazide @CHEMICAL@ impaired glucose tolerance @DISEASE@ @CID@ bendrofluazide @CHEMICAL@ gout @DISEASE@ @CID@ bendrofluazide @CHEMICAL@ dyspnoea @DISEASE@ @CID@ propranolol @CHEMICAL@ impotence @DISEASE@ @CID@ propranolol @CHEMICAL@ gout @DISEASE@ @CID@ propranolol @CHEMICAL@ dyspnoea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. We report the clinical and bioptic findings for a 57-year-old woman with severe \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m. Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide. Additional therapy with \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcq\u001b[00m) was started because of \u001b[48;2;173;216;230;38;2;0;0;0marthralgia\u001b[00m. At the same time, slightly increased creatine kinase (CK) levels were noted. \u001b[48;2;173;216;230;38;2;0;0;0mmyositis\u001b[00m was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive \u001b[48;2;173;216;230;38;2;0;0;0mmuscular weakness\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmuscular atrophy\u001b[00m. Routine controls revealed markedly elevated CK levels of 1,700 U/l. The neurological and electrophysiological findings were not typical of \u001b[48;2;173;216;230;38;2;0;0;0mmyositis\u001b[00m. Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m. As it revealed \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m, medication was stopped. Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "chloroquine ; cq @CHEMICAL@ muscular weakness @DISEASE@ @CID@ chloroquine ; cq @CHEMICAL@ muscular atrophy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "chloroquine ; cq @CHEMICAL@ myopathy @DISEASE@ @CID@ chloroquine ; cq @CHEMICAL@ arthralgia @DISEASE@ @CID@ chloroquine ; cq @CHEMICAL@ myositis @DISEASE@ @CID@ chloroquine ; cq @CHEMICAL@ muscular weakness @DISEASE@ @CID@ chloroquine ; cq @CHEMICAL@ muscular atrophy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m treatment for severe adenovirus disease in immunocompromised children. BACKGROUND: Adenovirus is an important cause of morbidity and mortality in the immunocompromised host. The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported. There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies. Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series. Experience is greatest with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcidofovir\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m is the treatment of choice for infection with hemorrhagic fever viruses. The most common adverse effect of intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m is reversible mild \u001b[48;2;173;216;230;38;2;0;0;0manemia\u001b[00m. The use of \u001b[48;2;173;216;230;38;2;0;0;0mcidofovir\u001b[00m in severe adenovirus infection has been limited by adverse effects, the most significant of which is \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m. OBJECTIVE: We report our experience with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m therapy for severe adenovirus disease in a series of immunocompromised children and review the literature. DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m for documented severe adenovirus disease. Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively. The bone marrow transplant patient also received intravenous \u001b[48;2;173;216;230;38;2;0;0;0mcidofovir\u001b[00m for progressive disseminated disease. An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome. The remaining infant had recently undergone a cardiac transplant. Intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m was administered on a compassionate-use protocol. RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia. The remaining 3 children died of adenovirus disease. Intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m therapy was well tolerated. Use of \u001b[48;2;173;216;230;38;2;0;0;0mcidofovir\u001b[00m in 1 child was associated with progressive \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mneutropenia\u001b[00m. DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency. Although intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection. Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response. CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m recovered. The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible. Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m, is clearly required to demonstrate the most effective and least toxic therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cidofovir @CHEMICAL@ progressive renal failure @DISEASE@ @CID@ cidofovir @CHEMICAL@ neutropenia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ribavirin @CHEMICAL@ anemia @DISEASE@ @CID@ ribavirin @CHEMICAL@ renal failure @DISEASE@ @CID@ cidofovir @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ cidofovir @CHEMICAL@ renal failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias. The use of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m has, however, been limited due to its serious side-effects. A patient with \u001b[48;2;173;216;230;38;2;0;0;0mcholestatic\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m treatment is presented below and a review of the \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m is given. It is concluded that solid evidence exists of \u001b[48;2;173;216;230;38;2;0;0;0mhepatic injury\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m treatment, including \u001b[48;2;173;216;230;38;2;0;0;0msteatosis\u001b[00m, alterations resembling alcoholic \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcholestatic\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmicronodular \u001b[48;2;144;238;144;38;2;0;0;0mcirrhosis of the liver\u001b[00m\u001b[00m. Patients receiving \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m should be regularly screened with respect to hepatic enzyme levels. Therapy should be discontinued on the suspicion of \u001b[48;2;173;216;230;38;2;0;0;0mcholestatic\u001b[00m injury or hepatomegaly.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ hepatotoxicity ; hepatitis ; hepatic injury @DISEASE@ @CID@ amiodarone @CHEMICAL@ cholestatic ; cholestatic injury @DISEASE@ @CID@ amiodarone @CHEMICAL@ steatosis @DISEASE@ @CID@ amiodarone @CHEMICAL@ cirrhosis of the liver @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ cholestatic ; cholestatic injury @DISEASE@ @CID@ amiodarone @CHEMICAL@ hepatitis ; hepatic injury @DISEASE@ @CID@ amiodarone @CHEMICAL@ steatosis @DISEASE@ @CID@ amiodarone @CHEMICAL@ micronodular cirrhosis of the liver @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mcatalepsy\u001b[00m induced by combinations of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m: potentiation, antagonism, tolerance and cross-tolerance in the rat. Previous studies demonstrated that both \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m induced analgesia and \u001b[48;2;144;238;144;38;2;0;0;0mcatalepsy\u001b[00m in the rat. Pre-treatment with \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m produced cross-tolerance to \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m, whereas pretreatment with \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m did not induce cross-tolerance to \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m but rather augmented the \u001b[48;2;173;216;230;38;2;0;0;0mcataleptic\u001b[00m response; this augmentation was attributed to residual \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m in the brain. The present studies explored the duration of the loss of righting reflex induced by sub-effective doses of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m, administered simultaneously. There was mutual potentiation between sub-effective doses of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m, but sub-effective doses of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m partly antagonized fully-effective doses of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m. Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m in each combination. Naloxone inhibited the induced \u001b[48;2;173;216;230;38;2;0;0;0mcataleptic\u001b[00m effects. The degree and time course of development of tolerance to daily administration of sub-effective dose combinations of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m were similar. Rats, tolerant to \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m-dominant combinations, were cross-tolerant to both drugs, while those tolerant to \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-dominant combinations were cross-tolerant to \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m but showed either no cross-tolerance or an augmented response to \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m. While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced \u001b[48;2;144;238;144;38;2;0;0;0mcatalepsy\u001b[00m, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ketamine @CHEMICAL@ catalepsy ; cataleptic @DISEASE@ @CID@ morphine @CHEMICAL@ catalepsy ; cataleptic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ketamine @CHEMICAL@ cataleptic ; cataleptic @DISEASE@ @CID@ morphine @CHEMICAL@ cataleptic ; cataleptic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Acute \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m in patients with AIDS on tenofovir while receiving prolonged \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m course for osteomyelitis. \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m developed after a prolonged course of \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m therapy in 2 patients who were receiving \u001b[48;2;173;216;230;38;2;0;0;0mtenofovir disoproxil fumarate\u001b[00m as part of an antiretroviral regimen. Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule. \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent. Clinicians should be aware that tenofovir may raise the risk of \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m during prolonged administration of \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "vancomycin @CHEMICAL@ acute renal failure @DISEASE@ @CID@ tenofovir disoproxil fumarate @CHEMICAL@ acute renal failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tenofovir disoproxil fumarate @CHEMICAL@ renal failure @DISEASE@ @CID@ vancomycin @CHEMICAL@ renal failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Delayed \u001b[48;2;173;216;230;38;2;0;0;0mleukoencephalopathy\u001b[00m with stroke-like presentation in chemotherapy recipients. BACKGROUND: A transient \u001b[48;2;173;216;230;38;2;0;0;0mleukoencephalopathy\u001b[00m mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal \u001b[48;2;173;216;230;38;2;0;0;0mmethotrexate\u001b[00m for childhood leukaemia. Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration. METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic \u001b[48;2;173;216;230;38;2;0;0;0mleukoencephalopathy\u001b[00m in patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mmethotrexate\u001b[00m (intrathecal, systemic), \u001b[48;2;173;216;230;38;2;0;0;0m5-fluorouracil\u001b[00m and its derivative \u001b[48;2;173;216;230;38;2;0;0;0mcarmofur\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mcapecitabine\u001b[00m. Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense \u001b[48;2;144;238;144;38;2;0;0;0mlesions within the subcortical white matter\u001b[00m of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients). Lesions exceeded the confines of adjacent vascular territories. Complete resolution of symptoms within 1-4 days was accompanied by normalisation of ADC abnormalities. However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent \u001b[48;2;144;238;144;38;2;0;0;0mwhite matter abnormalities\u001b[00m. CONCLUSIONS: Several pathophysiological models of delayed \u001b[48;2;173;216;230;38;2;0;0;0mleukoencephalopathy\u001b[00m after exposure to intrathecal or systemic chemotherapy have been proposed. DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methotrexate @CHEMICAL@ leukoencephalopathy ; lesions within the subcortical white matter ; white matter abnormalities @DISEASE@ @CID@ 5-fluorouracil @CHEMICAL@ leukoencephalopathy ; lesions within the subcortical white matter ; white matter abnormalities @DISEASE@ @CID@ carmofur @CHEMICAL@ leukoencephalopathy ; lesions within the subcortical white matter ; white matter abnormalities @DISEASE@ @CID@ capecitabine @CHEMICAL@ leukoencephalopathy ; lesions within the subcortical white matter ; white matter abnormalities @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methotrexate @CHEMICAL@ leukoencephalopathy ; toxic leukoencephalopathy @DISEASE@ @CID@ 5-fluorouracil @CHEMICAL@ leukoencephalopathy ; toxic leukoencephalopathy @DISEASE@ @CID@ carmofur @CHEMICAL@ leukoencephalopathy ; toxic leukoencephalopathy @DISEASE@ @CID@ capecitabine @CHEMICAL@ leukoencephalopathy ; toxic leukoencephalopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Down-regulation of norepinephrine transporter function induced by chronic administration of \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m linking to the alteration of sensitivity of local-anesthetics-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m and the counteraction by co-administration with local anesthetics. Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m induce by \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and local anesthetics were studied in mice. Daily administration of \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae. Co-administration of \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m, bupivacaine or tricaine with \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m reversed this effect. Daily treatment of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m increased [(3)H]norepinephrine uptake into the hippocampus. Daily administration of \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m increased the incidence of appearance of \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m and decreased that of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m. Co-administration of \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m reversed the changes of \u001b[48;2;144;238;144;38;2;0;0;0mconvulsive\u001b[00m activity of \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m induced by repeated administration of \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m. These results suggest that down-regulation of hippocampal NET induced by chronic administration of \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m may be relevant to \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m-induced sensitization of \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m. Inhibition of Na(+) channels by local anesthetics may regulate \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m-induced down-regulation of NET function. Repeated administration of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m induces up-regulation of hippocampal NET function. \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m-induced sensitization of \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m may have a mechanism distinct from kindling resulting from repeated administration of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ convulsions ; seizures ; convulsive @DISEASE@ @CID@ lidocaine @CHEMICAL@ convulsions ; seizures ; convulsive @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "desipramine @CHEMICAL@ convulsions ; seizures @DISEASE@ @CID@ cocaine @CHEMICAL@ convulsions ; seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Definition and management of anemia in patients infected with hepatitis C virus. Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated \u001b[48;2;144;238;144;38;2;0;0;0minterferon\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m. Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic anemia\u001b[00m. Hemoglobin concentrations decrease mainly as a result of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders. In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life. Although \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. Recombinant human erythropoietin has been used to manage \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m-associated anemia but has other potential disadvantages. Viramidine, a liver-targeting prodrug of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m, has the potential to maintain the virologic efficacy of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m while decreasing the risk of \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic anemia\u001b[00m in patients with chronic hepatitis C.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "interferon @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@ ribavirin @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ribavirin @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mcalcium carbonate\u001b[00m toxicity: the updated \u001b[48;2;144;238;144;38;2;0;0;0mmilk-alkali syndrome\u001b[00m; report of 3 cases and review of the literature. OBJECTIVE: To describe 3 patients with \u001b[48;2;144;238;144;38;2;0;0;0mcalcium carbonate\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mhypercalcemia\u001b[00m and gain insights into the cause and management of the \u001b[48;2;144;238;144;38;2;0;0;0mmilk-alkali syndrome\u001b[00m. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe \u001b[48;2;144;238;144;38;2;0;0;0mhypercalcemia\u001b[00m (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on \u001b[48;2;144;238;144;38;2;0;0;0mmilk-alkali syndrome\u001b[00m. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of furosemide. The 2 patients with the higher serum calcium concentrations received \u001b[48;2;173;216;230;38;2;0;0;0mpamidronate\u001b[00m intravenously (60 and 30 mg, respectively), which caused severe \u001b[48;2;173;216;230;38;2;0;0;0mhypocalcemia\u001b[00m. Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of \u001b[48;2;144;238;144;38;2;0;0;0mcalcium carbonate\u001b[00m. In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of \u001b[48;2;144;238;144;38;2;0;0;0mmilk-alkali syndrome\u001b[00m and summarize the cases reported from early 1995 to November 2003. CONCLUSION: \u001b[48;2;144;238;144;38;2;0;0;0mmilk-alkali syndrome\u001b[00m may be a common cause of unexplained \u001b[48;2;144;238;144;38;2;0;0;0mhypercalcemia\u001b[00m and can be precipitated by small amounts of orally ingested \u001b[48;2;144;238;144;38;2;0;0;0mcalcium carbonate\u001b[00m in susceptible persons. Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate. \u001b[48;2;173;216;230;38;2;0;0;0mpamidronate\u001b[00m treatment is associated with considerable risk for \u001b[48;2;173;216;230;38;2;0;0;0mhypocalcemia\u001b[00m, even in cases of initially severe \u001b[48;2;144;238;144;38;2;0;0;0mhypercalcemia\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "calcium carbonate @CHEMICAL@ milk-alkali syndrome ; hypercalcemia @DISEASE@ @CID@ pamidronate @CHEMICAL@ hypocalcemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pamidronate @CHEMICAL@ hypocalcemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Management strategies for \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic anemia\u001b[00m in the treatment of hepatitis C: clinical and economic implications. OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/\u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m compared with \u001b[48;2;144;238;144;38;2;0;0;0minterferon-alpha\u001b[00m monotherapy in the treatment of chronic hepatitis C (CHC). Combination therapy is associated with a clinically important adverse effect: \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic anemia\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m). The objective of this study was to evaluate the direct health-care costs and management of \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m during treatment of CHC in a clinical trial setting. METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m. Decision-analytic techniques were used to estimate the cost of treating \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m. Uncertainty was evaluated using sensitivity analyses. RESULTS: \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy. The standard of care for management of \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m is reduction or discontinuation of the \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m dosage. We estimated the direct cost of treating clinically significant \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692). The results of the one-way sensitivity analyses ranged from  57 to  317. In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m is 1% ( 170/ 16,459) of drug treatment costs. Questions remain about the optimal dose of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m and the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m in a real-world population. Despite these uncertainties, this initial evaluation of the direct cost of treating \u001b[48;2;173;216;230;38;2;0;0;0mriha\u001b[00m provides an estimate of the cost and management implications of this clinically important adverse effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ribavirin @CHEMICAL@ hemolytic anemia ; riha @DISEASE@ @CID@ interferon-alpha @CHEMICAL@ hemolytic anemia ; riha @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ribavirin @CHEMICAL@ hemolytic anemia ; riha @DISEASE@ @CID@ interferon and alpha-2b/ribavirin @CHEMICAL@ hemolytic anemia ; riha @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Obsolete but dangerous antacid preparations. One case of acute \u001b[48;2;173;216;230;38;2;0;0;0mhypercalcaemia\u001b[00m and two of recurrent \u001b[48;2;173;216;230;38;2;0;0;0mnephrolithiasis\u001b[00m are reported in patients who had regularly consumed large amounts of \u001b[48;2;173;216;230;38;2;0;0;0mcalcium carbon-ate-\u001b[48;2;144;238;144;38;2;0;0;0msodium bicarbonate\u001b[00m\u001b[00m powders for more than 20 years. The powders had been obtained from pharmacists unknown to the patients' medical practitioners. It is suggested that these preparations were responsible for the patient's problems, and that such powders should no longer be freely obtainable.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "calcium carbon-ate @CHEMICAL@ hypercalcaemia @DISEASE@ @CID@ calcium carbon-ate @CHEMICAL@ nephrolithiasis @DISEASE@ @CID@ sodium bicarbonate @CHEMICAL@ hypercalcaemia @DISEASE@ @CID@ sodium bicarbonate @CHEMICAL@ nephrolithiasis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "calcium carbon-ate-sodium bicarbonate @CHEMICAL@ hypercalcaemia @DISEASE@ @CID@ calcium carbon-ate-sodium bicarbonate @CHEMICAL@ nephrolithiasis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Prolonged paralysis due to \u001b[48;2;173;216;230;38;2;0;0;0mnondepolarizing neuromuscular blocking agents\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcorticosteroids\u001b[00m. The long-term use of \u001b[48;2;173;216;230;38;2;0;0;0mnondepolarizing neuromuscular blocking agents\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mnd-nmba\u001b[00m) has recently been implicated as a cause of prolonged muscle \u001b[48;2;173;216;230;38;2;0;0;0mweakness\u001b[00m, although the site of the lesion and the predisposing factors have been unclear. We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged \u001b[48;2;173;216;230;38;2;0;0;0mweakness\u001b[00m following the discontinuation of \u001b[48;2;144;238;144;38;2;0;0;0mnd-nmbas\u001b[00m. Two patients also received intravenous \u001b[48;2;173;216;230;38;2;0;0;0mcorticosteroids\u001b[00m. Renal function was normal but hepatic function was impaired in all patients, and all had acidosis. Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations. Repetitive stimulation at 2 Hz showed a decremental response in 2 patients. The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed \u001b[48;2;144;238;144;38;2;0;0;0mloss of thick, myosin filaments\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mweakness\u001b[00m in these patients is due to \u001b[48;2;144;238;144;38;2;0;0;0mpathology at both the neuromuscular junction\u001b[00m (most likely due to \u001b[48;2;173;216;230;38;2;0;0;0mnd-nmba\u001b[00m) and muscle (most likely due to \u001b[48;2;173;216;230;38;2;0;0;0mcorticosteroids\u001b[00m). Hepatic dysfunction and acidosis are contributing risk factors.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nondepolarizing neuromuscular blocking agents ; nd-nmba ; nd-nmbas @CHEMICAL@ muscle weakness ; weakness @DISEASE@ @CID@ nondepolarizing neuromuscular blocking agents ; nd-nmba ; nd-nmbas @CHEMICAL@ pathology at both the neuromuscular junction @DISEASE@ @CID@ corticosteroids @CHEMICAL@ loss of thick, myosin filaments @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "nondepolarizing neuromuscular blocking agents ; nd-nmba ; nd-nmba @CHEMICAL@ muscle weakness ; weakness @DISEASE@ @CID@ corticosteroids @CHEMICAL@ muscle weakness ; weakness @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin e2\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mbladder hyperactivity\u001b[00m in normal, conscious rats: involvement of tachykinins? In normal conscious rats investigated by continuous cystometry, intravesically instilled \u001b[48;2;144;238;144;38;2;0;0;0mprostaglandin (pg) e2\u001b[00m facilitated \u001b[48;2;173;216;230;38;2;0;0;0mmicturition\u001b[00m and increased basal intravesical pressure. The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors. Intra-arterially given \u001b[48;2;173;216;230;38;2;0;0;0mpge2\u001b[00m produced a distinct increase in bladder pressure before initiating a \u001b[48;2;173;216;230;38;2;0;0;0mmicturition\u001b[00m reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle. The effect of intra-arterial \u001b[48;2;173;216;230;38;2;0;0;0mpge2\u001b[00m could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the \u001b[48;2;173;216;230;38;2;0;0;0mmicturition\u001b[00m reflex elicited by intra-arterial \u001b[48;2;173;216;230;38;2;0;0;0mpge2\u001b[00m was mediated by pathways other than the reflex initiated when the PG was given intravesically. The present results thus suggest that intra-arterial \u001b[48;2;173;216;230;38;2;0;0;0mpge2\u001b[00m, given near the bladder, may initiate \u001b[48;2;173;216;230;38;2;0;0;0mmicturition\u001b[00m in the normal rat chiefly by directly contracting the smooth muscle of the detrusor. However, when given intravesically, \u001b[48;2;173;216;230;38;2;0;0;0mpge2\u001b[00m may stimulate \u001b[48;2;173;216;230;38;2;0;0;0mmicturition\u001b[00m by releasing tachykinins from nerves in and/or immediately below the urothelium. These tachykinins, in turn, initiate a \u001b[48;2;173;216;230;38;2;0;0;0mmicturition\u001b[00m reflex by stimulating NK1 and NK2 receptors. Prostanoids may, via release of tachykinins, contribute to both \u001b[48;2;173;216;230;38;2;0;0;0murge\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mbladder hyperactivity\u001b[00m seen in inflammatory conditions of the lower urinary tract.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prostaglandin e2 ; prostaglandin (pg) e2 ; pge2 @CHEMICAL@ bladder hyperactivity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prostaglandin e2 ; pge2 @CHEMICAL@ bladder hyperactivity ; bladder hyperactivity @DISEASE@ @CID@ prostaglandin e2 ; pge2 @CHEMICAL@ micturition @DISEASE@ @CID@ prostaglandin e2 ; pge2 @CHEMICAL@ urge @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Thiazide diuretics, \u001b[48;2;173;216;230;38;2;0;0;0mhypokalemia\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mcardiac arrhythmias\u001b[00m. Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs. \u001b[48;2;173;216;230;38;2;0;0;0mhypokalemia\u001b[00m is a commonly encountered metabolic consequence of chronic thiazide therapy. We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with \u001b[48;2;173;216;230;38;2;0;0;0mhydrochlorothiazide\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mhctc\u001b[00m) administered on a twice daily schedule. Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized. The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg \u001b[48;2;144;238;144;38;2;0;0;0mhctz\u001b[00m daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively. Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively. In 13 patients we observed the effects of \u001b[48;2;144;238;144;38;2;0;0;0mhctz\u001b[00m therapy (100 mg daily) on the occurrence of \u001b[48;2;173;216;230;38;2;0;0;0mpvc's\u001b[00m during rest as well as during static and dynamic exercise. During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively. Corresponding figures during \u001b[48;2;144;238;144;38;2;0;0;0mhctz\u001b[00m therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively. The occurrence of \u001b[48;2;173;216;230;38;2;0;0;0mpvc's\u001b[00m correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001. In conclusion we found that thiazide diuretics cause \u001b[48;2;173;216;230;38;2;0;0;0mhypokalemia\u001b[00m and depletion of body potassium. The more profound \u001b[48;2;173;216;230;38;2;0;0;0mhypokalemia\u001b[00m, the greater the propensity for the occurrence of \u001b[48;2;173;216;230;38;2;0;0;0mpvc's\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hydrochlorothiazide ; hctc ; hctz @CHEMICAL@ hypokalemia @DISEASE@ @CID@ hydrochlorothiazide ; hctc ; hctz @CHEMICAL@ cardiac arrhythmias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "hydrochlorothiazide ; hctc @CHEMICAL@ hypokalemia @DISEASE@ @CID@ hydrochlorothiazide ; hctc @CHEMICAL@ pvc's @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "GABA involvement in naloxone induced reversal of \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory paralysis\u001b[00m produced by \u001b[48;2;173;216;230;38;2;0;0;0mthiopental\u001b[00m. No agent is yet available to reverse \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory paralysis\u001b[00m produced by CNS depressants, such as general anesthetics. In this study naloxone reversed \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory paralysis\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mthiopental\u001b[00m in rats. 25 mg/kg, i.v. \u001b[48;2;173;216;230;38;2;0;0;0mthiopental\u001b[00m produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem. Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of \u001b[48;2;173;216;230;38;2;0;0;0mthiopental\u001b[00m. 50 mg/kg, i.v. \u001b[48;2;173;216;230;38;2;0;0;0mthiopental\u001b[00m produced \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory arrest\u001b[00m with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain. Naloxone (2.5 mg/kg, i.v.) reversed \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory paralysis\u001b[00m, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum. These data suggest naloxone reverses \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory paralysis\u001b[00m produced by \u001b[48;2;173;216;230;38;2;0;0;0mthiopental\u001b[00m and involves GABA in its action.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "thiopental @CHEMICAL@ respiratory paralysis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "thiopental @CHEMICAL@ respiratory paralysis ; respiratory arrest @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "National project on the prevention of mother-to-infant infection by \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m virus in Japan. In Japan, a nationwide prevention program against mother-to-infant infection by \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m surface antigen (\u001b[48;2;144;238;144;38;2;0;0;0mhbsag\u001b[00m) and \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m e antigen (\u001b[48;2;173;216;230;38;2;0;0;0mhbeag\u001b[00m) positive mothers. These infants are treated with two injections of \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m immune globulin (HBIG) and at least three injections of plasma derived \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for \u001b[48;2;144;238;144;38;2;0;0;0mhbsag\u001b[00m, and the positive rate was 1.4 to 1.5%. The \u001b[48;2;173;216;230;38;2;0;0;0mhbeag\u001b[00m positive rate in \u001b[48;2;144;238;144;38;2;0;0;0mhbsag\u001b[00m positive was 23 to 26%. The \u001b[48;2;144;238;144;38;2;0;0;0mhbsag\u001b[00m positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hepatitis b surface antigen ; hbsag @CHEMICAL@ infection by hepatitis b virus ; hepatitis b @DISEASE@ @CID@ hepatitis b e antigen ; hbeag @CHEMICAL@ infection by hepatitis b virus ; hepatitis b @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "hbeag @CHEMICAL@ hepatitis b @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Nociceptive effects induced by intrathecal administration of \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin d2\u001b[00m, E2, or F2 alpha to conscious mice. The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests. \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin d2\u001b[00m (0.5-3 ng/mouse) had a \u001b[48;2;144;238;144;38;2;0;0;0mhyperalgesic\u001b[00m action on the response to a hot plate during a 3-60 min period after injection. \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin e2\u001b[00m showed a \u001b[48;2;144;238;144;38;2;0;0;0mhyperalgesic\u001b[00m effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin d2\u001b[00m. Similar results were obtained by acetic acid writhing tests. The \u001b[48;2;144;238;144;38;2;0;0;0mhyperalgesic\u001b[00m effect of \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin d2\u001b[00m was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist. Conversely, \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin e2\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist. Prostaglandin F2 alpha had little effect on pain responses. These results demonstrate that both \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin d2\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin e2\u001b[00m exert \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m in the spinal cord, but in different ways.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prostaglandin d2 @CHEMICAL@ hyperalgesic ; hyperalgesia @DISEASE@ @CID@ prostaglandin e2 @CHEMICAL@ hyperalgesic ; hyperalgesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prostaglandin d2 @CHEMICAL@ hyperalgesia @DISEASE@ @CID@ prostaglandin e2 @CHEMICAL@ hyperalgesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Coenzyme Q10 treatment ameliorates acute \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m in mice. The nephroprotective effect of coenzyme Q10 was investigated in mice with acute \u001b[48;2;173;216;230;38;2;0;0;0mrenal injury\u001b[00m induced by a single i.p. injection of \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m administration. Also, histopathological \u001b[48;2;173;216;230;38;2;0;0;0mrenal tissue damage\u001b[00m mediated by \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m was ameliorated by coenzyme Q10 treatment. Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue. It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute \u001b[48;2;173;216;230;38;2;0;0;0mcisplatin\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m commonly encountered in clinical practice.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cisplatin @CHEMICAL@ acute renal injury @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cisplatin @CHEMICAL@ nephrotoxicity ; renal injury ; renal tissue damage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Sedation depth during spinal anesthesia and the development of \u001b[48;2;173;216;230;38;2;0;0;0mpostoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m in elderly patients undergoing hip fracture repair. OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of \u001b[48;2;173;216;230;38;2;0;0;0mpostoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m. PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m or severe dementia who underwent hip fracture repair under spinal anesthesia with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m sedation. Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation. \u001b[48;2;173;216;230;38;2;0;0;0mpostoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery. RESULTS: From April 2, 2005, through October 30, 2008, a total of 114 patients were randomized. The prevalence of \u001b[48;2;173;216;230;38;2;0;0;0mpostoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m will be prevented for every 4.7 patients treated with light sedation. The mean +/- SD number of days of \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01). CONCLUSION: The use of light \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m sedation decreased the prevalence of \u001b[48;2;173;216;230;38;2;0;0;0mpostoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m by 50% compared with deep sedation. Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing \u001b[48;2;173;216;230;38;2;0;0;0mpostoperative \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m in elderly patients that could be widely and readily adopted.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "propofol @CHEMICAL@ postoperative delirium @DISEASE@ @CID@ propofol @CHEMICAL@ delirium @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "propofol @CHEMICAL@ postoperative delirium @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m-induced acute \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery spasm\u001b[00m. A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest. Two weeks before his admission, \u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m had been started. He was diagnosed with non-ST-elevation \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m by laboratory data and electrocardiogram. Enhanced heart magnetic resonance imaging also showed subendocardial infarction. However, there was no stenosis in coronary arteries on angiography. \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery spasm\u001b[00m was induced by a provocative test. Cessation of \u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of \u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m. Addition of oral nicorandil reduced his symptoms and maintained stable angina status. We report the first case of \u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery spasm\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival. On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery spasm\u001b[00m. Our report may show an adverse effect on the Rho/ROCK pathway by \u001b[48;2;173;216;230;38;2;0;0;0msorafenib\u001b[00m use.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "sorafenib @CHEMICAL@ coronary artery spasm @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "sorafenib @CHEMICAL@ myocardial infarction @DISEASE@ @CID@ sorafenib @CHEMICAL@ coronary artery spasm @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Anxiogenic potential of \u001b[48;2;173;216;230;38;2;0;0;0mciprofloxacin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnorfloxacin\u001b[00m in rats. INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely \u001b[48;2;173;216;230;38;2;0;0;0mciprofloxacin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnorfloxacin\u001b[00m, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day. The tests included open-field exploratory behaviour, elevated plus maze and elevated zero maze, social interaction and novelty-suppressed feeding latency behaviour. RESULTS: The results indicate that \u001b[48;2;173;216;230;38;2;0;0;0mciprofloxacin\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mnorfloxacin\u001b[00m-treated rats showed \u001b[48;2;173;216;230;38;2;0;0;0manxious behaviour\u001b[00m in comparison to control rats in all the parameters studied. However, \u001b[48;2;173;216;230;38;2;0;0;0mciprofloxacin\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mnorfloxacin\u001b[00m-treated rats did not differ significantly from each other in various behavioural parameters. CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of \u001b[48;2;173;216;230;38;2;0;0;0mciprofloxacin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnorfloxacin\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ciprofloxacin @CHEMICAL@ anxious behaviour @DISEASE@ @CID@ norfloxacin @CHEMICAL@ anxious behaviour @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ciprofloxacin @CHEMICAL@ anxiety ; anxious behaviour @DISEASE@ @CID@ norfloxacin @CHEMICAL@ anxiety ; anxious behaviour @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Myocardial Fas ligand expression increases susceptibility to \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m. BACKGROUND: Dilated \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdcm\u001b[00m) and \u001b[48;2;173;216;230;38;2;0;0;0mmyocarditis\u001b[00m occur in many HIV-infected individuals, resulting in symptomatic \u001b[48;2;173;216;230;38;2;0;0;0mheart failure\u001b[00m in up to 5% of patients. Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies. METHODS AND RESULTS: In order to investigate whether the HAART component \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0m3'-azido-2',3'-deoxythymidine\u001b[00m; \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of \u001b[48;2;173;216;230;38;2;0;0;0mdcm\u001b[00m, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m (0, 0.07, 0.2, and 0.7 mg/ml). After 6 weeks, cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods. NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function. In contrast, \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-treated FasL Tg mice developed \u001b[48;2;144;238;144;38;2;0;0;0mcardiac dilation\u001b[00m and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles. These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis. These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity. CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m due to activation of apoptotic pathways, resulting in \u001b[48;2;144;238;144;38;2;0;0;0mcardiac dilation\u001b[00m and dysfunction.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "azt ; zidovudine ; 3'-azido-2',3'-deoxythymidine @CHEMICAL@ cardiomyopathy @DISEASE@ @CID@ azt ; zidovudine ; 3'-azido-2',3'-deoxythymidine @CHEMICAL@ dilated cardiomyopathy ; dcm ; cardiac dilation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "azt @CHEMICAL@ cardiomyopathy ; dcm @DISEASE@ @CID@ azt @CHEMICAL@ myocarditis @DISEASE@ @CID@ azt @CHEMICAL@ heart failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m in renal disease with proteinuria and/or glomerular \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m. Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available. In this study, we developed a new \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m-responsive reporter vector using a \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m-sensing transgenic rat. We then applied this animal model to the detection of tubulointerstitial \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m in the diseased kidney. With this model, we were able to identify diffuse cortical \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m in the \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m and focal and segmental \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m in the remnant kidney model. Expression of the \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes. The degree of \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m showed a positive correlation with microscopic tubulointerstitial injury in both models. Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the \u001b[48;2;144;238;144;38;2;0;0;0mhypoxic\u001b[00m cortical area in the remnant kidney model. We propose here a possible pathological tie between chronic tubulointerstitial \u001b[48;2;144;238;144;38;2;0;0;0mhypoxia\u001b[00m and progressive glomerular diseases.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "puromycin aminonucleoside @CHEMICAL@ hypoxia ; hypoxic @DISEASE@ @CID@ puromycin aminonucleoside @CHEMICAL@ nephrotic syndrome @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "puromycin aminonucleoside @CHEMICAL@ nephrotic syndrome @DISEASE@ @CID@ puromycin aminonucleoside @CHEMICAL@ hypertension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Consensus statement concerning \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases. Worldwide, over 650 patients have been transplanted in the context of phase I and II clinical trials. The results are encouraging enough to begin randomised phase III trials. However, as predicted, significant transplant-related morbidity and mortality have been observed. This is primarily due to complications related to either the stage of the disease at transplant or due to infections. The number of deaths related to cardiac toxicity is low. However, caution is required when \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0manthracyclines\u001b[00m such as \u001b[48;2;173;216;230;38;2;0;0;0mmitoxantrone\u001b[00m are used in patients with a possible underlying \u001b[48;2;173;216;230;38;2;0;0;0mheart damage\u001b[00m, for example, systemic sclerosis patients. In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine. The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients. A full cardiological assessment before and during the transplant emerged as the major recommendation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ heart damage @DISEASE@ @CID@ mitoxantrone @CHEMICAL@ heart damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ cardiotoxicity ; heart damage @DISEASE@ @CID@ anthracyclines @CHEMICAL@ cardiotoxicity ; heart damage @DISEASE@ @CID@ mitoxantrone @CHEMICAL@ cardiotoxicity ; heart damage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Low-molecular-weight \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m for the treatment of patients with mechanical heart valves. BACKGROUND: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy. Unfractionated \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m (UH) is currently the substitute for selected patients. Low-molecular-weight \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mlmwh\u001b[00m) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves. HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of \u001b[48;2;173;216;230;38;2;0;0;0mlmwh\u001b[00m in this patient population and to discuss its applicability in common practice. METHODS: For this paper, the current medical literature on \u001b[48;2;173;216;230;38;2;0;0;0mlmwh\u001b[00m in patients with mechanical heart valves was extensively reviewed. RESULTS: There were eight series and six case reports. None of the studies was randomized, and only one was prospective. Data to establish the \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolic\u001b[00m risk were incomplete. After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10). The incidence rate of \u001b[48;2;144;238;144;38;2;0;0;0mthromboembolism\u001b[00m was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhage\u001b[00m, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups). CONCLUSIONS: In patients with mechanical heart valves, short-term \u001b[48;2;173;216;230;38;2;0;0;0mlmwh\u001b[00m therapy compares favorably with UH. Data on mid- and long-term \u001b[48;2;173;216;230;38;2;0;0;0mlmwh\u001b[00m administration in these patients are sparse. Further randomized studies are needed to confirm the safety and precise indications for the use of \u001b[48;2;173;216;230;38;2;0;0;0mlmwh\u001b[00m in patients with mechanical heart valves.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "low-molecular-weight heparin ; lmwh @CHEMICAL@ thromboembolic ; thromboembolism @DISEASE@ @CID@ low-molecular-weight heparin ; lmwh @CHEMICAL@ hemorrhage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin ; lmwh @CHEMICAL@ thromboembolic @DISEASE@ @CID@ heparin ; lmwh @CHEMICAL@ hemorrhage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mtopiramate\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrolithiasis\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mtopiramate\u001b[00m is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures. Urologists should be aware that this medication can cause \u001b[48;2;173;216;230;38;2;0;0;0mmetabolic acidosis\u001b[00m in patients secondary to inhibition of carbonic anhydrase. In addition, a \u001b[48;2;173;216;230;38;2;0;0;0mdistal tubular acidification defect\u001b[00m may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate \u001b[48;2;173;216;230;38;2;0;0;0mnephrolithiasis\u001b[00m. We report the first two cases of \u001b[48;2;173;216;230;38;2;0;0;0mtopiramate\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrolithiasis\u001b[00m in the urologic literature.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "topiramate @CHEMICAL@ nephrolithiasis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "topiramate @CHEMICAL@ nephrolithiasis @DISEASE@ @CID@ topiramate @CHEMICAL@ metabolic acidosis @DISEASE@ @CID@ topiramate @CHEMICAL@ distal tubular acidification defect @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs. Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m arising in the limbic system. Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m at the cellular level. In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death. Here we analyze the occurrence of \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m and neurotoxicity in D2R -/- mice treated with the cholinergic agonist \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m. We compared these results with those previously obtained with \u001b[48;2;173;216;230;38;2;0;0;0mkainic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mka\u001b[00m), a potent glutamate agonist. Importantly, D2R -/- mice develop \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity. However, \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to \u001b[48;2;173;216;230;38;2;0;0;0mka\u001b[00m. Thus, the absence of D2R lowers the threshold for \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m induced by both glutamate and acetylcholine. Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ seizures @DISEASE@ @CID@ kainic acid ; ka @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ kainic acid ; ka @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcholestatic jaundice\u001b[00m associated with the use of \u001b[48;2;173;216;230;38;2;0;0;0mmetformin\u001b[00m. We report a patient who developed \u001b[48;2;173;216;230;38;2;0;0;0mcholestatic jaundice\u001b[00m shortly after initiation of treatment with \u001b[48;2;173;216;230;38;2;0;0;0mmetformin hydrochloride\u001b[00m. Ultrasound of the liver and abdominal CT were normal. An ERCP showed normal biliary anatomy. A percutaneous liver biopsy was obtained showing marked \u001b[48;2;173;216;230;38;2;0;0;0mcholestasis\u001b[00m, with portal \u001b[48;2;173;216;230;38;2;0;0;0medema\u001b[00m, ductular proliferation, and acute \u001b[48;2;173;216;230;38;2;0;0;0minflammation\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mmetformin hydrochloride\u001b[00m was discontinued, and the patient's jaundice resolved slowly over a period of several months. Given the onset of his jaundice 2 wk after the initiation of \u001b[48;2;173;216;230;38;2;0;0;0mmetformin\u001b[00m, we believe that this case represents an example of \u001b[48;2;173;216;230;38;2;0;0;0mmetformin\u001b[00m-associated hepatotoxicity, the first such case reported.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "metformin ; metformin hydrochloride @CHEMICAL@ cholestatic jaundice @DISEASE@ @CID@ metformin ; metformin hydrochloride @CHEMICAL@ cholestasis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "metformin ; metformin hydrochloride @CHEMICAL@ cholestatic jaundice @DISEASE@ @CID@ metformin ; metformin hydrochloride @CHEMICAL@ cholestasis @DISEASE@ @CID@ metformin ; metformin hydrochloride @CHEMICAL@ edema @DISEASE@ @CID@ metformin ; metformin hydrochloride @CHEMICAL@ inflammation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with \u001b[48;2;173;216;230;38;2;0;0;0mvigabatrin\u001b[00m-attributed \u001b[48;2;173;216;230;38;2;0;0;0mvisual field constriction\u001b[00m. PURPOSE: Symptomatic \u001b[48;2;173;216;230;38;2;0;0;0mvisual field constriction\u001b[00m thought to be associated with \u001b[48;2;173;216;230;38;2;0;0;0mvigabatrin\u001b[00m has been reported. The current study investigated the visual fields and visual electrophysiology of eight patients with known \u001b[48;2;173;216;230;38;2;0;0;0mvigabatrin\u001b[00m-attributed \u001b[48;2;173;216;230;38;2;0;0;0mvisual field loss\u001b[00m, three of whom were reported previously. Six of the patients were no longer receiving \u001b[48;2;173;216;230;38;2;0;0;0mvigabatrin\u001b[00m. METHODS: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer. Full visual electrophysiology, including flash electroretinography (ERG), pattern electroretinography, multifocal ERG using the VERIS system, electro-oculography, and flash and pattern visual evoked potentials, was undertaken. RESULTS: Seven patients showed marked \u001b[48;2;173;216;230;38;2;0;0;0mvisual field constriction\u001b[00m with some sparing of the temporal visual field. The eighth exhibited concentric constriction. Most electrophysiological responses were usually just within normal limits; two patients had subnormal Arden electro-oculography indices; and one patient showed an abnormally delayed photopic b wave. However, five patients showed delayed 30-Hz flicker b waves, and seven patients showed delayed oscillatory potentials. Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level. CONCLUSION: Marked \u001b[48;2;173;216;230;38;2;0;0;0mvisual field constriction\u001b[00m appears to be associated with \u001b[48;2;173;216;230;38;2;0;0;0mvigabatrin\u001b[00m therapy. The field defects and some electrophysiological abnormalities persist when \u001b[48;2;173;216;230;38;2;0;0;0mvigabatrin\u001b[00m therapy is withdrawn.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "vigabatrin @CHEMICAL@ visual field constriction ; visual field loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "vigabatrin @CHEMICAL@ visual field constriction ; visual field loss ; visual field defects @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Conversion to \u001b[48;2;173;216;230;38;2;0;0;0mrapamycin\u001b[00m immunosuppression in renal transplant recipients: report of an initial experience. BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing \u001b[48;2;144;238;144;38;2;0;0;0mcyclosporine\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mcsa\u001b[00m) or \u001b[48;2;144;238;144;38;2;0;0;0mtacrolimus\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mtac\u001b[00m) toxicity. METHODS: Twenty renal transplant recipients were switched to fixed dose \u001b[48;2;173;216;230;38;2;0;0;0mrapamycin\u001b[00m (RAPA) (5 mg/day) 0 to 204 months posttransplant. Drug monitoring was not initially used to adjust doses. The indications for switch were chronic \u001b[48;2;144;238;144;38;2;0;0;0mcsa\u001b[00m or \u001b[48;2;144;238;144;38;2;0;0;0mtac\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxicity\u001b[00m (12), acute \u001b[48;2;144;238;144;38;2;0;0;0mcsa\u001b[00m or \u001b[48;2;144;238;144;38;2;0;0;0mtac\u001b[00m toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxicity\u001b[00m there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed \u001b[48;2;173;216;230;38;2;0;0;0mpneumonia\u001b[00m (two Pneumocystis carinii \u001b[48;2;173;216;230;38;2;0;0;0mpneumonia\u001b[00m, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had \u001b[48;2;173;216;230;38;2;0;0;0mbronchiolitis obliterans\u001b[00m. There were no deaths. RAPA was discontinued in four patients, because of \u001b[48;2;173;216;230;38;2;0;0;0mpneumonia\u001b[00m in two, PTLD in one, and \u001b[48;2;173;216;230;38;2;0;0;0moral aphtous ulcers\u001b[00m in one. RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients. CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable \u001b[48;2;144;238;144;38;2;0;0;0mcsa\u001b[00m withdrawal. However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii \u001b[48;2;173;216;230;38;2;0;0;0mpneumonia\u001b[00m prophylaxis should be given.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclosporine ; csa @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ tacrolimus ; tac @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "rapamycin ; rap @CHEMICAL@ pneumonia @DISEASE@ @CID@ rapamycin ; rap @CHEMICAL@ bronchiolitis obliterans @DISEASE@ @CID@ rapamycin ; rap @CHEMICAL@ oral aphtous ulcers @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mstructural and functional impairment of mitochondria\u001b[00m in \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m in mice: suppression of cytochrome c oxidase II gene expression. The use of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity. Earlier observations that \u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate \u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with \u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m for several weeks. At various times during treatment, the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy. In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes. Similarly, samples obtained from the liver of the same animals were analyzed for comparative studies. Our results indicated that 1) treatment of mice with \u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m caused cardiovascular arrhythmias characterized by \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mextension of ventricular depolarization time\u001b[00m (tQRS), and \u001b[48;2;173;216;230;38;2;0;0;0mfailure of QRS\u001b[00m at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment. Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by \u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m treatment, mainly after 8 weeks in both heart and liver. Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of \u001b[48;2;173;216;230;38;2;0;0;0madr\u001b[00m on cardiovascular function involve \u001b[48;2;144;238;144;38;2;0;0;0mmitochondrial structural and functional impairment\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "adriamycin ; adr @CHEMICAL@ structural and functional impairment of mitochondria ; mitochondrial structural and functional impairment @DISEASE@ @CID@ adriamycin ; adr @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "adriamycin ; adr @CHEMICAL@ cardiomyopathy @DISEASE@ @CID@ adriamycin ; adr @CHEMICAL@ bradycardia @DISEASE@ @CID@ adriamycin ; adr @CHEMICAL@ extension of ventricular depolarization time @DISEASE@ @CID@ adriamycin ; adr @CHEMICAL@ failure of QRS @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Enhanced \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m induced by beta-adrenoceptor antagonists in rats pretreated with \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m. High doses of \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m increase \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m induced by vasodilators and change the accompanying reflex tachycardia to \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m of \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m significantly increased \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mpindolol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mlabetalol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0matenolol\u001b[00m, as well as after clonidine, but not after hexamethonium or carbachol. Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised. These results are compatible with interference by \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m with GABAergic inhibition of cardiac parasympathetic tone. Such interference could be exerted centrally, possibly at the nucleus ambiguus, or peripherally at the sinus node.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "isoniazid @CHEMICAL@ bradycardia @DISEASE@ @CID@ isoniazid @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "isoniazid @CHEMICAL@ bradycardia @DISEASE@ @CID@ propranolol @CHEMICAL@ hypotension @DISEASE@ @CID@ pindolol @CHEMICAL@ bradycardia @DISEASE@ @CID@ labetalol @CHEMICAL@ bradycardia @DISEASE@ @CID@ atenolol @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Epileptogenic activity of \u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m after drug induces \u001b[48;2;144;238;144;38;2;0;0;0msle\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m and epilepsy) OBJECTIVE: To study the effect of \u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of \u001b[48;2;173;216;230;38;2;0;0;0mstructural birth defects\u001b[00m and epilepsy-related side effects. STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females. RESULTS: Of 60 epileptic women with periconceptional \u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period. One epileptic woman delivered a newborn with cleft lip and palate. Another patient exhibited with a cluster of \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m after the periconception period using another multivitamin. This 22-year-old epileptic woman was treated continuously by carbamazepine and a \u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m (1 mg)-containing multivitamin from the 20th week of gestation. She developed \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m and later symptoms of \u001b[48;2;173;216;230;38;2;0;0;0msystemic \u001b[48;2;144;238;144;38;2;0;0;0mlupus\u001b[00m erythematodes\u001b[00m. Her pregnancy ended with stillbirth. CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced \u001b[48;2;144;238;144;38;2;0;0;0mlupus\u001b[00m) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of \u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m triggered a cluster of \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m. Physiological dose (<1 mg) of \u001b[48;2;173;216;230;38;2;0;0;0mfolic acid\u001b[00m both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "folic acid @CHEMICAL@ sle ; systemic lupus erythematodes ; lupus @DISEASE@ @CID@ folic acid @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "folic acid @CHEMICAL@ structural birth defects @DISEASE@ @CID@ folic acid @CHEMICAL@ status epilepticus @DISEASE@ @CID@ folic acid @CHEMICAL@ systemic lupus erythematodes @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. BACKGROUND: Irritable bowel syndrome is a common cause of \u001b[48;2;144;238;144;38;2;0;0;0mabdominal pain\u001b[00m and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS). METHODS: Thirty-eight patients with IBS (\u001b[48;2;173;216;230;38;2;0;0;0mconstipation\u001b[00m-predominant, n = 17; \u001b[48;2;173;216;230;38;2;0;0;0mdiarrhoea\u001b[00m-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [\u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m, 5 mg three times daily (n = 19) or placebo (n = 19)]. RESULTS: In \u001b[48;2;173;216;230;38;2;0;0;0mdiarrhoea\u001b[00m-predominant patients significant differences in contraction characteristics were observed between the \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m and placebo groups. In \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m-treated \u001b[48;2;173;216;230;38;2;0;0;0mdiarrhoea\u001b[00m-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the \u001b[48;2;173;216;230;38;2;0;0;0mconstipation\u001b[00m-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of \u001b[48;2;173;216;230;38;2;0;0;0mconstipation\u001b[00m were lower in \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m-treated \u001b[48;2;173;216;230;38;2;0;0;0mconstipation\u001b[00m-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm]. \u001b[48;2;173;216;230;38;2;0;0;0mdiarrhoea\u001b[00m-predominant IBS patients had a higher pain score after \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m therapy [score, 55 +/- 15 versus 34 +/- 12 mm, \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm]. CONCLUSION: \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m affects jejunal contraction characteristics and some symptoms in IBS.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cisapride @CHEMICAL@ abdominal pain @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cisapride @CHEMICAL@ constipation @DISEASE@ @CID@ cisapride @CHEMICAL@ diarrhoea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mclarithromycin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mventricular tachycardia\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mclarithromycin\u001b[00m is a relatively new macrolide antibiotic that offers twice-daily dosing. It differs from \u001b[48;2;144;238;144;38;2;0;0;0merythromycin\u001b[00m only in the methylation of the hydroxyl group at position 6. Although the side-effect profile of \u001b[48;2;144;238;144;38;2;0;0;0merythromycin\u001b[00m is established, including \u001b[48;2;144;238;144;38;2;0;0;0mgastroenteritis\u001b[00m and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded. Cardiotoxicity has been demonstrated after both intravenous and oral administration of \u001b[48;2;144;238;144;38;2;0;0;0merythromycin\u001b[00m but has never been reported with the newer macrolides. We report a case of \u001b[48;2;173;216;230;38;2;0;0;0mventricular dysrhythmias\u001b[00m that occurred after six therapeutic doses of \u001b[48;2;173;216;230;38;2;0;0;0mclarithromycin\u001b[00m. The dysrhythmias resolved after discontinuation of the drug.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "clarithromycin @CHEMICAL@ ventricular tachycardia @DISEASE@ @CID@ erythromycin @CHEMICAL@ gastroenteritis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "clarithromycin @CHEMICAL@ ventricular tachycardia ; ventricular dysrhythmias @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Persistent \u001b[48;2;173;216;230;38;2;0;0;0mnephrogenic diabetes insipidus\u001b[00m following \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy. We report the case of a patient who developed severe \u001b[48;2;173;216;230;38;2;0;0;0mhypernatraemic dehydration\u001b[00m following a head injury. Ten years previously he had been diagnosed to have \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrogenic diabetes insipidus\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy had been discontinued. He remained thirsty and \u001b[48;2;173;216;230;38;2;0;0;0mpolyuric\u001b[00m despite cessation of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of \u001b[48;2;173;216;230;38;2;0;0;0mnephrogenic diabetes insipidus\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrogenic diabetes insipidus\u001b[00m is considered to be reversible on cessation of therapy but \u001b[48;2;144;238;144;38;2;0;0;0mpolyuria\u001b[00m persisted in this patient for ten years after \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m was stopped. We discuss the possible renal mechanisms and the implications for management of patients with \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnephrogenic diabetes insipidus\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium @CHEMICAL@ nephrogenic diabetes insipidus @DISEASE@ @CID@ lithium @CHEMICAL@ polyuric ; polyuria @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium @CHEMICAL@ nephrogenic diabetes insipidus @DISEASE@ @CID@ lithium @CHEMICAL@ hypernatraemic dehydration @DISEASE@ @CID@ lithium @CHEMICAL@ polyuric @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Late \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m after treatment for a malignant bone tumor. Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m. Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment. Cumulative doses of \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m were 225-550 mg/m2 (median dose 360). The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography. Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction. The incidence of \u001b[48;2;144;238;144;38;2;0;0;0mcardiac abnormalities\u001b[00m increased with length of follow-up (P< or = .05). No correlation could be demonstrated between cumulative dose of \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m and cardiac status, except for heart rate variability. When adjusted to body surface area, the left ventricular posterior wall thickness (LVPW index) was decreased in all patients. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m is high and increases with follow-up, irrespective of cumulative dose. Life-long cardiac follow-up in these patients is warranted. The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "doxorubicin @CHEMICAL@ cardiac abnormalities @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin @CHEMICAL@ cardiotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mvenous complications\u001b[00m of \u001b[48;2;144;238;144;38;2;0;0;0mmidazolam\u001b[00m versus \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m. Although some studies have suggested fewer \u001b[48;2;173;216;230;38;2;0;0;0mvenous complications\u001b[00m are associated with \u001b[48;2;144;238;144;38;2;0;0;0mmidazolam\u001b[00m than with \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m for endoscopic procedures, this variable has not been well documented. We prospectively evaluated the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mvenous complications\u001b[00m after intravenous injection of \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m or \u001b[48;2;144;238;144;38;2;0;0;0mmidazolam\u001b[00m in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy. Overall, \u001b[48;2;173;216;230;38;2;0;0;0mvenous complications\u001b[00m were more frequent with \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m (22 of 62 patients) than with \u001b[48;2;144;238;144;38;2;0;0;0mmidazolam\u001b[00m (4 of 60 patients) (p < 0.001). A palpable venous cord was present in 23% (14 of 62) of patients in the \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m group, compared with 2% (1 of 60 patients) in the \u001b[48;2;144;238;144;38;2;0;0;0mmidazolam\u001b[00m group (p < 0.002). Pain at the injection site occurred in 35% (22 of 62) of patients in the \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m group compared with 7% (4 of 60 patients) in the \u001b[48;2;144;238;144;38;2;0;0;0mmidazolam\u001b[00m group (p < 0.001). Swelling and warmth at the injection site were not significantly different between the two groups. Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mvenous complications\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "midazolam @CHEMICAL@ venous complications @DISEASE@ @CID@ diazepam @CHEMICAL@ venous complications @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "diazepam @CHEMICAL@ venous complications @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m-induced damage in a model of chronic \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. Sprague-Dawley rats were injected intraperitoneally with \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m-treated rats as compared to controls at all time intervals. Additional neuronanatomical studies, including cresyl violet staining, \u001b[48;2;144;238;144;38;2;0;0;0mneuronal degeneration\u001b[00m methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to \u001b[48;2;144;238;144;38;2;0;0;0mneuronal loss\u001b[00m rather than to a decrease in GAD mRNA levels. The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer. Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals. No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer. The results indicate that, in this model, a subpopulation of GAD mRNA-containing neurons within the dentate gyrus is selectively vulnerable to \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m-induced damage. Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ pilocarpine @CHEMICAL@ neuronal degeneration ; neuronal loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxic\u001b[00m effects of \u001b[48;2;173;216;230;38;2;0;0;0maminoglycoside\u001b[00m treatment on renal protein reabsorption and accumulation. To quantify the effects of \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mkanamycin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days. Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i.v. administration of egg-white lysozyme and measurements of inulin clearance (GFR) were done in each treatment group. \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m administration decreased diameter, density and shape of endothelial fenestrae. \u001b[48;2;173;216;230;38;2;0;0;0mkanamycin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m appeared to have no effect at the dose used. All three \u001b[48;2;173;216;230;38;2;0;0;0maminoglycosides\u001b[00m decreased GFR and increased urinary excretion of sodium and potassium. While \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mkanamycin\u001b[00m decreased the percentage reabsorption and accumulation of lysozyme after i.v. administration of egg-white lysozyme \u001b[48;2;173;216;230;38;2;0;0;0mnetilmicin\u001b[00m had no effect. Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with \u001b[48;2;173;216;230;38;2;0;0;0mkanamycin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m. Thus, \u001b[48;2;173;216;230;38;2;0;0;0maminoglycosides\u001b[00m may act as nephrotoxicants at glomerular and/or tubular level inducing \u001b[48;2;173;216;230;38;2;0;0;0mimpairment of renal reabsorption and accumulation of proteins\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "gentamicin @CHEMICAL@ nephrotoxic ; impairment of renal reabsorption @DISEASE@ @CID@ kanamycin @CHEMICAL@ nephrotoxic ; impairment of renal reabsorption @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "aminoglycoside ; aminoglycosides @CHEMICAL@ impairment of renal reabsorption and accumulation of proteins @DISEASE@ @CID@ gentamicin @CHEMICAL@ impairment of renal reabsorption and accumulation of proteins @DISEASE@ @CID@ kanamycin @CHEMICAL@ impairment of renal reabsorption and accumulation of proteins @DISEASE@ @CID@ netilmicin @CHEMICAL@ impairment of renal reabsorption and accumulation of proteins @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Pharmacology of \u001b[48;2;173;216;230;38;2;0;0;0mgyki-41 099\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mchlorpropanol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtobanum\u001b[00m) a new potent beta-adrenergic antagonist. The compound \u001b[48;2;173;216;230;38;2;0;0;0mgyki-41 099\u001b[00m, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo. Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the \u001b[48;2;144;238;144;38;2;0;0;0mouabain\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0marrhythmia\u001b[00m in dogs and cats. GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective. The compound shows a rapid and long lasting effect. There was a prolonged elimination of the radioactivity after the injection of 14C-41 099 to rats and dogs. The half life of the unlabeled substance in humans was more than 10 hours.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ouabain @CHEMICAL@ arrhythmia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "gyki-41 099 ; chlorpropanol ; tobanum @CHEMICAL@ arrhythmia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mchorea\u001b[00m associated with \u001b[48;2;144;238;144;38;2;0;0;0moral contraception\u001b[00m. Three patients developed \u001b[48;2;173;216;230;38;2;0;0;0mchorea\u001b[00m while receiving \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m. Two were young patients whose \u001b[48;2;173;216;230;38;2;0;0;0mchorea\u001b[00m developed long after treatment had been started and disappeared soon after it had been discontinued. The third patient had acute \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mchorea\u001b[00m after prolonged \u001b[48;2;144;238;144;38;2;0;0;0moral contraception\u001b[00m. Prolonged administration of female sex hormones is a possible cause of \u001b[48;2;173;216;230;38;2;0;0;0mchorea\u001b[00m in women who have not previously had \u001b[48;2;173;216;230;38;2;0;0;0mchorea\u001b[00m or rheumatic fever.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraception ; oral contraceptives @CHEMICAL@ chorea @DISEASE@ @CID@ amphetamine @CHEMICAL@ chorea @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oral contraceptives ; oral contraceptive @CHEMICAL@ chorea @DISEASE@ @CID@ amphetamine @CHEMICAL@ chorea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Reversal of \u001b[48;2;173;216;230;38;2;0;0;0mammonia \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m\u001b[00m in rats by L-dopa: a peripheral effect. \u001b[48;2;173;216;230;38;2;0;0;0mammonia \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m\u001b[00m was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol \u001b[48;2;173;216;230;38;2;0;0;0mnh4cl\u001b[00m. This \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection. The effect of L-dopa was correlated with a decrease in blood and brain \u001b[48;2;173;216;230;38;2;0;0;0mammonia\u001b[00m, an increase in brain dopamine, and an increase in renal excretion of \u001b[48;2;173;216;230;38;2;0;0;0mammonia\u001b[00m and urea. Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the \u001b[48;2;173;216;230;38;2;0;0;0mammonia \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m\u001b[00m nor affect the blood and brain \u001b[48;2;173;216;230;38;2;0;0;0mammonia\u001b[00m concentrations. Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain \u001b[48;2;173;216;230;38;2;0;0;0mammonia\u001b[00m and the \u001b[48;2;173;216;230;38;2;0;0;0mammonia \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m\u001b[00m was not prevented. Thus, the reduction in blood and brain \u001b[48;2;173;216;230;38;2;0;0;0mammonia\u001b[00m and the prevention of \u001b[48;2;173;216;230;38;2;0;0;0mammonia \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m\u001b[00m after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action. These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nh4cl @CHEMICAL@ coma @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ammonia ; nh4cl @CHEMICAL@ ammonia coma @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m after liver transplantation. BACKGROUND: Unfractionated \u001b[48;2;173;216;230;38;2;0;0;0mheparin sodium\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mufh\u001b[00m) or low-molecular weight \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation. \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m) is an adverse immune-mediated reaction to \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, resulting in platelet count decreases of more than 50%. The frequencies of \u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m after liver transplantation and platelet factor 4/\u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-reactive antibody (\u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m antibody) positivity in liver transplantation patients, however, are unknown. PATIENTS AND METHODS: The 32 men and 20 women underwent living donor liver transplantation. We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to \u001b[48;2;173;216;230;38;2;0;0;0mufh\u001b[00m (5000 U/d) on POD 2 or 3. The dose of \u001b[48;2;173;216;230;38;2;0;0;0mufh\u001b[00m was changed according to the activated clotting time level. \u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m antibody levels were measured the day before surgery and on POD 7 and 14. Platelet count was measured daily for 3 weeks. RESULTS: The average platelet counts preoperatively, and on POD 7, 14, and 21 were 65, 88, 149, and 169 x 10(9)/L, respectively. Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were \u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m antibody-negative and their platelet counts were stable. In 2 other patients, the platelet count decreased suddenly from 107 x 10(9)/L on POD 4 to 65 x 10(9)/L on POD 6 and from 76 x 10(9)/L on POD 7 to 33 x 10(9)/L on POD 9, respectively. The \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced platelet aggregation test was negative in these patients. The percentage of \u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14. None of the subjects/patients developed \u001b[48;2;173;216;230;38;2;0;0;0mufh\u001b[00m-related \u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m. CONCLUSIONS: In our series, the occurrence of \u001b[48;2;173;216;230;38;2;0;0;0mhit\u001b[00m after liver transplantation was uncommon.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin ; unfractionated heparin sodium ; ufh @CHEMICAL@ thrombocytopenia ; hit @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin ; heparin sodium ; ufh @CHEMICAL@ thrombocytopenia ; hit @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mptu\u001b[00m-associated \u001b[48;2;144;238;144;38;2;0;0;0mvasculitis\u001b[00m in a girl with Turner Syndrome and Graves' disease. Palpable \u001b[48;2;173;216;230;38;2;0;0;0mpurpura\u001b[00m is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes. A rare cause, \u001b[48;2;173;216;230;38;2;0;0;0mdrug-induced \u001b[48;2;144;238;144;38;2;0;0;0mvasculitis\u001b[00m\u001b[00m, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication. We report a girl with Turner syndrome and Graves' disease who presented with palpable \u001b[48;2;173;216;230;38;2;0;0;0mpurpuric lesions\u001b[00m. The diagnosis of \u001b[48;2;173;216;230;38;2;0;0;0mpropylthiouracil\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mptu\u001b[00m)-associated \u001b[48;2;144;238;144;38;2;0;0;0mvasculitis\u001b[00m was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of \u001b[48;2;173;216;230;38;2;0;0;0mptu\u001b[00m. Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the \u001b[48;2;144;238;144;38;2;0;0;0mvasculitis\u001b[00m, a complication described in prior case reports.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ptu ; propylthiouracil @CHEMICAL@ vasculitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "propylthiouracil ; ptu @CHEMICAL@ purpura ; purpuric lesions @DISEASE@ @CID@ propylthiouracil ; ptu @CHEMICAL@ drug-induced vasculitis ; drug-induced purpura ; drug-induced purpuric lesions @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmasseter muscle rigidity\u001b[00m during bronchoscopic removal of a tracheal foreign body. \u001b[48;2;173;216;230;38;2;0;0;0mmasseter muscle rigidity\u001b[00m during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia. The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of \u001b[48;2;173;216;230;38;2;0;0;0mmasseter muscle rigidity\u001b[00m. Here, we describe a case of severe \u001b[48;2;173;216;230;38;2;0;0;0mmasseter muscle rigidity\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mjaw of steel\u001b[00m) after \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0msch\u001b[00m) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body. Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "succinylcholine ; sch @CHEMICAL@ masseter muscle rigidity ; jaw of steel @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "succinylcholine ; sch @CHEMICAL@ masseter muscle rigidity ; masseter muscle rigidity ; jaw of steel @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Minor \u001b[48;2;173;216;230;38;2;0;0;0mneurological dysfunction\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcognitive development\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0msomatic development\u001b[00m at the age of 3 to 7 years after \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m treatment in very-low birth-weight infants. The objective of this study was to assess minor \u001b[48;2;173;216;230;38;2;0;0;0mneurological dysfunction\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcognitive development\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0msomatic development\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m therapy in very-low-birthweight infants. Thirty-three children after \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m treatment were matched to 33 children without \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m treatment. Data were assessed at the age of 3-7 years. \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day. Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, \u001b[48;2;173;216;230;38;2;0;0;0mintraventricular haemorrhage\u001b[00m grades III and IV, \u001b[48;2;173;216;230;38;2;0;0;0mperiventricular leukomalacia\u001b[00m, and severe \u001b[48;2;173;216;230;38;2;0;0;0mpsychomotor retardation\u001b[00m. Each child was examined by a neuropediatrician for minor \u001b[48;2;144;238;144;38;2;0;0;0mneurological dysfunctions\u001b[00m and tested by a psychologist for \u001b[48;2;173;216;230;38;2;0;0;0mcognitive development\u001b[00m with a Kaufman Assessment Battery for Children and a Draw-a-Man Test. There were no differences in demographic data, growth, and socio-economic status between the two groups. Fine motor skills and gross motor function were significantly better in the control group (p<0.01). In the Draw-a-Man Test, the control group showed better results (p<0.001). There were no differences in development of speech, social development, and the Kaufman Assessment Battery for Children. After \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m treatment, children showed a higher rate of minor \u001b[48;2;144;238;144;38;2;0;0;0mneurological dysfunctions\u001b[00m. Neurological development was affected even without neurological diagnosis. Further long-term follow-up studies will be necessary to fully evaluate the impact of \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m on neurological and \u001b[48;2;173;216;230;38;2;0;0;0mcognitive development\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dexamethasone @CHEMICAL@ neurological dysfunction ; neurological dysfunctions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dexamethasone @CHEMICAL@ neurological dysfunction ; cognitive development ; somatic development @DISEASE@ @CID@ dexamethasone @CHEMICAL@ intraventricular haemorrhage @DISEASE@ @CID@ dexamethasone @CHEMICAL@ periventricular leukomalacia @DISEASE@ @CID@ dexamethasone @CHEMICAL@ psychomotor retardation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Force overflow and \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m in Parkinson's disease. We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m therapy, particularly to \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m). We studied two groups of Parkinson's disease patients with (Parkinson's disease + \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m, n = 23) and without \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m (Parkinson's disease - \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m, n = 10), and age-matched healthy controls. The motor score of the Unified Parkinson's Disease Rating Scale, a \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m score and force in a grip-lift paradigm were assessed ON and OFF \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m. A pathological increase of forces was seen in ON-state in Parkinson's disease + \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m only. In Parkinson's disease + \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m, the force involved in pressing down the object before lifting was significantly increased by \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m (by 61%, P < 0.05). An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition. In contrast, no excessive force was found in Parkinson's disease - \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m. Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m than in Parkinson's disease - \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m, while static grip force was increased by 138% (P < 0.01) between groups. Severity of peak-dose \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01). No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication. Force excess was only observed in patients with \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m and motor fluctuations. A close relationship was seen between the overshooting of forces and \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m in the ON-drug condition. We postulate that both \u001b[48;2;173;216;230;38;2;0;0;0mlid\u001b[00m and grip force excess share common pathophysiological mechanisms related to motor fluctuations.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; lid ; dyskinesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; lid @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Postinfarction \u001b[48;2;173;216;230;38;2;0;0;0mventricular septal defect\u001b[00m associated with long-term \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m therapy. Two cases of postinfarction \u001b[48;2;173;216;230;38;2;0;0;0mventricular \u001b[48;2;144;238;144;38;2;0;0;0mseptal rupture\u001b[00m\u001b[00m in patients on long-term \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m therapy are presented and the favourable outcome in both cases described. A possible association between \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m therapy and subsequent postinfarction \u001b[48;2;144;238;144;38;2;0;0;0mseptal rupture\u001b[00m is discussed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "steroid @CHEMICAL@ ventricular septal defect ; ventricular septal rupture ; septal rupture @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "steroid @CHEMICAL@ ventricular septal defect ; ventricular septal rupture @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mclarithromycin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mvisual hallucinations\u001b[00m in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. \u001b[48;2;173;216;230;38;2;0;0;0mvisual hallucinations\u001b[00m are a rare event in chronic renal failure and not related to uremia per se. Unreported in the literature is \u001b[48;2;173;216;230;38;2;0;0;0mvisual hallucinations\u001b[00m occurring in association with the new macrolide antibiotic, \u001b[48;2;173;216;230;38;2;0;0;0mclarithromycin\u001b[00m. We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD). The combination of a relatively high dose of \u001b[48;2;173;216;230;38;2;0;0;0mclarithromycin\u001b[00m in face of chronic renal failure in a functionally anephric patient, with underlying \u001b[48;2;173;216;230;38;2;0;0;0maluminum\u001b[00m intoxication, may have facilitated the appearance of this neurotoxic side effect. It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "clarithromycin @CHEMICAL@ visual hallucinations @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "clarithromycin @CHEMICAL@ visual hallucinations @DISEASE@ @CID@ aluminum @CHEMICAL@ visual hallucinations @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Acute renal toxicity of \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m)-loaded cyanoacrylate nanoparticles. Acute \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis. In normal rats, 2/6 rats given free \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mdx\u001b[00m) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived. A 3 times higher \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m appeared in animals treated with DXNP than in those treated with \u001b[48;2;144;238;144;38;2;0;0;0mdx\u001b[00m. Free NP did not provoke any \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m. Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free \u001b[48;2;144;238;144;38;2;0;0;0mdx\u001b[00m (p < 0.025). In rats with immune experimental glomerulonephritis, 5/6 rats given \u001b[48;2;144;238;144;38;2;0;0;0mdx\u001b[00m died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived. \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m treatment (400-700 mg/day), without significant difference between DXNP and \u001b[48;2;144;238;144;38;2;0;0;0mdx\u001b[00m. Rats treated by unloaded NP behaved as controls. These results demonstrate that, in these experimental conditions, DXNP killed less animals than free \u001b[48;2;144;238;144;38;2;0;0;0mdx\u001b[00m, despite of an enhanced renal toxicity of the former. Both effects (better survival and nephrosis) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system, including mesangial cells.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "doxorubicin ; adriamycin ; dx @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin ; adriamycin @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Subjective assessment of \u001b[48;2;173;216;230;38;2;0;0;0msexual dysfunction\u001b[00m of patients on long-term administration of \u001b[48;2;173;216;230;38;2;0;0;0mdigoxin\u001b[00m. Various data suggest that male patients who have received \u001b[48;2;173;216;230;38;2;0;0;0mdigoxin\u001b[00m on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH). This study was undertaken to investigate the links between the long-term administration of \u001b[48;2;173;216;230;38;2;0;0;0mdigoxin\u001b[00m therapy and \u001b[48;2;173;216;230;38;2;0;0;0msexual behavior\u001b[00m, and the effect of \u001b[48;2;173;216;230;38;2;0;0;0mdigoxin\u001b[00m on plasma levels of estradiol, testosterone, and LH. The patients of the study and control group (without \u001b[48;2;173;216;230;38;2;0;0;0mdigoxin\u001b[00m) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients. A subjective assessment of \u001b[48;2;173;216;230;38;2;0;0;0msexual behavior\u001b[00m in the study and control groups was carried out, using parameters such as \u001b[48;2;173;216;230;38;2;0;0;0msexual desire\u001b[00m, sexual excitement, and frequency of sexual relations. Personal interviews and a questionnaire were also used for the evaluation of \u001b[48;2;173;216;230;38;2;0;0;0msexual behavior\u001b[00m. The findings support the reports concerning \u001b[48;2;173;216;230;38;2;0;0;0mdigoxin\u001b[00m effect on plasma estradiol, testosterone, and LH. The differences in the means were significant. Tests used to evaluate the changes in \u001b[48;2;173;216;230;38;2;0;0;0msexual behavior\u001b[00m showed a significant decrease in \u001b[48;2;173;216;230;38;2;0;0;0msexual desire\u001b[00m, sexual excitement phase (erection), and frequency of sexual relations in the study group.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "digoxin @CHEMICAL@ sexual dysfunction ; decrease in sexual desire @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "digoxin @CHEMICAL@ sexual dysfunction ; sexual behavior ; sexual desire @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Plasma and urinary lipids and lipoproteins during the development of \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m induced in the rat by \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin \u001b[48;2;144;238;144;38;2;0;0;0maminonucleoside\u001b[00m\u001b[00m. This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin \u001b[48;2;144;238;144;38;2;0;0;0maminonucleoside\u001b[00m\u001b[00m were due to \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m per se, or, at least in part, to the \u001b[48;2;144;238;144;38;2;0;0;0maminonucleoside\u001b[00m. The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin \u001b[48;2;144;238;144;38;2;0;0;0maminonucleoside\u001b[00m\u001b[00m (20 mg/kg for 7 days) and the subsequent development of \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m. Since massive \u001b[48;2;173;216;230;38;2;0;0;0malbuminuria\u001b[00m occurred after 6 days of treatment, the time-course study was divided into two stages: pre-\u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m stage (day 1-5) and \u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m stage (day 6-11). In pre-\u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant. Plasma apolipoprotein A-I tended to increase (40% increase at day 5). At the beginning of \u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days. The plasma concentration of HDL followed the same pattern. Plasma VLDL and LDL increased at a later stage (day 9). Plasma apolipoprotein A-I was found not only in HDL (1.063-1.210 g/ml) but also in the LDL density class (1.025-1.050 g/ml). In the pre-\u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m stage lipoproteinuria was negligible, while in the early \u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m stage the urinary loss of plasma lipoproteins consisted mainly of HDL. These observations indicate that \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin \u001b[48;2;144;238;144;38;2;0;0;0maminonucleoside\u001b[00m\u001b[00m alters plasma lipoproteins by lowering VLDL and increasing HDL. It is likely that the early and striking increase of plasma HDL found in \u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m rats is related to a direct effect of the drug on HDL metabolism.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "puromycin aminonucleoside ; aminonucleoside @CHEMICAL@ nephrotic syndrome ; nephrotic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "puromycin aminonucleoside @CHEMICAL@ nephrotic syndrome @DISEASE@ @CID@ puromycin aminonucleoside @CHEMICAL@ albuminuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Circulating lysosomal enzymes and \u001b[48;2;144;238;144;38;2;0;0;0macute hepatic necrosis\u001b[00m. The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with \u001b[48;2;173;216;230;38;2;0;0;0mfulminant hepatic failure\u001b[00m. Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived \u001b[48;2;173;216;230;38;2;0;0;0mfulminant hepatic failure\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m overdose, whereas activities were increased equally in patients with \u001b[48;2;173;216;230;38;2;0;0;0mfulminant hepatic failure\u001b[00m due to viral hepatitis whether or not they survived. A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall. Circulating lysosomal proteases can damage other organs, and measurement of their activity may therefore be of added value in assessing prognosis in this condition.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "paracetamol @CHEMICAL@ acute hepatic necrosis ; fulminant hepatic failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "paracetamol @CHEMICAL@ fulminant hepatic failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Mechanisms of \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m: comparison with exercise-induced ischemia. The role of \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m in eliciting \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m was examined in patients with coronary artery disease. Objective signs of ischemia and factors increasing \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial oxygen consumption\u001b[00m were compared during \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m infusion and supine bicycle exercise. Both \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m and exercise produced \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m as evidenced by ST segment depression and angina. However, the mechanisms of \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m were significantly different from those of exercise. Exercise-induced \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product. These findings indicate that ischemia produced by \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "epinephrine @CHEMICAL@ myocardial ischemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "epinephrine @CHEMICAL@ myocardial ischemia ; myocardial oxygen consumption @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Transient \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m\u001b[00m following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m. Following unilateral 6-OHDA induced SN lesion, a transient period of \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m\u001b[00m has been reported to precede the predominant \u001b[48;2;144;238;144;38;2;0;0;0mipsilateral circling\u001b[00m. In order to clarify the nature of this initial \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m\u001b[00m we examined the effect of the duration of recovery period after the lesion, on \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mrotational behavior\u001b[00m. Three days post lesion, most rats circled predominantly contralaterally to the lesion. Such \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m\u001b[00m may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons. A substantial degree of \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral preference\u001b[00m was still evident when \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m\u001b[00m. However, regardless of the duration of recovery (and irrespective of either lesion volume, \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m dose, or post-lesion motor exercise), \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m injections. These findings suggest that \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m has an irreversible effect on the post-lesion DA pool contributing to \u001b[48;2;173;216;230;38;2;0;0;0mcontralateral \u001b[48;2;144;238;144;38;2;0;0;0mrotation\u001b[00m\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amphetamine @CHEMICAL@ contralateral rotation ; ipsilateral circling ; rotational behavior ; rotation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amphetamine @CHEMICAL@ contralateral rotation ; contralateral preference @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Thyroid function and urine-concentrating ability during \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m treatment. It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m during \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m treatment. We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m developed in eight patients while they were taking \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m. Impaired Umax was found in both euthyroid and \u001b[48;2;144;238;144;38;2;0;0;0mhypothyroid\u001b[00m patients while some \u001b[48;2;144;238;144;38;2;0;0;0mhypothyroid\u001b[00m patients concentrated their urine well. It is concluded that the dominant mechanisms by which \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m exerts these two effects are different.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium @CHEMICAL@ hypothyroidism ; hypothyroid @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium @CHEMICAL@ hypothyroidism @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Sensitivity of erythroid progenitor colonies to erythropoietin in \u001b[48;2;173;216;230;38;2;0;0;0mazidothymidine\u001b[00m treated immunodeficient mice. The \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m induced by \u001b[48;2;144;238;144;38;2;0;0;0m3'-azido-3'dideoxythymidine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m) is poorly understood. We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO). Mice in the early stage of LP-BM5 MuLV disease were given \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m in their drinking water at 1.0 and 2.5 mg/ml. \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m produced \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m in both groups, in a dose-dependent fashion. Despite the \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m, the number of splenic and bone marrow BFU-e in \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment. Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m for 15 d than for infected, untreated mice. By day 30, sensitivity of both splenic and bone marrow BFU-e of treated animals returned to that observed from cells of infected untreated animals. The mean plasma levels of EPO observed in \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m treated mice were appropriate for the degree of \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m observed when compared with phenylhydrazine (PHZ) treated mice. The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m and PHZ treated mice with similar degrees of \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m. However, reticulocytosis was inappropriate for the degree of \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m observed in \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m treated infected mice. \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-induced peripheral \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "azidothymidine ; 3'-azido-3'dideoxythymidine ; azt @CHEMICAL@ anaemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "azidothymidine ; azt @CHEMICAL@ anaemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Detection of abnormal cardiac adrenergic neuron activity in \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m with iodine-125-metaiodobenzylguanidine. Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function. Using a rat model of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m. The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m treatment (2 mg/kg, once a week). There were no abnormalities or only isolated degeneration in the 1- or 2-wk treatment groups, isolated or scattered degeneration in half of the 3-wk group, frequent scattered degeneration in the 4-wk group, scattered or focal degeneration in the 5-wk group, and extensive degeneration in the 8-wk group. Myocardial accumulation of [125I]MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less. However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05). In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001). In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001). Thus, MIBG accumulation in the myocardium decreased in an \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m dose-dependent manner. The appearance of impaired cardiac adrenergic neuron activity in the presence of slight \u001b[48;2;144;238;144;38;2;0;0;0mmyocardial impairment\u001b[00m (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "adriamycin @CHEMICAL@ cardiomyopathy ; myocardial impairment @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "adriamycin @CHEMICAL@ cardiomyopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mamnestic syndrome\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m toxicity: a case report. An elderly woman developed an Alzheimer-like subacute dementia as a result of \u001b[48;2;173;216;230;38;2;0;0;0mpropranolol\u001b[00m toxicity. Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities. There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "propranolol @CHEMICAL@ amnestic syndrome @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "propranolol @CHEMICAL@ amnestic syndrome ; amnesic @DISEASE@ @CID@ propranolol @CHEMICAL@ alzheimer's subacute dementia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0morthostatic hypotension\u001b[00m occurs following alpha 2-adrenoceptor blockade in chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m-pretreated conscious spontaneously \u001b[48;2;144;238;144;38;2;0;0;0mhypertensive\u001b[00m rats. 1. Studies were performed to evaluate whether chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously \u001b[48;2;144;238;144;38;2;0;0;0mhypertensive\u001b[00m rats (SHR). 2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m (0.1 mg kg-1 i.p.) or \u001b[48;2;173;216;230;38;2;0;0;0mrauwolscine\u001b[00m (3 mg kg-1 i.v.). \u001b[48;2;173;216;230;38;2;0;0;0morthostatic hypotension\u001b[00m was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period. The basal MAP of conscious SHR was reduced to a similar extent by \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m (-23%(-)-26% MAP) and \u001b[48;2;173;216;230;38;2;0;0;0mrauwolscine\u001b[00m (-16%(-)-33% MAP). However, the head-up tilt induced \u001b[48;2;173;216;230;38;2;0;0;0morthostatic hypotension\u001b[00m in the SHR treated with \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m (-16% MAP, n = 6), but not in the SHR treated with \u001b[48;2;173;216;230;38;2;0;0;0mrauwolscine\u001b[00m (less than +2% MAP, n = 6). 3. Conscious SHR were treated for 4 days with \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade. MAP in conscious SHR after chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m treatment was 14% lower than in the untreated SHR (n = 8). Head-up tilts in these rats did not produce \u001b[48;2;173;216;230;38;2;0;0;0morthostatic hypotension\u001b[00m when performed either prior to or after acute dosing of \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m (0.1 mg kg-1 i.p.). Conversely, administration of \u001b[48;2;173;216;230;38;2;0;0;0mrauwolscine\u001b[00m (3 mg kg-1 i.v.) in chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats. 4. The pressor responses and \u001b[48;2;144;238;144;38;2;0;0;0mbradycardia\u001b[00m to the alpha 1-agonist \u001b[48;2;144;238;144;38;2;0;0;0mcirazoline\u001b[00m (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist \u001b[48;2;144;238;144;38;2;0;0;0mabbott-53693\u001b[00m (1 and 3 micrograms kg-1 i.v.), and \u001b[48;2;144;238;144;38;2;0;0;0mnoradrenaline\u001b[00m (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m pretreatment. Both the pressor and \u001b[48;2;144;238;144;38;2;0;0;0mbradycardia\u001b[00m effects of \u001b[48;2;144;238;144;38;2;0;0;0mcirazoline\u001b[00m were abolished in chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m treated SHR (n = 4) as compared to the untreated SHR (n = 4). On the other hand, the pressor effects of \u001b[48;2;144;238;144;38;2;0;0;0mabbott-53693\u001b[00m were similar in both groups of SHR, but the accompanying \u001b[48;2;144;238;144;38;2;0;0;0mbradycardia\u001b[00m was greater in SHR with chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m treatment than without such treatment. Furthermore, the \u001b[48;2;144;238;144;38;2;0;0;0mbradycardia\u001b[00m that accompanied the \u001b[48;2;144;238;144;38;2;0;0;0mnoradrenaline\u001b[00m-induced pressor effect in SHR was similar with and without chronic \u001b[48;2;173;216;230;38;2;0;0;0mprazosin\u001b[00m treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prazosin @CHEMICAL@ orthostatic hypotension @DISEASE@ @CID@ cirazoline @CHEMICAL@ hypertensive @DISEASE@ @CID@ cirazoline @CHEMICAL@ bradycardia @DISEASE@ @CID@ abbott-53693 @CHEMICAL@ hypertensive @DISEASE@ @CID@ abbott-53693 @CHEMICAL@ bradycardia @DISEASE@ @CID@ noradrenaline @CHEMICAL@ hypertensive @DISEASE@ @CID@ noradrenaline @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prazosin @CHEMICAL@ orthostatic hypotension ; orthostatic bradycardia @DISEASE@ @CID@ rauwolscine @CHEMICAL@ orthostatic hypotension ; orthostatic bradycardia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Coexistence of cerebral venous sinus and \u001b[48;2;144;238;144;38;2;0;0;0minternal carotid artery thrombosis\u001b[00m associated with exogenous sex hormones. A case report. A forty-six year-old premenopausal woman developed \u001b[48;2;173;216;230;38;2;0;0;0mheadache\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mnausea\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mvomiting\u001b[00m, left \u001b[48;2;173;216;230;38;2;0;0;0mhemiparesis\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m two days after parenteral use of \u001b[48;2;173;216;230;38;2;0;0;0mprogesterone\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mestradiol\u001b[00m. Diabetes mellitus (DM) was found during admission. Computed tomography showed a \u001b[48;2;144;238;144;38;2;0;0;0mhemorrhagic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0minfarct\u001b[00m in the right frontal lobe and increased density in the superior sagittal sinus (SSS). Left carotid angiography found occlusion of the left internal carotid artery (ICA). Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of \u001b[48;2;144;238;144;38;2;0;0;0mvenous sinus thrombosis\u001b[00m. Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently. In this case, the authors postulate that the use of \u001b[48;2;173;216;230;38;2;0;0;0mestradiol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mprogesterone\u001b[00m and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "progesterone @CHEMICAL@ cerebral venous sinus thrombosis ; venous sinus thrombosis ; thrombosis of the venous sinus @DISEASE@ @CID@ progesterone @CHEMICAL@ internal carotid artery thrombosis ; thrombosis of the ica @DISEASE@ @CID@ progesterone @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ progesterone @CHEMICAL@ infarct ; cerebral artery occlusion @DISEASE@ @CID@ estradiol @CHEMICAL@ cerebral venous sinus thrombosis ; venous sinus thrombosis ; thrombosis of the venous sinus @DISEASE@ @CID@ estradiol @CHEMICAL@ internal carotid artery thrombosis ; thrombosis of the ica @DISEASE@ @CID@ estradiol @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ estradiol @CHEMICAL@ infarct ; cerebral artery occlusion @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "progesterone @CHEMICAL@ headache @DISEASE@ @CID@ progesterone @CHEMICAL@ nausea @DISEASE@ @CID@ progesterone @CHEMICAL@ vomiting @DISEASE@ @CID@ progesterone @CHEMICAL@ seizure @DISEASE@ @CID@ estradiol @CHEMICAL@ headache @DISEASE@ @CID@ estradiol @CHEMICAL@ hemiparesis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m related complete \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m with \u001b[48;2;144;238;144;38;2;0;0;0mblindness\u001b[00m: case report. A 27-year old African woman with history of regular \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m ingestion presented with progressive deterioration of vision, easy \u001b[48;2;144;238;144;38;2;0;0;0mfatiguability\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mdyspnoea\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mdizziness\u001b[00m progressing to \u001b[48;2;173;216;230;38;2;0;0;0msyncopal attacks\u001b[00m. Ophthalmological assessment revealed features of \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mretinopathy\u001b[00m, cardiac assessment revealed features of \u001b[48;2;173;216;230;38;2;0;0;0mheart failure\u001b[00m and a complete \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m with \u001b[48;2;144;238;144;38;2;0;0;0mright bundle branch block\u001b[00m pattern. The \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m was treated by pacemaker insertion and the \u001b[48;2;173;216;230;38;2;0;0;0mheart failure\u001b[00m resolved spontaneously following \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m discontinuation. She however remains \u001b[48;2;144;238;144;38;2;0;0;0mblind\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "chloroquine @CHEMICAL@ blindness ; blind @DISEASE@ @CID@ chloroquine @CHEMICAL@ fatiguability @DISEASE@ @CID@ chloroquine @CHEMICAL@ dyspnoea @DISEASE@ @CID@ chloroquine @CHEMICAL@ dizziness @DISEASE@ @CID@ chloroquine @CHEMICAL@ syncopal attacks @DISEASE@ @CID@ chloroquine @CHEMICAL@ retinopathy @DISEASE@ @CID@ chloroquine @CHEMICAL@ heart failure @DISEASE@ @CID@ chloroquine @CHEMICAL@ right bundle branch block @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "chloroquine @CHEMICAL@ heart block ; heart failure @DISEASE@ @CID@ chloroquine @CHEMICAL@ retinopathy @DISEASE@ @CID@ chloroquine @CHEMICAL@ syncopal attacks @DISEASE@ @CID@ chloroquine @CHEMICAL@ heart failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Systemic toxicity and resuscitation in \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m-, \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m-, or \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m-infused rats. We compared the systemic toxicity of \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m in anesthetized rats. We also compared the ability to resuscitate rats after lethal doses of these local anesthetics. \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m, or \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m was infused at a rate of 2 mg. kg(-1). min(-1) while electrocardiogram, electroencephalogram, and arterial pressure were continuously monitored. When \u001b[48;2;173;216;230;38;2;0;0;0masystole\u001b[00m was recorded, drug infusion was stopped and a resuscitation sequence was begun. Epinephrine 0.01 mg/kg was administered at 1-min intervals while external cardiac compressions were applied. Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min. The cumulative doses of \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m that produced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m were similar and were larger than those of \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m. The cumulative doses of \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m that produced \u001b[48;2;173;216;230;38;2;0;0;0mdysrhythmias\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0masystole\u001b[00m were smaller than the corresponding doses of \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m, but they were larger than those of \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m. The number of successful resuscitations did not differ among groups. However, a smaller dose of epinephrine was required in the \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m group than in the other groups. We conclude that the systemic toxicity of \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m is intermediate between that of \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m when administered at the same rate and that \u001b[48;2;173;216;230;38;2;0;0;0mropivacaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiac arrest\u001b[00m appears to be more susceptible to treatment than that induced by \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mlevobupivacaine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levobupivacaine @CHEMICAL@ asystole ; cardiac arrest @DISEASE@ @CID@ levobupivacaine @CHEMICAL@ seizures @DISEASE@ @CID@ levobupivacaine @CHEMICAL@ dysrhythmias @DISEASE@ @CID@ ropivacaine @CHEMICAL@ asystole ; cardiac arrest @DISEASE@ @CID@ ropivacaine @CHEMICAL@ seizures @DISEASE@ @CID@ ropivacaine @CHEMICAL@ dysrhythmias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupivacaine @CHEMICAL@ asystole @DISEASE@ @CID@ levobupivacaine @CHEMICAL@ seizures @DISEASE@ @CID@ levobupivacaine @CHEMICAL@ dysrhythmias @DISEASE@ @CID@ levobupivacaine @CHEMICAL@ asystole @DISEASE@ @CID@ ropivacaine @CHEMICAL@ cardiac arrest @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0m22-oxacalcitriol\u001b[00m suppresses secondary \u001b[48;2;173;216;230;38;2;0;0;0mhyperparathyroidism\u001b[00m without inducing \u001b[48;2;144;238;144;38;2;0;0;0mlow bone turnover\u001b[00m in dogs with renal failure. BACKGROUND: \u001b[48;2;144;238;144;38;2;0;0;0mcalcitriol\u001b[00m therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including \u001b[48;2;173;216;230;38;2;0;0;0mhypercalcemia\u001b[00m and/or marked \u001b[48;2;144;238;144;38;2;0;0;0msuppression of bone turnover\u001b[00m, which may lead to \u001b[48;2;144;238;144;38;2;0;0;0madynamic bone disease\u001b[00m. A new vitamin D analogue, \u001b[48;2;173;216;230;38;2;0;0;0m22-oxacalcitriol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m), has been shown to have promising characteristics. This study was undertaken to determine the effects of \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m on serum PTH levels and bone turnover in states of normal or impaired renal function. METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22). The animals received supplemental phosphate to enhance PTH secretion. Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m (three times per week); the other half were given vehicle for 60 weeks. Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months. Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m or vehicle treatment, and at the end of the crossover period. RESULTS: In Nx dogs, \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m significantly decreased serum PTH levels soon after the induction of renal insufficiency. In long-standing secondary \u001b[48;2;173;216;230;38;2;0;0;0mhyperparathyroidism\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m (0.03 microg/kg) stabilized serum PTH levels during the first months. Serum PTH levels rose thereafter, but the rise was less pronounced compared with baseline than the rise seen in Nx control. These effects were accompanied by episodes of \u001b[48;2;173;216;230;38;2;0;0;0mhypercalcemia\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mhyperphosphatemia\u001b[00m. In animals with normal renal function, \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses. In Nx dogs, \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover. In addition, \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs. CONCLUSIONS: These results indicate that even though \u001b[48;2;173;216;230;38;2;0;0;0moct\u001b[00m does not completely prevent the occurrence of \u001b[48;2;173;216;230;38;2;0;0;0mhypercalcemia\u001b[00m in experimental dogs with renal insufficiency, it may be of use in the management of secondary \u001b[48;2;173;216;230;38;2;0;0;0mhyperparathyroidism\u001b[00m because it does not induce \u001b[48;2;144;238;144;38;2;0;0;0mlow bone turnover\u001b[00m and, therefore, does not increase the risk of \u001b[48;2;144;238;144;38;2;0;0;0madynamic bone disease\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "22-oxacalcitriol ; oct @CHEMICAL@ hypercalcemia @DISEASE@ @CID@ 22-oxacalcitriol ; oct @CHEMICAL@ hyperphosphatemia @DISEASE@ @CID@ calcitriol @CHEMICAL@ low bone turnover ; suppression of bone turnover ; adynamic bone disease @DISEASE@ @CID@ calcitriol @CHEMICAL@ hypercalcemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "22-oxacalcitriol ; oct @CHEMICAL@ hyperparathyroidism @DISEASE@ @CID@ 22-oxacalcitriol ; oct @CHEMICAL@ hypercalcemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Chemotherapy of advanced inoperable non-small cell lung cancer with \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m: a phase II trial. \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtaxol\u001b[00m; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma. Two phase II trials of 24-hour \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%. Leukopenia was dose limiting: as many as 62.5% of patients experienced grade 4 leukopenia. We investigated the efficacy and toxicity of a 3-hour \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC. The 58 patients treated (41 men and 17 women) had a median age of 59 years (age range, 25 to 75) and a performance status of 0 through 2. Most patients (72.4%) had stage IV NSCLC. \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication. Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%). Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 \u001b[48;2;173;216;230;38;2;0;0;0mneutropenia\u001b[00m, while 29% had grade 1 or 2. Grade 1 or 2 \u001b[48;2;173;216;230;38;2;0;0;0mpolyneuropathy\u001b[00m affected 56% of patients while only one (2%) experienced severe \u001b[48;2;173;216;230;38;2;0;0;0mpolyneuropathy\u001b[00m. Similarly, grade 1 or 2 \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m/\u001b[48;2;144;238;144;38;2;0;0;0marthralgia\u001b[00m was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4. \u001b[48;2;144;238;144;38;2;0;0;0mnausea\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mvomiting\u001b[00m were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4. \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity. Further phase II studies with \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m combined with other drugs active against NSCLC are indicated, and phase III studies comparing \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m with standard chemotherapy remain to be completed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "paclitaxel ; taxol @CHEMICAL@ neutropenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ polyneuropathy @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ myalgia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ arthralgia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ nausea @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ vomiting @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "paclitaxel ; taxol @CHEMICAL@ neutropenia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ polyneuropathy @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ myalgia @DISEASE@ @CID@ paclitaxel ; taxol @CHEMICAL@ vomiting @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcerebral hemorrhage\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mphenylpropanolamine\u001b[00m in combination with \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mphenylpropanolamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mppa\u001b[00m) is a drug that has been associated with serious side effects including \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m. It is often combined with \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m in diet preparations and \"look-alike\" pills. In order to determine if \u001b[48;2;173;216;230;38;2;0;0;0mppa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m can lead to \u001b[48;2;144;238;144;38;2;0;0;0mstroke\u001b[00m in normotensive and/or \u001b[48;2;144;238;144;38;2;0;0;0mhypertensive\u001b[00m rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days. Subarachnoid and \u001b[48;2;173;216;230;38;2;0;0;0mcerebral hemorrhage\u001b[00m was noted in 18% of the \u001b[48;2;144;238;144;38;2;0;0;0mhypertensive\u001b[00m rats. A single \u001b[48;2;173;216;230;38;2;0;0;0mppa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m administration (same dose) lead to acute \u001b[48;2;144;238;144;38;2;0;0;0mhypertension\u001b[00m in both the normotensive and \u001b[48;2;144;238;144;38;2;0;0;0mhypertensive\u001b[00m animals. These results suggest that \u001b[48;2;173;216;230;38;2;0;0;0mppa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m can lead to \u001b[48;2;173;216;230;38;2;0;0;0mcerebral hemorrhage\u001b[00m in previously \u001b[48;2;144;238;144;38;2;0;0;0mhypertensive\u001b[00m animals when administered in greater than the allowed dosage. An acute elevation in blood pressure may be a contributing factor.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "phenylpropanolamine ; ppa @CHEMICAL@ cerebral hemorrhage @DISEASE@ @CID@ phenylpropanolamine ; ppa @CHEMICAL@ stroke @DISEASE@ @CID@ phenylpropanolamine ; ppa @CHEMICAL@ hypertensive ; hypertension @DISEASE@ @CID@ phenylpropanolamine ; ppa @CHEMICAL@ subarachnoid hemorrhage @DISEASE@ @CID@ caffeine @CHEMICAL@ cerebral hemorrhage @DISEASE@ @CID@ caffeine @CHEMICAL@ hypertensive ; hypertension @DISEASE@ @CID@ caffeine @CHEMICAL@ subarachnoid hemorrhage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "phenylpropanolamine ; ppa @CHEMICAL@ cerebral hemorrhage @DISEASE@ @CID@ caffeine @CHEMICAL@ cerebral hemorrhage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Long-term efficacy and toxicity of high-dose \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m therapy for ventricular tachycardia or ventricular fibrillation. \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs. The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day. Sixty-nine percent of patients continued treatment with \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2). Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m at a higher dose or by the addition of a conventional antiarrhythmic drug. One or more adverse drug reactions occurred in 51% of patients. Adverse effects forced a reduction in the dose of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m in 41% and discontinuation of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m in 10% of patients. The most common symptomatic adverse reactions were \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mataxia\u001b[00m (35%), \u001b[48;2;173;216;230;38;2;0;0;0mnausea\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0manorexia\u001b[00m (8%), visual halos or \u001b[48;2;173;216;230;38;2;0;0;0mblurring\u001b[00m (6%), \u001b[48;2;173;216;230;38;2;0;0;0mthyroid function abnormalities\u001b[00m (6%) and \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary interstitial infiltrates\u001b[00m (5%). Although large-dose \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients. However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ ataxia @DISEASE@ @CID@ amiodarone @CHEMICAL@ nausea @DISEASE@ @CID@ amiodarone @CHEMICAL@ anorexia @DISEASE@ @CID@ amiodarone @CHEMICAL@ visual halos or blurring @DISEASE@ @CID@ amiodarone @CHEMICAL@ thyroid function abnormalities @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ tremor @DISEASE@ @CID@ amiodarone @CHEMICAL@ ataxia @DISEASE@ @CID@ amiodarone @CHEMICAL@ nausea @DISEASE@ @CID@ amiodarone @CHEMICAL@ anorexia @DISEASE@ @CID@ amiodarone @CHEMICAL@ blurring @DISEASE@ @CID@ amiodarone @CHEMICAL@ thyroid function abnormalities @DISEASE@ @CID@ amiodarone @CHEMICAL@ anorexia @DISEASE@ @CID@ amiodarone @CHEMICAL@ pulmonary interstitial infiltrates @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of \u001b[48;2;144;238;144;38;2;0;0;0mcalcium chloride\u001b[00m and 4-aminopyridine therapy on \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m toxicity in rats. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m is a major contributor to mortality in tricyclic antidepressant overdose. Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues. This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m. METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose. \u001b[48;2;144;238;144;38;2;0;0;0mcacl2\u001b[00m and 4-aminopyridine. Anesthetized rats received the tricyclic antidepressant \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m IP to produce \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m, QRS prolongation, and \u001b[48;2;144;238;144;38;2;0;0;0mbradycardia\u001b[00m. Fifteen min later, animals received \u001b[48;2;144;238;144;38;2;0;0;0mcacl2\u001b[00m, NaHCO3, or saline. In a second experiment, rats received tricyclic antidepressant \u001b[48;2;173;216;230;38;2;0;0;0mdesipramine\u001b[00m IP followed in 15 min by 4-aminopyridine or saline. RESULTS: NaHCO3 briefly (5 min) reversed \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and QRS prolongation. \u001b[48;2;144;238;144;38;2;0;0;0mcacl2\u001b[00m and 4-aminopyridine failed to improve blood pressure. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mventricular arrhythmias\u001b[00m (p = 0.004) and \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m (p = 0.03) in the \u001b[48;2;144;238;144;38;2;0;0;0mcacl2\u001b[00m group was higher than the other groups. CONCLUSION: The administration of \u001b[48;2;144;238;144;38;2;0;0;0mcacl2\u001b[00m or 4-aminopyridine did not reverse tricyclic antidepressant-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m in rats. \u001b[48;2;144;238;144;38;2;0;0;0mcacl2\u001b[00m therapy may possibly worsen both cardiovascular and central nervous system toxicity. These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "calcium chloride ; cacl2 @CHEMICAL@ ventricular arrhythmias @DISEASE@ @CID@ desipramine @CHEMICAL@ hypotension @DISEASE@ @CID@ desipramine @CHEMICAL@ bradycardia @DISEASE@ @CID@ desipramine @CHEMICAL@ ventricular arrhythmias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "desipramine @CHEMICAL@ hypotension @DISEASE@ @CID@ desipramine @CHEMICAL@ ventricular arrhythmias @DISEASE@ @CID@ desipramine @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of calcium chloride on gross behavioural changes produced by \u001b[48;2;173;216;230;38;2;0;0;0mcarbachol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0meserine\u001b[00m in cats. The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon \u001b[48;2;173;216;230;38;2;0;0;0mvocalization\u001b[00m (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), \u001b[48;2;173;216;230;38;2;0;0;0mmydriasis\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mclonic-tonic convulsions\u001b[00m produced by \u001b[48;2;173;216;230;38;2;0;0;0mcarbachol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0meserine\u001b[00m injected similarly was investigated. Calcium chloride depressed or almost completely abolished the \u001b[48;2;173;216;230;38;2;0;0;0mvocalization\u001b[00m and fighting due to \u001b[48;2;173;216;230;38;2;0;0;0mcarbachol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0meserine\u001b[00m. On the other hand, \u001b[48;2;173;216;230;38;2;0;0;0mmydriasis\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mclonic-tonic convulsions\u001b[00m evoked by \u001b[48;2;173;216;230;38;2;0;0;0mcarbachol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0meserine\u001b[00m were not significantly changed by calcium chloride. It is apparent that calcium chloride can \"dissociate\" \u001b[48;2;173;216;230;38;2;0;0;0mvocalization\u001b[00m and fighting from autonomic and motor phenomena such as \u001b[48;2;173;216;230;38;2;0;0;0mmydriasis\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mclonic-tonic convulsions\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0mcarbachol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0meserine\u001b[00m. Calcium chloride inhibited the \u001b[48;2;173;216;230;38;2;0;0;0mvocalization\u001b[00m and fighting produced by \u001b[48;2;173;216;230;38;2;0;0;0mcarbachol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0meserine\u001b[00m most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "carbachol @CHEMICAL@ mydriasis @DISEASE@ @CID@ carbachol @CHEMICAL@ tremor @DISEASE@ @CID@ carbachol @CHEMICAL@ clonic-tonic convulsions @DISEASE@ @CID@ eserine @CHEMICAL@ mydriasis @DISEASE@ @CID@ eserine @CHEMICAL@ tremor @DISEASE@ @CID@ eserine @CHEMICAL@ clonic-tonic convulsions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "carbachol @CHEMICAL@ vocalization ; vocalizations @DISEASE@ @CID@ carbachol @CHEMICAL@ mydriasis @DISEASE@ @CID@ carbachol @CHEMICAL@ tremor @DISEASE@ @CID@ carbachol @CHEMICAL@ clonic-tonic convulsions @DISEASE@ @CID@ eserine @CHEMICAL@ vocalization ; vocalizations @DISEASE@ @CID@ eserine @CHEMICAL@ tremor @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants. Although most patients were receiving several drugs, \u001b[48;2;173;216;230;38;2;0;0;0mmellaril\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mthioridazine\u001b[00m) appeared to be responsible for five cases of \u001b[48;2;173;216;230;38;2;0;0;0mventricular tachycardia\u001b[00m, one of which was fatal in a 35 year old woman. \u001b[48;2;173;216;230;38;2;0;0;0msupraventricular tachycardia\u001b[00m developed in one patient receiving \u001b[48;2;173;216;230;38;2;0;0;0mthorazine\u001b[00m (chlorpromazine). \u001b[48;2;144;238;144;38;2;0;0;0maventyl\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mnortriptyline\u001b[00m) and \u001b[48;2;144;238;144;38;2;0;0;0melavil\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mamitriptyline\u001b[00m) each produced \u001b[48;2;173;216;230;38;2;0;0;0mleft bundle branch block\u001b[00m in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease. Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "mellaril ; thioridazine @CHEMICAL@ ventricular tachycardia @DISEASE@ @CID@ mellaril ; thioridazine @CHEMICAL@ supraventricular tachycardia @DISEASE@ @CID@ aventyl ; nortriptyline @CHEMICAL@ left bundle branch block @DISEASE@ @CID@ elavil ; amitriptyline @CHEMICAL@ left bundle branch block @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "mellaril ; thioridazine @CHEMICAL@ ventricular tachycardia @DISEASE@ @CID@ thorazine @CHEMICAL@ supraventricular tachycardia @DISEASE@ @CID@ mellaril ; thioridazine @CHEMICAL@ left bundle branch block @DISEASE@ @CID@ amitriptyline @CHEMICAL@ ventricular tachycardias @DISEASE@ @CID@ amitriptyline @CHEMICAL@ left bundle branch block @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Serotonergic drugs, benzodiazepines and baclofen block \u001b[48;2;173;216;230;38;2;0;0;0mmuscimol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonic jerks\u001b[00m in a strain of mice. In male Swiss mice, \u001b[48;2;173;216;230;38;2;0;0;0mmuscimol\u001b[00m produced \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonic jerks\u001b[00m. A 3 mg/kg (i.p.) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min. Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the \u001b[48;2;173;216;230;38;2;0;0;0mmuscimol\u001b[00m effect. However, in a similar experiment l-dopa (80-160 mg/kg) was without effect. In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of \u001b[48;2;173;216;230;38;2;0;0;0mmuscimol\u001b[00m. Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonic jerks\u001b[00m. While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of \u001b[48;2;173;216;230;38;2;0;0;0mmuscimol\u001b[00m, its (+)-isomer (5-20 mg/kg) lacked this property. Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonus\u001b[00m, the \u001b[48;2;173;216;230;38;2;0;0;0mmuscimol\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonus\u001b[00m seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition. Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonus\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "muscimol @CHEMICAL@ myoclonic jerks ; myoclonus @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "muscimol @CHEMICAL@ myoclonic jerks @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhyperglycemic \u001b[48;2;144;238;144;38;2;0;0;0macidotic\u001b[00m\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m and death in Kearns-Sayre syndrome. This paper presents the clinical and metabolic findings in two young boys with long-standing Kearns-Sayre syndrome. Following short exposure to oral \u001b[48;2;173;216;230;38;2;0;0;0mprednisone\u001b[00m, both boys developed \u001b[48;2;173;216;230;38;2;0;0;0mlethargy\u001b[00m, increasing somnolence, \u001b[48;2;173;216;230;38;2;0;0;0mpolydipsia\u001b[00m, polyphagia, and \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m. Both presented in the emergency room with profound \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m, severe \u001b[48;2;173;216;230;38;2;0;0;0mhyperglycemia\u001b[00m, and acidosis. Nonketotic \u001b[48;2;144;238;144;38;2;0;0;0mlactic acidosis\u001b[00m was present in one and \u001b[48;2;144;238;144;38;2;0;0;0mketosis\u001b[00m without a known serum lactate level was present in the other. Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation. We believe these two cases represent a newly described and catastrophic metabolic-endocrine failure in the Kearns-Sayre syndrome.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prednisone @CHEMICAL@ hyperglycemic ; hyperglycemia @DISEASE@ @CID@ prednisone @CHEMICAL@ acidotic ; lactic acidosis @DISEASE@ @CID@ prednisone @CHEMICAL@ coma @DISEASE@ @CID@ prednisone @CHEMICAL@ hypotension @DISEASE@ @CID@ prednisone @CHEMICAL@ ketosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prednisone @CHEMICAL@ hyperglycemic acidotic ; hyperglycemia @DISEASE@ @CID@ prednisone @CHEMICAL@ lethargy @DISEASE@ @CID@ prednisone @CHEMICAL@ polydipsia @DISEASE@ @CID@ prednisone @CHEMICAL@ polyuria @DISEASE@ @CID@ prednisone @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of active constituents of Crocus sativus L., crocin on \u001b[48;2;173;216;230;38;2;0;0;0mstreptozocin\u001b[00m-induced model of sporadic \u001b[48;2;173;216;230;38;2;0;0;0malzheimer's disease\u001b[00m in male rats. BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed. In the present study, the effect of crocins on sporadic \u001b[48;2;173;216;230;38;2;0;0;0malzheimer's disease\u001b[00m induced by intracerebroventricular (icv) \u001b[48;2;173;216;230;38;2;0;0;0mstreptozocin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m) in male rats was investigated. METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m; 5 and 6, \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m + crocins (15 and 30 mg/kg) groups. In \u001b[48;2;173;216;230;38;2;0;0;0malzheimer's disease\u001b[00m groups, rats were injected with \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m-icv application was repeated. In \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks. Prescription of crocin in each dose was repeated once for two days. However, the learning and memory performance was assessed using passive avoidance paradigm, and for spatial cognition evaluation, Y-maze task was used. RESULTS: It was found out that crocin (30 mg/kg)-treated \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m-injected rats. In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m-injected group in passive avoidance test. CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the \u001b[48;2;144;238;144;38;2;0;0;0mcognitive deficits\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0mstz\u001b[00m-icv in rats and its potential in the treatment of neurodegenerative diseases such as \u001b[48;2;173;216;230;38;2;0;0;0malzheimer's disease\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "streptozocin ; stz @CHEMICAL@ alzheimer's disease @DISEASE@ @CID@ streptozocin ; stz @CHEMICAL@ cognitive deficits @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "streptozocin ; stz @CHEMICAL@ alzheimer's disease @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Rosaceiform \u001b[48;2;144;238;144;38;2;0;0;0mdermatitis\u001b[00m associated with topical \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m treatment. We describe herein 3 patients who developed \u001b[48;2;173;216;230;38;2;0;0;0mrosacea\u001b[00m-like \u001b[48;2;144;238;144;38;2;0;0;0mdermatitis\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0meruptions\u001b[00m while using 0.03% or 0.1% \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m ointment for facial \u001b[48;2;144;238;144;38;2;0;0;0mdermatitis\u001b[00m. Skin biopsy specimens showed \u001b[48;2;144;238;144;38;2;0;0;0mtelangiectasia\u001b[00m and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis. Continuous topical use of immunomodulators such as \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m or \u001b[48;2;144;238;144;38;2;0;0;0mpimecrolimus\u001b[00m should be regarded as a potential cause of rosaceiform \u001b[48;2;144;238;144;38;2;0;0;0mdermatitis\u001b[00m, although many cases have not been reported.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pimecrolimus @CHEMICAL@ dermatitis @DISEASE@ @CID@ pimecrolimus @CHEMICAL@ eruptions @DISEASE@ @CID@ pimecrolimus @CHEMICAL@ telangiectasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tacrolimus @CHEMICAL@ rosacea ; rosacea dermatitis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB. The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound. A Tween 80-coated poly-L-lactid acid nanoparticles was used as a model of colloidal drug delivery system, able to trespass the BBB. \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m, administered in \u001b[48;2;144;238;144;38;2;0;0;0mlicl\u001b[00m pre-treated rats, induces electrocorticographic \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m and delayed \u001b[48;2;144;238;144;38;2;0;0;0mhippocampal damage\u001b[00m. The toxic effects of \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p. administration in \u001b[48;2;144;238;144;38;2;0;0;0mlicl\u001b[00m-pre-treated Wistar rats. All the animals treated with \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively). In addition, \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m-loaded nanoparticles administration induced \u001b[48;2;144;238;144;38;2;0;0;0mdamage of neuronal cells\u001b[00m in CA1 field of the hippocampus in all treated animals, while the saline solution of \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m only in 60% of animals. Empty nanoparticles provided similar results to control (saline-treated) group of animals. In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the \u001b[48;2;173;216;230;38;2;0;0;0mtacrine\u001b[00m-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tacrine @CHEMICAL@ seizures @DISEASE@ @CID@ tacrine @CHEMICAL@ hippocampal damage ; damage of neuronal cells @DISEASE@ @CID@ licl @CHEMICAL@ seizures @DISEASE@ @CID@ licl @CHEMICAL@ hippocampal damage ; damage of neuronal cells @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tacrine @CHEMICAL@ seizures ; epileptic ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models. This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both \u001b[48;2;173;216;230;38;2;0;0;0maconitine\u001b[00m-induced rat and \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m-induced guinea pig \u001b[48;2;173;216;230;38;2;0;0;0marrhythmia\u001b[00m models. Confocal microscopy was used to measure intracellular free-calcium concentrations ([Ca(2+)](i)) in isolated myocytes. The current data showed that pilocarpine significantly delayed onset of \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m, decreased the time course of ventricular tachycardia and fibrillation, reduced \u001b[48;2;173;216;230;38;2;0;0;0marrhythmia\u001b[00m score, and increased the survival time of \u001b[48;2;173;216;230;38;2;0;0;0marrhythmic\u001b[00m rats and guinea pigs. [Ca(2+)](i) overload induced by \u001b[48;2;173;216;230;38;2;0;0;0maconitine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m was reduced in isolated myocytes pretreated with pilocarpine. Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine. These data suggest that pilocarpine produced antiarrhythmic actions on \u001b[48;2;173;216;230;38;2;0;0;0marrhythmic\u001b[00m rat and guinea pig models induced by \u001b[48;2;173;216;230;38;2;0;0;0maconitine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "aconitine @CHEMICAL@ arrhythmia ; arrhythmias ; arrhythmic @DISEASE@ @CID@ ouabain @CHEMICAL@ arrhythmia ; arrhythmias ; arrhythmic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "aconitine @CHEMICAL@ arrhythmia ; arrhythmic ; arrhythmic @DISEASE@ @CID@ ouabain @CHEMICAL@ arrhythmia ; arrhythmic ; arrhythmic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mdisulfiram\u001b[00m-induced transient optic and peripheral neuropathy: a case report. AIM: To report a case of optic and peripheral neuropathy after chronic use of \u001b[48;2;173;216;230;38;2;0;0;0mdisulfiram\u001b[00m for alcohol dependence management. MATERIALS AND METHODS: A case report. RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months. He also complained of \u001b[48;2;173;216;230;38;2;0;0;0mparaesthesia\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mnumbness\u001b[00m in both feet. His vision was 6/15 and 2/60 in the right and left eyes, respectively. Fundoscopy revealed bilaterally swollen optic nerve heads. Visual field testing confirmed bilateral central-caecal \u001b[48;2;173;216;230;38;2;0;0;0mscotomata\u001b[00m. He had been taking \u001b[48;2;173;216;230;38;2;0;0;0mdisulfiram\u001b[00m for alcohol dependence for the preceding 3 years. \u001b[48;2;173;216;230;38;2;0;0;0mdisulfiram\u001b[00m discontinuation lead to an immediate symptomatic improvement. CONCLUSION: Physicians initiating long-term \u001b[48;2;173;216;230;38;2;0;0;0mdisulfiram\u001b[00m therapy should be aware of these adverse effects. They should recommend annual ophthalmic reviews with visual field testing. Patients should be reassured with respect to the reversibility of these adverse effects.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "disulfiram @CHEMICAL@ optic neuropathy @DISEASE@ @CID@ disulfiram @CHEMICAL@ paraesthesia @DISEASE@ @CID@ disulfiram @CHEMICAL@ scotomata @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "disulfiram @CHEMICAL@ optic neuropathy @DISEASE@ @CID@ disulfiram @CHEMICAL@ paraesthesia @DISEASE@ @CID@ disulfiram @CHEMICAL@ numbness @DISEASE@ @CID@ disulfiram @CHEMICAL@ scotomata @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dual effects of \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m on \u001b[48;2;173;216;230;38;2;0;0;0mbarbiturate\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m in rats. \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0msodium thiopenthal\u001b[00m was administered intraperitoneally into male rats pre-treated with \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m (0.05, 0.5, 5 and 50 mg/kg). \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m pre-treatment affected in a dual manner \u001b[48;2;173;216;230;38;2;0;0;0mbarbiturate\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m, however, no dose-effect correlation was found. In particular, low doses reduced the latency to and prolonged the duration of \u001b[48;2;173;216;230;38;2;0;0;0mbarbiturate\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m. In contrast, the highest dose of \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m, and a reduction in mortality rate. \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m 0.5 and 5 mg/kg influenced the duration but not the latency of \u001b[48;2;173;216;230;38;2;0;0;0mketamine\u001b[00m- or \u001b[48;2;173;216;230;38;2;0;0;0mdiazepam\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m. Thus, the dual action of \u001b[48;2;144;238;144;38;2;0;0;0mmelatonin\u001b[00m on pharmacological \u001b[48;2;173;216;230;38;2;0;0;0mnarcosis\u001b[00m seems to be specific for the \u001b[48;2;173;216;230;38;2;0;0;0mbarbiturate\u001b[00m mechanism of action.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "melatonin @CHEMICAL@ narcosis @DISEASE@ @CID@ sodium thiopenthal @CHEMICAL@ narcosis @DISEASE@ @CID@ ketamine @CHEMICAL@ narcosis @DISEASE@ @CID@ diazepam @CHEMICAL@ narcosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "barbiturate @CHEMICAL@ narcosis @DISEASE@ @CID@ sodium thiopenthal @CHEMICAL@ narcosis @DISEASE@ @CID@ ketamine @CHEMICAL@ narcosis @DISEASE@ @CID@ diazepam @CHEMICAL@ narcosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m on cholinesterase and \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m. The effects of \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m on cholinesterase, \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors \u001b[48;2;144;238;144;38;2;0;0;0mtacrine\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0me-2020\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mtacrine\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0me-2020\u001b[00m all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively). In addition, \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mtacrine\u001b[00m, but not \u001b[48;2;144;238;144;38;2;0;0;0me-2020\u001b[00m, strongly inhibited butyrylcholinestrase (BuChE) in human serum. All three drugs produced mixed inhibition of AChE activity. Moreover, the inhibitory effect of \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m on AChE was reversible. All compounds at 0.1-1 mg/kg p.o. significantly improved the \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m (0.5 mg/kg s.c.) in rats performing a passive avoidance task. The three compounds at 1 and 3 mg/kg p.o. did not significantly decrease spontaneous movement by rats. These findings suggest that \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m at a low dose (0.1-1 mg/kg p.o.) improves \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m but does not affect spontaneous movement. The findings suggest that \u001b[48;2;144;238;144;38;2;0;0;0mnik-247\u001b[00m may be a useful drug for the treatment of Alzheimer's disease.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nik-247 @CHEMICAL@ amnesia @DISEASE@ @CID@ scopolamine @CHEMICAL@ amnesia @DISEASE@ @CID@ tacrine @CHEMICAL@ amnesia @DISEASE@ @CID@ e-2020 @CHEMICAL@ amnesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "scopolamine @CHEMICAL@ amnesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mnightmares\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m after long-term intake of \u001b[48;2;173;216;230;38;2;0;0;0mtramadol\u001b[00m combined with antidepressants. \u001b[48;2;173;216;230;38;2;0;0;0mtramadol\u001b[00m is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain. This drug was initiated in association with \u001b[48;2;173;216;230;38;2;0;0;0mparoxetine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdosulepine hydrochloride\u001b[00m in a tetraparetic patient with chronic pain. Fifty-six days after initiation of the treatment the patient presented \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m that only stopped after the withdrawal of psycho-active drugs and \u001b[48;2;173;216;230;38;2;0;0;0mtramadol\u001b[00m. The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tramadol @CHEMICAL@ hallucinations @DISEASE@ @CID@ paroxetine @CHEMICAL@ hallucinations @DISEASE@ @CID@ dosulepine hydrochloride @CHEMICAL@ hallucinations @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tramadol @CHEMICAL@ nightmares @DISEASE@ @CID@ tramadol @CHEMICAL@ hallucinations @DISEASE@ @CID@ paroxetine @CHEMICAL@ nightmares @DISEASE@ @CID@ dosulepine hydrochloride @CHEMICAL@ hallucinations @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney. Acute experimental models of \u001b[48;2;173;216;230;38;2;0;0;0mrenal damage\u001b[00m to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of \u001b[48;2;173;216;230;38;2;0;0;0mhexachloro-1:3-butadiene\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mhcbd\u001b[00m), \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin aminonucleoside\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mpan\u001b[00m), and \u001b[48;2;173;216;230;38;2;0;0;0m2-bromoethylamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mbea\u001b[00m), respectively. Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of \u001b[48;2;144;238;144;38;2;0;0;0mprotein excretion\u001b[00m were determined on urine samples. Tubular damage produced by \u001b[48;2;173;216;230;38;2;0;0;0mhcbd\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mbea\u001b[00m was discriminated both quantitatively and qualitatively from glomerular damage produced by \u001b[48;2;173;216;230;38;2;0;0;0mpan\u001b[00m. The latter was characterized by a pronounced increase in \u001b[48;2;144;238;144;38;2;0;0;0mprotein excretion\u001b[00m, especially proteins with molecular weight greater than 40,000 Da. In contrast, \u001b[48;2;144;238;144;38;2;0;0;0mprotein excretion\u001b[00m in tubular damage was raised only slightly and characterized by \u001b[48;2;144;238;144;38;2;0;0;0mexcretion of proteins\u001b[00m of a wide range of molecular weights. Proximal tubular damage caused by \u001b[48;2;173;216;230;38;2;0;0;0mhcbd\u001b[00m and papillary damage caused by \u001b[48;2;173;216;230;38;2;0;0;0mbea\u001b[00m were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes. Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage. It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of \u001b[48;2;173;216;230;38;2;0;0;0mrenal damage\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hexachloro-1:3-butadiene ; hcbd @CHEMICAL@ acute experimental models of renal damage @DISEASE@ @CID@ puromycin aminonucleoside ; pan @CHEMICAL@ acute experimental models of renal damage @DISEASE@ @CID@ puromycin aminonucleoside ; pan @CHEMICAL@ protein excretion ; excretion of proteins @DISEASE@ @CID@ 2-bromoethylamine ; bea @CHEMICAL@ acute experimental models of renal damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "hexachloro-1:3-butadiene ; hcbd @CHEMICAL@ renal damage ; renal tubular damage @DISEASE@ @CID@ puromycin aminonucleoside ; pan @CHEMICAL@ renal damage ; renal tubular damage @DISEASE@ @CID@ 2-bromoethylamine ; bea @CHEMICAL@ renal damage ; renal tubular damage @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mneuromuscular blockade\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mmagnesium sulfate\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnifedipine\u001b[00m. A patient who received tocolysis with \u001b[48;2;173;216;230;38;2;0;0;0mnifedipine\u001b[00m developed \u001b[48;2;173;216;230;38;2;0;0;0mneuromuscular blockade\u001b[00m after 500 mg of \u001b[48;2;173;216;230;38;2;0;0;0mmagnesium sulfate\u001b[00m was administered. This reaction demonstrates that \u001b[48;2;173;216;230;38;2;0;0;0mnifedipine\u001b[00m can seriously potentiate the toxicity of magnesium. Caution should be exercised when these two tocolytics are combined.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "magnesium sulfate @CHEMICAL@ neuromuscular blockade @DISEASE@ @CID@ nifedipine @CHEMICAL@ neuromuscular blockade @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "nifedipine @CHEMICAL@ neuromuscular blockade @DISEASE@ @CID@ magnesium sulfate @CHEMICAL@ neuromuscular blockade @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m in pregnancy associated with \u001b[48;2;173;216;230;38;2;0;0;0mclomiphene citrate\u001b[00m for ovulation induction: a case report. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mclomiphene citrate\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcc\u001b[00m) is commonly prescribed for ovulation induction. It is considered safe, with minimal side effects. \u001b[48;2;144;238;144;38;2;0;0;0mthromboembolism\u001b[00m is a rare but life-threatening complication that has been reported after ovulation induction with \u001b[48;2;173;216;230;38;2;0;0;0mcc\u001b[00m. Spontaneous coronary thrombosis or \u001b[48;2;144;238;144;38;2;0;0;0mthromboembolism\u001b[00m with subsequent clot lysis has been suggested as one of the most common causes of \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmi\u001b[00m) during pregnancy, with a subsequently normal coronary angiogram. CASE: A 33-year-old woman with a 5-week gestation had recently received \u001b[48;2;173;216;230;38;2;0;0;0mcc\u001b[00m for ovulation induction and presented with chest pain. An electrocardiogram showed a lateral and anterior wall \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m. Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal. At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester. It showed normal coronary vessels. CONCLUSION: This appears to be the first reported case documenting a possible association between \u001b[48;2;173;216;230;38;2;0;0;0mcc\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial infarction\u001b[00m. Thrombosis might be a rare but hazardous complication of \u001b[48;2;173;216;230;38;2;0;0;0mcc\u001b[00m. Given this life-threatening complication, appropriate prophylactic measures should be used in high-risk woman undergoing ovarian stimulation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "clomiphene citrate ; cc @CHEMICAL@ myocardial infarction ; mi @DISEASE@ @CID@ clomiphene citrate ; cc @CHEMICAL@ thromboembolism @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "clomiphene citrate ; cc @CHEMICAL@ myocardial infarction ; mi @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhepatonecrosis\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcholangitis\u001b[00m related to long-term \u001b[48;2;173;216;230;38;2;0;0;0mphenobarbital\u001b[00m therapy: an autopsy report of two patients. \u001b[48;2;173;216;230;38;2;0;0;0mphenobarbital\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m) has a reputation for safety, and it is commonly believed that \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic \u001b[48;2;144;238;144;38;2;0;0;0mliver disease\u001b[00m. Here we report of two adult patients with a long history of epilepsy treated with \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m who died suddenly: one as consequence of \u001b[48;2;173;216;230;38;2;0;0;0mcardiac arrest\u001b[00m, the other of acute \u001b[48;2;173;216;230;38;2;0;0;0mbronchopneumonia\u001b[00m. At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue. Inflammatory reactions of internal and external hepatic biliary ducts were also seen. Our findings illustrate that \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m may be associated with chronic \u001b[48;2;144;238;144;38;2;0;0;0mliver damage\u001b[00m, which may lead to more serious and deleterious consequences. For this reason, each clinician should recognize this entity in the differential diagnosis of \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m-related asymptomatic chronic hepatic enzyme dysfunction.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "phenobarbital ; pb @CHEMICAL@ cholangitis @DISEASE@ @CID@ phenobarbital ; pb @CHEMICAL@ liver disease ; liver damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "phenobarbital ; pb @CHEMICAL@ hepatonecrosis @DISEASE@ @CID@ phenobarbital ; pb @CHEMICAL@ cholangitis @DISEASE@ @CID@ phenobarbital ; pb @CHEMICAL@ cardiac arrest @DISEASE@ @CID@ phenobarbital ; pb @CHEMICAL@ bronchopneumonia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m. INTRODUCTION: \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent \u001b[48;2;144;238;144;38;2;0;0;0mvisual loss\u001b[00m. We report 3 cases which presented with \u001b[48;2;173;216;230;38;2;0;0;0mbitemporal hemianopia\u001b[00m. CLINICAL PICTURE: Three patients with \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mtoxic \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m\u001b[00m are described. All 3 patients had \u001b[48;2;144;238;144;38;2;0;0;0mloss of central visual acuity, colour vision (ishihara) and visual field\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mvisual field loss\u001b[00m had a bitemporal flavour, suggesting involvement of the optic chiasm. TREATMENT: Despite stopping \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m on diagnosis, visual function continued to deteriorate for a few months. Subsequent improvement was mild in 2 cases. In the third case, visual acuity and colour vision normalised but the optic discs were pale. OUTCOME: All 3 patients had some permanent \u001b[48;2;144;238;144;38;2;0;0;0mloss of visual function\u001b[00m. CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m usage is associated with permanent \u001b[48;2;144;238;144;38;2;0;0;0mvisual loss\u001b[00m and should be avoided if possible or used with caution and proper ophthalmological follow-up. The author postulates that in cases of \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m associated chiasmopathy, \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m may initially affect the optic nerves and subsequently progress to involve the optic chiasm.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ethambutol @CHEMICAL@ optic neuropathy @DISEASE@ @CID@ ethambutol @CHEMICAL@ visual loss ; loss of central visual acuity, colour vision (ishihara) and visual field ; visual field loss ; loss of visual function @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ethambutol @CHEMICAL@ optic neuropathy ; toxic optic neuropathy @DISEASE@ @CID@ ethambutol @CHEMICAL@ bitemporal hemianopia @DISEASE@ @CID@ ethambutol @CHEMICAL@ visual field loss @DISEASE@ @CID@ ethambutol @CHEMICAL@ optic chiasmopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Tolerability of \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m in patients with \u001b[48;2;173;216;230;38;2;0;0;0mnsaid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m. Previous studies evaluated the tolerance of \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m in subjects with cutaneous, respiratory and anaphylactoid reactions induced by \u001b[48;2;173;216;230;38;2;0;0;0mnonsteroidal anti-inflammatory drugs\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mnsaids\u001b[00m). In this study we investigated tolerability and reliability of \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m in a very large number of patients with an exclusive well-documented history of \u001b[48;2;173;216;230;38;2;0;0;0mnsaid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m. Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m. A single-placebo-controlled oral challenge procedure with \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m was applied to 829 patients with a history of \u001b[48;2;173;216;230;38;2;0;0;0mnsaid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m. A total of 75/829 (9.4%) patients experienced reactions to \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m. Of the 715 patients tested with \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m, 13 (9.6%) did not tolerate this drug. Furthermore, 18.28% of patients with a history of chronic \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m and 11.8% of subjects with an history of \u001b[48;2;173;216;230;38;2;0;0;0mnsaid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m alone (with or without chronic \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m) resulted to be intolerant to alternative drugs. Taken together, our results confirm the good tolerability of \u001b[48;2;144;238;144;38;2;0;0;0mnimesulide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m in patients who experienced \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0mnsaids\u001b[00m. However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic \u001b[48;2;173;216;230;38;2;0;0;0murticaria\u001b[00m and, above all, by a history of \u001b[48;2;173;216;230;38;2;0;0;0mnsaid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mangioedema\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nimesulide @CHEMICAL@ angioedema @DISEASE@ @CID@ paracetamol @CHEMICAL@ angioedema @DISEASE@ @CID@ nsaid ; nonsteroidal anti-inflammatory drugs ; nsaids @CHEMICAL@ angioedema @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "nsaid ; nonsteroidal anti-inflammatory drugs ; nsaids @CHEMICAL@ urticaria @DISEASE@ @CID@ nsaid ; nonsteroidal anti-inflammatory drugs ; nsaids @CHEMICAL@ angioedema @DISEASE@ @CID@ paracetamol @CHEMICAL@ urticaria @DISEASE@ @CID@ paracetamol @CHEMICAL@ angioedema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Lifetime treatment of mice with \u001b[48;2;173;216;230;38;2;0;0;0mazidothymidine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m) produces \u001b[48;2;173;216;230;38;2;0;0;0mmyelodysplasia\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m has induced a \u001b[48;2;144;238;144;38;2;0;0;0mmacrocytic anemia\u001b[00m in AIDS patients on long term \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m therapy. It is generally assumed that DNA elongation is stopped by the insertion of \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such \u001b[48;2;144;238;144;38;2;0;0;0mthrombocytopenia\u001b[00m showed changes compatible with \u001b[48;2;173;216;230;38;2;0;0;0mmyelodysplastic syndrome\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmds\u001b[00m). A variety of histological patterns was observed. There were two cases of hypocellular \u001b[48;2;173;216;230;38;2;0;0;0mmyelodysplasia\u001b[00m, two cases of hypersegmented \u001b[48;2;144;238;144;38;2;0;0;0mmyelodysplastic\u001b[00m granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, \u001b[48;2;144;238;144;38;2;0;0;0mdysmyelopoiesis\u001b[00m and a hypocellular marrow and two cases of \u001b[48;2;173;216;230;38;2;0;0;0mmyelodysplasia\u001b[00m with dyserythropoiesis, hemosiderosis and a hypocellular marrow. Above mentioned \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the \u001b[48;2;173;216;230;38;2;0;0;0mmyelodysplastic syndrome\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "azidothymidine ; azt @CHEMICAL@ myelodysplasia ; myelodysplastic syndrome ; mds ; myelodysplastic ; dysmyelopoiesis @DISEASE@ @CID@ azidothymidine ; azt @CHEMICAL@ macrocytic anemia @DISEASE@ @CID@ azidothymidine ; azt @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "azidothymidine ; azt @CHEMICAL@ myelodysplasia ; myelodysplastic syndrome ; mds @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Influence of diet free of NAD-precursors on \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m in mice. Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m)-\u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m, suggesting that the \u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mliver injury\u001b[00m involves a step which depends on adenoribosylation. The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with \u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m and evaluates the influence of simultaneous \u001b[48;2;173;216;230;38;2;0;0;0methanol\u001b[00m consumption in these animals. \u001b[48;2;144;238;144;38;2;0;0;0mliver injuries\u001b[00m were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT). While \u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by \u001b[48;2;173;216;230;38;2;0;0;0methanol\u001b[00m and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD. In these animals, only minor increases of serum transaminase activities were measured in the presence of \u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m, and unlike the exacerbation caused by \u001b[48;2;173;216;230;38;2;0;0;0methanol\u001b[00m in mice on a standard diet, the \u001b[48;2;144;238;144;38;2;0;0;0mliver damage\u001b[00m was inhibited by 50% by \u001b[48;2;173;216;230;38;2;0;0;0methanol\u001b[00m. A further 64% reduction of \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m was observed, when NAA was given to \u001b[48;2;173;216;230;38;2;0;0;0methanol\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m-mice. Our results provide evidence that the \u001b[48;2;173;216;230;38;2;0;0;0maap\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m and its exacerbation by \u001b[48;2;173;216;230;38;2;0;0;0methanol\u001b[00m can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD. We see the main application of NAA as for the combinational use in pharmaceutical preparations of \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m in order to avoid \u001b[48;2;144;238;144;38;2;0;0;0mhepatic damage\u001b[00m in patients treated with this widely used analgesic.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "acetaminophen ; aap @CHEMICAL@ hepatotoxicity ; hepatitis ; liver injury ; liver injuries ; liver damage ; hepatic damage @DISEASE@ @CID@ ethanol @CHEMICAL@ hepatotoxicity ; hepatitis ; liver injury ; liver injuries ; liver damage ; hepatic damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "acetaminophen ; aap @CHEMICAL@ hepatotoxicity ; hepatitis ; liver injury @DISEASE@ @CID@ ethanol @CHEMICAL@ hepatotoxicity ; hepatitis ; liver injury @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Antiarrhythmic plasma concentrations of \u001b[48;2;173;216;230;38;2;0;0;0mcibenzoline\u001b[00m on canine \u001b[48;2;173;216;230;38;2;0;0;0mventricular \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m\u001b[00m. Using two-stage coronary ligation-, \u001b[48;2;173;216;230;38;2;0;0;0mdigitalis\u001b[00m-, and \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced canine \u001b[48;2;173;216;230;38;2;0;0;0mventricular \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m\u001b[00m, antiarrhythmic effects of \u001b[48;2;173;216;230;38;2;0;0;0mcibenzoline\u001b[00m were examined and the minimum effective plasma concentration for each \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m model was determined. \u001b[48;2;173;216;230;38;2;0;0;0mcibenzoline\u001b[00m suppressed all the \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m, and the minimum effective plasma concentrations for \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m induced by 24-h coronary ligation, 48-h coronary ligation, \u001b[48;2;173;216;230;38;2;0;0;0mdigitalis\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7). The concentration for \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m was significantly higher than those for the other types of \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m. This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because \u001b[48;2;173;216;230;38;2;0;0;0mcibenzoline\u001b[00m had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m dogs, its clinical usefulness is expected.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "digitalis @CHEMICAL@ ventricular arrhythmias ; arrhythmia ; arrhythmias @DISEASE@ @CID@ adrenaline @CHEMICAL@ ventricular arrhythmias ; arrhythmia ; arrhythmias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cibenzoline @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia @DISEASE@ @CID@ digitalis @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia @DISEASE@ @CID@ adrenaline @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Immunopathology of \u001b[48;2;173;216;230;38;2;0;0;0mpenicillamine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mglomerular disease\u001b[00m. Four patients with rheumatoid arthritis developed heavy \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m after five to 12 months of treatment with \u001b[48;2;173;216;230;38;2;0;0;0md-\u001b[48;2;173;216;230;38;2;0;0;0mpenicillamine\u001b[00m\u001b[00m. Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal. Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity. Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3. The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4. It is tentatively concluded that complement was activated by the classical pathway.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "penicillamine ; d-penicillamine @CHEMICAL@ glomerular disease @DISEASE@ @CID@ penicillamine ; d-penicillamine @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "penicillamine ; d-penicillamine @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mventricular fibrillation\u001b[00m from \u001b[48;2;173;216;230;38;2;0;0;0mdiatrizoate\u001b[00m with and without chelating agents. The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs. Renografin contains the chelating agents \u001b[48;2;173;216;230;38;2;0;0;0msodium citrate\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mdisodium edetate\u001b[00m, while Hypaque contains \u001b[48;2;173;216;230;38;2;0;0;0mcalcium \u001b[48;2;144;238;144;38;2;0;0;0mdisodium edetate\u001b[00m\u001b[00m and no \u001b[48;2;173;216;230;38;2;0;0;0msodium citrate\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mventricular fibrillation\u001b[00m occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "renografin 76% ; hypaque 76% @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ sodium citrate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ disodium edetate ; calcium disodium edetate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "diatrizoate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ sodium citrate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ calcium disodium edetate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mintracerebral hemorrhage\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mintracerebral hemorrhage\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mw-\u001b[48;2;144;238;144;38;2;0;0;0mich\u001b[00m\u001b[00m) is a severe type of stroke. There is no consensus on the optimal treatment for \u001b[48;2;173;216;230;38;2;0;0;0mw-\u001b[48;2;144;238;144;38;2;0;0;0mich\u001b[00m\u001b[00m. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume. Male CD-1 mice were treated with \u001b[48;2;173;216;230;38;2;0;0;0mwarfarin\u001b[00m (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9. First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice. Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum. Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay. The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015). In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL). In contrast, such extensive lesions were never found in the PCC group. We provide experimental data suggesting PCC to be an effective acute treatment for \u001b[48;2;173;216;230;38;2;0;0;0mw-\u001b[48;2;144;238;144;38;2;0;0;0mich\u001b[00m\u001b[00m in terms of reducing hemorrhagic blood volume. Future studies are needed to assess the therapeutic potential emerging from our finding for human \u001b[48;2;173;216;230;38;2;0;0;0mw-\u001b[48;2;144;238;144;38;2;0;0;0mich\u001b[00m\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "warfarin @CHEMICAL@ intracerebral hemorrhage ; ich @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "warfarin @CHEMICAL@ intracerebral hemorrhage ; w-ich @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Impact of \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m exposure after pregnancy recognition on ultrasonographic fetal growth measures. BACKGROUND: More than 3 decades after Jones and Smith (1973) reported on the devastation caused by \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m exposure on fetal development, the rates of heavy drinking during pregnancy remain relatively unchanged. Early identification of fetal \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m exposure and maternal abstinence led to better infant outcomes. This study examined the utility of biometry for detecting \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m-related \u001b[48;2;173;216;230;38;2;0;0;0mfetal \u001b[48;2;144;238;144;38;2;0;0;0mgrowth impairment\u001b[00m\u001b[00m. METHODS: We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m intervention study. The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies. Because intensity of \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m consumers. Fetal measures from the heavy-exposed fetuses were also compared with measures from a nondrinking group that was representative of normal, uncomplicated pregnancies from our clinics. Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse. RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies. When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-\u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m-exposed group, regardless of prior drinking patterns. Any \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m consumption postpregnancy recognition among the heavy drinkers resulted in \u001b[48;2;144;238;144;38;2;0;0;0mreduced cerebellar growth\u001b[00m as well as \u001b[48;2;144;238;144;38;2;0;0;0mdecreased cranial to body growth\u001b[00m in comparison with women who either quit drinking or who were nondrinkers. \u001b[48;2;144;238;144;38;2;0;0;0mamphetamine\u001b[00m abuse was predictive of larger cranial to body growth ratios. CONCLUSIONS: Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies. Although the reliance on self-reported drinking is a limitation in this study, these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal \u001b[48;2;173;216;230;38;2;0;0;0malcohol\u001b[00m effects.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "alcohol @CHEMICAL@ growth impairment ; reduced cerebellar growth ; decreased cranial to body growth @DISEASE@ @CID@ amphetamine @CHEMICAL@ growth impairment ; reduced cerebellar growth ; decreased cranial to body growth @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "alcohol @CHEMICAL@ fetal growth impairment ; fetal cerebellar growth impairment ; decreased cranial to body growth ratios @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Urinary symptoms and quality of life changes in Thai women with overactive bladder after \u001b[48;2;173;216;230;38;2;0;0;0mtolterodine\u001b[00m treatment. OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after \u001b[48;2;173;216;230;38;2;0;0;0mtolterodine\u001b[00m treatment. MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study. \u001b[48;2;173;216;230;38;2;0;0;0mtolterodine\u001b[00m 2 mg, twice daily was given. After 8 weeks treatment, changes in micturition diary variables and tolerability were determined. Short form 36 (SF36) questionaires (Thai version) were given before and after 8 weeks of treatment. RESULTS: At 8 weeks, all micturition per day decreased from 16. 7 +/- 5. 3 to 6. 7 +/- 2.4 times per day. The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night. The most common side effect was \u001b[48;2;173;216;230;38;2;0;0;0mdry month\u001b[00m in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree. Only one case (3.3%) withdrew from the present study due to a severe \u001b[48;2;173;216;230;38;2;0;0;0mdry mouth\u001b[00m. The SF-36 scores changed significantly in the domains of physical functioning, role function emotional, social function and mental heath. CONCLUSION: \u001b[48;2;173;216;230;38;2;0;0;0mtolterodine\u001b[00m was well tolerated and its effects improved the quality of life in Thai women with OAB.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tolterodine @CHEMICAL@ dry month ; dry mouth @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tolterodine @CHEMICAL@ dry month @DISEASE@ @CID@ tolterodine @CHEMICAL@ dry mouth @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Absence of acute cerebral vasoconstriction after \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0msubarachnoid hemorrhage\u001b[00m. INTRODUCTION: \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m use has been associated with neurovascular complications, including \u001b[48;2;173;216;230;38;2;0;0;0marterial vasoconstriction\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mvasculitis\u001b[00m. However, there are few studies of angiographic effects of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m on human cerebral arteries. Information on these effects could be obtained from angiograms of patients with \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0msubarachnoid hemorrhage\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0msah\u001b[00m) who underwent angiography shortly after \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m use. METHODS: We screened patients with \u001b[48;2;173;216;230;38;2;0;0;0msah\u001b[00m retrospectively and identified those with positive urine toxicology for \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m or its metabolites. Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with \u001b[48;2;173;216;230;38;2;0;0;0msah\u001b[00m who were matched for factors known to influence arterial diameter. Qualitative comparisons of small artery changes also were made. RESULTS: Thirteen patients with positive \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m toxicology were compared to 26 controls. There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests). There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests). Qualitative assessments showed two arterial irregularities in the distal vasculature in each group. CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for \u001b[48;2;173;216;230;38;2;0;0;0mdistal narrowing\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mvasculitis\u001b[00m could be found in patients who underwent angiography after \u001b[48;2;144;238;144;38;2;0;0;0maneurysmal\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0msah\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m use.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ subarachnoid hemorrhage ; sah @DISEASE@ @CID@ cocaine @CHEMICAL@ aneurysmal @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ subarachnoid hemorrhage ; sah @DISEASE@ @CID@ cocaine @CHEMICAL@ arterial vasoconstriction ; arterial narrowing ; distal narrowing @DISEASE@ @CID@ cocaine @CHEMICAL@ vasculitis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors. The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats. \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m (1 mg/kg ip) induced \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonian\u001b[00m-like \u001b[48;2;144;238;144;38;2;0;0;0mmuscle rigidity\u001b[00m, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-treated animals. AIDA in doses of 7.5-15 microg/0.5 microl diminished the \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mmuscle rigidity\u001b[00m. In contrast, 2R,4R-APDC injections were ineffective. The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonian\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mmuscle rigidity\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ muscle rigidity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ parkinsonian ; parkinsonian muscle rigidity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m due to \u001b[48;2;144;238;144;38;2;0;0;0mcoronary artery spasm\u001b[00m during \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m stress echocardiography. \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m stress echocardiography (DSE) is a useful and safe provocation test for \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m. Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis. The aim of the present study is to examine whether \u001b[48;2;173;216;230;38;2;0;0;0mmyocardial ischemia\u001b[00m due to \u001b[48;2;144;238;144;38;2;0;0;0mcoronary spasm\u001b[00m is induced by \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m. We performed DSE on 51 patients with \u001b[48;2;144;238;144;38;2;0;0;0mcoronary spastic angina\u001b[00m but without significant fixed coronary artery stenosis. All patients had anginal attacks at rest with ST elevation on the electrocardiogram (\u001b[48;2;144;238;144;38;2;0;0;0mvariant angina\u001b[00m). \u001b[48;2;144;238;144;38;2;0;0;0mcoronary spasm\u001b[00m was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients. DSE was performed with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes. Of the 51 patients, 7 patients showed asynergy with ST elevation. All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy. These findings indicate that \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m can provoke \u001b[48;2;144;238;144;38;2;0;0;0mcoronary spasm\u001b[00m in some patients with \u001b[48;2;144;238;144;38;2;0;0;0mcoronary spastic angina\u001b[00m. When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also \u001b[48;2;144;238;144;38;2;0;0;0mcoronary spasm\u001b[00m should be considered as a genesis of asynergy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dobutamine @CHEMICAL@ coronary artery spasm ; coronary spasm @DISEASE@ @CID@ dobutamine @CHEMICAL@ coronary spastic angina ; variant angina @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dobutamine @CHEMICAL@ myocardial ischemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Risk for \u001b[48;2;173;216;230;38;2;0;0;0mvalvular heart disease\u001b[00m among users of \u001b[48;2;173;216;230;38;2;0;0;0mfenfluramine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdexfenfluramine\u001b[00m who underwent echocardiography before use of medication. BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of \u001b[48;2;173;216;230;38;2;0;0;0mfenfluramine\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdexfenfluramine\u001b[00m had \u001b[48;2;173;216;230;38;2;0;0;0mvalvular disease\u001b[00m, these drugs were withdrawn from the market. OBJECTIVE: To determine the risk for new or worsening \u001b[48;2;173;216;230;38;2;0;0;0mvalvular abnormalities\u001b[00m among users of \u001b[48;2;173;216;230;38;2;0;0;0mfenfluramine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mdexfenfluramine\u001b[00m who underwent echocardiography before they began to take these medications. DESIGN: Cohort study. SETTING: Academic primary care practices. PATIENTS: 46 patients who used \u001b[48;2;173;216;230;38;2;0;0;0mfenfluramine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mdexfenfluramine\u001b[00m for 14 days or more and had echocardiograms obtained before therapy. MEASUREMENTS: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or \u001b[48;2;173;216;230;38;2;0;0;0mmitral regurgitation\u001b[00m by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild \u001b[48;2;173;216;230;38;2;0;0;0maortic regurgitation\u001b[00m or moderate \u001b[48;2;173;216;230;38;2;0;0;0mmitral regurgitation\u001b[00m). RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving \u001b[48;2;173;216;230;38;2;0;0;0mfenfluramine\u001b[00m-\u001b[48;2;144;238;144;38;2;0;0;0mphentermine\u001b[00m developed \u001b[48;2;173;216;230;38;2;0;0;0mvalvular heart disease\u001b[00m. One had baseline bicuspid aortic valve and mild \u001b[48;2;173;216;230;38;2;0;0;0maortic regurgitation\u001b[00m that progressed to moderate regurgitation. The second patient developed new moderate \u001b[48;2;173;216;230;38;2;0;0;0maortic insufficiency\u001b[00m. CONCLUSION: Users of diet medications are at risk for \u001b[48;2;173;216;230;38;2;0;0;0mvalvular heart disease\u001b[00m. However, the incidence may be lower than that reported previously.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fenfluramine @CHEMICAL@ aortic regurgitation ; aortic insufficiency @DISEASE@ @CID@ phentermine @CHEMICAL@ aortic regurgitation ; aortic insufficiency @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fenfluramine ; dexfenfluramine @CHEMICAL@ valvular heart disease ; valvular abnormalities ; valvular disease @DISEASE@ @CID@ fenfluramine ; dexfenfluramine @CHEMICAL@ aortic regurgitation @DISEASE@ @CID@ dexfenfluramine ; dexfenfluramine @CHEMICAL@ mitral regurgitation @DISEASE@ @CID@ dexfenfluramine ; dexfenfluramine @CHEMICAL@ aortic insufficiency @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcarboplatin\u001b[00m toxic effects on the peripheral nervous system of the rat. BACKGROUND: The most striking of \u001b[48;2;173;216;230;38;2;0;0;0mcarboplatin\u001b[00m's advantages (\u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m) over \u001b[48;2;144;238;144;38;2;0;0;0mcisplatin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcddp\u001b[00m) is its markedly reduced rate of neurotoxic effects. However, the use of \u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to \u001b[48;2;173;216;230;38;2;0;0;0mperipheral nervous system damage\u001b[00m. MATERIALS AND METHODS: Two different schedules of \u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats. Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects. RESULTS: \u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m administration induced dose-dependent \u001b[48;2;173;216;230;38;2;0;0;0mperipheral neurotoxicity\u001b[00m. Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment. The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by \u001b[48;2;173;216;230;38;2;0;0;0mcddp\u001b[00m, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons. Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after \u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m treatment. CONCLUSIONS: \u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by \u001b[48;2;173;216;230;38;2;0;0;0mcddp\u001b[00m that it is probable that neurotoxicity is induced in the two drugs by the same mechanism. This model can be used alone or in combination with other drugs to explore the effect of \u001b[48;2;144;238;144;38;2;0;0;0mcbdca\u001b[00m on the peripheral nervous system.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "carboplatin ; cbdca @CHEMICAL@ peripheral nervous system damage ; peripheral neurotoxicity @DISEASE@ @CID@ cisplatin ; cddp @CHEMICAL@ peripheral nervous system damage ; peripheral neurotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "carboplatin ; cddp @CHEMICAL@ peripheral nervous system damage ; peripheral neurotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Iatrogenic risks of \u001b[48;2;173;216;230;38;2;0;0;0mendometrial carcinoma\u001b[00m after treatment for breast cancer in a large French case-control study. F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Since \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined. We have investigated the association between \u001b[48;2;144;238;144;38;2;0;0;0mendometrial cancer\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m use or other treatments in women treated for breast cancer in a case-control study. Cases of \u001b[48;2;144;238;144;38;2;0;0;0mendometrial cancer\u001b[00m diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included. Women who had received \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m were significantly more likely to have \u001b[48;2;144;238;144;38;2;0;0;0mendometrial cancer\u001b[00m diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001). Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m received (p = 0.0001), irrespective of the daily dose. Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001). After adjusting for confounding factors, the risk was higher for \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012). Women who had \u001b[48;2;144;238;144;38;2;0;0;0mendometrial cancer\u001b[00m and had received \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m had more advanced disease and poorer prognosis than those with \u001b[48;2;144;238;144;38;2;0;0;0mendometrial cancer\u001b[00m who had not received this treatment. Our results suggest a causal role of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m in \u001b[48;2;144;238;144;38;2;0;0;0mendometrial cancer\u001b[00m, particularly when used as currently proposed for breast cancer prevention. Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer. \u001b[48;2;173;216;230;38;2;0;0;0mendometrial cancers\u001b[00m diagnosed in women treated with \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m have poorer prognosis. Women who receive \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m for breast cancer should be offered gynaecological surveillance during and after treatment. A long-term evaluation of the risk-benefit ratio of \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m as a preventive treatment for breast cancer is clearly warranted.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tamoxifen @CHEMICAL@ endometrial carcinoma ; endometrial cancer ; endometrial cancers @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tamoxifen @CHEMICAL@ endometrial carcinoma ; endometrial cancers @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A murine model of \u001b[48;2;144;238;144;38;2;0;0;0madenomyosis\u001b[00m: the effects of \u001b[48;2;173;216;230;38;2;0;0;0mhyperprolactinemia\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine hydrochloride\u001b[00m, a selective serotonin reuptake inhibitor, on \u001b[48;2;144;238;144;38;2;0;0;0madenomyosis\u001b[00m induction in Wistar albino rats. OBJECTIVE: The aim of this study was to investigate whether \u001b[48;2;144;238;144;38;2;0;0;0mfluoxetine\u001b[00m given to castrated and noncastrated rats caused \u001b[48;2;173;216;230;38;2;0;0;0mhyperprolactinemia\u001b[00m and its effects with respect to \u001b[48;2;144;238;144;38;2;0;0;0madenomyosis\u001b[00m. DESIGN: \u001b[48;2;144;238;144;38;2;0;0;0mfluoxetine\u001b[00m, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce \u001b[48;2;173;216;230;38;2;0;0;0mhyperprolactinemia\u001b[00m. The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls. Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days. SETTING: Marmara University School of Medicine, Department of Histology and Embryology, Zeynep Kamil Women and Children's Hospital. MAIN OUTCOME MEASURES: Serum prolactin levels, uterine histopathology. RESULTS: The prolactin levels of castrated and noncastrated groups treated with \u001b[48;2;144;238;144;38;2;0;0;0mfluoxetine\u001b[00m were statistically significantly higher when compared to their respective control groups. Histological studies revealed 11 cases of \u001b[48;2;144;238;144;38;2;0;0;0madenomyosis\u001b[00m, all within the noncastrated group receiving \u001b[48;2;144;238;144;38;2;0;0;0mfluoxetine\u001b[00m. CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma. This invasion eventually progresses to \u001b[48;2;144;238;144;38;2;0;0;0madenomyosis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluoxetine hydrochloride ; fluoxetine @CHEMICAL@ adenomyosis @DISEASE@ @CID@ fluoxetine hydrochloride ; fluoxetine @CHEMICAL@ hyperprolactinemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluoxetine hydrochloride @CHEMICAL@ hyperprolactinemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Auditory disturbance associated with interscalene brachial plexus block. We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block (IBPB). \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m 0.75% with \u001b[48;2;144;238;144;38;2;0;0;0madrenaline\u001b[00m was given followed by a 24-hr continuous infusion of 0.25% \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m. Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation. In four patients \u001b[48;2;173;216;230;38;2;0;0;0mhearing impairment\u001b[00m on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day. The frequencies at which the impairment occurred varied between patients; in one only low frequencies (0.25-0.5 kHz) were involved. The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m. This patient had \u001b[48;2;173;216;230;38;2;0;0;0mhearing threshold changes\u001b[00m (15-20 dB) at 6-10 kHz on the opposite side also. IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupivacaine @CHEMICAL@ hearing impairment @DISEASE@ @CID@ adrenaline @CHEMICAL@ hearing impairment @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupivacaine @CHEMICAL@ hearing impairment ; hearing threshold changes @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmidazolam\u001b[00m compared with \u001b[48;2;144;238;144;38;2;0;0;0mthiopentone\u001b[00m as an induction agent. In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of \u001b[48;2;173;216;230;38;2;0;0;0mmidazolam\u001b[00m 0.15 mg/kg i.v. was clearly slower in onset than that of \u001b[48;2;144;238;144;38;2;0;0;0mthiopentone\u001b[00m 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the \u001b[48;2;173;216;230;38;2;0;0;0mmidazolam\u001b[00m group, but, although \u001b[48;2;173;216;230;38;2;0;0;0mapnoea\u001b[00m occurred less often in the \u001b[48;2;173;216;230;38;2;0;0;0mmidazolam\u001b[00m group it lasted longer. On the whole, the differences between \u001b[48;2;173;216;230;38;2;0;0;0mmidazolam\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mthiopentone\u001b[00m had no apparent clinical consequences. \u001b[48;2;173;216;230;38;2;0;0;0mmidazolam\u001b[00m is a new alternative agent for induction in combination anaesthesia.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "midazolam @CHEMICAL@ apnoea @DISEASE@ @CID@ thiopentone @CHEMICAL@ apnoea @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "midazolam @CHEMICAL@ apnoea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Cardiotoxic and possible leukemogenic effects of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m in nonhuman primates. 10 monkeys (macaques) received \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive \u001b[48;2;173;216;230;38;2;0;0;0mheart failure\u001b[00m at an average cumulative \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man. Histologically, the myocardial lesions resembled those found in human anthracycline-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiomyopathy\u001b[00m. 1 of the 10 monkeys developed \u001b[48;2;173;216;230;38;2;0;0;0macute myeloblastic leukemia\u001b[00m after receiving 324 mg/m2 of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m; the 10th monkey is alive and well 26 months after the last dose of drug. Our results suggest that \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "adriamycin @CHEMICAL@ congestive heart failure @DISEASE@ @CID@ adriamycin @CHEMICAL@ acute myeloblastic leukemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "adriamycin @CHEMICAL@ congestive heart failure ; heart failure @DISEASE@ @CID@ adriamycin @CHEMICAL@ cardiomyopathy @DISEASE@ @CID@ adriamycin @CHEMICAL@ acute myeloblastic leukemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Promotional effects of \u001b[48;2;173;216;230;38;2;0;0;0mtestosterone\u001b[00m and dietary fat on prostate carcinogenesis in genetically susceptible rats. Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed \u001b[48;2;173;216;230;38;2;0;0;0mprostate adenocarcinomas\u001b[00m spontaneously (10% incidence) at average age 34 months. Conventional LW rats, implanted with \u001b[48;2;173;216;230;38;2;0;0;0mtestosterone\u001b[00m at age 4 months, developed a higher incidence of \u001b[48;2;173;216;230;38;2;0;0;0mprostate cancer\u001b[00m after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors. Preliminary results indicate that \u001b[48;2;173;216;230;38;2;0;0;0mtestosterone\u001b[00m-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed \u001b[48;2;173;216;230;38;2;0;0;0mprostate cancer\u001b[00m after intervals of 6-12 months. Aged GF Sprague-Dawley (SD) rats have not developed \u001b[48;2;173;216;230;38;2;0;0;0mprostate cancer\u001b[00m spontaneously. Conventional SD rats fed diet L-485 and treated with \u001b[48;2;173;216;230;38;2;0;0;0mtestosterone\u001b[00m developed only \u001b[48;2;144;238;144;38;2;0;0;0mprostatitis\u001b[00m. Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental \u001b[48;2;173;216;230;38;2;0;0;0mprostate cancer\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "testosterone @CHEMICAL@ prostate adenocarcinomas ; prostate cancer @DISEASE@ @CID@ testosterone @CHEMICAL@ prostatitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "testosterone @CHEMICAL@ prostate adenocarcinomas ; prostate cancer @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m associated \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic uremic syndrome\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m associated \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic uremic syndrome\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mhus\u001b[00m) is a potentially fatal but uncommon condition that is not yet widely recognised. It consists of microangiopathic hemolytic anemia, \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m and progressive \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m treatment and affects about 10% of patients treated with this agent. The \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m usually develops about 8-10 mth after start of \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m treatment and the mortality is approximately 60% from \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary edema\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mrenal lesions\u001b[00m are similar to those seen in idiopathic \u001b[48;2;173;216;230;38;2;0;0;0mhus\u001b[00m and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of \u001b[48;2;173;216;230;38;2;0;0;0mglomerular basement membranes\u001b[00m and mesangiolysis. The mechanism of action is postulated as \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m-induced endothelial cell damage. We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m while on treatment with \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m and died in \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary edema\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "mitomycin c @CHEMICAL@ hemolytic uremic syndrome ; hus @DISEASE@ @CID@ mitomycin c @CHEMICAL@ renal failure ; renal lesions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "mitomycin c @CHEMICAL@ hemolytic uremic syndrome ; hus @DISEASE@ @CID@ mitomycin c @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ mitomycin c @CHEMICAL@ renal failure ; renal lesions ; glomerular basement membranes @DISEASE@ @CID@ mitomycin c @CHEMICAL@ pulmonary edema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Continuous ambulatory ECG monitoring during \u001b[48;2;173;216;230;38;2;0;0;0mfluorouracil\u001b[00m therapy: a prospective study. Although there have been anecdotal reports of cardiac toxicity associated with \u001b[48;2;173;216;230;38;2;0;0;0mfluorouracil\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m) therapy, this phenomenon has not been studied in a systematic fashion. We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion for treatment of solid tumors in order to assess the incidence of \u001b[48;2;144;238;144;38;2;0;0;0mischemic\u001b[00m ST changes. Patients were monitored for 23 +/- 4 hours before \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion, and 98 +/- 9 hours during \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion. \u001b[48;2;144;238;144;38;2;0;0;0manginal\u001b[00m episodes were rare: only one patient had \u001b[48;2;173;216;230;38;2;0;0;0mangina\u001b[00m (during \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion). However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion v 17 (68%) during \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion (P less than .002). The incidence of \u001b[48;2;144;238;144;38;2;0;0;0mischemic\u001b[00m episodes per patient per hour was 0.05 +/- 0.02 prior to \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion v 0.13 +/- 0.03 during \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m v 1.9 +/- 0.5 minutes per patient per hour during \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m (P less than .01). ECG changes were more common among patients with known \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery disease\u001b[00m. There were two cases of sudden death, both of which occurred at the end of the chemotherapy course. We conclude that \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m infusion is associated with a significant increase in silent ST segment deviation suggestive of \u001b[48;2;144;238;144;38;2;0;0;0mischemia\u001b[00m, particularly among patients with \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery disease\u001b[00m. The mechanism and clinical significance of these ECG changes remain to be determined.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluorouracil ; 5-fu @CHEMICAL@ ischemic ; ischemia @DISEASE@ @CID@ fluorouracil ; 5-fu @CHEMICAL@ anginal ; angina @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluorouracil ; 5-fu @CHEMICAL@ angina @DISEASE@ @CID@ fluorouracil ; 5-fu @CHEMICAL@ coronary artery disease @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Lethal \u001b[48;2;173;216;230;38;2;0;0;0manuria\u001b[00m complicating high dose \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m chemotherapy in a breast cancer patient with an \u001b[48;2;144;238;144;38;2;0;0;0mimpaired renal function\u001b[00m. A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0manuria\u001b[00m, the day after 5 g/m2 bolus \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mpostrenal failure\u001b[00m was excluded by echography. A prerenal component could have contributed to \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m because of a transient hypotension, due to an increasing ascitis, occurring just before \u001b[48;2;173;216;230;38;2;0;0;0manuria\u001b[00m. However, correction of the hemodynamic parameters did not improve renal function. \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m is a known \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxic\u001b[00m drug with demonstrated \u001b[48;2;144;238;144;38;2;0;0;0mtubulopathies\u001b[00m. We strongly suspect that this lethal \u001b[48;2;173;216;230;38;2;0;0;0manuria\u001b[00m was mainly due to \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension. We recommend careful use of \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m in patients pretreated with \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxic\u001b[00m chemotherapy and inadequate renal perfusion.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ifosfamide @CHEMICAL@ anuria @DISEASE@ @CID@ ifosfamide @CHEMICAL@ impaired renal function ; postrenal failure ; nephrotoxic ; tubulopathies @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ifosfamide @CHEMICAL@ anuria @DISEASE@ @CID@ ifosfamide @CHEMICAL@ renal failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcentral \u001b[48;2;144;238;144;38;2;0;0;0mvein thrombosis\u001b[00m\u001b[00m and topical \u001b[48;2;173;216;230;38;2;0;0;0mdipivalyl epinephrine\u001b[00m. A report is given on an 83-year-old female who acquired \u001b[48;2;173;216;230;38;2;0;0;0mcentral \u001b[48;2;144;238;144;38;2;0;0;0mvein thrombosis\u001b[00m\u001b[00m in her seeing eye one day after having started topical medication with \u001b[48;2;173;216;230;38;2;0;0;0mdipivalyl epinephrine\u001b[00m for advanced glaucoma discovered in the other eye. From present knowledge about the effects of adrenergic eye drops on ocular blood circulation, it is difficult to suggest an association between the two events, which may be coincidental only.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dipivalyl epinephrine @CHEMICAL@ vein thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dipivalyl epinephrine @CHEMICAL@ central vein thrombosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m: case presentation and literature review. PURPOSE: We present a case of a patient who developed \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m shortly after initiating treatment with \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid. The main search terms utilized were case report and \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m. The search was limited to studies published in English. RESULTS: Six cases of \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m have been reported in the literature. Drug-drug interactions related to the inhibition of CYP1A2 by \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m are likely involved in the clinical outcome of these cases. CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating \u001b[48;2;173;216;230;38;2;0;0;0mlevofloxacin\u001b[00m therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levofloxacin @CHEMICAL@ seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levofloxacin @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Mice lacking mPGES-1 are resistant to \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m. Cyclooxygenase-2 activity is required for the development of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m. However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated. The present study was undertaken to assess \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1). A 2-wk administration of \u001b[48;2;144;238;144;38;2;0;0;0mlicl\u001b[00m (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m with hyposmotic urine. This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion. In contrast, mPGES-1 -/- mice were largely resistant to \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output. Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-treated +/+ mice. This decrease was significantly attenuated in the -/- mice. qRT-PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex. Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m treatment. In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice. We conclude that mPGES-1-derived PGE(2) mediates \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpolyuria\u001b[00m likely via inhibition of AQP2 and NKCC2 expression.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "licl @CHEMICAL@ polyuria @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium @CHEMICAL@ polyuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Identification of a simple and sensitive microplate method for the detection of \u001b[48;2;173;216;230;38;2;0;0;0moversulfated \u001b[48;2;144;238;144;38;2;0;0;0mchondroitin sulfate\u001b[00m\u001b[00m in heparin products. Heparin is a commonly implemented anticoagulant used to treat critically ill patients. Recently, a number of commercial lots of heparin products were found to be contaminated with an \u001b[48;2;173;216;230;38;2;0;0;0moversulfated \u001b[48;2;144;238;144;38;2;0;0;0mchondroitin sulfate\u001b[00m\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0moscs\u001b[00m) derivative that could elicit a \u001b[48;2;173;216;230;38;2;0;0;0mhypotensive\u001b[00m response in pigs following a single high-dose infusion. Using both contaminated heparin products and the synthetically produced derivative, we showed that the \u001b[48;2;173;216;230;38;2;0;0;0moscs\u001b[00m produces dose-dependent \u001b[48;2;144;238;144;38;2;0;0;0mhypotension\u001b[00m in pigs. The no observed effect level (NOEL) for this contaminant appears to be approximately 1mg/kg, corresponding to a contamination level of approximately 3%. We also demonstrated that \u001b[48;2;173;216;230;38;2;0;0;0moscs\u001b[00m can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL. This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "chondroitin sulfate @CHEMICAL@ hypotensive ; hypotension @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oversulfated chondroitin sulfate ; oscs @CHEMICAL@ hypotensive @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0msulfasalazine\u001b[00m in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases. We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients. METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years. Patients', who had \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m on \u001b[48;2;173;216;230;38;2;0;0;0msulfasalazine\u001b[00m and met a definition of a serious ADR, were identified. Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument. The likely frequency of \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0msulfasalazine\u001b[00m was estimated by making a series of conservative assumptions. RESULTS: Ten cases were identified: eight occurred during surveillance. Eight patients were hospitalised, two in \u001b[48;2;173;216;230;38;2;0;0;0mhepatic failure\u001b[00m - one died after a liver transplant. All but one event occurred within 6 weeks of treatment. Seven patients had a \u001b[48;2;173;216;230;38;2;0;0;0mskin rash\u001b[00m, three \u001b[48;2;173;216;230;38;2;0;0;0meosinophilia\u001b[00m and one \u001b[48;2;173;216;230;38;2;0;0;0minterstitial nephritis\u001b[00m. Five patients were of Black British of African or Caribbean descent. Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six. Drug-related \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m was judged probable or highly probable in 8 patients. The likely frequency of serious \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0msulfasalazine\u001b[00m was estimated at 0.4% of treated patients. CONCLUSION: Serious \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0msulfasalazine\u001b[00m appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "sulfasalazine @CHEMICAL@ hepatotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "sulfasalazine @CHEMICAL@ hepatotoxicity ; hepatic failure ; hepatotoxicity @DISEASE@ @CID@ sulfasalazine @CHEMICAL@ skin rash @DISEASE@ @CID@ sulfasalazine @CHEMICAL@ eosinophilia @DISEASE@ @CID@ sulfasalazine @CHEMICAL@ interstitial nephritis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmemory function\u001b[00m and serotonin transporter promoter gene polymorphism in \u001b[48;2;173;216;230;38;2;0;0;0mecstasy\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m) users. Although \u001b[48;2;173;216;230;38;2;0;0;0m3,4-methylenedioxymethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mecstasy\u001b[00m) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m as well as cognitive functioning. The aim of the study was to investigate the effects of moderate and heavy \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m use on cognitive function, as well as the effects of long-term abstention from \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m, in subjects genotyped for 5-HTTLPR. A second aim of the study was to determine whether these effects differ for females and males. Fifteen moderate \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m users (<55 lifetime tablets), 22 heavy \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m+ users (>55 lifetime tablets), 16 ex-\u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests. DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.A significant group effect was observed only on \u001b[48;2;173;216;230;38;2;0;0;0mmemory function\u001b[00m tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59). Heavy and ex-\u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m+ users performed significantly poorer on memory tasks than controls. In contrast, no evidence of \u001b[48;2;173;216;230;38;2;0;0;0mmemory impairment\u001b[00m was observed in moderate \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m users. No significant effect of 5-HTTLPR or gender was observed. While the use of \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m in quantities that may be considered \"moderate\" is not associated with \u001b[48;2;173;216;230;38;2;0;0;0mimpaired memory functioning\u001b[00m, heavy use of \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m use may lead to long lasting \u001b[48;2;173;216;230;38;2;0;0;0mmemory impairments\u001b[00m. No effect of 5-HTTLPR or gender on \u001b[48;2;173;216;230;38;2;0;0;0mmemory function\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mmdma\u001b[00m use was observed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ecstasy ; mdma ; 3,4-methylenedioxymethamphetamine @CHEMICAL@ memory impairment ; impaired memory functioning ; memory impairments @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "3,4-methylenedioxymethamphetamine ; mdma ; ecstasy @CHEMICAL@ memory function ; memory impairment ; memory impairments @DISEASE@ @CID@ 3,4-methylenedioxymethamphetamine ; mdma ; ecstasy @CHEMICAL@ impaired memory functioning ; memory impairments @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Does supplemental \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m increase \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m risk in women with diabetes? BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro. These observations led us to hypothesize that a high intake of \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m in diabetic persons might promote atherosclerosis. OBJECTIVE: The objective was to examine the relation between \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m intake and mortality from \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m. DESIGN: We studied the relation between \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m intake and mortality from total \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m (n = 281), \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery disease\u001b[00m (n = 175), and \u001b[48;2;173;216;230;38;2;0;0;0mstroke\u001b[00m (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline. Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery disease\u001b[00m were prospectively followed for 15 y. RESULTS: After adjustment for \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m intake from food and supplements. Adjusted relative risks of \u001b[48;2;173;216;230;38;2;0;0;0mcoronary artery disease\u001b[00m were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of \u001b[48;2;173;216;230;38;2;0;0;0mstroke\u001b[00m were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01). When dietary and supplemental \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m were analyzed separately, only supplemental \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m showed a positive association with mortality endpoints. \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m intake was unrelated to mortality from \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m in the nondiabetic subjects at baseline. CONCLUSION: A high \u001b[48;2;173;216;230;38;2;0;0;0mvitamin c\u001b[00m intake from supplements is associated with an increased risk of \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular disease\u001b[00m mortality in postmenopausal women with diabetes.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "vitamin c @CHEMICAL@ cardiovascular disease @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "vitamin c @CHEMICAL@ cardiovascular disease @DISEASE@ @CID@ vitamin c @CHEMICAL@ coronary artery disease @DISEASE@ @CID@ vitamin c @CHEMICAL@ stroke @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Absolute and attributable risk of \u001b[48;2;173;216;230;38;2;0;0;0mvenous thromboembolism\u001b[00m in women on combined \u001b[48;2;173;216;230;38;2;0;0;0mcyproterone acetate\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0methinylestradiol\u001b[00m. OBJECTIVE: To achieve absolute risk estimates of \u001b[48;2;173;216;230;38;2;0;0;0mvenous thromboembolism\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mvte\u001b[00m) among women on \u001b[48;2;173;216;230;38;2;0;0;0mcyproterone acetate\u001b[00m plus \u001b[48;2;173;216;230;38;2;0;0;0methinylestradiol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcpa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mee\u001b[00m), and among women on \u001b[48;2;144;238;144;38;2;0;0;0mcombined oral contraceptives\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m). METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of \u001b[48;2;173;216;230;38;2;0;0;0mvte\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mcoc\u001b[00m use was ascertained through mailed questionnaires. Sales statistics of \u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcpa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mee\u001b[00m were provided through Danish Drug Statistics. RESULTS: During the time frame of the study, 330 women were found to have had \u001b[48;2;173;216;230;38;2;0;0;0mvte\u001b[00m while on \u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m. Of these women, 67 were on levonorgestrel-containing \u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m. Eleven were on \u001b[48;2;173;216;230;38;2;0;0;0mcpa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mee\u001b[00m. The corresponding absolute risk of \u001b[48;2;173;216;230;38;2;0;0;0mvte\u001b[00m was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on \u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing \u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on \u001b[48;2;173;216;230;38;2;0;0;0mcpa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mee\u001b[00m. CONCLUSION: Our results suggest the absolute risk of \u001b[48;2;173;216;230;38;2;0;0;0mvte\u001b[00m among Danish women on \u001b[48;2;144;238;144;38;2;0;0;0mcocs\u001b[00m is similar to that among women taking \u001b[48;2;173;216;230;38;2;0;0;0mcpa\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mee\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "combined oral contraceptives ; cocs ; coc @CHEMICAL@ venous thromboembolism ; vte @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyproterone acetate ; cpa @CHEMICAL@ venous thromboembolism ; vte @DISEASE@ @CID@ ethinylestradiol ; ee @CHEMICAL@ venous thromboembolism ; vte @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m associated with sleep deprivation and sustained-release \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m. This case report describes a generalized \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m associated with sustained-release \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m use and sleep deprivation. The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m as an active control. After 5 weeks of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m use, the subject experienced a generalized \u001b[48;2;173;216;230;38;2;0;0;0mtonic clonic \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m\u001b[00m after staying up nearly all night packing and moving to a new residence. The patient had no other risk factors for \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m. We suggest that sleep deprivation may add to the risk of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m-associated \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupropion @CHEMICAL@ seizure ; seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupropion @CHEMICAL@ seizure ; seizure @DISEASE@ @CID@ bupropion @CHEMICAL@ tonic clonic seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxic\u001b[00m effects in high-risk patients undergoing angiography. BACKGROUND: The use of iodinated \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m can result in \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m. Whether iso-osmolar \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m is less \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxic\u001b[00m than low-osmolar \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m in high-risk patients is uncertain. METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxic\u001b[00m effects of an iso-osmolar, dimeric, nonionic \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m, with those of a low-osmolar, nonionic, monomeric \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m. The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography. The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography. Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7. RESULTS: The creatinine concentration increased significantly less in patients who received \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m. From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m group and 0.55 mg per deciliter in the \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m group (P=0.001; the increase with \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m minus the increase with \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]). Two of the 64 patients in the \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m group (26 percent) (P=0.002; odds ratio for such an increase in the \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m group, 0.09 [95 percent confidence interval, 0.02 to 0.41]). No patient receiving \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m had an increase of 1.0 mg per deciliter or more, but 10 patients in the \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m group (15 percent) did. The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m group and 0.24 mg per deciliter in the \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m group (P=0.003; value in the \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m group minus the value in the \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]). CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m may be less likely to develop in high-risk patients when \u001b[48;2;173;216;230;38;2;0;0;0miodixanol\u001b[00m is used rather than a low-osmolar, nonionic \u001b[48;2;173;216;230;38;2;0;0;0mcontrast medium\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "iohexol @CHEMICAL@ nephrotoxic ; nephropathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "contrast medium @CHEMICAL@ nephrotoxic ; nephrotoxic @DISEASE@ @CID@ iodixanol @CHEMICAL@ nephrotoxic ; nephropathy @DISEASE@ @CID@ iohexol @CHEMICAL@ nephrotoxic ; nephropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Experimental cranial \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m elicited by \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m: a PET study. Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval. It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'. To test this hypothesis we performed an experimental \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m study in seven healthy volunteers, using the same positioning in the PET scanner as in the migraine patients. A small amount of \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m was administered subcutaneously in the right forehead to evoke a burning \u001b[48;2;144;238;144;38;2;0;0;0mpainful\u001b[00m sensation in the first division of the trigeminal nerve. Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum. Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m state compared to the \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m free state. The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m as such, rather than in a specific type of headache as was suggested for cluster headache.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "capsaicin @CHEMICAL@ pain ; painful @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "capsaicin @CHEMICAL@ pain ; pain @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Hepatic and extrahepatic angiotensinogen gene expression in rats with acute \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m. Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with \u001b[48;2;173;216;230;38;2;0;0;0mnephrotic syndrome\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mns\u001b[00m). In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, \u001b[48;2;144;238;144;38;2;0;0;0mnephrotic\u001b[00m, and pair-fed (PF) rats. \u001b[48;2;173;216;230;38;2;0;0;0mns\u001b[00m was induced by a single injection of \u001b[48;2;173;216;230;38;2;0;0;0mpuromycin amino-nucleoside\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mpan\u001b[00m). Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after \u001b[48;2;173;216;230;38;2;0;0;0mpan\u001b[00m injection, when \u001b[48;2;173;216;230;38;2;0;0;0mns\u001b[00m was clearly established, hepatic Ao mRNA levels did not change. Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after \u001b[48;2;173;216;230;38;2;0;0;0mpan\u001b[00m injection. These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute \u001b[48;2;173;216;230;38;2;0;0;0mns\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mpan\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "puromycin amino-nucleoside ; pan @CHEMICAL@ nephrotic syndrome ; ns ; nephrotic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "puromycin amino-nucleoside ; pan @CHEMICAL@ nephrotic syndrome ; ns @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mleg and back pain\u001b[00m after spinal anaesthesia involving hyperbaric 5% \u001b[48;2;173;216;230;38;2;0;0;0mlignocaine\u001b[00m. Fifty-four patients, aged 27-90 years, who were given \u001b[48;2;173;216;230;38;2;0;0;0mlignocaine\u001b[00m 5% in 6.8% glucose solution for spinal anaesthesia were studied. Thirteen of these patients experienced \u001b[48;2;173;216;230;38;2;0;0;0mpain in the legs and/or back\u001b[00m after recovery from anaesthesia. The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain. Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor. \u001b[48;2;144;238;144;38;2;0;0;0mleg and/or back pain\u001b[00m is associated with the intrathecal use of hyperbaric 5% \u001b[48;2;173;216;230;38;2;0;0;0mlignocaine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lignocaine @CHEMICAL@ leg and back pain ; pain in the legs and/or back ; leg and/or back pain @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lignocaine @CHEMICAL@ pain in the legs and/or back @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Acute blood pressure elevations with \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m in men with borderline systemic \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m. Whether the vasoconstrictive actions of \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m are enhanced in \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m persons has not been demonstrated. Thus, \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m (3.3 mg/kg) versus placebo was tested in 48 healthy men (aged 20 to 35 years) selected after screening on 2 separate occasions. Borderline \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg. Low-risk controls (n = 24) reported no parental history of \u001b[48;2;173;216;230;38;2;0;0;0mhypertension\u001b[00m and had screening BP < 130/85 mm Hg. Participants were then tested on 2 occasions after 12-hour abstinence from \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m in each of 2 protocols; this required a total of 4 laboratory visits. \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004). These findings were consistent and reached significance in both protocols. The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96%. Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m BP levels after \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m ingestion. Thus, in borderline \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m men, exaggerated responses to \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline \u001b[48;2;144;238;144;38;2;0;0;0mhypertensives\u001b[00m. We suspect that the potential for \u001b[48;2;173;216;230;38;2;0;0;0mcaffeine\u001b[00m to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "caffeine @CHEMICAL@ hypertension ; hypertensive ; hypertensives @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "caffeine @CHEMICAL@ hypertension ; hypertensive @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced neurotoxicity. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m as a symptom of central neurotoxicity are a known but poorly described side effect of \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m. Most cases of \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m have been reported with other mental status changes. METHODS: The authors interviewed six persons with \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m in the presence of a clear sensorium. All patients were receiving high-dose \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m as part of their bone marrow transplant procedure. RESULTS: \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m occurred only when the patient's eyes were closed and, in all but one case, were reported as disturbing or frightening. Underreporting of these \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m by patients is likely. CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m may be the sole or first manifestation of neurotoxicity. The incidence may be dose and infusion-time related. The clinician should be alerted for possible \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhallucinations\u001b[00m, which may occur without other signs of neurotoxicity. \"Eyes-closed\" \u001b[48;2;144;238;144;38;2;0;0;0mhallucinatory\u001b[00m experiences appear to be an unusual feature of this presentation. Patients anxious about this experience respond well to support and education about this occurrence. Optimal pharmacologic management of disturbed patients is unclear. If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ifosfamide @CHEMICAL@ hallucinations ; hallucinatory @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ifosfamide @CHEMICAL@ hallucinations @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mchlorpropamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m. A 65-year-old woman with adult-onset diabetes treated with \u001b[48;2;173;216;230;38;2;0;0;0mchlorpropamide\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdiabenese\u001b[00m) had a toxic \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m that resolved with discontinuation of \u001b[48;2;173;216;230;38;2;0;0;0mchlorpropamide\u001b[00m therapy. Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy. The possibility of a drug-induced \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m should be considered in the differential diagnosis of visual loss in diabetics.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "chlorpropamide ; diabenese @CHEMICAL@ optic neuropathy ; toxic optic neuropathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "chlorpropamide ; diabenese @CHEMICAL@ optic neuropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Cardiac transplantation: improved quality of survival with a modified immunosuppressive protocol. The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients. In group I, \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporine\u001b[00m was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml. In group II, \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporine\u001b[00m was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week. Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels. Group II also showed a significant decrease of \u001b[48;2;173;216;230;38;2;0;0;0mchronic \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxicity\u001b[00m\u001b[00m secondary to long-term therapy with \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporine\u001b[00m. Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine. We think that even these lower dosages of \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporine\u001b[00m can cause \u001b[48;2;173;216;230;38;2;0;0;0mchronic \u001b[48;2;144;238;144;38;2;0;0;0mnephrotoxicity\u001b[00m\u001b[00m and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclosporine @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclosporine @CHEMICAL@ chronic nephrotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Reversible \u001b[48;2;173;216;230;38;2;0;0;0mcholestasis\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mbile duct injury\u001b[00m following \u001b[48;2;173;216;230;38;2;0;0;0mazathioprine\u001b[00m therapy. A case report. A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe \u001b[48;2;173;216;230;38;2;0;0;0mcholestasis\u001b[00m 3 months after initiation of \u001b[48;2;173;216;230;38;2;0;0;0mazathioprine\u001b[00m therapy. Liver biopsy showed \u001b[48;2;173;216;230;38;2;0;0;0mcholestasis\u001b[00m with both cytological and architectural alterations of interlobular bile ducts. \u001b[48;2;173;216;230;38;2;0;0;0mazathioprine\u001b[00m withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities. It is believed that this is the first reported case of reversible \u001b[48;2;173;216;230;38;2;0;0;0mazathioprine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcholestasis\u001b[00m associated with histological evidence of \u001b[48;2;173;216;230;38;2;0;0;0mbile duct injury\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "azathioprine @CHEMICAL@ cholestasis ; bile duct injury @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "azathioprine @CHEMICAL@ cholestasis @DISEASE@ @CID@ azathioprine @CHEMICAL@ bile duct injury @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m and its enantiomers. The metabolism of the cardioselective beta-blocker \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m is under genetic control of the debrisoquine/sparteine type. The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m in EMs. We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m. The drug effect studied was the antagonism by \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m of \u001b[48;2;173;216;230;38;2;0;0;0mterbutaline\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypokalemia\u001b[00m. By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m plasma concentrations resulting in half-maximum receptor occupancy. Six EMs received 0.5 mg of \u001b[48;2;173;216;230;38;2;0;0;0mterbutaline\u001b[00m s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m p.o. Five PMs were studied according to the same protocol, except for a higher \u001b[48;2;173;216;230;38;2;0;0;0mterbutaline\u001b[00m dose (0.75 mg) on day 2. Blood samples for the analysis of plasma potassium, \u001b[48;2;173;216;230;38;2;0;0;0mterbutaline\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m. In PMs, \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m increased the \u001b[48;2;173;216;230;38;2;0;0;0mterbutaline\u001b[00m area under the plasma concentration vs. time curve (+67%). Higher \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m/alpha-hydroxymetoprolol ratios in PMs were predictive for higher R-/S-isomer ratios of unchanged drug. There was a difference in \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m potency with higher racemic \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "terbutaline @CHEMICAL@ hypokalemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "metoprolol @CHEMICAL@ hypokalemia @DISEASE@ @CID@ terbutaline @CHEMICAL@ hypokalemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mserotonin syndrome\u001b[00m from \u001b[48;2;173;216;230;38;2;0;0;0mvenlafaxine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mtranylcypromine\u001b[00m interaction. Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of \u001b[48;2;173;216;230;38;2;0;0;0mserotonin excess\u001b[00m that consists of shivering, muscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0msalivation\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mconfusion\u001b[00m, agitation and \u001b[48;2;144;238;144;38;2;0;0;0mhyperthermia\u001b[00m. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. \u001b[48;2;173;216;230;38;2;0;0;0mvenlafaxine\u001b[00m is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine. We report a \u001b[48;2;173;216;230;38;2;0;0;0mvenlafaxine\u001b[00m-MAOI interaction that resulted in the \u001b[48;2;173;216;230;38;2;0;0;0mserotonin syndrome\u001b[00m in a 23-y-old male who was taking \u001b[48;2;173;216;230;38;2;0;0;0mtranylcypromine\u001b[00m for depression. He had been well until the morning of presentation when he took 1/2 tab of \u001b[48;2;173;216;230;38;2;0;0;0mvenlafaxine\u001b[00m. Within 2 h he became confused with jerking movements of his extremities, \u001b[48;2;144;238;144;38;2;0;0;0mtremors\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m. He was brought directly to a hospital where he was found to be agitated and confused with shivering, \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonic jerks\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0msalivation\u001b[00m and diaphoresis. His pupils were 7 mm and sluggishly reactive to light. Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m and clenched jaws. He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m. His subsequent course was remarkable for non-immune \u001b[48;2;144;238;144;38;2;0;0;0mthrombocytopenia\u001b[00m which resolved. The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis. His mental status normalized and he was transferred to a psychiatry ward. This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "venlafaxine @CHEMICAL@ serotonin syndrome @DISEASE@ @CID@ venlafaxine @CHEMICAL@ muscle rigidity ; rigidity @DISEASE@ @CID@ venlafaxine @CHEMICAL@ salivation @DISEASE@ @CID@ venlafaxine @CHEMICAL@ confusion @DISEASE@ @CID@ venlafaxine @CHEMICAL@ hyperthermia @DISEASE@ @CID@ venlafaxine @CHEMICAL@ tremors @DISEASE@ @CID@ venlafaxine @CHEMICAL@ myoclonic jerks @DISEASE@ @CID@ venlafaxine @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ serotonin syndrome @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ muscle rigidity ; rigidity @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ salivation @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ confusion @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ hyperthermia @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ tremors @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ myoclonic jerks @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "venlafaxine @CHEMICAL@ serotonin syndrome ; serotonin excess @DISEASE@ @CID@ tranylcypromine @CHEMICAL@ serotonin syndrome ; serotonin excess @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of nondopaminergic drugs on \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m in \u001b[48;2;173;216;230;38;2;0;0;0mmptp\u001b[00m-treated monkeys. A group of four monkeys was rendered \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonian\u001b[00m with the toxin \u001b[48;2;173;216;230;38;2;0;0;0mmptp\u001b[00m. They were then treated chronically with \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m. A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m to see if the \u001b[48;2;173;216;230;38;2;0;0;0mdyskinetic movements\u001b[00m would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the \u001b[48;2;173;216;230;38;2;0;0;0mdyskinetic movements\u001b[00m but at the cost of a return of \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonian\u001b[00m symptomatology. However, yohimbine and meperidine reduced predominantly the \u001b[48;2;173;216;230;38;2;0;0;0mdyskinetic movements\u001b[00m. Baclofen was also useful in one monkey against a more dystonic form of \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m. Atropine converted the dystonic movements into chorea.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "mptp @CHEMICAL@ parkinsonian @DISEASE@ @CID@ l-dopa/benserazide @CHEMICAL@ dyskinesias ; dyskinesia ; dyskinetic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "l-dopa @CHEMICAL@ dyskinesias ; dyskinetic movements @DISEASE@ @CID@ mptp @CHEMICAL@ parkinsonian @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mccnu\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mlomustine\u001b[00m) toxicity in dogs: a retrospective study (2002-07). OBJECTIVE: To describe the incidence of haematological, renal, hepatic and \u001b[48;2;144;238;144;38;2;0;0;0mgastrointestinal toxicities\u001b[00m in tumour-bearing dogs receiving \u001b[48;2;144;238;144;38;2;0;0;0m1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mccnu\u001b[00m). DESIGN: The medical records of 206 dogs that were treated with \u001b[48;2;173;216;230;38;2;0;0;0mccnu\u001b[00m at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated. RESULTS: Of the 206 dogs treated with \u001b[48;2;173;216;230;38;2;0;0;0mccnu\u001b[00m, 185 met the inclusion criteria for at least one class of toxicity. \u001b[48;2;173;216;230;38;2;0;0;0mccnu\u001b[00m was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced \u001b[48;2;173;216;230;38;2;0;0;0mneutropenia\u001b[00m, 34.2% experienced \u001b[48;2;173;216;230;38;2;0;0;0manaemia\u001b[00m and 14.2% experienced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mgastrointestinal toxicosis\u001b[00m was detected in 37.8% of dogs, the most common sign of which was \u001b[48;2;173;216;230;38;2;0;0;0mvomiting\u001b[00m (24.3%). Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mhepatic failure\u001b[00m was 1.2%. CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0mccnu\u001b[00m-associated toxicity in dogs is common, but is usually not life threatening.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ renal toxicities @DISEASE@ @CID@ ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ gastrointestinal toxicities ; gastrointestinal toxicosis @DISEASE@ @CID@ ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ neutropenia @DISEASE@ @CID@ ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ anaemia @DISEASE@ @CID@ ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ vomiting @DISEASE@ @CID@ ccnu ; lomustine ; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea @CHEMICAL@ hepatic failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ccnu ; lomustine @CHEMICAL@ neutropenia @DISEASE@ @CID@ ccnu ; lomustine @CHEMICAL@ anaemia @DISEASE@ @CID@ ccnu ; lomustine @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ ccnu ; lomustine @CHEMICAL@ vomiting @DISEASE@ @CID@ ccnu ; lomustine @CHEMICAL@ hepatic failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Neuroactive steroids protect against \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mkainic acid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mlimbic \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m in mice. Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m-, \u001b[48;2;173;216;230;38;2;0;0;0mkainic acid\u001b[00m- and N-methyl-D-aspartate (NMDA)-induced \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m in mice. Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m (416 mg/kg, s.c.)-induced \u001b[48;2;173;216;230;38;2;0;0;0mlimbic motor \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m (ED50 values, 7.0-18.7 mg/kg, i.p.). The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.). Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity. Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of \u001b[48;2;173;216;230;38;2;0;0;0mlimbic \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mkainic acid\u001b[00m (32 mg/kg, s.c.), but did not completely protect against the \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m. However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the \u001b[48;2;173;216;230;38;2;0;0;0mkainic acid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mlimbic \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m was obtained. The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m or lethality. We conclude that neuroactive steroids are highly effective in protecting against \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mkainic acid\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m in mice, and may be of utility in the treatment of some forms of \u001b[48;2;173;216;230;38;2;0;0;0mstatus epilepticus\u001b[00m in humans.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ pilocarpine @CHEMICAL@ status epilepticus @DISEASE@ @CID@ kainic acid @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@ kainic acid @CHEMICAL@ status epilepticus @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ limbic seizures ; limbic motor seizures @DISEASE@ @CID@ kainic acid @CHEMICAL@ limbic seizures ; limbic motor seizures @DISEASE@ @CID@ kainic acid @CHEMICAL@ status epilepticus @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The safety and efficacy of combination \u001b[48;2;173;216;230;38;2;0;0;0mn-butyl-deoxynojirimycin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0msc-48334\u001b[00m) and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m in patients with HIV-1 infection and 200-500 CD4 cells/mm3. We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with \u001b[48;2;173;216;230;38;2;0;0;0mn-butyl-deoxynojirimycin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0msc-48334\u001b[00m) (an alpha-glucosidase I inhibitor) and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m versus \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m alone. Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m therapy received \u001b[48;2;173;216;230;38;2;0;0;0msc-48334\u001b[00m (1000 mg every 8 h) and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m (100 mg every 8 h) or \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m and placebo. Sixty patients received combination therapy and 58, \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m and placebo. Twenty-three patients (38%) and 15 (26%), in the combination and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m groups, respectively, discontinued therapy (p = 0.15). The mean \u001b[48;2;173;216;230;38;2;0;0;0msc-48334\u001b[00m steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m groups, respectively (p > 0.36). For patients with prior \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m therapy, the mean change in CD4 cells in the combination and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and \u001b[48;2;144;238;144;38;2;0;0;0mzidovudine\u001b[00m groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. \u001b[48;2;173;216;230;38;2;0;0;0mdiarrhea\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mflatulence\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mabdominal pain\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mweight loss\u001b[00m were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ diarrhea @DISEASE@ @CID@ n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ flatulence @DISEASE@ @CID@ n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ abdominal pain @DISEASE@ @CID@ n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ weight loss @DISEASE@ @CID@ zidovudine @CHEMICAL@ diarrhea @DISEASE@ @CID@ zidovudine @CHEMICAL@ flatulence @DISEASE@ @CID@ zidovudine @CHEMICAL@ abdominal pain @DISEASE@ @CID@ zidovudine @CHEMICAL@ weight loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ diarrhea @DISEASE@ @CID@ n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ flatulence @DISEASE@ @CID@ n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ abdominal pain @DISEASE@ @CID@ n-butyl-deoxynojirimycin ; sc-48334 @CHEMICAL@ weight loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Recent preclinical and clinical studies with the thymidylate synthase inhibitor \u001b[48;2;173;216;230;38;2;0;0;0mn10-propargyl-5,8-dideazafolic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m). \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mn10-propargyl-5,8-dideazafolic acid\u001b[00m, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme. Recent preclinical studies have focused on the intracellular formation of \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m polyglutamates. Following a 12-hour exposure of L1210 cells to 50 microM [3H]\u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m, 30% of the extractable radioactivity could be accounted for as \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses. As inhibitors of isolated L1210 TS, \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m, respectively, and their formation may, therefore, be an important determinant of \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m cytotoxicity. In early clinical studies with \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma. Toxicities included \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mmalaise\u001b[00m, and dose-limiting \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m. This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m under acidic conditions. In an attempt to overcome this problem, a clinical trial of \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m administered with alkaline diuresis is under way. Preliminary results at 400 and 500 mg/m2 suggest that a reduction in \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m may have been achieved with only 1 instance of \u001b[48;2;144;238;144;38;2;0;0;0mrenal toxicity\u001b[00m in 10 patients. \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmalaise\u001b[00m are again the most frequent side effects. Evidence of antitumor activity has been seen in 3 patients. Pharmacokinetic investigations have shown that alkaline diuresis does not alter \u001b[48;2;173;216;230;38;2;0;0;0mcb 3717\u001b[00m plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "n10-propargyl-5,8-dideazafolic acid ; cb 3717 @CHEMICAL@ hepatotoxicity @DISEASE@ @CID@ n10-propargyl-5,8-dideazafolic acid ; cb 3717 @CHEMICAL@ malaise @DISEASE@ @CID@ n10-propargyl-5,8-dideazafolic acid ; cb 3717 @CHEMICAL@ nephrotoxicity ; renal toxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "n10-propargyl-5,8-dideazafolic acid ; cb 3717 @CHEMICAL@ hepatotoxicity @DISEASE@ @CID@ n10-propargyl-5,8-dideazafolic acid ; cb 3717 @CHEMICAL@ malaise @DISEASE@ @CID@ n10-propargyl-5,8-dideazafolic acid ; cb 3717 @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Ethopropazine and \u001b[48;2;173;216;230;38;2;0;0;0mbenztropine\u001b[00m in neuroleptic-induced \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonism\u001b[00m. In a 12-week controlled study ethopropazine was compared to \u001b[48;2;173;216;230;38;2;0;0;0mbenztropine\u001b[00m in the treatment of \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonism\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mfluphenazine enanthate\u001b[00m in 60 schizophrenic outpatients. Ethopropazine and \u001b[48;2;173;216;230;38;2;0;0;0mbenztropine\u001b[00m were found to be equally effective in controlling \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonian symptoms\u001b[00m and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, \u001b[48;2;173;216;230;38;2;0;0;0mbenztropine\u001b[00m treated patients had a significant increase in \u001b[48;2;173;216;230;38;2;0;0;0mtardive dyskinesia\u001b[00m compared to their condition during procyclindine treatment, and significantly more \u001b[48;2;173;216;230;38;2;0;0;0manxiety\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mdepression\u001b[00m than ethopropazine treated patients. This suggests that \u001b[48;2;173;216;230;38;2;0;0;0mbenztropine\u001b[00m is not the anticholinergic drug of choice in the treatment of neuroleptic-induced \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonian symptoms\u001b[00m, because of its more toxic central and peripheral atropinic effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "benztropine @CHEMICAL@ tardive dyskinesia @DISEASE@ @CID@ benztropine @CHEMICAL@ anxiety @DISEASE@ @CID@ benztropine @CHEMICAL@ depression @DISEASE@ @CID@ fluphenazine enanthate @CHEMICAL@ parkinsonism ; parkinsonian symptoms @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluphenazine enanthate @CHEMICAL@ parkinsonism ; parkinsonian symptoms @DISEASE@ @CID@ benztropine @CHEMICAL@ tardive dyskinesia @DISEASE@ @CID@ benztropine @CHEMICAL@ anxiety @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of alpha-tocopherol and deferoxamine on \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m-induced neurotoxicity. \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals. This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m-induced neurotoxicity. Male rats were treated with \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m (10 mg/kg, every 2 h for four injections). The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m administration or DFO (50 mg/kg) subcutaneously 30 min before \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m administration. The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperthermia\u001b[00m as well as the \u001b[48;2;173;216;230;38;2;0;0;0malterations in the locomotor activity\u001b[00m. The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m-treated rats. These changes were significantly attenuated by alpha-TC and DFO. This suggests that alpha-TC and DFO ameliorate the \u001b[48;2;173;216;230;38;2;0;0;0mma\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mneuronal damage\u001b[00m by decreasing the level of oxidative stress.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methamphetamine ; ma @CHEMICAL@ hyperthermia @DISEASE@ @CID@ methamphetamine ; ma @CHEMICAL@ neuronal damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methamphetamine ; ma @CHEMICAL@ hyperthermia @DISEASE@ @CID@ methamphetamine ; ma @CHEMICAL@ alterations in the locomotor activity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Behavioral effects of \u001b[48;2;173;216;230;38;2;0;0;0mmk-801\u001b[00m on \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m-treated mice. The effects of \u001b[48;2;173;216;230;38;2;0;0;0mdizocilpine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmk-801\u001b[00m), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m treatments. This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or \u001b[48;2;173;216;230;38;2;0;0;0mtardive dyskinesia\u001b[00m, and its response after glutamatergic blockage. \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of \u001b[48;2;173;216;230;38;2;0;0;0mtardive dyskinesia\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m also produced \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m, which are signs suggestive of Parkinson's disease. \u001b[48;2;173;216;230;38;2;0;0;0mmk-801\u001b[00m (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m. However, \u001b[48;2;173;216;230;38;2;0;0;0mmk-801\u001b[00m injection produced a significant increase of \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m in \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m-treated mice. \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice. On the other hand, \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m induced increases in \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m compared to control mice. \u001b[48;2;173;216;230;38;2;0;0;0mmk-801\u001b[00m (0.1 mg/kg) administration attenuated the \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m. Pretreatment with \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m, whereas \u001b[48;2;173;216;230;38;2;0;0;0mmk-801\u001b[00m (0.1 mg/kg) injection 90 min before the test reversed the effects of \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m. These results show that \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m produces different and \u001b[48;2;144;238;144;38;2;0;0;0mabnormal movements\u001b[00m, which are related to dose and schedule employed and can be considered as parkinsonian-like and \u001b[48;2;173;216;230;38;2;0;0;0mtardive dsykinesia\u001b[00m signs. The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtremor\u001b[00m according to the employed model.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "reserpine @CHEMICAL@ tardive dyskinesia ; abnormal movements ; tardive dsykinesia @DISEASE@ @CID@ reserpine @CHEMICAL@ tremor @DISEASE@ @CID@ reserpine @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "reserpine ; dizocilpine ; mk-801 @CHEMICAL@ tardive dyskinesia ; tardive dsykinesia @DISEASE@ @CID@ reserpine ; dizocilpine ; mk-801 @CHEMICAL@ tremor @DISEASE@ @CID@ reserpine ; dizocilpine ; mk-801 @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of glyceryl trinitrate on the \u001b[48;2;173;216;230;38;2;0;0;0msphincter of oddi \u001b[48;2;144;238;144;38;2;0;0;0mspasm\u001b[00m\u001b[00m evoked by \u001b[48;2;173;216;230;38;2;0;0;0mprostigmine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m administration. OBJECTIVE: In this study the effect of glyceryl trinitrate on the \u001b[48;2;173;216;230;38;2;0;0;0mprostigmine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0msphincter of oddi \u001b[48;2;144;238;144;38;2;0;0;0mspasm\u001b[00m\u001b[00m was evaluated in nine female patients with \u001b[48;2;144;238;144;38;2;0;0;0msphincter of oddi dyskinesia\u001b[00m. METHOD: \u001b[48;2;173;216;230;38;2;0;0;0msphincter of oddi \u001b[48;2;144;238;144;38;2;0;0;0mspasm\u001b[00m\u001b[00m was induced by \u001b[48;2;173;216;230;38;2;0;0;0mprostigmine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m administration (0.5 mg \u001b[48;2;173;216;230;38;2;0;0;0mprostigmine\u001b[00m intramuscularly and 10 mg \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m subcutaneously) and visualized by quantitative hepatobiliary scintigraphy. The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min). RESULTS: \u001b[48;2;173;216;230;38;2;0;0;0mprostigmine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete \u001b[48;2;144;238;144;38;2;0;0;0mspasm\u001b[00m at the level of the sphincter of Oddi. Glyceryl trinitrate infusion completely normalized the \u001b[48;2;173;216;230;38;2;0;0;0mprostigmine\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate. CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0msphincter of oddi \u001b[48;2;144;238;144;38;2;0;0;0mspasm\u001b[00m\u001b[00m in humans. Since glyceryl trinitrate is able to overcome even the drastic effect of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m, it might be of relevance in the treatment of \u001b[48;2;144;238;144;38;2;0;0;0msphincter of oddi dyskinesia\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prostigmine @CHEMICAL@ sphincter of oddi spasm ; sphincter of oddi dyskinesia @DISEASE@ @CID@ prostigmine @CHEMICAL@ spasm @DISEASE@ @CID@ morphine @CHEMICAL@ sphincter of oddi spasm ; sphincter of oddi dyskinesia @DISEASE@ @CID@ morphine @CHEMICAL@ spasm @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prostigmine @CHEMICAL@ sphincter of oddi spasm @DISEASE@ @CID@ morphine @CHEMICAL@ sphincter of oddi spasm @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of acute steroid administration on ventilatory and peripheral muscles in rats. Occasional case reports have shown that acute \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m may occur in patients treated with massive doses of corticosteroids. The mechanism of this \u001b[48;2;173;216;230;38;2;0;0;0mmyopathy\u001b[00m is poorly understood. Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mm\u001b[00m), or \u001b[48;2;173;216;230;38;2;0;0;0mtriamcinolone\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mt\u001b[00m) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant \u001b[48;2;144;238;144;38;2;0;0;0mreduction of food intake\u001b[00m in the steroid-treated groups (-50 and -79% in \u001b[48;2;173;216;230;38;2;0;0;0mm\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mt\u001b[00m, respectively). This was associated with a similar \u001b[48;2;144;238;144;38;2;0;0;0mloss in body weight\u001b[00m. In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied. Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment. Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the \u001b[48;2;173;216;230;38;2;0;0;0mm\u001b[00m group (837 +/- 171 g/cm(2); p < 0.05) and the \u001b[48;2;173;216;230;38;2;0;0;0mt\u001b[00m group (765 +/- 145 g/cm(2), NS). Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with \u001b[48;2;173;216;230;38;2;0;0;0mm\u001b[00m, whereas tetanic tensions were similar. Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05). ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber \u001b[48;2;144;238;144;38;2;0;0;0matrophy\u001b[00m in the steroid groups and also diaphragmatic type IIa \u001b[48;2;144;238;144;38;2;0;0;0matrophy\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mt\u001b[00m, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis. Finally, a pair-fed (PF) study, performed in 18 rats (C, \u001b[48;2;173;216;230;38;2;0;0;0mt\u001b[00m, and PF), showed that \u001b[48;2;144;238;144;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0matrophy\u001b[00m\u001b[00m was considerably less pronounced in PF animals than in \u001b[48;2;173;216;230;38;2;0;0;0mt\u001b[00m-treated animals. We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb \u001b[48;2;144;238;144;38;2;0;0;0matrophy\u001b[00m, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb \u001b[48;2;144;238;144;38;2;0;0;0matrophy\u001b[00m was not caused by acute nutritional deprivation alone.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methylprednisolone ; m @CHEMICAL@ reduction of food intake @DISEASE@ @CID@ methylprednisolone ; m @CHEMICAL@ loss in body weight @DISEASE@ @CID@ methylprednisolone ; m @CHEMICAL@ atrophy ; muscle atrophy @DISEASE@ @CID@ triamcinolone ; t @CHEMICAL@ reduction of food intake @DISEASE@ @CID@ triamcinolone ; t @CHEMICAL@ loss in body weight @DISEASE@ @CID@ triamcinolone ; t @CHEMICAL@ atrophy ; muscle atrophy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methylprednisolone ; m @CHEMICAL@ myopathy @DISEASE@ @CID@ triamcinolone ; t @CHEMICAL@ myopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Refractory \u001b[48;2;173;216;230;38;2;0;0;0mcardiogenic shock\u001b[00m and complete \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mverapamil\u001b[00m SR and \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m treatment. A case report. A seventy-eight-year-old woman presented with complete \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m and refractory \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m two days after a therapeutic dose of sustained-release \u001b[48;2;173;216;230;38;2;0;0;0mverapamil\u001b[00m with concomitant use of \u001b[48;2;173;216;230;38;2;0;0;0mmetoprolol\u001b[00m. The patient continued to remain \u001b[48;2;144;238;144;38;2;0;0;0mhypotensive\u001b[00m with complete \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine. However, shortly after the use of intravenous calcium chloride, the refractory \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and complete \u001b[48;2;173;216;230;38;2;0;0;0mheart block\u001b[00m resolved.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "verapamil @CHEMICAL@ heart block @DISEASE@ @CID@ verapamil @CHEMICAL@ hypotension ; hypotensive @DISEASE@ @CID@ metoprolol @CHEMICAL@ heart block @DISEASE@ @CID@ metoprolol @CHEMICAL@ hypotension ; hypotensive @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "verapamil ; verapamil sr @CHEMICAL@ cardiogenic shock @DISEASE@ @CID@ verapamil ; verapamil sr @CHEMICAL@ heart block @DISEASE@ @CID@ verapamil ; verapamil sr @CHEMICAL@ hypotension @DISEASE@ @CID@ metoprolol @CHEMICAL@ cardiogenic shock @DISEASE@ @CID@ metoprolol @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Involvement of the mu-opiate receptor in peripheral analgesia. The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of \u001b[48;2;173;216;230;38;2;0;0;0mprostaglandin e2\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m. The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin. Morphine did not, however, alter the \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m induced by \u001b[48;2;144;238;144;38;2;0;0;0m8-bromo cyclic adenosine monophosphate\u001b[00m. We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prostaglandin e2 @CHEMICAL@ hyperalgesia @DISEASE@ @CID@ 8-bromo cyclic adenosine monophosphate @CHEMICAL@ hyperalgesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prostaglandin e2 @CHEMICAL@ hyperalgesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Adequate timing of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m reduction in patients with hemolysis during combination therapy of \u001b[48;2;173;216;230;38;2;0;0;0minterferon\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m for chronic hepatitis C. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic anemia\u001b[00m is one of the major adverse events of the combination therapy of \u001b[48;2;173;216;230;38;2;0;0;0minterferon\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m. Because of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m-related \u001b[48;2;173;216;230;38;2;0;0;0mhemolytic anemia\u001b[00m, dose reduction is a common event in this therapy. In this clinical retrospective cohort study we have examined the suitable timing of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m reduction in patients with hemolysis during combination therapy. METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy. After that, these 37 patients were reduced one tablet of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m (200 mg) per day. After reduction of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m, 27 of 37 patients could continue combination therapy for a total of 24 weeks (group A). However, 10 of 37 patients with reduction of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B). We assessed the final efficacy and safety after reduction of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively. A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance. With respect to hemoglobin level at the time of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036). CONCLUSIONS: Reduction of \u001b[48;2;173;216;230;38;2;0;0;0mribavirin\u001b[00m at hemoglobin level > or =10 g/dl is suitable in terms of efficacy and side effects.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ribavirin @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@ interferon @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ribavirin @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@ interferon ; interferon @CHEMICAL@ hemolytic anemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Does hormone therapy for the treatment of breast cancer have a \u001b[48;2;144;238;144;38;2;0;0;0mdetrimental effect on memory\u001b[00m and cognition? A pilot study. This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of \u001b[48;2;173;216;230;38;2;0;0;0manastrozole\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtamoxifen\u001b[00m alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures. Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups. Patient group performance was not significantly related to length of treatment or measures of psychological morbidity. The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer. Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women. In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "anastrozole @CHEMICAL@ detrimental effect on memory @DISEASE@ @CID@ anastrozole @CHEMICAL@ detrimental effect on cognition @DISEASE@ @CID@ tamoxifen @CHEMICAL@ detrimental effect on memory @DISEASE@ @CID@ tamoxifen @CHEMICAL@ detrimental effect on cognition @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "anastrozole @CHEMICAL@ memory impairments ; memory impairments ; verbal memory impairments @DISEASE@ @CID@ tamoxifen @CHEMICAL@ memory impairments ; memory impairments ; verbal memory impairments @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m in rats. It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment. Neuroleptic-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m was not considered a specific test for neuroleptic-induced akathisia. Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist. Carteolol, as well as propranolol and biperiden, inhibited the \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m. The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden. Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats. Carteolol did not antagonize the inhibitory effects of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m on \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m-induced stereotypy and locomotor activity in rats. In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit \u001b[48;2;173;216;230;38;2;0;0;0m5-hydroxytryptophan\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhead twitch\u001b[00m in rats. Finally, carteolol did not inhibit physostigmine-induced lethality in rats. These results strongly suggest that carteolol improves \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ catalepsy @DISEASE@ @CID@ apomorphine @CHEMICAL@ catalepsy @DISEASE@ @CID@ 5-hydroxytryptophan @CHEMICAL@ head twitch @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mpenicillamine\u001b[00m-induced rapidly progressive \u001b[48;2;173;216;230;38;2;0;0;0mglomerulonephritis\u001b[00m in a patient with rheumatoid arthritis. A 67-year-old woman with rheumatoid arthritis presented rapidly progressive \u001b[48;2;173;216;230;38;2;0;0;0mglomerulonephritis\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mrpgn\u001b[00m) after 5 months of \u001b[48;2;173;216;230;38;2;0;0;0md-\u001b[48;2;144;238;144;38;2;0;0;0mpenicillamine\u001b[00m\u001b[00m (250 mg/day) treatment. Light microscopy study showed severe \u001b[48;2;173;216;230;38;2;0;0;0mglomerulonephritis\u001b[00m with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole. Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium. The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents. A complete recovery of renal function was achieved in a few weeks. This new case of \u001b[48;2;173;216;230;38;2;0;0;0mrpgn\u001b[00m in the course of \u001b[48;2;173;216;230;38;2;0;0;0md-\u001b[48;2;144;238;144;38;2;0;0;0mpenicillamine\u001b[00m\u001b[00m treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m in these patients. The prompt discontinuation of \u001b[48;2;173;216;230;38;2;0;0;0md-\u001b[48;2;144;238;144;38;2;0;0;0mpenicillamine\u001b[00m\u001b[00m and vigorous treatment measures could allow for a good prognosis as in this case.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "penicillamine ; d-penicillamine @CHEMICAL@ glomerulonephritis ; rpgn @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "d-penicillamine @CHEMICAL@ glomerulonephritis ; rpgn @DISEASE@ @CID@ d-penicillamine @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Nature, time course and dose dependence of \u001b[48;2;173;216;230;38;2;0;0;0mzidovudine\u001b[00m-related side effects: results from the Multicenter Canadian \u001b[48;2;144;238;144;38;2;0;0;0mazidothymidine\u001b[00m Trial. To characterize the nature, time course and dose dependency of \u001b[48;2;173;216;230;38;2;0;0;0mzidovudine\u001b[00m-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with \u001b[48;2;173;216;230;38;2;0;0;0mzidovudine\u001b[00m 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly \u001b[48;2;173;216;230;38;2;0;0;0mnausea\u001b[00m (64%), \u001b[48;2;173;216;230;38;2;0;0;0mfatigue\u001b[00m (55%) and \u001b[48;2;173;216;230;38;2;0;0;0mheadache\u001b[00m (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. \u001b[48;2;173;216;230;38;2;0;0;0mbone marrow changes\u001b[00m occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "zidovudine ; azidothymidine @CHEMICAL@ nausea @DISEASE@ @CID@ zidovudine ; azidothymidine @CHEMICAL@ fatigue @DISEASE@ @CID@ zidovudine ; azidothymidine @CHEMICAL@ headache @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "zidovudine @CHEMICAL@ nausea @DISEASE@ @CID@ zidovudine @CHEMICAL@ fatigue @DISEASE@ @CID@ zidovudine @CHEMICAL@ headache @DISEASE@ @CID@ zidovudine @CHEMICAL@ bone marrow changes @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Bilateral \u001b[48;2;173;216;230;38;2;0;0;0moptic neuropathy\u001b[00m due to combined \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m treatment. The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m is reported. A \u001b[48;2;144;238;144;38;2;0;0;0mbilateral retrobulbar neuropathy\u001b[00m with an unusual central bitemporal hemianopic \u001b[48;2;144;238;144;38;2;0;0;0mscotoma\u001b[00m was found. \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m was stopped and only small improvement of the visual acuity followed. \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m was discontinued later, followed by a dramatic improvement in the visual acuity. The hazards of \u001b[48;2;173;216;230;38;2;0;0;0moptic nerve toxicity\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m are known. We emphasize the potential danger in the use of \u001b[48;2;173;216;230;38;2;0;0;0methambutol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0misoniazid\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ethambutol @CHEMICAL@ bilateral optic neuropathy ; bilateral retrobulbar neuropathy @DISEASE@ @CID@ ethambutol @CHEMICAL@ scotoma @DISEASE@ @CID@ isoniazid @CHEMICAL@ bilateral optic neuropathy ; bilateral retrobulbar neuropathy @DISEASE@ @CID@ isoniazid @CHEMICAL@ scotoma @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ethambutol @CHEMICAL@ optic neuropathy ; optic nerve toxicity @DISEASE@ @CID@ isoniazid @CHEMICAL@ optic neuropathy ; optic nerve toxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Progestational agents and \u001b[48;2;144;238;144;38;2;0;0;0mblood coagulation\u001b[00m. VII. \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolic\u001b[00m and other complications of \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive\u001b[00m therapy in relationship to pretreatment levels of \u001b[48;2;144;238;144;38;2;0;0;0mblood coagulation\u001b[00m factors: summary report of a ten-year study. During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m to changes in hematologic parameters. Significant increases in certain factors of the \u001b[48;2;144;238;144;38;2;0;0;0mblood coagulation\u001b[00m and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups. Severe complications developed in four patients. All four had an abnormal \u001b[48;2;144;238;144;38;2;0;0;0mblood coagulation\u001b[00m profile, suggesting \"hypercoagulability\" before initiation of therapy. Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy. One of these patients developed a \u001b[48;2;144;238;144;38;2;0;0;0mmyocardial infarction\u001b[00m before receiving any medication, shortly after the base-line values were obtained. One patient developed \u001b[48;2;144;238;144;38;2;0;0;0mretinopathy\u001b[00m 19 months after she began therapy, and another developed \u001b[48;2;144;238;144;38;2;0;0;0mthrombophlebitis\u001b[00m after 27 months of therapy. The fourth patient developed \u001b[48;2;144;238;144;38;2;0;0;0mthrombophlebitis\u001b[00m 14 days after initiation of contraceptive therapy. All four patients were of the A or AB blood group. Previous studies suggested the possiblility of increased propensity for \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolic\u001b[00m episodes in patients possessing the A antigen. It appears from these data that hematologic work-ups may be useful in women who are about to start long-term \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive\u001b[00m therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptive ; oral contraceptives @CHEMICAL@ blood coagulation @DISEASE@ @CID@ oral contraceptive ; oral contraceptives @CHEMICAL@ myocardial infarction @DISEASE@ @CID@ oral contraceptive ; oral contraceptives @CHEMICAL@ retinopathy @DISEASE@ @CID@ oral contraceptive ; oral contraceptives @CHEMICAL@ thrombophlebitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oral contraceptives ; oral contraceptive @CHEMICAL@ thromboembolic ; thromboembolic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m in mice. Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the \u001b[48;2;144;238;144;38;2;0;0;0mconvulsive\u001b[00m, lethal, locomotor stimulatory and rewarding actions of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m in mice. In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable. To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies. Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors. In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m and locomotor activity, but not lethality. When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions. Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m, and further development of more selective, high affinity ligands are warranted.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ convulsive ; convulsions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ convulsions ; convulsion @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmethimazole\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcholestatic jaundice\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mmethimazole\u001b[00m is a widely used and generally well-tolerated antithyroid agent. A 43-year-old woman had severe jaundice and \u001b[48;2;173;216;230;38;2;0;0;0mitching\u001b[00m 1 month after receiving \u001b[48;2;173;216;230;38;2;0;0;0mmethimazole\u001b[00m (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism. The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications. When seen at the emergency department 2 weeks later, she still had severe icterus, \u001b[48;2;173;216;230;38;2;0;0;0mpruritus\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mhyperbilirubinemia\u001b[00m, formed mainly of the conjugated fraction. \u001b[48;2;173;216;230;38;2;0;0;0mmethimazole\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcholestasis\u001b[00m was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without \u001b[48;2;173;216;230;38;2;0;0;0mmethimazole\u001b[00m. In rare cases within the first few weeks of therapy, this drug can cause severe and reversible \u001b[48;2;173;216;230;38;2;0;0;0mcholestatic jaundice\u001b[00m. Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue \u001b[48;2;173;216;230;38;2;0;0;0mmethimazole\u001b[00m therapy and avoid unnecessary invasive procedures.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methimazole @CHEMICAL@ cholestatic jaundice @DISEASE@ @CID@ methimazole @CHEMICAL@ itching ; pruritus @DISEASE@ @CID@ methimazole @CHEMICAL@ hyperbilirubinemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methimazole @CHEMICAL@ cholestatic jaundice ; cholestasis @DISEASE@ @CID@ methimazole @CHEMICAL@ itching ; pruritus @DISEASE@ @CID@ methimazole @CHEMICAL@ hyperbilirubinemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mvasopressin\u001b[00m in the treatment of \u001b[48;2;173;216;230;38;2;0;0;0mmilrinone\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m in severe heart failure. The use of phosphodiesterase inhibitors such as \u001b[48;2;173;216;230;38;2;0;0;0mmilrinone\u001b[00m in the treatment of severe heart failure is frequently restricted because they cause vasodilation and \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m. In patients with decompensated heart failure with \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m after treatment with \u001b[48;2;173;216;230;38;2;0;0;0mmilrinone\u001b[00m, low doses of \u001b[48;2;144;238;144;38;2;0;0;0mvasopressin\u001b[00m restored blood pressure without inhibiting the inotropic effect of \u001b[48;2;173;216;230;38;2;0;0;0mmilrinone\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "vasopressin @CHEMICAL@ hypotension @DISEASE@ @CID@ milrinone @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "milrinone @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Halogenated anesthetics form liver adducts and antigens that cross-react with \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m-induced antibodies. Two halogenated anesthetics, \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0misoflurane\u001b[00m, have been associated with an \u001b[48;2;173;216;230;38;2;0;0;0mallergic-type \u001b[48;2;144;238;144;38;2;0;0;0mhepatic injury\u001b[00m\u001b[00m both alone and following previous exposure to \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m appears to involve an aberrant immune response. An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m patients. This study was performed to determine cross-reactivity between \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0misoflurane\u001b[00m with the \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m induced by \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m. The subcellular and lobular production of hepatic neoantigens recognized by \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m-induced antibodies following \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0misoflurane\u001b[00m, and the biochemical nature of these neoantigens was investigated in two animal models. \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver. In the same liver, biochemical analysis detected fluorinated liver adducts that were up to 20-fold greater in guinea pigs than in rats. This supports and extends previous evidence for a mechanism by which \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m and/or \u001b[48;2;173;216;230;38;2;0;0;0misoflurane\u001b[00m could produce a \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m condition similar to that of \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m either alone or subsequent to \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m administration. The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "halothane @CHEMICAL@ hepatic injury ; hepatitis @DISEASE@ @CID@ enflurane @CHEMICAL@ hepatic injury ; hepatitis @DISEASE@ @CID@ isoflurane @CHEMICAL@ hepatic injury ; hepatitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "enflurane @CHEMICAL@ allergic-type hepatic injury ; hepatitis ; hypersensitivity ; allergic-type hepatitis @DISEASE@ @CID@ isoflurane @CHEMICAL@ allergic-type hepatic injury ; hepatitis ; hypersensitivity ; allergic-type hepatitis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Induction by \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m of bladder and \u001b[48;2;144;238;144;38;2;0;0;0mliver tumours\u001b[00m in the rat. Effects on hepatocyte fine structure. Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m by weight for up to 18 months. At the 1.0% dosage level, 20% of rats of both sexes developed \u001b[48;2;173;216;230;38;2;0;0;0mneoplastic nodules of the liver\u001b[00m, a statistically significant incidence. These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration, the latter also being observed in the low dosage male rats. Papillomas of the transitional epithelium of the bladder developed in all \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m-treated groups, and three rats bore \u001b[48;2;173;216;230;38;2;0;0;0mbladder carcinomas\u001b[00m. However, significant yields of \u001b[48;2;173;216;230;38;2;0;0;0mbladder tumours\u001b[00m were only obtained from low dosage females and high dosage males. Additionally, 20 to 25% of \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m-treated rats developed \u001b[48;2;173;216;230;38;2;0;0;0mhyperplasia of the bladder epithelium\u001b[00m, which was not coincident with the presence of \u001b[48;2;173;216;230;38;2;0;0;0mbladder calculi\u001b[00m. A low yield of tumours at various other sites also arose following \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m feeding. An electron microscope study of the livers of \u001b[48;2;173;216;230;38;2;0;0;0mparacetamol\u001b[00m-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known \u001b[48;2;144;238;144;38;2;0;0;0mhepatocarcinogens\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "paracetamol @CHEMICAL@ bladder tumours ; bladder carcinomas @DISEASE@ @CID@ paracetamol @CHEMICAL@ liver tumours ; hepatocarcinogens @DISEASE@ @CID@ paracetamol @CHEMICAL@ hyperplasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "paracetamol @CHEMICAL@ bladder tumours ; bladder carcinomas @DISEASE@ @CID@ paracetamol @CHEMICAL@ neoplastic nodules of the liver @DISEASE@ @CID@ paracetamol @CHEMICAL@ hyperplasia of the bladder epithelium @DISEASE@ @CID@ paracetamol @CHEMICAL@ bladder calculi @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Rat extraocular muscle regeneration. Repair of local anesthetic-induced damage. Local anesthetics that are commonly used in ophthalmic surgery (0.75% \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine hydrochloride\u001b[00m, 2.0% \u001b[48;2;173;216;230;38;2;0;0;0mmepivacaine hydrochloride\u001b[00m, and 2.0% \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine hydrochloride\u001b[00m plus 1:100,000 \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m) were injected into the retrobulbar area of rat eyes. Controls were injected with physiological saline. All three anesthetics produced massive \u001b[48;2;173;216;230;38;2;0;0;0mdegeneration of the extraocular muscles\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mmuscle degeneration\u001b[00m is followed by regeneration of the damaged muscle fibers. In addition to \u001b[48;2;144;238;144;38;2;0;0;0mmuscle damage\u001b[00m, severe damage was also seen in harderian glands, especially after exposure to \u001b[48;2;144;238;144;38;2;0;0;0mmepivacaine\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mlidocaine\u001b[00m plus \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m. With these findings in rats, it is hypothesized that the temporary \u001b[48;2;173;216;230;38;2;0;0;0mdiplopia\u001b[00m sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupivacaine hydrochloride @CHEMICAL@ muscle degeneration ; muscle damage @DISEASE@ @CID@ mepivacaine hydrochloride ; mepivacaine @CHEMICAL@ muscle degeneration ; muscle damage @DISEASE@ @CID@ lidocaine hydrochloride ; lidocaine @CHEMICAL@ muscle degeneration ; muscle damage @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupivacaine hydrochloride @CHEMICAL@ degeneration of the extraocular muscles @DISEASE@ @CID@ mepivacaine hydrochloride @CHEMICAL@ degeneration of the extraocular muscles @DISEASE@ @CID@ lidocaine hydrochloride @CHEMICAL@ degeneration of the extraocular muscles @DISEASE@ @CID@ epinephrine @CHEMICAL@ diplopia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mdiazepam\u001b[00m facilitates reflex \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m in conscious rats. The effects of \u001b[48;2;144;238;144;38;2;0;0;0mdiazepam\u001b[00m on cardiovascular function were assessed in conscious rats. Intravenous administration of \u001b[48;2;144;238;144;38;2;0;0;0mdiazepam\u001b[00m (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate. Also, reflex \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m was produced in rats by intravenous infusion of \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m (1.25-2.5 micrograms kg-1). Intravenous pretreatment of the rats with \u001b[48;2;144;238;144;38;2;0;0;0mdiazepam\u001b[00m, although causing no change in the \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced pressor effect, did enhance the \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced reflex \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m. However, the \u001b[48;2;144;238;144;38;2;0;0;0mdiazepam\u001b[00m enhancement of \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced reflex \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex). The data indicate that \u001b[48;2;144;238;144;38;2;0;0;0mdiazepam\u001b[00m acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "diazepam @CHEMICAL@ bradycardia @DISEASE@ @CID@ adrenaline @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "adrenaline @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Preservation of renal blood flow during \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m induced with \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam\u001b[00m in dogs. The introduction of drugs that could induce \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy. Specific dopamine-1, (DA1) and dopamine-2 (DA2) receptor agonists are now under clinical investigation. \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam mesylate\u001b[00m is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation. The hypothesis that \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam\u001b[00m could be used to induce \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m and preserve blood flow to the kidney was tested. Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0msodium \u001b[48;2;144;238;144;38;2;0;0;0mnitroprusside\u001b[00m\u001b[00m in ten dogs under \u001b[48;2;144;238;144;38;2;0;0;0mhalothane\u001b[00m general anaesthesia. Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam\u001b[00m (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of \u001b[48;2;173;216;230;38;2;0;0;0msodium \u001b[48;2;144;238;144;38;2;0;0;0mnitroprusside\u001b[00m\u001b[00m (5.9 micrograms.kg-1.min-1) (NS). Renal blood flow (RBF) increased during \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m 11 +/- 7 per cent and decreased 21 +/- 8 per cent during \u001b[48;2;173;216;230;38;2;0;0;0msodium \u001b[48;2;144;238;144;38;2;0;0;0mnitroprusside\u001b[00m\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m (P less than 0.01). \u001b[48;2;173;216;230;38;2;0;0;0msodium \u001b[48;2;144;238;144;38;2;0;0;0mnitroprusside\u001b[00m\u001b[00m is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mfenoldopam\u001b[00m is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced \u001b[48;2;173;216;230;38;2;0;0;0mhypotension\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fenoldopam ; fenoldopam mesylate @CHEMICAL@ hypotension @DISEASE@ @CID@ nitroprusside @CHEMICAL@ hypotension @DISEASE@ @CID@ halothane @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fenoldopam ; fenoldopam mesylate @CHEMICAL@ hypotension @DISEASE@ @CID@ sodium nitroprusside @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Antiarrhythmic effects of optical isomers of cibenzoline on canine \u001b[48;2;173;216;230;38;2;0;0;0mventricular \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m\u001b[00m. Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine \u001b[48;2;173;216;230;38;2;0;0;0mventricular \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m\u001b[00m models. Digitalis \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of \u001b[48;2;173;216;230;38;2;0;0;0mouabain\u001b[00m in pentobarbital-anesthetized dogs. \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m, which is suppressed by Ca channel blockers, was induced by \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m infusion in halothane-anesthetized dogs. Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m, respectively. The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6). A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m, whereas 5 mg/kg i.v. was needed to suppress \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0marrhythmias\u001b[00m. The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and \u001b[48;2;173;216;230;38;2;0;0;0madrenaline\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0marrhythmia\u001b[00m were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6). The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ouabain @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia ; arrhythmia ; adrenaline arrhythmia ; arrhythmias @DISEASE@ @CID@ adrenaline @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia ; arrhythmia ; adrenaline arrhythmia ; arrhythmias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ouabain @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia @DISEASE@ @CID@ adrenaline @CHEMICAL@ ventricular arrhythmias ; ventricular arrhythmia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of Hibiscus rosa sinensis on \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m-induced neurobehavioral and biochemical alterations in rats. Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0morofacial \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m\u001b[00m and neurochemical alterations. The rats were treated with intraperitoneal \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m (1 mg/kg, ip) for 3 days every other day. On day 5, vacuous chewing movements and tongue protrusions were counted for 5 min. \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects. Biochemical analysis of brain revealed that the \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process. Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels. The results of the present study suggested that Hibiscus rosa sinensis had a protective role against \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0morofacial \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m\u001b[00m and oxidative stress.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "reserpine @CHEMICAL@ dyskinesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "reserpine @CHEMICAL@ orofacial dyskinesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0m5 flourouracil\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mapical ballooning syndrome\u001b[00m: a case report. The \u001b[48;2;173;216;230;38;2;0;0;0mapical ballooning syndrome\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mabs\u001b[00m) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with \u001b[48;2;173;216;230;38;2;0;0;0mhyperkinesis\u001b[00m of the basal left ventricular (LV) segments without obstructive epicardial coronary disease. Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents. However, there are no reports of \u001b[48;2;173;216;230;38;2;0;0;0mabs\u001b[00m secondary to chemotherapeutic agents. We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer. A 79-year-old woman presented with typical ischemic \u001b[48;2;144;238;144;38;2;0;0;0mchest pain\u001b[00m, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram. She underwent recent chemotherapy with \u001b[48;2;173;216;230;38;2;0;0;0mfluorouracil\u001b[00m for metastatic colorectal cancer. Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic. Coronary angiography revealed no obstructive coronary lesions. The patient was stabilized with medical therapy. Four weeks later she remained completely asymptomatic. Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis. Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation. In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of \u001b[48;2;173;216;230;38;2;0;0;0mabs\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "5 flourouracil ; fluorouracil @CHEMICAL@ apical ballooning syndrome ; abs @DISEASE@ @CID@ 5 flourouracil ; fluorouracil @CHEMICAL@ chest pain @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluorouracil @CHEMICAL@ apical ballooning syndrome ; abs @DISEASE@ @CID@ fluorouracil @CHEMICAL@ hyperkinesis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Reduction of \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m during induction with target-controlled \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m on injection of \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m is unpleasant. We hypothesized that \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m infusion \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m might be prevented by infusing \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m before starting the \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used. A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m to prevent the \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m without producing complications. METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI. After the target Ce was achieved, the infusion of \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m was started. \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m-related complications were assessed during the \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m infusion, and \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m was evaluated using a four-point scale during the \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m infusion. RESULTS: The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001). \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001). However, both incidence and severity of \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m were not different between Groups R4 and R6. No significant complications were observed during the study. CONCLUSIONS: During induction of anaesthesia with TCI of \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m, a significant reduction in \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m infusion \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m was achieved without significant complications by prior administration of \u001b[48;2;173;216;230;38;2;0;0;0mremifentanil\u001b[00m at a target Ce of 4 ng ml(-1).\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "propofol @CHEMICAL@ pain @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "propofol @CHEMICAL@ pain @DISEASE@ @CID@ remifentanil @CHEMICAL@ pain @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Prenatal exposure to \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m induces fetal \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary hypertension\u001b[00m in the rat. RATIONALE: \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women. Epidemiological data suggest that \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m exposure prenatally increases the prevalence of persistent \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary hypertension\u001b[00m syndrome of the newborn. The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary hypertension\u001b[00m protective \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m effect in adult rodents. OBJECTIVES: To evaluate the \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate. METHODS: Pregnant rats were treated with \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m (10 mg/kg) from Day 11 through Day 21 of gestation. MEASUREMENTS AND MAIN RESULTS: Fetuses were delivered by cesarean section. As compared with controls, \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m exposure resulted in fetal \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary hypertension\u001b[00m as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01). Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m-exposed pups (79 +/- 2%). In vitro, \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01). After in utero exposure to a low \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01). CONCLUSIONS: In contrast to the adult, \u001b[48;2;173;216;230;38;2;0;0;0mfluoxetine\u001b[00m exposure in utero induces \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary hypertension\u001b[00m in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluoxetine @CHEMICAL@ fetal pulmonary hypertension @DISEASE@ @CID@ fluoxetine @CHEMICAL@ pulmonary hypertension ; pulmonary hypertension syndrome @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluoxetine @CHEMICAL@ pulmonary hypertension ; pulmonary hypertension syndrome of the newborn @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0msyncope\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mqt prolongation\u001b[00m among patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m for heroin dependence in the city of Copenhagen. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m is prescribed to heroin addicts to decrease illicit opioid use. Prolongation of the QT interval in the ECG of patients with \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m) has been reported in \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m users. As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of \u001b[48;2;144;238;144;38;2;0;0;0msyncope\u001b[00m to illicit drug use and thereby underestimate the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m. METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m or buprenorphine on a daily basis. Of the patients at the Drug Addiction Service in the municipal of Copenhagen, 450 (approximately 52%) were included. The QT interval was estimated from 12 lead ECGs. All participants were interviewed about any experience of \u001b[48;2;144;238;144;38;2;0;0;0msyncope\u001b[00m. The association between opioid dose and QT, and \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m dose and reporting of \u001b[48;2;144;238;144;38;2;0;0;0msyncope\u001b[00m was assessed using multivariate linear regression and logistic regression, respectively. RESULTS: \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002). No association between buprenorphine and QTc was found. Among the subjects treated with \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m, 28% men and 32% women had \u001b[48;2;144;238;144;38;2;0;0;0mprolonged qtc interval\u001b[00m. None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)). A 50 mg higher \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for \u001b[48;2;144;238;144;38;2;0;0;0msyncope\u001b[00m. CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0mmethadone\u001b[00m is associated with \u001b[48;2;144;238;144;38;2;0;0;0mqt prolongation\u001b[00m and higher reporting of \u001b[48;2;144;238;144;38;2;0;0;0msyncope\u001b[00m in a population of heroin addicts.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methadone @CHEMICAL@ syncope @DISEASE@ @CID@ methadone @CHEMICAL@ qt prolongation ; prolonged qtc interval @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methadone @CHEMICAL@ torsade de pointes ; tdp @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m. Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors. Their ester prodrugs 6 and 8 were orally active in three models of \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m: reversal of \u001b[48;2;173;216;230;38;2;0;0;0mformalin\u001b[00m-induced paw licking, \u001b[48;2;173;216;230;38;2;0;0;0mcarrageenan\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthermal hyperalgesia\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmechanical hyperalgesia\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "carrageenan @CHEMICAL@ thermal hyperalgesia ; mechanical hyperalgesia @DISEASE@ @CID@ capsaicin @CHEMICAL@ thermal hyperalgesia ; mechanical hyperalgesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "formalin @CHEMICAL@ pain @DISEASE@ @CID@ carrageenan @CHEMICAL@ thermal hyperalgesia @DISEASE@ @CID@ capsaicin @CHEMICAL@ mechanical hyperalgesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The role of nitrergic system in \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsion\u001b[00m in the mouse. The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m. In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively. Thirty minutes after these injections, all mice received \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m (50 mg/kg, i.p.). In the second experiment, four groups of mice received similar treatment in the first experiment, and 30 min after these injections, all mice received a higher dose of \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m (80 mg/kg). L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m (50 mg/kg)-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m. In contrast, the L-arginine treatment increased the incidence of \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m (80 mg/kg, i.p.)-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m significantly. These results may suggest that NO is a proconvulsant mediator in \u001b[48;2;173;216;230;38;2;0;0;0mlidocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lidocaine @CHEMICAL@ convulsion ; convulsions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lidocaine @CHEMICAL@ convulsions ; convulsion ; convulsions @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mprednisolone\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmuscle dysfunction\u001b[00m is caused more by atrophy than by altered acetylcholine receptor expression. Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood. We investigated the effects of moderate and large doses of \u001b[48;2;173;216;230;38;2;0;0;0mprednisolone\u001b[00m on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression. With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg \u001b[48;2;173;216;230;38;2;0;0;0mprednisolone\u001b[00m (P10 group), 100 mg/kg \u001b[48;2;173;216;230;38;2;0;0;0mprednisolone\u001b[00m (P100 group), or an equal volume of saline (S group) for 7 days. A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group). On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs. Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group. Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups. The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group. The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups. AChR expression was less in the P10 group than in the S group. The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression. Our results suggest that the neuromuscular dysfunction after \u001b[48;2;173;216;230;38;2;0;0;0mprednisolone\u001b[00m is dose-dependent, and derives primarily from \u001b[48;2;144;238;144;38;2;0;0;0mmuscle atrophy\u001b[00m and derives less so from changes in AChR expression. IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear. We suggest that the observed effects are dose-dependent and derive primarily from \u001b[48;2;144;238;144;38;2;0;0;0mmuscle atrophy\u001b[00m and derive less from changes in acetylcholine receptor expression.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "prednisolone @CHEMICAL@ muscle dysfunction @DISEASE@ @CID@ prednisolone @CHEMICAL@ muscle atrophy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "prednisolone @CHEMICAL@ muscle dysfunction @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage. Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties. Their safety in patients undergoing intracranial surgery is under debate. Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either \u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m, 100 mg, three times a day (\u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH. Treatment was continued for 3 days postoperatively. Test blood samples were taken before treatment and surgery as well as on the first, third, and fifth postoperative mornings. Maximal \u001b[48;2;144;238;144;38;2;0;0;0mplatelet aggregation\u001b[00m induced by 6 microM of adenosine diphosphate decreased after administration of \u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m. Aggregation was lower (P < .05) in the \u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m group than in the acetaminophen group just before surgery and on the third postoperative day. In contrast, maximal \u001b[48;2;144;238;144;38;2;0;0;0mplatelet aggregation\u001b[00m increased in the acetaminophen group on the third postoperative day as compared with the pretreatment \u001b[48;2;144;238;144;38;2;0;0;0mplatelet aggregation\u001b[00m results (P < .05). One patient in the \u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m group developed a postoperative \u001b[48;2;173;216;230;38;2;0;0;0mintracranial \u001b[48;2;144;238;144;38;2;0;0;0mhematoma\u001b[00m\u001b[00m. Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups. \u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m but not acetaminophen impaired platelet function in patients with SAH. If \u001b[48;2;173;216;230;38;2;0;0;0mketoprofen\u001b[00m is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ketoprofen @CHEMICAL@ platelet aggregation @DISEASE@ @CID@ ketoprofen @CHEMICAL@ hematoma @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ketoprofen @CHEMICAL@ intracranial hematoma @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Value of methylprednisolone in prevention of the \u001b[48;2;173;216;230;38;2;0;0;0marthralgia\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m syndrome associated with the total dose infusion of \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m: a double blind randomized trial. The safety and efficacy of total dose infusion (TDI) of \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m has been well documented. In 40% of treated patients, an \u001b[48;2;173;216;230;38;2;0;0;0marthralgia\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m syndrome develops. The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication. Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v. MP before and saline after TDI (group 2), or 125 mg i.v. MP before and after TDI (group 3). Patients were observed for 72 hours and reactions were recorded and graded according to severity. Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI. The severity of reactions (minimal, mild, and moderate, respectively) was as follows: group 1--6, 6, and 2; group 2--1, 5, and 0; group 3--5, 1, and 0. Data were analyzed by the two-sided Fisher's exact test using 95% confidence intervals with the approximation of Woolf. These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the \u001b[48;2;173;216;230;38;2;0;0;0marthralgia\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m syndrome. We conclude that 125 mg i.v. MP should be given routinely before and after TDI of \u001b[48;2;173;216;230;38;2;0;0;0miron dextran\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "iron dextran @CHEMICAL@ arthralgia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "iron dextran @CHEMICAL@ arthralgia @DISEASE@ @CID@ iron dextran @CHEMICAL@ myalgia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Long-term effects of \u001b[48;2;173;216;230;38;2;0;0;0mvincristine\u001b[00m on the \u001b[48;2;173;216;230;38;2;0;0;0mperipheral nervous system\u001b[00m. Forty patients with Non-Hodgkin's Lymphoma treated with \u001b[48;2;173;216;230;38;2;0;0;0mvincristine\u001b[00m between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of \u001b[48;2;173;216;230;38;2;0;0;0mvincristine\u001b[00m on the \u001b[48;2;173;216;230;38;2;0;0;0mperipheral nervous system\u001b[00m. The patients were interviewed with emphasis on \u001b[48;2;144;238;144;38;2;0;0;0mneuropathic symptoms\u001b[00m. Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after \u001b[48;2;173;216;230;38;2;0;0;0mvincristine\u001b[00m treatment. Twenty-seven patients reported \u001b[48;2;144;238;144;38;2;0;0;0mneuropathic symptoms\u001b[00m. In 13 of these 27 patients symptoms were still present at the time of examination. In these patients sensory signs and symptoms predominated. In the other 14 patients symptoms had been present in the past. Symptoms persisted maximally 40 months since cessation of therapy. There was no age difference between patients with and without complaints at the time of examination. Normal reflexes were found in two third of patients. Neuropathic complaints were not very troublesome on the long term. It is concluded that with the above mentioned \u001b[48;2;173;216;230;38;2;0;0;0mvincristine\u001b[00m dose schedule signs and symptoms of \u001b[48;2;173;216;230;38;2;0;0;0mvincristine\u001b[00m neuropathy are reversible for a great deal and prognosis is fairly good.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "vincristine @CHEMICAL@ neuropathic symptoms @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "vincristine @CHEMICAL@ peripheral nervous system ; peripheral nervous system ; peripheral neuropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A case of \u001b[48;2;173;216;230;38;2;0;0;0mpolymyositis\u001b[00m in a patient with primary biliary cirrhosis treated with \u001b[48;2;173;216;230;38;2;0;0;0md-penicillamine\u001b[00m. Although \u001b[48;2;173;216;230;38;2;0;0;0md-penicillamine\u001b[00m has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients. \u001b[48;2;173;216;230;38;2;0;0;0mpolymyositis\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mdermatomyositis\u001b[00m can develop as one of the autoimmune complications of \u001b[48;2;173;216;230;38;2;0;0;0md-penicillamine\u001b[00m treatment, but its exact pathogenesis remains unclear. We report a patient with primary biliary cirrhosis, who developed \u001b[48;2;173;216;230;38;2;0;0;0mpolymyositis\u001b[00m while receiving \u001b[48;2;173;216;230;38;2;0;0;0md-penicillamine\u001b[00m therapy. We described the special clinical course of the patient. Patients receiving \u001b[48;2;173;216;230;38;2;0;0;0md-penicillamine\u001b[00m therapy should be followed carefully for the development of autoimmune complications like \u001b[48;2;173;216;230;38;2;0;0;0mpolymyositis\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mdermatomyositis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "d-penicillamine @CHEMICAL@ polymyositis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "d-penicillamine @CHEMICAL@ polymyositis ; dermatomyositis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Photodistributed \u001b[48;2;173;216;230;38;2;0;0;0mnifedipine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mfacial \u001b[48;2;144;238;144;38;2;0;0;0mtelangiectasia\u001b[00m\u001b[00m. Five months after starting \u001b[48;2;173;216;230;38;2;0;0;0mnifedipine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0madalat\u001b[00m), two patients developed photodistributed \u001b[48;2;173;216;230;38;2;0;0;0mfacial \u001b[48;2;144;238;144;38;2;0;0;0mtelangiectasia\u001b[00m\u001b[00m, which became more noticeable with time. Neither patient complained of photosensitivity or flushing. Both patients reported a significant cosmetic improvement after discontinuing the drug. One commenced the closely related drug \u001b[48;2;144;238;144;38;2;0;0;0mamlodipine\u001b[00m 3 years later, with recurrence of \u001b[48;2;144;238;144;38;2;0;0;0mtelangiectasia\u001b[00m. The photodistribution of the \u001b[48;2;144;238;144;38;2;0;0;0mtelangiectasia\u001b[00m suggests a significant drug/light interaction.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nifedipine ; adalat @CHEMICAL@ telangiectasia @DISEASE@ @CID@ amlodipine @CHEMICAL@ telangiectasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "nifedipine ; adalat @CHEMICAL@ facial telangiectasia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m of \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporin a\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m: inhibition of calcineurin phosphatase. \u001b[48;2;173;216;230;38;2;0;0;0mcyclosporin a\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m; 50 mg/kg) and \u001b[48;2;144;238;144;38;2;0;0;0mfujimycine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m toxicity were investigated. Cyclophilin A and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m-binding protein, the main intracytoplasmic receptors for \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m, respectively, were each detected in renal tissue extract. In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m, but not by rapamycin. Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m, but not rapamycin. These results suggest that the \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxic\u001b[00m effects of \u001b[48;2;173;216;230;38;2;0;0;0mcsa\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfk506\u001b[00m is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclosporin a ; csa @CHEMICAL@ nephrotoxicity ; nephrotoxic @DISEASE@ @CID@ fk506 ; fujimycine @CHEMICAL@ nephrotoxicity ; nephrotoxic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclosporin a ; csa @CHEMICAL@ nephrotoxicity ; nephrotoxic @DISEASE@ @CID@ fk506 ; fk506 @CHEMICAL@ nephrotoxicity ; nephrotoxic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Massive \u001b[48;2;173;216;230;38;2;0;0;0mcerebral edema\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mfulminant \u001b[48;2;144;238;144;38;2;0;0;0mhepatic failure\u001b[00m\u001b[00m in \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m overdose: possible role of cranial decompression. \u001b[48;2;173;216;230;38;2;0;0;0mcerebral edema\u001b[00m may complicate the course of \u001b[48;2;173;216;230;38;2;0;0;0mfulminant \u001b[48;2;144;238;144;38;2;0;0;0mhepatic failure\u001b[00m\u001b[00m. Response to conventional therapy has been disappointing. We present a patient with fatal \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mfulminant \u001b[48;2;144;238;144;38;2;0;0;0mhepatic failure\u001b[00m\u001b[00m, with signs and symptoms of \u001b[48;2;173;216;230;38;2;0;0;0mcerebral edema\u001b[00m, unresponsive to conventional medical therapy. Cranial decompression was carried out. A justification of the need for further evaluation of cranial decompression in such patients is presented.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "acetaminophen @CHEMICAL@ cerebral edema @DISEASE@ @CID@ acetaminophen @CHEMICAL@ hepatic failure ; fulminant hepatic failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "acetaminophen @CHEMICAL@ cerebral edema @DISEASE@ @CID@ acetaminophen @CHEMICAL@ fulminant hepatic failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Anti-\u001b[48;2;173;216;230;38;2;0;0;0mcarcinogenic\u001b[00m action of \u001b[48;2;173;216;230;38;2;0;0;0mphenobarbital\u001b[00m given simultaneously with \u001b[48;2;173;216;230;38;2;0;0;0mdiethylnitrosamine\u001b[00m in the rat. The present work has been planned in order to elucidate the effect of \u001b[48;2;173;216;230;38;2;0;0;0mphenobarbital\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with \u001b[48;2;173;216;230;38;2;0;0;0mdiethylnitrosamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m: 10 mg/kg/day). Wistar rats (180 g) were treated by \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m alone or by \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m + \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis. After the end of the treatment, the number and the size of induced PAS positive \u001b[48;2;144;238;144;38;2;0;0;0mpreneoplastic foci\u001b[00m was significantly reduced when \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m was given simultaneously with \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m for 4 and 6 weeks. The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m treated rats were also significantly decreased in \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m + \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m treated rats. When the treatment last only 2 weeks, the presence of \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m did not change significantly the last parameters. In \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m + \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m alone. It is concluded that \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m, which promotes carcinogenesis when administered after the \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m treatment, reduces the \u001b[48;2;173;216;230;38;2;0;0;0mcarcinogen\u001b[00m effect when given simultaneously with \u001b[48;2;173;216;230;38;2;0;0;0mden\u001b[00m. This 'anti-\u001b[48;2;173;216;230;38;2;0;0;0mcarcinogen\u001b[00m' effect acts on the initiation as well as on the promotion of the \u001b[48;2;144;238;144;38;2;0;0;0mprecancerous lesions\u001b[00m. Biochemical investigations are in progress to obtain more information about this 'paradoxical' \u001b[48;2;173;216;230;38;2;0;0;0mpb\u001b[00m effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "diethylnitrosamine ; den @CHEMICAL@ preneoplastic foci ; precancerous lesions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "phenobarbital ; pb @CHEMICAL@ carcinogenic ; carcinogen @DISEASE@ @CID@ diethylnitrosamine ; den @CHEMICAL@ carcinogenic ; carcinogen @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Post-operative \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mfentanyl\u001b[00m administration. A case of \u001b[48;2;173;216;230;38;2;0;0;0mthoraco-abdominal \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m leading to \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory failure\u001b[00m is described in the post-operative period in an elderly patient who received a moderate dose of \u001b[48;2;173;216;230;38;2;0;0;0mfentanyl\u001b[00m. This was successfully reversed by naloxone. The mechanisms possibly implicated in this accident are discussed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fentanyl @CHEMICAL@ rigidity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fentanyl @CHEMICAL@ thoraco-abdominal rigidity @DISEASE@ @CID@ fentanyl @CHEMICAL@ respiratory failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpostpartum \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mbromocriptine\u001b[00m. Two multigravida patients with no prior psychiatric history were seen with \u001b[48;2;173;216;230;38;2;0;0;0mpostpartum \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m\u001b[00m, having received \u001b[48;2;173;216;230;38;2;0;0;0mbromocriptine\u001b[00m for inhibition of lactation. \u001b[48;2;173;216;230;38;2;0;0;0mbromocriptine\u001b[00m given in high doses has been associated with \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m in patients receiving the drug for Parkinson's disease. These cases demonstrate that \u001b[48;2;173;216;230;38;2;0;0;0mbromocriptine\u001b[00m may cause \u001b[48;2;144;238;144;38;2;0;0;0mpsychosis\u001b[00m even when given in low doses.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bromocriptine @CHEMICAL@ psychosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bromocriptine @CHEMICAL@ postpartum psychosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A prospective study on the dose dependency of \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m. Since 1975 \u001b[48;2;173;216;230;38;2;0;0;0mmitomycin c\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmmc\u001b[00m) has been suggested to be \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxic\u001b[00m, especially when combined with or given following \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m. Data on dose dependency or incidence concerning this side effect were not known. We have initiated a prospective study to obtain some more data on these subjects. Forty-four \u001b[48;2;173;216;230;38;2;0;0;0mmmc\u001b[00m-treated patients were studied, 37 of them could be evaluated. All patients were studied by repeated physical examinations, chest X-rays, electro- and echocardiography and radionuclide left ventricular ejection fraction (EF) determinations. The results were evaluated per cumulative dose level. One of the patients developed \u001b[48;2;173;216;230;38;2;0;0;0mcardiac failure\u001b[00m after 30 mg m-2 \u001b[48;2;173;216;230;38;2;0;0;0mmmc\u001b[00m and only 150 mg m-2 \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mcardiac failure\u001b[00m was predicted by a drop in EF determined during a cold pressor test. None of the other patients developed clinical \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m, nor did the studied parameters change. The literature on this subject was also reviewed. Based on the combined data from the present study and the literature, we suggest that \u001b[48;2;173;216;230;38;2;0;0;0mmmc\u001b[00m-related \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m. The incidence is likely to be less than 10% even for this risk group.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "mitomycin c ; mmc @CHEMICAL@ cardiac failure @DISEASE@ @CID@ doxorubicin @CHEMICAL@ cardiac failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "mitomycin c ; mmc @CHEMICAL@ cardiotoxicity ; cardiotoxic @DISEASE@ @CID@ mitomycin c ; mmc @CHEMICAL@ cardiac failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mphlorizin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mglycosuria\u001b[00m does not prevent \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m nephrotoxicity in rats. Because rats with \u001b[48;2;144;238;144;38;2;0;0;0mstreptozotocin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mdiabetes mellitus\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mdm\u001b[00m) have a high solute diuresis (\u001b[48;2;173;216;230;38;2;0;0;0mglycosuria\u001b[00m of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0macute renal failure\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0marf\u001b[00m). The protection from \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m nephrotoxicity was studied in non-\u001b[48;2;144;238;144;38;2;0;0;0mdiabetic\u001b[00m rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with \u001b[48;2;173;216;230;38;2;0;0;0mphlorizin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m). \u001b[48;2;144;238;144;38;2;0;0;0mdm\u001b[00m rats with mild \u001b[48;2;173;216;230;38;2;0;0;0mglycosuria\u001b[00m (similar in degree to that of the \u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m treated animals) were also studied. Unanesthetized adult female, Sprague-Dawley rats were divided in four groups and studied for 15 days. Group 1 (\u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m alone) received \u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m, 360 mg/day, for 15 days; Group II (\u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m + \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m); Group III (\u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m alone) and Group IV (mild \u001b[48;2;144;238;144;38;2;0;0;0mdm\u001b[00m + \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m). Nephrotoxic doses (40 mg/kg body wt/day) of \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m were injected during the last nine days of study to the animals of groups II to IV. In Group I, \u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m induced a moderate and stable \u001b[48;2;173;216;230;38;2;0;0;0mglycosuria\u001b[00m (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero). In Group II, \u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m did not prevent \u001b[48;2;173;216;230;38;2;0;0;0mgentamicin\u001b[00m-\u001b[48;2;173;216;230;38;2;0;0;0marf\u001b[00m (maximal decrease in CCr at day 9.89%, \u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1). These values were not different from those of Group III: maximal decrease in CCr 73% (\u001b[48;2;173;216;230;38;2;0;0;0mp\u001b[00m less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "gentamicin @CHEMICAL@ acute renal failure ; arf @DISEASE@ @CID@ streptozotocin @CHEMICAL@ diabetes mellitus ; dm ; diabetic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "phlorizin ; p @CHEMICAL@ glycosuria @DISEASE@ @CID@ gentamicin @CHEMICAL@ acute renal failure ; arf @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Tiapride in \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0minvoluntary movements\u001b[00m. Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced peak dose \u001b[48;2;144;238;144;38;2;0;0;0minvoluntary movements\u001b[00m in 16 patients with idiopathic Parkinson's disease. However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose \u001b[48;2;144;238;144;38;2;0;0;0makinesia\u001b[00m led to its cessation in 14 patients. Tiapride had no effect on \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced early morning of \"off-period\" segmental dystonia. These results fail to support the notion that \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m are caused by overstimulation of a separate group of dopamine receptors.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ involuntary movements ; akinesia ; dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of the hippocampal deep brain stimulation on cortical \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m discharges in \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m - induced \u001b[48;2;173;216;230;38;2;0;0;0mepilepsy\u001b[00m model in rats. AIM: Experimental and clinical studies have revealed that hippocampal DBS can control \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m activity, but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined. The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m activity in \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mepilepsy\u001b[00m model. MATERIAL AND METHODS: Twenty-five Sprague-Dawley rats were implanted DBS electrodes. In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m G injection intracortically. In the control group hippocampal DBS was on following 8  l saline injection intracortically. EEG recordings were obtained before and 15 minutes following \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-G injection, and at 10th minutes following each stimulus for analysis in terms of frequency, amplitude, and power spectrum. RESULTS: High frequency hippocampal DBS suppressed the acute \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced cortical \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m activity independent from stimulus intensity. In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation. CONCLUSION: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m activity effectively without causing secondary \u001b[48;2;173;216;230;38;2;0;0;0mepileptic\u001b[00m discharges. These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with \u001b[48;2;173;216;230;38;2;0;0;0mepilepsy\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "penicillin g ; penicillin-g @CHEMICAL@ epileptic ; epilepsy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "penicillin @CHEMICAL@ epilepsy ; epileptic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Neural correlates of \u001b[48;2;173;216;230;38;2;0;0;0ms-\u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m\u001b[00m induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m during overt continuous verbal fluency. The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m leads to psychopathological symptoms similar to those observed in schizophrenia. In patients with schizophrenia, \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction. In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic \u001b[48;2;173;216;230;38;2;0;0;0ms-\u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m\u001b[00m infusion while differences in BOLD responses measured with fMRI were detected. During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic). \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m-induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m elicited \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m like \u001b[48;2;173;216;230;38;2;0;0;0mpsychopathology\u001b[00m. Post-hoc t-tests revealed significant differences between placebo and \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected. \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency, but not for semantic verbal fluency. \u001b[48;2;144;238;144;38;2;0;0;0mketamine\u001b[00m induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions. Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ketamine @CHEMICAL@ psychosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "s-ketamine @CHEMICAL@ psychosis ; psychopathology @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dopamine is not essential for the development of \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m. It is widely believed that dopamine (DA) mediates \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity. However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data. Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced DA \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m is also confounded by drug effects on body temperature. Further, we show that mice genetically engineered to be deficient in brain DA develop \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m, as long as the thermic effects of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m are preserved. In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain. Taken together, these findings demonstrate that DA is not essential for the development of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced dopaminergic \u001b[48;2;173;216;230;38;2;0;0;0mneurotoxicity\u001b[00m and suggest that mechanisms independent of DA warrant more intense investigation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ neurotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ neurotoxicity ; neurotoxic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mbrainstem dysgenesis\u001b[00m in an infant prenatally exposed to \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m. Many authors described the effects on the fetus of maternal \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m abuse during pregnancy. Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies. We report on an infant with \u001b[48;2;144;238;144;38;2;0;0;0mmultiple cranial-nerve involvement\u001b[00m attributable to \u001b[48;2;173;216;230;38;2;0;0;0mbrainstem dysgenesis\u001b[00m, born to a \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-addicted mother.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ multiple cranial-nerve involvement @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ brainstem dysgenesis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The protective role of Nrf2 in \u001b[48;2;173;216;230;38;2;0;0;0mstreptozotocin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m. OBJECTIVE: \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS). Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis. Here, we report our findings demonstrating a protective role of Nrf2 against \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m. RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m using human kidney biopsy tissues from \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m patients, a \u001b[48;2;173;216;230;38;2;0;0;0mstreptozotocin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m model in Nrf2(-/-) mice, and cultured human mesangial cells. RESULTS: The glomeruli of human \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m patients were under oxidative stress and had elevated Nrf2 levels. In the animal study, Nrf2 was demonstrated to be crucial in ameliorating \u001b[48;2;173;216;230;38;2;0;0;0mstreptozotocin\u001b[00m-induced renal damage. This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice. Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production. In human renal mesangial cells, high \u001b[48;2;173;216;230;38;2;0;0;0mglucose\u001b[00m induced ROS production and activated expression of Nrf2 and its downstream genes. Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production. CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of \u001b[48;2;173;216;230;38;2;0;0;0mdiabetic nephropathy\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "streptozotocin @CHEMICAL@ diabetic nephropathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "streptozotocin @CHEMICAL@ diabetic nephropathy @DISEASE@ @CID@ glucose @CHEMICAL@ diabetic nephropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "High-dose \u001b[48;2;173;216;230;38;2;0;0;0mtranexamic acid\u001b[00m is associated with nonischemic clinical \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m in cardiac surgical patients. BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative \u001b[48;2;173;216;230;38;2;0;0;0mconvulsive\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures. These events were temporally coincident with the initial use of high-dose \u001b[48;2;173;216;230;38;2;0;0;0mtranexamic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtxa\u001b[00m) therapy after withdrawal of aprotinin from general clinical usage. The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between \u001b[48;2;173;216;230;38;2;0;0;0mtxa\u001b[00m usage and \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m after cardiac surgery. METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. Electroencephalographic activity was recorded in 11 of these patients, and all patients had a formal neurological evaluation and brain imaging studies. RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m were likely due to ischemic brain injury in 3 patients. All patients with \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m did not have permanent neurological abnormalities. All 24 patients with \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m received high doses of \u001b[48;2;173;216;230;38;2;0;0;0mtxa\u001b[00m intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures. All but one patient were managed using cardiopulmonary bypass. No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m was apparent. CONCLUSION: Our results suggest that use of high-dose \u001b[48;2;173;216;230;38;2;0;0;0mtxa\u001b[00m in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m in susceptible patients.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tranexamic acid ; txa @CHEMICAL@ seizures ; convulsive @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tranexamic acid ; txa @CHEMICAL@ seizures ; convulsive ; seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Longitudinal assessment of air conduction audiograms in a phase III clinical trial of \u001b[48;2;173;216;230;38;2;0;0;0mdifluoromethylornithine\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0msulindac\u001b[00m for prevention of sporadic colorectal adenomas. A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with \u001b[48;2;173;216;230;38;2;0;0;0mdifluoromethylornithine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdfmo\u001b[00m) plus \u001b[48;2;144;238;144;38;2;0;0;0msulindac\u001b[00m or matched placebos. Temporary \u001b[48;2;173;216;230;38;2;0;0;0mhearing loss\u001b[00m is a known toxicity of treatment with \u001b[48;2;173;216;230;38;2;0;0;0mdfmo\u001b[00m, thus a comprehensive approach was developed to analyze serial air conduction audiograms. The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies. Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with \u001b[48;2;173;216;230;38;2;0;0;0mdfmo\u001b[00m plus \u001b[48;2;144;238;144;38;2;0;0;0msulindac\u001b[00m compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies. In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected. Dose intensity did not add information to models. There were 14 of 151 (9.3%) in the \u001b[48;2;173;216;230;38;2;0;0;0mdfmo\u001b[00m plus \u001b[48;2;144;238;144;38;2;0;0;0msulindac\u001b[00m group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02). Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms. There was no significant difference in the proportion of subjects in the \u001b[48;2;173;216;230;38;2;0;0;0mdfmo\u001b[00m plus \u001b[48;2;144;238;144;38;2;0;0;0msulindac\u001b[00m group who experienced clinically significant \u001b[48;2;173;216;230;38;2;0;0;0mhearing loss\u001b[00m compared with the placebo group. The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12). There is a <2 dB difference in mean threshold for patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mdfmo\u001b[00m plus \u001b[48;2;144;238;144;38;2;0;0;0msulindac\u001b[00m compared with those treated with placebo.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "sulindac @CHEMICAL@ hearing loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "difluoromethylornithine ; dfmo @CHEMICAL@ hearing loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Increased \u001b[48;2;173;216;230;38;2;0;0;0mmental slowing\u001b[00m associated with the APOE epsilon4 allele after \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m oral anticholinergic challenge in healthy elderly. OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m on measures reflecting sedation and confusion and to investigate the relationship between \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m-induced subjective effects and objective memory performance. METHODS: This study comprised 24 cognitively intact, health elderly adults (12 APOE epsilon4 carriers) at an outpatient geriatric psychiatry research clinic. This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design. All participants received 1.0 mg or 2.0 mg \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m or placebo administered in counterbalanced sequences over a period of three consecutive weeks. Bond and Lader's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline, 1, 2.5, and 5 hours postdrug administration. RESULTS: A 2.0-mg oral dose of \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m resulted in increased subjective ratings of \u001b[48;2;144;238;144;38;2;0;0;0mmental slowness\u001b[00m in carriers of the APOE epsilon4 allele only. Drug effects as determined by difference scores between 2.0 mg \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m and placebo on ratings of \u001b[48;2;144;238;144;38;2;0;0;0mmental slowness\u001b[00m significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only. However, no significant effects were found with other visual analog scales reflecting subjective sedation and clear-headedness. CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective \u001b[48;2;173;216;230;38;2;0;0;0mmental slowing\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mtrihexyphenidyl\u001b[00m anticholinergic challenge.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "trihexyphenidyl @CHEMICAL@ mental slowing ; mental slowness @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "trihexyphenidyl @CHEMICAL@ mental slowing @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin. The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats. Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (\u001b[48;2;173;216;230;38;2;0;0;0mpcpa\u001b[00m 100 mg/kg, every other day); controls received saline. At puberty (P40), half the \u001b[48;2;173;216;230;38;2;0;0;0mpcpa\u001b[00m-treated rats and half the saline-treated rats began treatment with \u001b[48;2;173;216;230;38;2;0;0;0mtestosterone\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mt\u001b[00m, 5 mg/kg, 5 days/week). Behavioral measures included locomotion, \u001b[48;2;144;238;144;38;2;0;0;0mirritability\u001b[00m, copulation, partner preference, and \u001b[48;2;173;216;230;38;2;0;0;0maggression\u001b[00m. Animals were tested for \u001b[48;2;173;216;230;38;2;0;0;0maggression\u001b[00m in their home cage, both with and without physical provocation (mild tail pinch). Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC. \u001b[48;2;173;216;230;38;2;0;0;0mpcpa\u001b[00m significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined. Chronic \u001b[48;2;144;238;144;38;2;0;0;0mt\u001b[00m treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than \u001b[48;2;173;216;230;38;2;0;0;0mpcpa\u001b[00m. Chronic exposure to \u001b[48;2;173;216;230;38;2;0;0;0mpcpa\u001b[00m alone significantly \u001b[48;2;173;216;230;38;2;0;0;0mdecreased locomotor activity\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mincreased \u001b[48;2;144;238;144;38;2;0;0;0mirritability\u001b[00m\u001b[00m but had no effect on sexual behavior, partner preference, or \u001b[48;2;173;216;230;38;2;0;0;0maggression\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mt\u001b[00m alone had no effect on locomotion, \u001b[48;2;144;238;144;38;2;0;0;0mirritability\u001b[00m, or sexual behavior but \u001b[48;2;173;216;230;38;2;0;0;0mincreased partner preference\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0maggression\u001b[00m. The most striking effect of combining \u001b[48;2;144;238;144;38;2;0;0;0mt\u001b[00m+\u001b[48;2;173;216;230;38;2;0;0;0mpcpa\u001b[00m was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation. Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit \u001b[48;2;144;238;144;38;2;0;0;0maggressive behavior\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "testosterone ; t @CHEMICAL@ irritability ; aggression ; aggressive behavior @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pcpa @CHEMICAL@ decreased locomotor activity @DISEASE@ @CID@ pcpa @CHEMICAL@ increased irritability @DISEASE@ @CID@ pcpa @CHEMICAL@ decreased partner preference @DISEASE@ @CID@ pcpa @CHEMICAL@ aggression @DISEASE@ @CID@ testosterone @CHEMICAL@ increased partner preference @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Intracavitary chemotherapy (\u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mcarboplatin\u001b[00m liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations. Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy. Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels. Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity. For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcarboplatin\u001b[00m encapsulated by liquid crystalline cubic phases are examined in a pilot study. A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcarboplatin\u001b[00m cubic phases in different dosages. Six of the patients received more than 15 mg \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m and suffered from moderate to severe \u001b[48;2;173;216;230;38;2;0;0;0mbrain edema\u001b[00m, while the remaining patients received only a total of 15 mg \u001b[48;2;173;216;230;38;2;0;0;0mpaclitaxel\u001b[00m. In the latter group, \u001b[48;2;173;216;230;38;2;0;0;0mbrain edema\u001b[00m was markedly reduced and dealt medically. Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "paclitaxel @CHEMICAL@ brain edema @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "paclitaxel @CHEMICAL@ brain edema @DISEASE@ @CID@ carboplatin @CHEMICAL@ brain edema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmethylphenidate\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mobsessive-compulsive symptoms\u001b[00m in an elderly man. An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on \u001b[48;2;173;216;230;38;2;0;0;0mmethylphenidate\u001b[00m. Significant \u001b[48;2;144;238;144;38;2;0;0;0mobsessive-compulsive behavior\u001b[00m ensued but diminished over several weeks when \u001b[48;2;173;216;230;38;2;0;0;0mmethylphenidate\u001b[00m was replaced by fluvoxamine. The patient had no prior psychiatric history, but he had a sister with \u001b[48;2;173;216;230;38;2;0;0;0mobsessive-compulsive disorder\u001b[00m. It appears that \u001b[48;2;173;216;230;38;2;0;0;0mmethylphenidate\u001b[00m precipitated the patient's pathological behavior.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methylphenidate @CHEMICAL@ obsessive-compulsive symptoms ; obsessive-compulsive behavior ; obsessive-compulsive disorder @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methylphenidate @CHEMICAL@ obsessive-compulsive symptoms ; obsessive-compulsive disorder @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcardiac arrest\u001b[00m after intravenous \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m - a case of five repeated injections of \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m causing five episodes of \u001b[48;2;173;216;230;38;2;0;0;0mcardiac arrest\u001b[00m. We describe a patient where intravenous injection of \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m was immediately followed by \u001b[48;2;173;216;230;38;2;0;0;0masystole\u001b[00m repeatedly. The patient received \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m 10 mg i.v. five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m was immediately (within s) followed by \u001b[48;2;173;216;230;38;2;0;0;0masystole\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0masystole\u001b[00m lasted 15-30 s on four occasions, on one occasion it lasted 2 min. The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over. We interpret this as episodes of \u001b[48;2;173;216;230;38;2;0;0;0mcardiac arrest\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m. The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "metoclopramide @CHEMICAL@ cardiac arrest ; asystole @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "metoclopramide @CHEMICAL@ cardiac arrest @DISEASE@ @CID@ metoclopramide @CHEMICAL@ asystole @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Cortical motor overactivation in parkinsonian patients with \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m-induced peak-dose \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesia\u001b[00m. We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m medication, the first one without \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesia\u001b[00m (n = 23) and the other with moderate peak-dose \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesia\u001b[00m (n = 15), and of a group of 14 normal subjects. Single photon emission tomography with i.v. 133Xe was used to measure the rCBF changes. The \u001b[48;2;144;238;144;38;2;0;0;0mdyskinetic\u001b[00m parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-\u001b[48;2;144;238;144;38;2;0;0;0mdyskinetic\u001b[00m parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas. These results are compatible with the hypothesis that an \u001b[48;2;173;216;230;38;2;0;0;0mhyperkinetic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mabnormal involuntary movement\u001b[00m, like \u001b[48;2;173;216;230;38;2;0;0;0ml-dopa\u001b[00m-induced peak dose \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesia\u001b[00m, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "l-dopa @CHEMICAL@ dyskinesia ; dyskinetic ; abnormal involuntary movement @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "l-dopa @CHEMICAL@ dyskinesia ; hyperkinetic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcognitive deterioration\u001b[00m from long-term abuse of \u001b[48;2;173;216;230;38;2;0;0;0mdextromethorphan\u001b[00m: a case report. \u001b[48;2;173;216;230;38;2;0;0;0mdextromethorphan\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdm\u001b[00m), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from \u001b[48;2;173;216;230;38;2;0;0;0mnausea\u001b[00m, restlessness, \u001b[48;2;173;216;230;38;2;0;0;0minsomnia\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mataxia\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mslurred speech\u001b[00m and nystagmus to mood changes, perceptual alterations, inattention, \u001b[48;2;173;216;230;38;2;0;0;0mdisorientation\u001b[00m and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from \u001b[48;2;173;216;230;38;2;0;0;0mdm\u001b[00m overdoses (Fleming 1986). However, there are no reports describing the effects of chronic abuse. This report describes a case of \u001b[48;2;173;216;230;38;2;0;0;0mcognitive deterioration\u001b[00m resulting from prolonged use of \u001b[48;2;173;216;230;38;2;0;0;0mdm\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dextromethorphan ; dm @CHEMICAL@ cognitive deterioration @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dextromethorphan ; dm @CHEMICAL@ cognitive deterioration @DISEASE@ @CID@ dextromethorphan ; dm @CHEMICAL@ nausea @DISEASE@ @CID@ dextromethorphan ; dm @CHEMICAL@ insomnia @DISEASE@ @CID@ dextromethorphan ; dm @CHEMICAL@ ataxia @DISEASE@ @CID@ dextromethorphan ; dm @CHEMICAL@ slurred speech @DISEASE@ @CID@ dextromethorphan ; dm @CHEMICAL@ disorientation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mphenylethylbarbiturate\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mfulminant \u001b[48;2;144;238;144;38;2;0;0;0mhepatitis\u001b[00m\u001b[00m in a pregnant woman. A case report. We report the case of a 19-year-old Laotian patient affected by \u001b[48;2;173;216;230;38;2;0;0;0mfulminant \u001b[48;2;144;238;144;38;2;0;0;0mhepatitis\u001b[00m\u001b[00m during the third trimester of her pregnancy after a 1-month administration of \u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mphenylethylbarbiturate\u001b[00m. After delivery, the patient underwent orthotopic liver transplantation. The patient was in good condition 16 months after liver transplantation. \u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m itself or \u001b[48;2;144;238;144;38;2;0;0;0mphenylethylbarbiturate\u001b[00m may be responsible for \u001b[48;2;173;216;230;38;2;0;0;0mfulminant \u001b[48;2;144;238;144;38;2;0;0;0mhepatitis\u001b[00m\u001b[00m in this patient.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "quinidine phenylethylbarbiturate ; phenylethylbarbiturate @CHEMICAL@ hepatitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "quinidine @CHEMICAL@ fulminant hepatitis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The epidemiology of the \u001b[48;2;173;216;230;38;2;0;0;0macute \u001b[48;2;144;238;144;38;2;0;0;0mflank pain\u001b[00m syndrome\u001b[00m from \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent. Until physicians began reporting an unusual \u001b[48;2;173;216;230;38;2;0;0;0macute \u001b[48;2;144;238;144;38;2;0;0;0mflank pain\u001b[00m syndrome\u001b[00m to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported. To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 \u001b[48;2;173;216;230;38;2;0;0;0msuprofen\u001b[00m-exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt. These were findings that were suggestive but did not reach conventional statistical significance. These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "suprofen @CHEMICAL@ flank pain @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "suprofen @CHEMICAL@ acute flank pain syndrome @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mpyeloureteral filling defects\u001b[00m associated with systemic anticoagulation: a case report. The etiology of \u001b[48;2;173;216;230;38;2;0;0;0mpyeloureteritis cystica\u001b[00m has long been attributed to chronic infection and inflammation. A case is presented that is unique in that the acute onset and the rapid resolution of \u001b[48;2;173;216;230;38;2;0;0;0mpyeloureteral filling defects\u001b[00m in this patient were documented by radiography. There is no evidence of antecedent or concurrent infection in this patient. The disease occurred subsequent to the initiation of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation. The rate of resolution of the radiographic findings may be helpful in distinguishing between true \u001b[48;2;173;216;230;38;2;0;0;0mpyeloureteritis cystica\u001b[00m and submucosal hemorrhage.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ pyeloureteritis cystica @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ pyeloureteral filling defects ; pyeloureteritis cystica @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Changes in peroxisomes in preneoplastic liver and \u001b[48;2;173;216;230;38;2;0;0;0mhepatoma\u001b[00m of mice induced by \u001b[48;2;173;216;230;38;2;0;0;0malpha-benzene hexachloride\u001b[00m. Peroxisomes in \u001b[48;2;173;216;230;38;2;0;0;0mhepatomas\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhyperplastic preneoplastic liver lesions\u001b[00m induced in mice by 500 ppm \u001b[48;2;173;216;230;38;2;0;0;0malpha-benzene hexachloride\u001b[00m were examined histochemically and electron microscopically. Although most of the \u001b[48;2;173;216;230;38;2;0;0;0mhepatomas\u001b[00m were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes. At the 16th week of carcinogen feeding, \u001b[48;2;173;216;230;38;2;0;0;0mhyperplastic nodules\u001b[00m appeared and advanced to further stages. A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes. Within the nodules, foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared. These cells proliferated further, replacing the most part of the nodules, and with this process \u001b[48;2;173;216;230;38;2;0;0;0mhepatomas\u001b[00m appeared to have been formed. No abnormal matrical inclusions of peroxisomes were formed in the cells of \u001b[48;2;173;216;230;38;2;0;0;0mhyperplastic nodules\u001b[00m by ethyl-alpha-p-chlorophenoxyisobutyrate unlike in the case of rats.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "alpha-benzene hexachloride @CHEMICAL@ hepatoma ; hepatomas @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "alpha-benzene hexachloride @CHEMICAL@ hepatomas ; hepatoma @DISEASE@ @CID@ alpha-benzene hexachloride @CHEMICAL@ hyperplastic preneoplastic liver lesions ; hyperplastic nodules @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m. Long-term administration of \u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase. Liver biopsy showed active \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis\u001b[00m. Discontinuance of \u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m therapy led to normalization of liver function tests. A challenge dose of \u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values. We concluded that this patient had \u001b[48;2;173;216;230;38;2;0;0;0mquinidine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m and believe that this is the first case reported with liver biopsy documentation. This report also suggests that, even after long-term administration, the \u001b[48;2;144;238;144;38;2;0;0;0mhepatic toxicity\u001b[00m is reversible.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "quinidine @CHEMICAL@ hepatitis ; hepatotoxicity ; hepatic toxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "quinidine @CHEMICAL@ hepatitis ; hepatotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcholesteryl hemisuccinate\u001b[00m treatment protects rodents from the toxic effects of \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mcarbon tetrachloride\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mchloroform\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mgalactosamine\u001b[00m. In addition to its use as a stabilizer/rigidifier of membranes, \u001b[48;2;173;216;230;38;2;0;0;0mcholesteryl hemisuccinate\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mtris salt\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m) administration has also been shown to protect rats from the \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxic\u001b[00m effects of \u001b[48;2;144;238;144;38;2;0;0;0mcarbon tetrachloride\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mccl4\u001b[00m). To further our understanding of the mechanism of \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m cytoprotection, we examined in rats and mice the protective abilities of \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m and the non-hydrolyzable ether form of \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m, gamma-cholesteryloxybutyric acid, \u001b[48;2;173;216;230;38;2;0;0;0mtris salt\u001b[00m (CSE) against \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m-, \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m-, \u001b[48;2;144;238;144;38;2;0;0;0mcarbon tetrachloride\u001b[00m-, \u001b[48;2;173;216;230;38;2;0;0;0mchloroform\u001b[00m- and \u001b[48;2;173;216;230;38;2;0;0;0mgalactosamine\u001b[00m-induced toxicity. The results of these studies demonstrated that \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m-mediated protection is not selective for a particular species, organ system or toxic chemical. A 24-h pretreatment of both rats and mice with a single dose of \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m (100mg/kg, i.p.), resulted in significant protection against the \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxic\u001b[00m effects of \u001b[48;2;144;238;144;38;2;0;0;0mccl4\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mchcl3\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0macetaminophen\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mgalactosamine\u001b[00m and against the lethal (and presumably \u001b[48;2;144;238;144;38;2;0;0;0mcardiotoxic\u001b[00m) effect of \u001b[48;2;173;216;230;38;2;0;0;0madriamycin\u001b[00m administration. Maximal \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult. These data suggest that \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m intervenes in a critical cellular event that is an important common pathway to toxic cell death. The mechanism of \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against \u001b[48;2;173;216;230;38;2;0;0;0mgalactosamine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mhepatotoxicity\u001b[00m). However, based on the data presented, we can not exclude the possibility that \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m administration inhibits chemical bioactivation. Our findings do suggest that \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m-mediated protection is dependent on the action of the intact anionic \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m molecule (non-hydrolyzable CSE was as protective as \u001b[48;2;173;216;230;38;2;0;0;0mcs\u001b[00m), whose mechanism has yet to be defined.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "acetaminophen @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ adriamycin @CHEMICAL@ cardiotoxic @DISEASE@ @CID@ carbon tetrachloride ; ccl4 @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ chloroform ; chcl3 @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ galactosamine @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cholesteryl hemisuccinate ; tris salt ; cs @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ acetaminophen @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ adriamycin @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ chloroform @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ chloroform @CHEMICAL@ hepatotoxic ; hepatotoxicity @DISEASE@ @CID@ galactosamine @CHEMICAL@ hepatotoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "DSMM XI study: dose definition for intravenous \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m in combination with \u001b[48;2;144;238;144;38;2;0;0;0mbortezomib\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m for remission induction in patients with newly diagnosed myeloma. A clinical trial was initiated to evaluate the recommended dose of \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m in combination with \u001b[48;2;144;238;144;38;2;0;0;0mbortezomib\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of \u001b[48;2;144;238;144;38;2;0;0;0mbortezomib\u001b[00m 1.3 mg/m(2) on days 1, 4, 8, and 11 plus \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m 40 mg on the day of \u001b[48;2;144;238;144;38;2;0;0;0mbortezomib\u001b[00m injection and the day after plus \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m at 900, 1,200, or 1,500 mg/m(2) on day 1. The maximum tolerated dose of \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m was defined as 900 mg/m(2). At this dose level, 92% of patients achieved at least a partial response. The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate. No patient experienced progressive disease. The most frequent adverse events were hematological and \u001b[48;2;173;216;230;38;2;0;0;0mgastrointestinal toxicities\u001b[00m as well as \u001b[48;2;173;216;230;38;2;0;0;0mneuropathy\u001b[00m. The results suggest that \u001b[48;2;144;238;144;38;2;0;0;0mbortezomib\u001b[00m in combination with \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m at 900 mg/m(2) and \u001b[48;2;173;216;230;38;2;0;0;0mdexamethasone\u001b[00m is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ hematological toxicities @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ gastrointestinal toxicities @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ neuropathy @DISEASE@ @CID@ bortezomib @CHEMICAL@ hematological toxicities @DISEASE@ @CID@ bortezomib @CHEMICAL@ gastrointestinal toxicities @DISEASE@ @CID@ bortezomib @CHEMICAL@ neuropathy @DISEASE@ @CID@ dexamethasone @CHEMICAL@ hematological toxicities @DISEASE@ @CID@ dexamethasone @CHEMICAL@ gastrointestinal toxicities @DISEASE@ @CID@ dexamethasone @CHEMICAL@ neuropathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclophosphamide @CHEMICAL@ hematological toxicities @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ gastrointestinal toxicities @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ neuropathy @DISEASE@ @CID@ dexamethasone @CHEMICAL@ hematological toxicities @DISEASE@ @CID@ dexamethasone @CHEMICAL@ gastrointestinal toxicities @DISEASE@ @CID@ dexamethasone @CHEMICAL@ neuropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of \u001b[48;2;173;216;230;38;2;0;0;0mtelmisartan\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m versus \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m monotherapy in Indian adults with stage II hypertension. OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of \u001b[48;2;173;216;230;38;2;0;0;0mtelmisartan\u001b[00m 40 mg + \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m 5 mg (T+A) compared with \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m 5-mg monotherapy (A) in adult Indian patients with stage II hypertension. METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension. Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position. Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study. Tolerability was assessed by treatment-emergent adverse events, identified using physical examination, laboratory analysis, and electrocardiography. RESULTS: A total of 210 patients were enrolled in the study; 203 patients (143 men, 60 women) completed the study while 7 were lost to follow-up (4 patients in the T+A group and 3 in the A group) and considered with-drawn. At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05). Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05). The prevalences of adverse events were not significantly different between the 2 treatment groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]). \u001b[48;2;173;216;230;38;2;0;0;0mperipheral \u001b[48;2;144;238;144;38;2;0;0;0medema\u001b[00m\u001b[00m was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and \u001b[48;2;144;238;144;38;2;0;0;0mcough\u001b[00m was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance. The incidences of \u001b[48;2;173;216;230;38;2;0;0;0mheadache\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mdizziness\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mdiarrhea\u001b[00m were similar between the 2 groups. CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "telmisartan @CHEMICAL@ edema @DISEASE@ @CID@ telmisartan @CHEMICAL@ cough @DISEASE@ @CID@ telmisartan @CHEMICAL@ headache @DISEASE@ @CID@ telmisartan @CHEMICAL@ dizziness @DISEASE@ @CID@ telmisartan @CHEMICAL@ diarrhea @DISEASE@ @CID@ amlodipine @CHEMICAL@ edema @DISEASE@ @CID@ amlodipine @CHEMICAL@ cough @DISEASE@ @CID@ amlodipine @CHEMICAL@ headache @DISEASE@ @CID@ amlodipine @CHEMICAL@ dizziness @DISEASE@ @CID@ amlodipine @CHEMICAL@ diarrhea @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "telmisartan @CHEMICAL@ peripheral edema @DISEASE@ @CID@ telmisartan @CHEMICAL@ headache @DISEASE@ @CID@ telmisartan @CHEMICAL@ dizziness @DISEASE@ @CID@ telmisartan @CHEMICAL@ diarrhea @DISEASE@ @CID@ amlodipine @CHEMICAL@ peripheral edema @DISEASE@ @CID@ amlodipine @CHEMICAL@ headache @DISEASE@ @CID@ amlodipine @CHEMICAL@ dizziness @DISEASE@ @CID@ amlodipine @CHEMICAL@ diarrhea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Cutaneous \u001b[48;2;144;238;144;38;2;0;0;0mleucocytoclastic vasculitis\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0moxacillin\u001b[00m. A 67-year-old man who was treated with \u001b[48;2;173;216;230;38;2;0;0;0moxacillin\u001b[00m for one week because of Staphylococcus aureus bacteremia, developed \u001b[48;2;173;216;230;38;2;0;0;0mrenal failure\u001b[00m and diffuse, symmetric, palpable \u001b[48;2;173;216;230;38;2;0;0;0mpurpuric lesions\u001b[00m on his feet. \u001b[48;2;173;216;230;38;2;0;0;0mnecrotic\u001b[00m blisters were noted on his fingers. Skin biopsies showed findings diagnostic of \u001b[48;2;144;238;144;38;2;0;0;0mleucocytoclastic vasculitis\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0moxacillin\u001b[00m was discontinued and patient was treated with \u001b[48;2;144;238;144;38;2;0;0;0mcorticosteroids\u001b[00m. The rash disappeared after three weeks and renal function returned to normal. \u001b[48;2;144;238;144;38;2;0;0;0mleucocytoclastic vasculitis\u001b[00m presents as palpable \u001b[48;2;173;216;230;38;2;0;0;0mpurpura\u001b[00m of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement. Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia. However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but \u001b[48;2;144;238;144;38;2;0;0;0mcorticosteroid\u001b[00m therapy may be needed in life-threatening cases since early treatment with \u001b[48;2;144;238;144;38;2;0;0;0mcorticosteroids\u001b[00m in severe cases can prevent complications. \u001b[48;2;173;216;230;38;2;0;0;0moxacillin\u001b[00m should be included among the drugs that can cause \u001b[48;2;144;238;144;38;2;0;0;0mleucocytoclastic vasculitis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oxacillin @CHEMICAL@ cutaneous leucocytoclastic vasculitis ; leucocytoclastic vasculitis @DISEASE@ @CID@ oxacillin @CHEMICAL@ renal failure @DISEASE@ @CID@ corticosteroids ; corticosteroid @CHEMICAL@ cutaneous leucocytoclastic vasculitis ; leucocytoclastic vasculitis @DISEASE@ @CID@ corticosteroids ; corticosteroid @CHEMICAL@ renal failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oxacillin @CHEMICAL@ purpuric lesions ; purpura @DISEASE@ @CID@ oxacillin @CHEMICAL@ necrotic blisters ; necrotic lesions ; necrotic @DISEASE@ @CID@ oxacillin @CHEMICAL@ renal failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m. Behavioral and cardiorespiratory responses to a lethal dose of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors. Pretreatment with naloxazone significantly blocked \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m analgesia, \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhypothermia\u001b[00m at a dose which completely eliminated high-affinity binding in brain membranes. Moreover, naloxazone significantly attenuated the \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mhypotension\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mrespiratory depression\u001b[00m, whereas \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mbradycardia\u001b[00m was less affected. Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "morphine @CHEMICAL@ catalepsy @DISEASE@ @CID@ morphine @CHEMICAL@ hypothermia @DISEASE@ @CID@ morphine @CHEMICAL@ hypotension @DISEASE@ @CID@ morphine @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "morphine @CHEMICAL@ catalepsy @DISEASE@ @CID@ morphine @CHEMICAL@ hypothermia @DISEASE@ @CID@ morphine @CHEMICAL@ respiratory depression @DISEASE@ @CID@ morphine @CHEMICAL@ bradycardia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dexrazoxane protects against \u001b[48;2;173;216;230;38;2;0;0;0mmyelosuppression\u001b[00m from the DNA cleavage-enhancing drugs \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m but not \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m. PURPOSE: The anthracyclines \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m and the epipodophyllotoxin \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, \u001b[48;2;173;216;230;38;2;0;0;0mmyelosuppression\u001b[00m and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiotoxicity\u001b[00m. EXPERIMENTAL DESIGN: Because of their widespread use, the \u001b[48;2;144;238;144;38;2;0;0;0mhematologic toxicity\u001b[00m following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m, and \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays. Likewise, in vivo, B6D2F1 mice were treated with \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m, and \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done. RESULTS: Nontoxic doses of dexrazoxane reduced \u001b[48;2;173;216;230;38;2;0;0;0mmyelosuppression\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mweight loss\u001b[00m from \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced \u001b[48;2;173;216;230;38;2;0;0;0mmyelosuppression\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mweight loss\u001b[00m, nor the in vitro cytotoxicity from \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m. CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from \u001b[48;2;144;238;144;38;2;0;0;0mdoxorubicin\u001b[00m clinically, the potent antagonism of \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention. Our data also suggest that significant \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m dose escalation is perhaps possible by the use of dexrazoxane. Clinical trials in patients with brain metastases combining dexrazoxane and high doses of \u001b[48;2;173;216;230;38;2;0;0;0metoposide\u001b[00m is ongoing with the aim of improving efficacy without aggravating \u001b[48;2;144;238;144;38;2;0;0;0mhematologic toxicity\u001b[00m. If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "etoposide @CHEMICAL@ hematologic toxicity @DISEASE@ @CID@ etoposide @CHEMICAL@ weight loss @DISEASE@ @CID@ daunorubicin @CHEMICAL@ hematologic toxicity @DISEASE@ @CID@ daunorubicin @CHEMICAL@ weight loss @DISEASE@ @CID@ doxorubicin @CHEMICAL@ hematologic toxicity @DISEASE@ @CID@ doxorubicin @CHEMICAL@ weight loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "etoposide @CHEMICAL@ myelosuppression @DISEASE@ @CID@ etoposide @CHEMICAL@ cardiotoxicity @DISEASE@ @CID@ etoposide @CHEMICAL@ weight loss @DISEASE@ @CID@ daunorubicin @CHEMICAL@ myelosuppression @DISEASE@ @CID@ daunorubicin @CHEMICAL@ weight loss @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effects of the novel compound \u001b[48;2;173;216;230;38;2;0;0;0maniracetam\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mro 13-5057\u001b[00m) upon \u001b[48;2;173;216;230;38;2;0;0;0mimpaired learning\u001b[00m and memory in rodents. The effect of \u001b[48;2;173;216;230;38;2;0;0;0maniracetam\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mro 13-5057\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0m1-anisoyl-2-pyrrolidinone\u001b[00m) was studied on various forms of experimentally \u001b[48;2;173;216;230;38;2;0;0;0mimpaired cognitive functions\u001b[00m (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the \u001b[48;2;144;238;144;38;2;0;0;0mscopolamine\u001b[00m-induced short-term \u001b[48;2;144;238;144;38;2;0;0;0mamnesia\u001b[00m for a passive avoidance task; (3) complete protection against \u001b[48;2;144;238;144;38;2;0;0;0mamnesia\u001b[00m for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by \u001b[48;2;173;216;230;38;2;0;0;0mchloramphenicol\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mcycloheximide\u001b[00m administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by \u001b[48;2;173;216;230;38;2;0;0;0mcycloheximide\u001b[00m injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of \u001b[48;2;173;216;230;38;2;0;0;0mimpaired cognitive functions\u001b[00m were seen at oral \u001b[48;2;173;216;230;38;2;0;0;0maniracetam\u001b[00m doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of \u001b[48;2;173;216;230;38;2;0;0;0maniracetam\u001b[00m and its 'therapeutic window' are unknown. Piracetam, another pyrrolidinone derivative was used for comparison. It was active only in six of nine tests and had about one-tenth the potency of \u001b[48;2;173;216;230;38;2;0;0;0maniracetam\u001b[00m. The results indicate that \u001b[48;2;173;216;230;38;2;0;0;0maniracetam\u001b[00m improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "scopolamine @CHEMICAL@ amnesia @DISEASE@ @CID@ chloramphenicol @CHEMICAL@ impaired memory @DISEASE@ @CID@ cycloheximide @CHEMICAL@ impaired memory @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "aniracetam ; ro 13-5057 ; 1-anisoyl-2-pyrrolidinone @CHEMICAL@ impaired learning ; impaired memory ; impaired cognitive functions ; learning deficit @DISEASE@ @CID@ chloramphenicol @CHEMICAL@ impaired learning ; impaired memory ; impaired cognitive functions @DISEASE@ @CID@ cycloheximide @CHEMICAL@ impaired learning ; impaired memory ; impaired cognitive functions @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m potentiation of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m in mice. In the present study, effects of \u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m on \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m in mice have been investigated. \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m but not \u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m induced a dose-dependent \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m. The response of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m was potentiated by \u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m. Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m induced by a combination of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m with \u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m. Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m plus \u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m. Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m. It was concluded that \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m can be elicited by opioid and cholinergic receptors, and the potentiation of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m induced by \u001b[48;2;144;238;144;38;2;0;0;0mnicotine\u001b[00m may also be mediated through cholinergic receptor mechanisms.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "nicotine @CHEMICAL@ catalepsy @DISEASE@ @CID@ morphine @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "morphine @CHEMICAL@ catalepsy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mcyclophosphamide\u001b[00m compared with conventional \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mcyclophosphamide\u001b[00m in a randomized, multicenter trial of metastatic breast cancer. PURPOSE: To determine whether \u001b[48;2;144;238;144;38;2;0;0;0mmyocet\u001b[00m (liposome-encapsulated \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with \u001b[48;2;144;238;144;38;2;0;0;0mcyclophosphamide\u001b[00m significantly reduces \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC). PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of \u001b[48;2;144;238;144;38;2;0;0;0mmyocet\u001b[00m (M) or conventional \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (A), in combination with 600 mg/m(2) of \u001b[48;2;144;238;144;38;2;0;0;0mcyclophosphamide\u001b[00m (C), every 3 weeks until disease progression or unacceptable toxicity. Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or \u001b[48;2;173;216;230;38;2;0;0;0mcongestive heart failure\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mchf\u001b[00m). Antitumor efficacy was assessed by objective tumor response rates (World Health Organization criteria), time to progression, and survival. RESULTS: Six percent of \u001b[48;2;173;216;230;38;2;0;0;0mmc\u001b[00m patients versus 21% (including five cases of \u001b[48;2;173;216;230;38;2;0;0;0mchf\u001b[00m) of AC patients developed cardiotoxicity (P =.0002). Median cumulative \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m dose at onset was more than 2,220 mg/m(2) for \u001b[48;2;173;216;230;38;2;0;0;0mmc\u001b[00m versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04). \u001b[48;2;173;216;230;38;2;0;0;0mmc\u001b[00m patients also experienced less grade 4 \u001b[48;2;144;238;144;38;2;0;0;0mneutropenia\u001b[00m. Antitumor efficacy of \u001b[48;2;173;216;230;38;2;0;0;0mmc\u001b[00m versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months. CONCLUSION: \u001b[48;2;144;238;144;38;2;0;0;0mmyocet\u001b[00m improves the therapeutic index of \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m by significantly reducing cardiotoxicity and grade 4 \u001b[48;2;144;238;144;38;2;0;0;0mneutropenia\u001b[00m and provides comparable antitumor efficacy, when used in combination with \u001b[48;2;144;238;144;38;2;0;0;0mcyclophosphamide\u001b[00m as first-line therapy for MBC.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "doxorubicin ; myocet @CHEMICAL@ congestive heart failure ; chf @DISEASE@ @CID@ doxorubicin ; myocet @CHEMICAL@ neutropenia @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ congestive heart failure ; chf @DISEASE@ @CID@ cyclophosphamide @CHEMICAL@ neutropenia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin ; mc @CHEMICAL@ congestive heart failure ; chf @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Protective effect of a specific platelet-activating factor antagonist, BN 52021, on \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular impairments\u001b[00m in rats. Administration of the local anaesthetic \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m (1.5 or 2 mg/kg, i.v.) to rats elicited a marked \u001b[48;2;173;216;230;38;2;0;0;0mdecrease of mean arterial blood pressure\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmbp\u001b[00m) and \u001b[48;2;173;216;230;38;2;0;0;0mheart rate\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mhr\u001b[00m) leading to death (in 67% or 90% of animals respectively). Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m administration (2 mg/kg i.v.) suppressed both the decrease of \u001b[48;2;173;216;230;38;2;0;0;0mmbp\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhr\u001b[00m. In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v. injection of \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m were ineffective. When BN 52021 (20 mg/kg i.v.) was injected immediately after \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m (2 mg/kg), a partial reversion of the decrease of \u001b[48;2;173;216;230;38;2;0;0;0mmbp\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhr\u001b[00m was observed, whereas the dose of 10 mg/kg was ineffective. A partial recovery of \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m-induced ECG alterations was observed after pretreatment of the rats with BN 52021. Since the administration of BN 52021, at all doses studied, did not alter \u001b[48;2;173;216;230;38;2;0;0;0mmbp\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhr\u001b[00m at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiovascular toxicity\u001b[00m. Thus, consistent with its direct effect on heart, PAF appears to be implicated in \u001b[48;2;173;216;230;38;2;0;0;0mbupivacaine\u001b[00m-induced cardiovascular alterations.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupivacaine @CHEMICAL@ decrease of heart rate (hr) ; decrease of hr @DISEASE@ @CID@ bupivacaine @CHEMICAL@ decrease of mean arterial blood pressure (mbp) ; decrease of mbp @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupivacaine @CHEMICAL@ cardiovascular impairments ; cardiovascular toxicity @DISEASE@ @CID@ bupivacaine @CHEMICAL@ decrease of mean arterial blood pressure ; mbp @DISEASE@ @CID@ bupivacaine @CHEMICAL@ heart rate ; hr @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Benzylacyclouridine reverses \u001b[48;2;173;216;230;38;2;0;0;0mazidothymidine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mmarrow suppression\u001b[00m without impairment of anti-human immunodeficiency virus activity. Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, \u001b[48;2;173;216;230;38;2;0;0;0mazidothymidine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity. Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0manemia\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mleukopenia\u001b[00m was assessed. This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity. In mice rendered \u001b[48;2;144;238;144;38;2;0;0;0manemic\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mleukopenic\u001b[00m by the administration of \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m for 28 days in drinking water (1.5 mg/mL), the continued administration of \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m plus daily BAU (300 mg/kg, orally) partially reversed \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0manemia\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mleukopenia\u001b[00m (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved \u001b[48;2;173;216;230;38;2;0;0;0mmegaloblastosis\u001b[00m. When coadministered with \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m from the onset of drug administration, BAU reduced \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mmarrow toxicity\u001b[00m. In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of \u001b[48;2;173;216;230;38;2;0;0;0mazt\u001b[00m to reverse the HIV-induced cytopathic effect in MT4 cells. The clinical and biochemical implications of these findings are discussed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "azidothymidine ; azt @CHEMICAL@ marrow suppression ; marrow toxicity @DISEASE@ @CID@ azidothymidine ; azt @CHEMICAL@ anemia ; anemic @DISEASE@ @CID@ azidothymidine ; azt @CHEMICAL@ leukopenia ; leukopenic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "azidothymidine ; azt @CHEMICAL@ anemia @DISEASE@ @CID@ azidothymidine ; azt @CHEMICAL@ leukopenia @DISEASE@ @CID@ azidothymidine ; azt @CHEMICAL@ megaloblastosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcystitis\u001b[00m in freely-moving conscious rats: behavioral approach to a new model of visceral pain. PURPOSE: To develop a model of visceral pain in rats using a behavioral approach. \u001b[48;2;173;216;230;38;2;0;0;0mcyclophosphamide\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite \u001b[48;2;144;238;144;38;2;0;0;0macrolein\u001b[00m, was used to induce \u001b[48;2;173;216;230;38;2;0;0;0mcystitis\u001b[00m. MATERIALS AND METHODS: \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m was administered at doses of 50, 100 and 200 mg./kg. i.p. to male rats, and their behavior observed and scored. The effects of morphine (0.5 to 4 mg./kg. i.v.) on \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg. s.c.). In addition, 90 minutes after \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination. Finally, to show that the bladder is essential for the \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m-induced behavioral modifications, female rats also received \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m at doses of 200 mg./kg. i.p. and of 20 mg. by the intravesical route, and \u001b[48;2;144;238;144;38;2;0;0;0macrolein\u001b[00m at doses of 0.5 mg. by the intravesical route and of 5 mg./kg. i.v. RESULTS: \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures. Morphine dose-dependently reversed these behavioral disorders. A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m 200 mg./kg. This effect was completely prevented by pretreatment with naloxone. At the time of administration of morphine, histological modifications of the bladder wall, such as \u001b[48;2;173;216;230;38;2;0;0;0mchorionic\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmuscle layer edema\u001b[00m, were observed. In female rats, \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m 200 mg./kg. i.p. produced the same marked behavioral modifications as those observed in male rats. Administered at the dose of 20 mg. intravesically, \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m did not produce any behavioral effects, whereas \u001b[48;2;144;238;144;38;2;0;0;0macrolein\u001b[00m at 0.5 mg. intravesically induced behavioral modifications identical to those under \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m 200 mg./kg. i.p., with the same maximal levels. Conversely, \u001b[48;2;144;238;144;38;2;0;0;0macrolein\u001b[00m 5 mg./kg. i.v. did not produce any behavioral effects at all. CONCLUSIONS: Overall, these results indicate that this experimental model of \u001b[48;2;173;216;230;38;2;0;0;0mcp\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcystitis\u001b[00m may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these \u001b[48;2;144;238;144;38;2;0;0;0mpainful syndromes\u001b[00m and thus a better therapeutic approach to them.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cyclophosphamide ; cp @CHEMICAL@ cystitis @DISEASE@ @CID@ cyclophosphamide ; cp @CHEMICAL@ painful syndromes @DISEASE@ @CID@ acrolein @CHEMICAL@ painful syndromes @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cyclophosphamide ; cp @CHEMICAL@ cystitis @DISEASE@ @CID@ cyclophosphamide ; cp @CHEMICAL@ chorionic @DISEASE@ @CID@ cyclophosphamide ; cp @CHEMICAL@ muscle layer edema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonus\u001b[00m in terminal cancer patients treated with continuous intravenous \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m. Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m developed \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m. All cases were retrospectively sampled from three different hospitals in Copenhagen. Five patients developed universal \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhyperesthesia\u001b[00m which in 2 cases were accompanied by \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonus\u001b[00m. In 3 patients a pre-existing \u001b[48;2;144;238;144;38;2;0;0;0mneuralgia\u001b[00m increased to excruciating intensity and in 2 of these cases \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonus\u001b[00m occurred simultaneously. Although only few clinical descriptions of the relationship between \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m/\u001b[48;2;173;216;230;38;2;0;0;0mmyoclonus\u001b[00m and high doses of \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m are available, experimental support from animal studies indicates that \u001b[48;2;173;216;230;38;2;0;0;0mmorphine\u001b[00m, or its metabolites, plays a causative role for the observed behavioural syndrome. The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "morphine @CHEMICAL@ hyperalgesia @DISEASE@ @CID@ morphine @CHEMICAL@ myoclonus @DISEASE@ @CID@ morphine @CHEMICAL@ hyperesthesia @DISEASE@ @CID@ morphine @CHEMICAL@ neuralgia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "morphine @CHEMICAL@ hyperalgesia ; hyperesthesia @DISEASE@ @CID@ morphine @CHEMICAL@ myoclonus @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A prospective study of adverse reactions associated with \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m therapy. A prospective evaluation of the efficacy and safety of \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m was conducted in 54 consecutive patients over a 16-month period. \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m was curative in 95% of 43 patients with proven infection. Drugs were ceased in six patients because of adverse reactions; in three of these \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m was considered the likely cause. Reactions included \u001b[48;2;173;216;230;38;2;0;0;0mthrombophlebitis\u001b[00m (20 of 54 patients), \u001b[48;2;173;216;230;38;2;0;0;0mrash\u001b[00m (4 of 54), \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m (4 of 50), \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m (1 of 50) and \u001b[48;2;173;216;230;38;2;0;0;0mototoxicity\u001b[00m (1 of 11 patients tested by audiometry). \u001b[48;2;173;216;230;38;2;0;0;0mthrombophlebitis\u001b[00m occurred only with infusion through peripheral cannulae; \u001b[48;2;173;216;230;38;2;0;0;0mnephrotoxicity\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mototoxicity\u001b[00m were confined to patients receiving an aminoglycoside plus \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m. We conclude that \u001b[48;2;173;216;230;38;2;0;0;0mvancomycin\u001b[00m, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "vancomycin @CHEMICAL@ thrombophlebitis @DISEASE@ @CID@ vancomycin @CHEMICAL@ rash @DISEASE@ @CID@ vancomycin @CHEMICAL@ proteinuria @DISEASE@ @CID@ vancomycin @CHEMICAL@ ototoxicity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "vancomycin @CHEMICAL@ thrombophlebitis @DISEASE@ @CID@ vancomycin @CHEMICAL@ rash @DISEASE@ @CID@ vancomycin @CHEMICAL@ nephrotoxicity @DISEASE@ @CID@ vancomycin @CHEMICAL@ proteinuria @DISEASE@ @CID@ vancomycin @CHEMICAL@ ototoxicity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Dextran-\u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m conjugates: synthesis, in vitro and in vivo evaluation. \u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0me\u001b[00m), is a non-narcotic analgesic and antiinflammatory drug. A biodegradable polymer dextran has been utilized as a carrier for synthesis of \u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects. An activated moiety, i.\u001b[48;2;173;216;230;38;2;0;0;0me\u001b[00m. N-acylimidazole derivative of \u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000). IR spectral data confirmed formation of ester bonding in the conjugates. \u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m contents were evaluated by UV-spectrophotometric analysis. The molecular weights were determined by measuring viscosity using the Mark-Howink-Sakurada equation. In vitro hydrolysis of ED was done in aqueous buffers (pH 1.2, 7.4, 9) and in 80% (v/v) human plasma (pH 7.4). At pH 9, a higher rate of \u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics. In vivo investigations were performed in animals. Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced \u001b[48;2;144;238;144;38;2;0;0;0mwrithing\u001b[00m model (mice) and \u001b[48;2;173;216;230;38;2;0;0;0mcarrageenan\u001b[00m-induced rat \u001b[48;2;173;216;230;38;2;0;0;0mpaw \u001b[48;2;144;238;144;38;2;0;0;0medema\u001b[00m\u001b[00m model, respectively. In comparison to control, \u001b[48;2;173;216;230;38;2;0;0;0me\u001b[00m and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001). Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced \u001b[48;2;173;216;230;38;2;0;0;0mulcerogenicity\u001b[00m as compared to their parent drug--\u001b[48;2;173;216;230;38;2;0;0;0metodolac\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "carrageenan @CHEMICAL@ writhing @DISEASE@ @CID@ carrageenan @CHEMICAL@ edema @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "etodolac ; e @CHEMICAL@ ulcerogenicity @DISEASE@ @CID@ carrageenan @CHEMICAL@ paw edema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m complicating hypertrophic cardiomyopathy heart. The present report describes a case of \u001b[48;2;173;216;230;38;2;0;0;0meosinophilic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m complicating hypertrophic cardiomyopathy. The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m infusion and other drugs while being assessed for heart transplantation. On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation. The recipient's heart showed the features of apical hypertrophic cardiomyopathy and \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m with abundant eosinophils. \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m is rare and \u001b[48;2;173;216;230;38;2;0;0;0meosinophilic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m is rarer. It is likely that the \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0meosinophilic\u001b[00m) \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m was related to \u001b[48;2;173;216;230;38;2;0;0;0mdobutamine\u001b[00m infusion therapy. \u001b[48;2;173;216;230;38;2;0;0;0meosinophilic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mmyocarditis\u001b[00m has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dobutamine @CHEMICAL@ hypersensitivity @DISEASE@ @CID@ dobutamine @CHEMICAL@ myocarditis @DISEASE@ @CID@ dobutamine @CHEMICAL@ eosinophilic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dobutamine @CHEMICAL@ hypersensitivity ; eosinophilic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Delayed-onset \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m presents 5 to 12 days after \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m exposure, with or without arterial or \u001b[48;2;144;238;144;38;2;0;0;0mvenous thromboemboli\u001b[00m. Delayed recognition and treatment of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m contribute to poor patient outcomes. OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m are delayed. DESIGN: Retrospective case series. SETTING: Three large urban hospitals (with active cardiovascular surgery programs). PATIENTS: 14 patients seen over a 3-year period in whom \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced platelet factor 4 antibody tests, and outcomes. RESULTS: Patients went home after hospitalizations that had included \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m exposure--in most cases, with no \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m recognized--only to return to the hospital (median, day 14) with thromboembolic complications. Thromboemboli were venous (12 patients, 7 with \u001b[48;2;144;238;144;38;2;0;0;0mpulmonary emboli\u001b[00m) or arterial (4 patients) or both. Platelet counts were mildly decreased in all but 2 patients on second presentation. On readmission, 11 patients received therapeutic \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m re-exposure, 39 x 10(9) cells/L). Results of serologic tests for \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced antibodies were positive in all patients. Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients). Three patients died. CONCLUSIONS: Delayed-onset \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m is increasingly being recognized. To avoid disastrous outcomes, physicians must consider \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, should be initiated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ heparin @CHEMICAL@ arterial thromboemboli @DISEASE@ @CID@ heparin @CHEMICAL@ venous thromboemboli @DISEASE@ @CID@ heparin @CHEMICAL@ pulmonary emboli @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m. OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m, with a reference therapy, \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m or 5 mg \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m for 12 weeks. After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m was added to the initial therapy. Patients were assessed at 4, 8, and 12 weeks. The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks. Secondary variables included change in sitting systolic blood pressure and responder rates. RESULTS: Both \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m were effective at lowering blood pressure at 4, 8, and 12 weeks. Similar decreases were observed in both groups, with no statistically significant differences between the groups for any variable analyzed. For the primary variable the difference was 0.5 mm Hg in favor of \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m (p = 0.68; 95% confidence interval, -2.7 to 1.7). Responder rates at 8 weeks were 66.7% for \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m and 60.2% for \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m (p = 0.39). Both treatments were well tolerated. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mdrug-related dependent \u001b[48;2;144;238;144;38;2;0;0;0medema\u001b[00m\u001b[00m was somewhat higher in the \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m group, particularly at a dose of 10 mg per day (2.4% for 80 mg \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m; 3.6% for 5 mg \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m; 0% for \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m plus 5 mg \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m; 14.3% for 10 mg \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m). CONCLUSIONS: The data show that \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m is at least as effective as \u001b[48;2;173;216;230;38;2;0;0;0mamlodipine\u001b[00m in the treatment of mild to moderate hypertension. The results also show \u001b[48;2;144;238;144;38;2;0;0;0mvalsartan\u001b[00m to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "valsartan @CHEMICAL@ edema @DISEASE@ @CID@ amlodipine @CHEMICAL@ edema @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amlodipine @CHEMICAL@ drug-related dependent edema @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. \u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m is a novel selective adenosine A2A receptor antagonist. Oral administration of \u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the \u001b[48;2;173;216;230;38;2;0;0;0mcataleptic\u001b[00m responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, \u001b[48;2;144;238;144;38;2;0;0;0mcgs 21680\u001b[00m (10 micrograms), in a dose-dependent manner. \u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m also reduced the \u001b[48;2;173;216;230;38;2;0;0;0mcatalepsy\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m (1 mg/kg i.p.) and by \u001b[48;2;173;216;230;38;2;0;0;0mreserpine\u001b[00m (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, \u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus \u001b[48;2;173;216;230;38;2;0;0;0mbenserazide\u001b[00m (6.25 mg/kg i.p.). These results suggested that \u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, \u001b[48;2;173;216;230;38;2;0;0;0mkf17837\u001b[00m may be a useful drug in the treatment of parkinsonism.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cgs 21680 @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@ haloperidol @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@ reserpine @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "kf17837 @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@ haloperidol @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@ reserpine @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@ benserazide @CHEMICAL@ cataleptic ; catalepsy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Some central effects of repeated treatment with \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m. We investigated the effect of repeated treatment with \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and \u001b[48;2;173;216;230;38;2;0;0;0mmethoxamine\u001b[00m and on the animal behavior in the \"behavioral despair\" test. A repeated treatment with \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m (twice daily for 14 days) potentiated in mice and in rats (weaker) the \u001b[48;2;173;216;230;38;2;0;0;0mamphetamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhyperactivity\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mhyperactivity\u001b[00m induced by \u001b[48;2;144;238;144;38;2;0;0;0mnomifensine\u001b[00m in mice remained unaffected by \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m. The stimulation of locomotor activity by intracerebroventricularly administered \u001b[48;2;173;216;230;38;2;0;0;0mmethoxamine\u001b[00m was not affected by repeated treatment with \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m. Given three times \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m had no effect on the immobilization time in the \"behavioral despair\" test in rats. The results indicate that \u001b[48;2;173;216;230;38;2;0;0;0mfluvoxamine\u001b[00m given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluvoxamine @CHEMICAL@ hyperactivity @DISEASE@ @CID@ methoxamine @CHEMICAL@ hyperactivity @DISEASE@ @CID@ amphetamine @CHEMICAL@ hyperactivity @DISEASE@ @CID@ nomifensine @CHEMICAL@ hyperactivity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluvoxamine @CHEMICAL@ hyperactivity @DISEASE@ @CID@ amphetamine @CHEMICAL@ hyperactivity @DISEASE@ @CID@ methoxamine @CHEMICAL@ hyperactivity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Severe congestive heart failure patient on \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m presenting with \u001b[48;2;144;238;144;38;2;0;0;0mmyxedemic\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m: a case report. This is a case report of \u001b[48;2;173;216;230;38;2;0;0;0mmyxedema\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m secondary to \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m in a patient with severe congestive heart failure (CHF). To our knowledge and after reviewing the literature there is one case report of \u001b[48;2;173;216;230;38;2;0;0;0mmyxedema\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m during long term \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m therapy. \u001b[48;2;173;216;230;38;2;0;0;0mmyxedema\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m is a life threatening condition that carries a mortality reaching as high as 20% with treatment. The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3). Patients with CHF on \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m may suffer serious morbidity and mortality from \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels. This case report carries an important clinical application given the frequent usage of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m among CHF patients. The myriad clinical presentation of \u001b[48;2;173;216;230;38;2;0;0;0mmyxedema\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0mcoma\u001b[00m and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ myxedemic ; myxedema @DISEASE@ @CID@ amiodarone @CHEMICAL@ coma @DISEASE@ @CID@ amiodarone @CHEMICAL@ hypothyroidism @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ myxedema @DISEASE@ @CID@ amiodarone @CHEMICAL@ hypothyroidism @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mfear-potentiated \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m\u001b[00m, but not light-enhanced \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m, is enhanced by anxiogenic drugs. RATIONALE AND OBJECTIVES: The light-enhanced \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect. In contrast, the \u001b[48;2;173;216;230;38;2;0;0;0mfear-potentiated \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m) is suggested to model conditioned fear. However, the pharmacological profiles of these two paradigms are very similar. The present study investigated the effects of putative anxiogenic drugs on LES and \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms. METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist \u001b[48;2;173;216;230;38;2;0;0;0mm-chlorophenylpiperazine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmcpp\u001b[00m, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist \u001b[48;2;173;216;230;38;2;0;0;0mpentylenetetrazole\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mptz\u001b[00m, 3-30mg/kg) and were subsequently tested in either LES or \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m. RESULTS: None of the drugs enhanced LES, whereas \u001b[48;2;173;216;230;38;2;0;0;0mmcpp\u001b[00m increased percentage \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m increased absolute \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m values. Furthermore, \u001b[48;2;173;216;230;38;2;0;0;0myohimbine\u001b[00m increased baseline \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m amplitude in the LES, while \u001b[48;2;173;216;230;38;2;0;0;0mmcpp\u001b[00m suppressed baseline \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m in both the LES and \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mptz\u001b[00m suppressed baseline \u001b[48;2;144;238;144;38;2;0;0;0mstartle\u001b[00m in the \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m. CONCLUSIONS: In contrast to findings in the \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m paradigm, none of the drugs were able to exacerbate the LES response. Thus, a clear pharmacological differentiation was found between LES and \u001b[48;2;173;216;230;38;2;0;0;0mfps\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "yohimbine @CHEMICAL@ startle @DISEASE@ @CID@ m-chlorophenylpiperazine ; mcpp @CHEMICAL@ startle @DISEASE@ @CID@ pentylenetetrazole ; ptz @CHEMICAL@ startle @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "yohimbine @CHEMICAL@ fear-potentiated startle ; fps @DISEASE@ @CID@ m-chlorophenylpiperazine ; mcpp @CHEMICAL@ fear-potentiated startle ; fps @DISEASE@ @CID@ pentylenetetrazole ; ptz @CHEMICAL@ fear-potentiated startle ; fps @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing \u001b[48;2;173;216;230;38;2;0;0;0mglomerulonephritis\u001b[00m after restarting \u001b[48;2;173;216;230;38;2;0;0;0msulphasalazine\u001b[00m treatment. A 59-year-old woman with ulcerative colitis developed \u001b[48;2;173;216;230;38;2;0;0;0mred eyes\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mpleural effusion\u001b[00m, eosinophilia and urinary abnormalities after restarting of \u001b[48;2;173;216;230;38;2;0;0;0msulphasalazine\u001b[00m treatment. Light microscopy of a kidney biopsy revealed segmental necrotizing \u001b[48;2;173;216;230;38;2;0;0;0mglomerulonephritis\u001b[00m without deposition of immunoglobulin or complement. Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in \u001b[48;2;173;216;230;38;2;0;0;0mpleural effusions\u001b[00m on right and left side, respectively. Although cessation of \u001b[48;2;173;216;230;38;2;0;0;0msulphasalazine\u001b[00m treatment resulted in improvements in \u001b[48;2;173;216;230;38;2;0;0;0mfever\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mred eyes\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mchest pain\u001b[00m, titer of C-reactive protein and volume of the \u001b[48;2;173;216;230;38;2;0;0;0mpleural effusions\u001b[00m, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the \u001b[48;2;173;216;230;38;2;0;0;0mpleural effusion\u001b[00m remained. One month after steroid therapy, the \u001b[48;2;173;216;230;38;2;0;0;0mpleural effusion\u001b[00m disappeared, and PR3-ANCA titer normalized 3 months later. This case suggests that \u001b[48;2;173;216;230;38;2;0;0;0msulphasalazine\u001b[00m can induce PR3-ANCA-positive necrotizing \u001b[48;2;173;216;230;38;2;0;0;0mglomerulonephritis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "sulphasalazine @CHEMICAL@ pleural effusion ; pleural effusions @DISEASE@ @CID@ sulphasalazine @CHEMICAL@ segmental necrotizing glomerulonephritis @DISEASE@ @CID@ sulphasalazine @CHEMICAL@ fever @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "sulphasalazine @CHEMICAL@ glomerulonephritis @DISEASE@ @CID@ sulphasalazine @CHEMICAL@ red eyes @DISEASE@ @CID@ sulphasalazine @CHEMICAL@ pleural effusion ; pleural effusions @DISEASE@ @CID@ sulphasalazine @CHEMICAL@ fever @DISEASE@ @CID@ sulphasalazine @CHEMICAL@ chest pain @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m related \u001b[48;2;173;216;230;38;2;0;0;0mtic-like symptoms\u001b[00m in an adolescent schizophrenic. \u001b[48;2;173;216;230;38;2;0;0;0mtic disorders\u001b[00m can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone. However, there are two case reports that show \u001b[48;2;173;216;230;38;2;0;0;0mtic-like symptoms\u001b[00m, including \u001b[48;2;173;216;230;38;2;0;0;0mmotor and phonic variants\u001b[00m, occurring during treatment with \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mclozapine\u001b[00m. We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m treatment (1000 mg per day). The \u001b[48;2;173;216;230;38;2;0;0;0mtic-like symptoms\u001b[00m resolved completely after we reduced the dose of \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m down to 800 mg per day. However, her psychosis recurred after the dose reduction. We then placed her on an additional 100 mg per day of \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m. She has been in complete remission under the combined medications for more than one year and maintains a fair role function. No more \u001b[48;2;173;216;230;38;2;0;0;0mtic-like symptoms\u001b[00m or other side effects have been reported. Together with previously reported cases, our patient suggests that \u001b[48;2;173;216;230;38;2;0;0;0mtic-like symptoms\u001b[00m might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as \u001b[48;2;173;216;230;38;2;0;0;0mquetiapine\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mclozapine\u001b[00m, or \u001b[48;2;173;216;230;38;2;0;0;0mamisulpride\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amisulpride @CHEMICAL@ tic-like symptoms ; tic disorders @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amisulpride @CHEMICAL@ tic-like symptoms ; tic disorders ; motor and phonic variants @DISEASE@ @CID@ quetiapine @CHEMICAL@ tic-like symptoms ; tic disorders ; motor and phonic variants @DISEASE@ @CID@ clozapine @CHEMICAL@ tic-like symptoms ; tic disorders ; motor and phonic variants @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Comparison of developmental toxicology of \u001b[48;2;173;216;230;38;2;0;0;0maspirin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0macetylsalicylic acid\u001b[00m) in rats using selected dosing paradigms. BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of \u001b[48;2;144;238;144;38;2;0;0;0mdevelopmental anomalies\u001b[00m occurs in rats given NSAIDs on specific days during organogenesis. \u001b[48;2;173;216;230;38;2;0;0;0maspirin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0macetylsalicylic acid\u001b[00m [\u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces \u001b[48;2;144;238;144;38;2;0;0;0mdevelopmental anomalies\u001b[00m when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ. Teratology 4:15-24, 1971). There are no published \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m studies using the multiple dosing paradigm of GDs 6 to 17. Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence \u001b[48;2;144;238;144;38;2;0;0;0mmalformations\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m when a multiple dosing paradigm is used. METHODS: \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats. Animals were killed on GD 21, and fetuses were examined viscerally. RESULTS: The literature evaluation suggested that NSAIDs induce \u001b[48;2;173;216;230;38;2;0;0;0mventricular septal defects\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mvsds\u001b[00m) and \u001b[48;2;173;216;230;38;2;0;0;0mmidline defects\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmds\u001b[00m) in rats and \u001b[48;2;173;216;230;38;2;0;0;0mdiaphragmatic hernia\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdh\u001b[00m), \u001b[48;2;173;216;230;38;2;0;0;0mmds\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mvsds\u001b[00m in rabbits (Cook JC et al., 2003); hence, the present study focused on these \u001b[48;2;144;238;144;38;2;0;0;0mmalformations\u001b[00m, even though \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m induces several other low-incidence \u001b[48;2;144;238;144;38;2;0;0;0mmalformations\u001b[00m. In single dose studies, \u001b[48;2;173;216;230;38;2;0;0;0mdh\u001b[00m, MD, and \u001b[48;2;144;238;144;38;2;0;0;0mvsd\u001b[00m were induced on GDs 9 and 10. \u001b[48;2;144;238;144;38;2;0;0;0mvsd\u001b[00m also was noted following treatment on GD 11. In contrast, \u001b[48;2;173;216;230;38;2;0;0;0mdh\u001b[00m and MD were noted in the multiple dose study design only in the high-dose group, and \u001b[48;2;144;238;144;38;2;0;0;0mvsd\u001b[00m was noted across all dose groups. CONCLUSIONS: High concordance in major \u001b[48;2;144;238;144;38;2;0;0;0mdevelopmental anomalies\u001b[00m between Wistar and SD rats were noted with the exception of \u001b[48;2;144;238;144;38;2;0;0;0mvsd\u001b[00m in the SD rats and \u001b[48;2;173;216;230;38;2;0;0;0mhydrocephalus\u001b[00m in the Wistar rats. Variations and \u001b[48;2;144;238;144;38;2;0;0;0mmalformations\u001b[00m were similar when \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m was administered as a single dose or during the period of organogenesis (GDs 6 to 17). It was also evident that, by titrating the dose to achieve a maximum tolerated dose, \u001b[48;2;144;238;144;38;2;0;0;0mmalformations\u001b[00m that normally occur at low incidence, as reported from previous single dose studies, could also be induced with \u001b[48;2;173;216;230;38;2;0;0;0masa\u001b[00m given at multiple doses.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ developmental anomalies ; malformations @DISEASE@ @CID@ aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ ventricular septal defects ; vsds ; vsd @DISEASE@ @CID@ aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ diaphragmatic hernia ; dh @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ ventricular septal defects ; vsds @DISEASE@ @CID@ aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ midline defects ; mds @DISEASE@ @CID@ aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ diaphragmatic hernia ; dh @DISEASE@ @CID@ aspirin ; acetylsalicylic acid ; asa @CHEMICAL@ hydrocephalus @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m in an elderly woman with preexisting complete left bundle branch block. There is a growing list of drugs implicated in acquired long QT syndrome and \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m. However, the \u001b[48;2;173;216;230;38;2;0;0;0mtorsadogenic\u001b[00m potential of \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide. We report on a 92-year-old woman with preexisting complete left bundle branch block who developed \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m after intravenous and oral administration of \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m. This patient also developed \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m when \u001b[48;2;173;216;230;38;2;0;0;0mcisapride\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0merythromycin\u001b[00m were given simultaneously. These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs. This is the first documentation that \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m provokes \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m clinically. \u001b[48;2;173;216;230;38;2;0;0;0mmetoclopramide\u001b[00m should be used cautiously in patients with a risk of \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "metoclopramide @CHEMICAL@ torsade de pointes @DISEASE@ @CID@ cisapride @CHEMICAL@ torsade de pointes @DISEASE@ @CID@ erythromycin @CHEMICAL@ torsade de pointes @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "metoclopramide @CHEMICAL@ torsade de pointes ; torsadogenic @DISEASE@ @CID@ cisapride @CHEMICAL@ torsade de pointes ; torsadogenic @DISEASE@ @CID@ erythromycin @CHEMICAL@ torsade de pointes ; torsadogenic @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m: an underutilized therapy for Parkinson's disease. \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m injections produce antiparkinsonian benefit close if not identical to that seen with \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m and that \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m infusions is associated with marked reductions of preexisting \u001b[48;2;144;238;144;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesias\u001b[00m. The main side effects of subcutaneous \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m treatment are related to \u001b[48;2;173;216;230;38;2;0;0;0mcutaneous tolerability problems\u001b[00m, whereas \u001b[48;2;173;216;230;38;2;0;0;0msedation\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mpsychiatric complications\u001b[00m play a lesser role. Given the marked degree of efficacy of subcutaneous \u001b[48;2;173;216;230;38;2;0;0;0mapomorphine\u001b[00m treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "apomorphine @CHEMICAL@ cutaneous tolerability problems @DISEASE@ @CID@ apomorphine @CHEMICAL@ sedation @DISEASE@ @CID@ apomorphine @CHEMICAL@ psychiatric complications @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Fatal \u001b[48;2;173;216;230;38;2;0;0;0mexcited \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m following \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m use: epidemiologic findings provide new evidence for mechanisms of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m toxicity. We describe an outbreak of deaths from \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mexcited \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0medds\u001b[00m) in Dade County, Florida between 1979 and 1990. From a registry of all \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m-related deaths in Dade County, Florida, from 1969-1990, 58 \u001b[48;2;173;216;230;38;2;0;0;0medds\u001b[00m were compared with 125 victims of accidental \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m overdose without \u001b[48;2;173;216;230;38;2;0;0;0mexcited \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m\u001b[00m. Compared with controls, \u001b[48;2;173;216;230;38;2;0;0;0medds\u001b[00m were more frequently black, male, and younger. They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed \u001b[48;2;173;216;230;38;2;0;0;0mhyperthermia\u001b[00m, and to have died in summer months. \u001b[48;2;173;216;230;38;2;0;0;0medds\u001b[00m had concentrations of \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m and benzoylecgonine in autopsy blood that were similar to those for controls. The epidemiologic findings are most consistent with the hypothesis that chronic \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m use disrupts dopaminergic function and, when coupled with recent \u001b[48;2;173;216;230;38;2;0;0;0mcocaine\u001b[00m use, may precipitate agitation, \u001b[48;2;144;238;144;38;2;0;0;0mdelirium\u001b[00m, aberrant thermoregulation, \u001b[48;2;144;238;144;38;2;0;0;0mrhabdomyolysis\u001b[00m, and \u001b[48;2;144;238;144;38;2;0;0;0msudden death\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "cocaine @CHEMICAL@ delirium ; edds @DISEASE@ @CID@ cocaine @CHEMICAL@ rhabdomyolysis @DISEASE@ @CID@ cocaine @CHEMICAL@ sudden death @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "cocaine @CHEMICAL@ excited delirium ; edds @DISEASE@ @CID@ cocaine @CHEMICAL@ hyperthermia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m, thrombosis, and \u001b[48;2;144;238;144;38;2;0;0;0mhemorrhage\u001b[00m. Sixty-two patients with a \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m are reported. Clinical manifestations of this disorder include \u001b[48;2;144;238;144;38;2;0;0;0mhemorrhage\u001b[00m or, more frequently, \u001b[48;2;173;216;230;38;2;0;0;0mthromboembolic events\u001b[00m in patients receiving \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m. Laboratory testing has revealed a falling platelet count, increased resistance to \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, and aggregation of platelets by the patient's plasma when \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m is added. Immunologic testing has demonstrated the presence of a \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-dependent platelet membrane antibody. The 20 deaths, 52 \u001b[48;2;173;216;230;38;2;0;0;0mhemorrhagic\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mthromboembolic\u001b[00m complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder. Specific risk factors have not been identified; therefore, all patients receiving \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m should be monitored. If the platelet count falls to less than 100,000/mm3, while the patient is receiving \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, platelet aggregation testing, using the patient's plasma, is indicated. Management consists of cessation of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, platelet anti-aggregating agents, and alternate forms of anticoagulation when indicated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ heparin @CHEMICAL@ hemorrhage ; hemorrhagic complications @DISEASE@ @CID@ heparin @CHEMICAL@ thromboembolic ; thromboembolic complications @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia ; thromboembolic events @DISEASE@ @CID@ heparin @CHEMICAL@ hemorrhagic @DISEASE@ @CID@ heparin @CHEMICAL@ thromboembolic events @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Cardiac toxicity of \u001b[48;2;173;216;230;38;2;0;0;0m5-fluorouracil\u001b[00m. Report of a case of spontaneous \u001b[48;2;173;216;230;38;2;0;0;0mangina\u001b[00m. We report a case of a patient with colon carcinoma and liver metastasis who presented \u001b[48;2;144;238;144;38;2;0;0;0mchest pain\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0m5-fluorouracil\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's \u001b[48;2;173;216;230;38;2;0;0;0mangina\u001b[00m, and \u001b[48;2;144;238;144;38;2;0;0;0mchest pain\u001b[00m promptly resolved with nifedipine. These data suggest that \u001b[48;2;173;216;230;38;2;0;0;0mcoronary spasm\u001b[00m may be the cause of cardiotoxicity due to \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m, and that calcium antagonists may probably be used in the prevention or treatment of \u001b[48;2;173;216;230;38;2;0;0;0m5-fu\u001b[00m cardiotoxicity.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "5-fluorouracil ; 5-fu @CHEMICAL@ chest pain @DISEASE@ @CID@ 5-fluorouracil ; 5-fu @CHEMICAL@ prinzmetal's angina @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "5-fluorouracil ; 5-fu @CHEMICAL@ angina @DISEASE@ @CID@ 5-fluorouracil ; 5-fu @CHEMICAL@ coronary spasm @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Toxicity due to remission inducing drugs in rheumatoid arthritis. Association with HLA-B35 and Cw4 antigens. Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens. A strong association has been found between \u001b[48;2;173;216;230;38;2;0;0;0mnephritis\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mdermatitis\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mtiopronin\u001b[00m (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between \u001b[48;2;173;216;230;38;2;0;0;0mdermatitis\u001b[00m due to \u001b[48;2;144;238;144;38;2;0;0;0mgold\u001b[00m thiosulphate and B35. Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the \u001b[48;2;173;216;230;38;2;0;0;0mtiopronin\u001b[00m related \u001b[48;2;173;216;230;38;2;0;0;0mnephritis\u001b[00m group.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tiopronin @CHEMICAL@ nephritis @DISEASE@ @CID@ tiopronin @CHEMICAL@ dermatitis @DISEASE@ @CID@ gold @CHEMICAL@ dermatitis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tiopronin @CHEMICAL@ nephritis @DISEASE@ @CID@ tiopronin @CHEMICAL@ dermatitis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Transient \u001b[48;2;173;216;230;38;2;0;0;0mhemiparesis\u001b[00m: a rare manifestation of \u001b[48;2;173;216;230;38;2;0;0;0mdiphenylhydantoin\u001b[00m toxicity. Report of two cases. Among the common side effects of \u001b[48;2;173;216;230;38;2;0;0;0mdiphenylhydantoin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdph\u001b[00m) \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m, the most frequently encountered neurological signs are those of \u001b[48;2;144;238;144;38;2;0;0;0mcerebellar dysfunction\u001b[00m. Very rarely, the toxic neurological manifestations of this drug are of cerebral origin. Two patients are presented who suffered progressive \u001b[48;2;173;216;230;38;2;0;0;0mhemiparesis\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mdph\u001b[00m \u001b[48;2;144;238;144;38;2;0;0;0moverdose\u001b[00m. Both had brain surgery before \u001b[48;2;173;216;230;38;2;0;0;0mdph\u001b[00m treatment. It is assumed that patients with some cerebral damage are liable to manifest \u001b[48;2;173;216;230;38;2;0;0;0mdph\u001b[00m toxicity as focal neurological signs.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "diphenylhydantoin ; dph @CHEMICAL@ hemiparesis @DISEASE@ @CID@ diphenylhydantoin ; dph @CHEMICAL@ overdose @DISEASE@ @CID@ diphenylhydantoin ; dph @CHEMICAL@ cerebellar dysfunction @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "diphenylhydantoin ; dph @CHEMICAL@ hemiparesis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m: no evidence for an inflammatory origin. A common side effect associated with \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m is postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m. The pathogenesis of this \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m is still unclear; inflammation has been suggested but without convincing evidence. We designed the present study to investigate whether an inflammatory reaction contributes to this \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m. The incidence and severity of \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m was determined in 64 patients pretreated with saline or dexamethasone before \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m (n = 32 for each). Incidence and severity of \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m compared with 18 patients in the saline group, and severe \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m was reported by five patients and three patients, respectively (not significant). At 48 h after surgery, 12 patients in both groups still suffered from \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m (not significant). In addition, interleukin-6 (IL-6) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline. We found an increase of IL-6 for only three patients, but only one patient reported \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m; no relationship between \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m and the increase of IL-6 was found. In conclusion, there is no evidence for an inflammatory origin of \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m. IMPLICATIONS: Administration of dexamethasone before \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m was not effective in decreasing the incidence or the severity of \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m-induced postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m. Furthermore, there was no significant relationship between postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m and time course of interleukin-6 concentrations, a marker of inflammation. Pretreatment with dexamethasone is not justified to prevent postoperative \u001b[48;2;173;216;230;38;2;0;0;0mmyalgia\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0msuccinylcholine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "succinylcholine @CHEMICAL@ postoperative myalgia @DISEASE@ @CID@ succinylcholine @CHEMICAL@ myalgia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "succinylcholine @CHEMICAL@ myalgia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moromandibular \u001b[48;2;144;238;144;38;2;0;0;0mdystonia\u001b[00m\u001b[00m in progressive supranuclear palsy. \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy. Cranial \u001b[48;2;144;238;144;38;2;0;0;0mdystonias\u001b[00m are rare in patients with progressive supranuclear palsy (PSP). In this report we describe an unusual case of reversible \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0moromandibular \u001b[48;2;144;238;144;38;2;0;0;0mdystonia\u001b[00m\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0momd\u001b[00m) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dystonia ; dystonias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ oromandibular dystonia ; omd @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Steroid structure and pharmacological properties determine the anti-\u001b[48;2;144;238;144;38;2;0;0;0mamnesic\u001b[00m effects of pregnenolone sulphate in the passive avoidance task in rats. Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process. The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems. This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs). Moreover, PREGS is able to reverse the \u001b[48;2;144;238;144;38;2;0;0;0mamnesic\u001b[00m-like effects of NMDAR and GABA(A)R ligands. To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function. The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs). The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m. Both PREGS and its (-) enantiomer blocked the effects of \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m. The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS. Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing \u001b[48;2;173;216;230;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m. These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "scopolamine @CHEMICAL@ amnesic ; amnesia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "scopolamine @CHEMICAL@ amnesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m states but not with acute noxious stimulation. The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m-evoked mechanical \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m. METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m ratings in response to acute heat stimuli and areas of mechanical \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mallodynia\u001b[00m after intradermal \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m injection were determined. RESULTS: Adenosine produced no effect on \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m report to acute noxious thermal or chemical stimulation but reduced mechanical \u001b[48;2;173;216;230;38;2;0;0;0mhyperalgesia\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mallodynia\u001b[00m from intradermal \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h). CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity\u001b[00m, presumed to reflect central sensitization in humans after peripheral \u001b[48;2;173;216;230;38;2;0;0;0mcapsaicin\u001b[00m injection. The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic \u001b[48;2;173;216;230;38;2;0;0;0mpain\u001b[00m and is not due to prolonged residence of adenosine in cerebrospinal fluid.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "capsaicin @CHEMICAL@ mechanical hyperalgesia ; allodynia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "capsaicin @CHEMICAL@ hypersensitivity ; hyperalgesia ; allodynia @DISEASE@ @CID@ capsaicin @CHEMICAL@ pain @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m maintenance therapy on thyroid and parathyroid function. OBJECTIVES: To assess changes induced by \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m maintenance therapy on the incidence of thyroid, parathyroid and ion alterations. These were evaluated with respect to the duration of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease). DESIGN: Prospective study. SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal. PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m maintenance therapy ranging from 1 year's to 32 years' duration. The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics. OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy and at biannual follow-up. RESULTS: \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m developed in 40 patients, excluding 8 patients who were \u001b[48;2;144;238;144;38;2;0;0;0mhypothyroid\u001b[00m at baseline. All patients having first-degree relatives affected by thyroid illness had accelerated onset of \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m (3.7 years after onset of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy) compared with patients without a family history (8.6 years after onset of \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy). Women over 60 years of age were more often affected by \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m than women under 60 years of age (34.6% versus 31.9%). Magnesium levels in patients on \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m treatment were unchanged from baseline levels. After \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m treatment, calcium levels were higher than either baseline levels or control levels. Thus, \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m treatment counteracted the decrease in plasma calcium levels associated with aging. CONCLUSIONS: Familial thyroid illness is a risk factor for \u001b[48;2;173;216;230;38;2;0;0;0mhypothyroidism\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mhypercalcemia\u001b[00m during \u001b[48;2;173;216;230;38;2;0;0;0mlithium\u001b[00m therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium @CHEMICAL@ hypothyroidism ; hypothyroid @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium @CHEMICAL@ hypothyroidism @DISEASE@ @CID@ lithium @CHEMICAL@ hypercalcemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Systemic toxicity following administration of \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mformerly \u001b[48;2;144;238;144;38;2;0;0;0mrapamycin\u001b[00m\u001b[00m) for psoriasis: association of \u001b[48;2;173;216;230;38;2;0;0;0mcapillary leak syndrome\u001b[00m with apoptosis of lesional lymphocytes. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mformerly \u001b[48;2;144;238;144;38;2;0;0;0mrapamycin\u001b[00m\u001b[00m) is an immunosuppressive agent that interferes with T-cell activation. After 2 individuals with psoriasis developed a \u001b[48;2;173;216;230;38;2;0;0;0mcapillary leak syndrome\u001b[00m following treatment with oral \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis. OBSERVATIONS: A keratome skin specimen from 1 patient with \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcapillary leak syndrome\u001b[00m had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m-treated patient with psoriasis (21%). Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m. CONCLUSIONS: Severe adverse effects of \u001b[48;2;173;216;230;38;2;0;0;0msirolimus\u001b[00m include \u001b[48;2;173;216;230;38;2;0;0;0mfever\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0manemia\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mcapillary leak syndrome\u001b[00m. These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators. Because patients with severe psoriasis may develop \u001b[48;2;144;238;144;38;2;0;0;0mcapillary leak\u001b[00m from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "sirolimus ; rapamycin @CHEMICAL@ capillary leak syndrome ; capillary leak @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "sirolimus ; formerly rapamycin @CHEMICAL@ capillary leak syndrome @DISEASE@ @CID@ sirolimus ; formerly rapamycin @CHEMICAL@ fever @DISEASE@ @CID@ sirolimus ; formerly rapamycin @CHEMICAL@ anemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mextrapyramidal side effects\u001b[00m and oral \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m: an analysis of explanatory patient and treatment characteristics. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mextrapyramidal side effects\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m) was evaluated in 98 patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m. The incidence of \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonism\u001b[00m was higher at higher doses of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m and in younger patients. Prophylactic antiparkinsonian medication was effective in younger but not in older patients. However, these medications were more effective in both young and old patients when given after \u001b[48;2;173;216;230;38;2;0;0;0mparkinsonism\u001b[00m developed. \u001b[48;2;173;216;230;38;2;0;0;0makathisia\u001b[00m was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective. The present study points to patient characteristics that may be of significance in the development of \u001b[48;2;173;216;230;38;2;0;0;0meps\u001b[00m due to \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ parkinsonism @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ extrapyramidal side effects ; eps @DISEASE@ @CID@ haloperidol @CHEMICAL@ parkinsonism @DISEASE@ @CID@ haloperidol @CHEMICAL@ akathisia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Hepatic \u001b[48;2;173;216;230;38;2;0;0;0mveno-occlusive disease\u001b[00m caused by \u001b[48;2;173;216;230;38;2;0;0;0m6-thioguanine\u001b[00m. Clinically reversible \u001b[48;2;173;216;230;38;2;0;0;0mveno-occlusive disease of the liver\u001b[00m developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with \u001b[48;2;173;216;230;38;2;0;0;0m6-thioguanine\u001b[00m. Serial liver biopsies showed the development and resolution of intense \u001b[48;2;173;216;230;38;2;0;0;0msinusoidal engorgement\u001b[00m. Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted. This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic \u001b[48;2;173;216;230;38;2;0;0;0mveno-occlusive disease\u001b[00m over time, and may be the first case of veno-occlusive related solely to \u001b[48;2;173;216;230;38;2;0;0;0m6-thioguanine\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "6-thioguanine @CHEMICAL@ hepatic veno-occlusive disease ; veno-occlusive disease of the liver @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "6-thioguanine @CHEMICAL@ veno-occlusive disease ; veno-occlusive disease of the liver @DISEASE@ @CID@ 6-thioguanine @CHEMICAL@ sinusoidal engorgement @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Treatment of \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0murothelial toxicity\u001b[00m by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer. The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against \u001b[48;2;144;238;144;38;2;0;0;0murothelial toxicity\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mifosfamide\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mif\u001b[00m) was tested in a group of 45 patients with inoperable lung cancer under treatment with \u001b[48;2;173;216;230;38;2;0;0;0mif\u001b[00m (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle. MESNA was given orally on the days of treatment with \u001b[48;2;173;216;230;38;2;0;0;0mif\u001b[00m in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of \u001b[48;2;173;216;230;38;2;0;0;0mif\u001b[00m), 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic \u001b[48;2;173;216;230;38;2;0;0;0mhaematuria\u001b[00m and no episodes of gross \u001b[48;2;173;216;230;38;2;0;0;0mhaematuria\u001b[00m. In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%). A further group of 25 patients under polychemotherapy with \u001b[48;2;173;216;230;38;2;0;0;0mif\u001b[00m were treated by conventional prophylactic measures (raised fluid intake and forced diuresis). In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross \u001b[48;2;173;216;230;38;2;0;0;0mhaematuria\u001b[00m and/or symptoms of \u001b[48;2;144;238;144;38;2;0;0;0mbladder irritation\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcystitis\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mpollakisuria\u001b[00m). There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment. Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include \u001b[48;2;173;216;230;38;2;0;0;0mif\u001b[00m, simplifies the treatment and provides optimum protection for the urinary epithelium. Protection with oral MESNA is particularly suitable for outpatients.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ifosfamide ; if @CHEMICAL@ urothelial toxicity ; bladder irritation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "ifosfamide ; if @CHEMICAL@ haematuria @DISEASE@ @CID@ ifosfamide ; if @CHEMICAL@ cystitis @DISEASE@ @CID@ ifosfamide ; if @CHEMICAL@ pollakisuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Time course alterations of QTC interval due to \u001b[48;2;173;216;230;38;2;0;0;0mhypaque 76\u001b[00m. Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of \u001b[48;2;173;216;230;38;2;0;0;0mhypaque 76\u001b[00m. The subjects were ten patients found to have normal left ventricles and coronary arteries. Significant \u001b[48;2;144;238;144;38;2;0;0;0mqtc prolongation\u001b[00m occurred in 30 seconds to one minute in association with marked \u001b[48;2;144;238;144;38;2;0;0;0mhypotension\u001b[00m and elevation of cardiac output.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hypaque 76 @CHEMICAL@ qtc prolongation @DISEASE@ @CID@ hypaque 76 @CHEMICAL@ hypotension @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "hypaque 76 @CHEMICAL@ qt interval alterations ; qt prolongation @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Production of autochthonous \u001b[48;2;144;238;144;38;2;0;0;0mprostate cancer\u001b[00m in Lobund-Wistar rats by treatments with \u001b[48;2;173;216;230;38;2;0;0;0mn-nitroso-n-methylurea\u001b[00m and testosterone. More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable \u001b[48;2;173;216;230;38;2;0;0;0mprostate adenocarcinomas\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mpas\u001b[00m) following treatments with \u001b[48;2;173;216;230;38;2;0;0;0mn-nitroso-n-methylurea\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mcas: 684-93-5\u001b[00m) and \u001b[48;2;173;216;230;38;2;0;0;0mtestosterone propionate\u001b[00m [(\u001b[48;2;173;216;230;38;2;0;0;0mtp\u001b[00m) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions. The incubation periods averaged 10.6 months. Within the same timeframe, no L-W rat developed a similar palpable \u001b[48;2;144;238;144;38;2;0;0;0mpa\u001b[00m when treated only with \u001b[48;2;173;216;230;38;2;0;0;0mtp\u001b[00m. In L-W rats, \u001b[48;2;173;216;230;38;2;0;0;0mtp\u001b[00m acted as a tumor enhancement agent, with primary emphasis on the development of \u001b[48;2;144;238;144;38;2;0;0;0mprostate cancer\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "n-nitroso-n-methylurea @CHEMICAL@ prostate cancer ; prostate adenocarcinomas ; pas ; pa @DISEASE@ @CID@ testosterone propionate ; tp @CHEMICAL@ prostate cancer ; prostate adenocarcinomas ; pas ; pa @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "n-nitroso-n-methylurea ; cas: 684-93-5 @CHEMICAL@ prostate adenocarcinomas ; pas @DISEASE@ @CID@ testosterone propionate ; tp @CHEMICAL@ prostate adenocarcinomas ; pas @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "A \u001b[48;2;173;216;230;38;2;0;0;0mdystonia\u001b[00m-like syndrome after neuropeptide (\u001b[48;2;173;216;230;38;2;0;0;0mmsh/\u001b[48;2;144;238;144;38;2;0;0;0macth\u001b[00m\u001b[00m) stimulation of the rat locus ceruleus. The movement disorder investigated in these studies has some features in common with human idiopathic \u001b[48;2;173;216;230;38;2;0;0;0mdystonia\u001b[00m, and information obtained in these studies may be of potential clinical benefit. The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway. However, it is not certain as to the following: (a) what receptors were stimulated by the \u001b[48;2;144;238;144;38;2;0;0;0macth\u001b[00m N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder. These questions are currently being investigated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "msh @CHEMICAL@ dystonia @DISEASE@ @CID@ acth @CHEMICAL@ dystonia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "msh/acth @CHEMICAL@ dystonia ; dystonia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mdexmedetomidine\u001b[00m, acting through central alpha-2 adrenoceptors, prevents opiate-induced \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m in the rat. The highly-selective alpha-2 adrenergic agonist \u001b[48;2;173;216;230;38;2;0;0;0mdexmedetomidine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m) is capable of inducing \u001b[48;2;173;216;230;38;2;0;0;0mmuscle flaccidity\u001b[00m and anesthesia in rats and dogs. Intense generalized \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m is an undesirable side effect of potent opiate agonists. Although the neurochemistry of opiate-induced \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism. In the present study, the authors determined if treatment with \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m prevents the \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m caused by high-dose \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m anesthesia in the rat. Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m, 10 micrograms/kg; 3) \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m, 30 micrograms/kg; 4) \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline. Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment. Each rat was then injected with \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0malf\u001b[00m, 0.5 mg/kg sc). \u001b[48;2;144;238;144;38;2;0;0;0malf\u001b[00m injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline. In contrast, \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m prevented \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m in a dose-dependent fashion. The small EMG values obtained in the high-dose \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m group were comparable with those recorded in earlier studies from control animals not given any opiate. The high-dose \u001b[48;2;173;216;230;38;2;0;0;0md-med\u001b[00m animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "alfentanil ; alf @CHEMICAL@ muscle rigidity ; rigidity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dexmedetomidine ; d-med @CHEMICAL@ muscle rigidity ; muscle flaccidity @DISEASE@ @CID@ alfentanil @CHEMICAL@ muscle rigidity ; muscle flaccidity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m activity with \u001b[48;2;173;216;230;38;2;0;0;0mimipenem\u001b[00m therapy: incidence and risk factors. Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m while receiving maximum doses of \u001b[48;2;173;216;230;38;2;0;0;0mimipenem\u001b[00m/cilastatin. Neither patient had reported previous \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mseizure-like activity\u001b[00m nor was receiving anticonvulsant agents. All \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m were controlled with therapeutic doses of phenytoin. Both patients had received maximum doses of other beta-lactam antibiotics without evidence of \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m activity.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "imipenem/cilastatin @CHEMICAL@ seizure ; seizures @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "imipenem ; imipenem/cilastatin @CHEMICAL@ seizure ; seizure-like activity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by \u001b[48;2;173;216;230;38;2;0;0;0mstreptozotocin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdiabetes mellitus\u001b[00m. 1. The effects of insulin treatment on in vivo and in vitro urinary bladder function in \u001b[48;2;173;216;230;38;2;0;0;0mstreptozotocin\u001b[00m-\u001b[48;2;144;238;144;38;2;0;0;0mdiabetic\u001b[00m rats were investigated. 2. \u001b[48;2;144;238;144;38;2;0;0;0mdiabetes\u001b[00m of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment. 3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from \u001b[48;2;144;238;144;38;2;0;0;0mdiabetic\u001b[00m rats to nerve stimulation, ATP, and bethanechol. 4. \u001b[48;2;144;238;144;38;2;0;0;0mdiabetes\u001b[00m of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study. 5. Insulin treatment reversed the increases in contractile responses of bladder body strips from \u001b[48;2;144;238;144;38;2;0;0;0mdiabetic\u001b[00m rats to nerve stimulation, ATP, and bethanechol. 6. The data indicate that the effects of \u001b[48;2;173;216;230;38;2;0;0;0mstreptozotocin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mdiabetes\u001b[00m on urinary bladder function are both prevented and reversed by insulin treatment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "streptozotocin @CHEMICAL@ diabetes mellitus ; diabetic ; diabetes @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "streptozotocin @CHEMICAL@ diabetes mellitus @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary toxicity\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being \u001b[48;2;144;238;144;38;2;0;0;0mpneumonitis\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary toxicity\u001b[00m of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated \u001b[48;2;173;216;230;38;2;0;0;0mhypersensitivity \u001b[48;2;144;238;144;38;2;0;0;0mpneumonitis\u001b[00m\u001b[00m. The clinical and radiographic features of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpulmonary toxicity\u001b[00m are characteristic but nonspecific. The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy. While withdrawal of \u001b[48;2;173;216;230;38;2;0;0;0mamiodarone\u001b[00m leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant steroid therapy may have a role in selected patients.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ pneumonitis @DISEASE@ @CID@ amiodarone @CHEMICAL@ hypersensitivity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amiodarone @CHEMICAL@ pulmonary toxicity ; pulmonary injury @DISEASE@ @CID@ amiodarone @CHEMICAL@ hypersensitivity pneumonitis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mlight chain \u001b[48;2;144;238;144;38;2;0;0;0mproteinuria\u001b[00m\u001b[00m and cellular mediated immunity in \u001b[48;2;173;216;230;38;2;0;0;0mrifampin\u001b[00m treated patients with \u001b[48;2;173;216;230;38;2;0;0;0mtuberculosis\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mlight chain \u001b[48;2;144;238;144;38;2;0;0;0mproteinuria\u001b[00m\u001b[00m was found in 9 of 17 \u001b[48;2;173;216;230;38;2;0;0;0mtuberculosis\u001b[00m patients treated with \u001b[48;2;173;216;230;38;2;0;0;0mrifampin\u001b[00m. Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different. Response to Varidase skin test antigen was negative for all eight \u001b[48;2;173;216;230;38;2;0;0;0mtuberculosis\u001b[00m patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P). as well as of those of seven other tuberculous patients. This last finding may be related to time of testing and/or endogenous serum binding of \u001b[48;2;173;216;230;38;2;0;0;0mrifampin\u001b[00m which could have inhibited mitogen activity for the lymphocyte.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "rifampin @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "rifampin @CHEMICAL@ light chain proteinuria @DISEASE@ @CID@ rifampin @CHEMICAL@ tuberculosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Intraocular pressure in patients with uveitis treated with \u001b[48;2;173;216;230;38;2;0;0;0mfluocinolone acetonide\u001b[00m implants. OBJECTIVE: To report the incidence and management of \u001b[48;2;173;216;230;38;2;0;0;0melevated intraocular pressure\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m) in patients with uveitis treated with the \u001b[48;2;173;216;230;38;2;0;0;0mfluocinolone acetonide\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mfa\u001b[00m) intravitreal implant. DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg \u001b[48;2;173;216;230;38;2;0;0;0mfa\u001b[00m intravitreal implant or standard therapy were analyzed. RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively. Topical \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m-lowering medication was administered in 74.8% of implanted eyes, and \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes. Intraocular pressure-lowering surgeries were considered a success (postoperative \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m of 6-21 mm Hg with or without additional \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m-lowering medication) in 85.1% of eyes at 1 year. The rate of hypotony (\u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m </= 5 mm Hg) following \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09). CONCLUSION: Elevated \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m is a significant complication with the \u001b[48;2;173;216;230;38;2;0;0;0mfa\u001b[00m intravitreal implant but may be controlled with medication and surgery.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluocinolone acetonide ; fa @CHEMICAL@ elevated intraocular pressure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluocinolone acetonide ; fa @CHEMICAL@ elevated intraocular pressure ; iop @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Pallidal stimulation: an alternative to pallidotomy? A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985. Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community. Another lesioning procedure, ventrolateral thalamotomy, has become a powerful alternative to stimulate the nucleus ventralis intermedius, producing high long-term success rates and low morbidity rates. Pallidal stimulation has not met with the same success. According to the literature pallidotomy improves the \"on\" symptoms of PD, such as \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m, as well as the \"off\" symptoms, such as rigidity, \u001b[48;2;173;216;230;38;2;0;0;0mbradykinesia\u001b[00m, and on-off fluctuations. Pallidal stimulation improves \u001b[48;2;173;216;230;38;2;0;0;0mbradykinesia\u001b[00m and rigidity to a minor extent; however, its strength seems to be in improving \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m. Stimulation often produces an improvement in the hyper- or \u001b[48;2;173;216;230;38;2;0;0;0mdyskinetic\u001b[00m upper limbs, but increases the \"freezing\" phenomenon in the lower limbs at the same time. Considering the small increase in the patient's independence, the high costs of bilateral implants, and the difficulty most patients experience in handling the devices, the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; dyskinetic @DISEASE@ @CID@ levodopa @CHEMICAL@ bradykinesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mrisperidone\u001b[00m-associated, benign transient \u001b[48;2;173;216;230;38;2;0;0;0mvisual disturbances\u001b[00m in schizophrenic patients with a past history of LSD abuse. Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with \u001b[48;2;173;216;230;38;2;0;0;0mrisperidone\u001b[00m. They both reported short episodes of transient \u001b[48;2;173;216;230;38;2;0;0;0mvisual disturbances\u001b[00m, which appeared immediately after starting treatment with \u001b[48;2;173;216;230;38;2;0;0;0mrisperidone\u001b[00m. This imagery resembled \u001b[48;2;173;216;230;38;2;0;0;0mvisual disturbances\u001b[00m previously experienced as \"flashbacks\" related to prior LSD consumption. \u001b[48;2;173;216;230;38;2;0;0;0mrisperidone\u001b[00m administration was continued and the \u001b[48;2;173;216;230;38;2;0;0;0mvisual disturbances\u001b[00m gradually wore off. During a six-month follow-up period, there was no recurrence of \u001b[48;2;173;216;230;38;2;0;0;0mvisual disturbances\u001b[00m. This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of \u001b[48;2;173;216;230;38;2;0;0;0mrisperidone\u001b[00m or interfere with treatment. Conclusions based on two case reports should be taken with appropriate caution.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "risperidone @CHEMICAL@ visual disturbances @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "risperidone @CHEMICAL@ visual disturbances ; visual disturbances @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m. OBJECTIVE: To present a case of \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m-associated \u001b[48;2;173;216;230;38;2;0;0;0mtorsade de pointes\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m) and discuss \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m's role in causing \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m. CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m eight days after commencing oral \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m The patient had no other risk factors for \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m resolved when \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m was discontinued; however, the patient continued to have \u001b[48;2;173;216;230;38;2;0;0;0mpremature ventricular contractions\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnonsustained ventricular tachycardia\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mnsvt\u001b[00m) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m and the development of \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m. The possible mechanism is depression of rapidly activating delayed rectifier potassium currents. In our patient, there was no other etiology identified that could explain QT prolongation or \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m The complete disappearance of \u001b[48;2;173;216;230;38;2;0;0;0mnsvt\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mpremature ventricular contractions\u001b[00m followed by normalization of QT interval after the drug was stopped strongly suggests \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m as the etiology. CONCLUSIONS: Clinicians should be aware that \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m, even at low doses, may cause prolongation of the QT interval, leading to \u001b[48;2;173;216;230;38;2;0;0;0mtdp\u001b[00m. Serial electrocardiographic monitoring may be considered when \u001b[48;2;173;216;230;38;2;0;0;0mfluconazole\u001b[00m is administered in patients who are at risk for ventricular arrhythmias.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "fluconazole @CHEMICAL@ torsade de pointes ; tdp @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "fluconazole @CHEMICAL@ torsade de pointes ; tdp @DISEASE@ @CID@ fluconazole @CHEMICAL@ premature ventricular contractions @DISEASE@ @CID@ fluconazole @CHEMICAL@ nonsustained ventricular tachycardia ; nsvt @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "High-dose \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m may do more harm for spinal cord injury. Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m became the standard of care for the acute spinal cord injury. In the NASCIS, there was no mention regarding the possibility of acute \u001b[48;2;173;216;230;38;2;0;0;0mcorticosteroid \u001b[48;2;144;238;144;38;2;0;0;0mmyopathy\u001b[00m\u001b[00m that high-dose \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m may cause. The dosage of \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition. We hypothesize that it may cause some \u001b[48;2;144;238;144;38;2;0;0;0mdamage to the muscle\u001b[00m of spinal cord injury patients. Further, steroid \u001b[48;2;144;238;144;38;2;0;0;0mmyopathy\u001b[00m recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid \u001b[48;2;144;238;144;38;2;0;0;0mmyopathy\u001b[00m, instead of any protection that \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m offers to the spinal cord injury. To our knowledge, this is the first discussion considering the possibility that the \u001b[48;2;173;216;230;38;2;0;0;0mmethylprednisolone\u001b[00m recommended by NASCIS may cause acute \u001b[48;2;173;216;230;38;2;0;0;0mcorticosteroid \u001b[48;2;144;238;144;38;2;0;0;0mmyopathy\u001b[00m\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methylprednisolone @CHEMICAL@ myopathy ; damage to the muscle @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methylprednisolone @CHEMICAL@ corticosteroid myopathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Probing peripheral and central cholinergic system responses. OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied. This study assessed the effect of normal aging on (1) the \u001b[48;2;173;216;230;38;2;0;0;0mtropicamide\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mincrease in pupil diameter\u001b[00m, and (2) the reversal of this effect with \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m. \u001b[48;2;144;238;144;38;2;0;0;0mscopolamine\u001b[00m was used as a positive control to detect age-dependent changes in central cholinergic functioning in the elderly. DESIGN: Randomized double-blind controlled trial. PARTICIPANTS: Ten healthy elderly (mean age 70) and 9 young (mean age 33) volunteers. INTERVENTIONS: Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours. The study involved 4 sessions. In 1 session, \u001b[48;2;173;216;230;38;2;0;0;0mtropicamide\u001b[00m (20 microL, 0.01%) was administered to one eye and placebo to the other. In another session, \u001b[48;2;173;216;230;38;2;0;0;0mtropicamide\u001b[00m (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m (20 microL, 0.1%) to one eye and placebo to the other. All eye drops were given in a randomized order. In 2 separate sessions, a single dose of \u001b[48;2;144;238;144;38;2;0;0;0mscopolamine\u001b[00m (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours. OUTCOME MEASURES: Pupil size at time points after administration of \u001b[48;2;173;216;230;38;2;0;0;0mtropicamide\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m; \u001b[48;2;144;238;144;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mimpairment in word recall\u001b[00m. RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to \u001b[48;2;173;216;230;38;2;0;0;0mtropicamide\u001b[00m at any time point (p > 0.05). The elderly group had a significantly greater \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05). Compared with the young group, the elderly group had greater \u001b[48;2;144;238;144;38;2;0;0;0mscopolamine\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mimpairment in word recall\u001b[00m 60, 90 and 120 minutes after administration (p < 0.05). CONCLUSION: There is an age-related pupillary response to \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m that is not found with \u001b[48;2;173;216;230;38;2;0;0;0mtropicamide\u001b[00m. Thus, \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m may be useful to assess variations in central cholinergic function in elderly patients.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "scopolamine @CHEMICAL@ impairment in word recall @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tropicamide @CHEMICAL@ increase in pupil diameter @DISEASE@ @CID@ pilocarpine @CHEMICAL@ decrease in pupil diameter @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0macetazolamide\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mgerstmann syndrome\u001b[00m. Acute \u001b[48;2;173;216;230;38;2;0;0;0mconfusion\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0macetazolamide\u001b[00m is a well known adverse drug reaction in patients with renal impairment. We report a case of \u001b[48;2;173;216;230;38;2;0;0;0macetazolamide\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mgerstmann syndrome\u001b[00m in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "acetazolamide @CHEMICAL@ gerstmann syndrome @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "acetazolamide @CHEMICAL@ confusion @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhypomania-like syndrome\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0molanzapine\u001b[00m. We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed \u001b[48;2;173;216;230;38;2;0;0;0mhypomania\u001b[00m shortly after the introduction of \u001b[48;2;173;216;230;38;2;0;0;0molanzapine\u001b[00m treatment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "olanzapine @CHEMICAL@ hypomania @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "olanzapine @CHEMICAL@ hypomania ; hypomania-like syndrome @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Absence of effect of sertraline on time-based sensitization of \u001b[48;2;173;216;230;38;2;0;0;0mcognitive impairment\u001b[00m with \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m. This double-blind, randomized, placebo-controlled study evaluated the effects of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m alone and \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m plus sertraline on cognitive and psychomotor function in 24 healthy male subjects. METHOD: All subjects received placebo on Day 1 and \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m 2 mg on Days 2 and 25. From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period. Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25. RESULTS: \u001b[48;2;144;238;144;38;2;0;0;0mimpairment of cognitive function\u001b[00m was observed 6 to 8 hours after administration of \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m on Day 2 but was not evident 23 hours after dosing. When single-dose \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect. There was no indication that sertraline exacerbated the impairment produced by \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m since an equivalent effect also occurred in the placebo group. Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects. Ten subjects in each group reported side effects related to treatment. The side effect profiles of sertraline and of placebo were similar. CONCLUSION: \u001b[48;2;173;216;230;38;2;0;0;0mhaloperidol\u001b[00m produced a clear profile of \u001b[48;2;173;216;230;38;2;0;0;0mcognitive impairment\u001b[00m that was not worsened by concomitant sertraline administration.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ cognitive impairment ; impairment of cognitive function @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "haloperidol @CHEMICAL@ cognitive impairment ; cognitive impairment @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Time dependence of plasma \u001b[48;2;173;216;230;38;2;0;0;0mmalondialdehyde\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0moxypurines\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mnucleosides\u001b[00m during \u001b[48;2;173;216;230;38;2;0;0;0mincomplete \u001b[48;2;173;216;230;38;2;0;0;0mcerebral ischemia\u001b[00m\u001b[00m in the rat. \u001b[48;2;173;216;230;38;2;0;0;0mincomplete \u001b[48;2;173;216;230;38;2;0;0;0mcerebral ischemia\u001b[00m\u001b[00m (30 min) was induced in the rat by bilaterally clamping the common carotid arteries. Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia. Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of \u001b[48;2;173;216;230;38;2;0;0;0mmalondialdehyde\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0moxypurines\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mnucleosides\u001b[00m. During ischemia, a time-dependent increase of plasma \u001b[48;2;173;216;230;38;2;0;0;0moxypurines\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mnucleosides\u001b[00m was observed. Plasma \u001b[48;2;173;216;230;38;2;0;0;0mmalondialdehyde\u001b[00m, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078). Increased plasma \u001b[48;2;173;216;230;38;2;0;0;0mmalondialdehyde\u001b[00m was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group \u001b[48;2;173;216;230;38;2;0;0;0mmalondialdehyde\u001b[00m was significantly higher. The present data indicate that the determination of \u001b[48;2;173;216;230;38;2;0;0;0mmalondialdehyde\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0moxypurines\u001b[00m, and \u001b[48;2;173;216;230;38;2;0;0;0mnucleosides\u001b[00m in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "malondialdehyde @CHEMICAL@ cerebral ischemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "malondialdehyde @CHEMICAL@ incomplete cerebral ischemia ; cerebral ischemia @DISEASE@ @CID@ oxypurines @CHEMICAL@ incomplete cerebral ischemia ; cerebral ischemia @DISEASE@ @CID@ nucleosides @CHEMICAL@ incomplete cerebral ischemia ; cerebral ischemia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcholinergic toxicity\u001b[00m resulting from ocular instillation of \u001b[48;2;173;216;230;38;2;0;0;0mechothiophate iodide\u001b[00m eye drops. A patient developed a severe \u001b[48;2;173;216;230;38;2;0;0;0mcholinergic syndrome\u001b[00m from the use of \u001b[48;2;173;216;230;38;2;0;0;0mechothiophate iodide\u001b[00m ophthalmic drops, presented with profound \u001b[48;2;173;216;230;38;2;0;0;0mmuscle weakness\u001b[00m and was initially given the diagnosis of myasthenia gravis. Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "echothiophate iodide @CHEMICAL@ muscle weakness @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "echothiophate iodide @CHEMICAL@ cholinergic toxicity ; cholinergic syndrome @DISEASE@ @CID@ echothiophate iodide @CHEMICAL@ muscle weakness @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Induction of the \u001b[48;2;173;216;230;38;2;0;0;0mobstructive \u001b[48;2;173;216;230;38;2;0;0;0msleep apnea\u001b[00m\u001b[00m syndrome in a woman by exogenous \u001b[48;2;173;216;230;38;2;0;0;0mandrogen\u001b[00m administration. We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of \u001b[48;2;173;216;230;38;2;0;0;0mobstructive \u001b[48;2;173;216;230;38;2;0;0;0msleep apnea\u001b[00m\u001b[00m while being administered exogenous \u001b[48;2;173;216;230;38;2;0;0;0mandrogens\u001b[00m. When the \u001b[48;2;173;216;230;38;2;0;0;0mandrogens\u001b[00m were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal. A rechallenge with \u001b[48;2;173;216;230;38;2;0;0;0mandrogen\u001b[00m produced symptoms of \u001b[48;2;173;216;230;38;2;0;0;0mobstructive \u001b[48;2;173;216;230;38;2;0;0;0msleep apnea\u001b[00m\u001b[00m that abated upon withdrawal of the hormone. Previous reports have favored a role of \u001b[48;2;173;216;230;38;2;0;0;0mandrogens\u001b[00m in the pathogenesis of \u001b[48;2;173;216;230;38;2;0;0;0msleep apnea\u001b[00m. Our report provides direct evidence for this role. Structural and functional measurements indicate that \u001b[48;2;173;216;230;38;2;0;0;0mandrogens\u001b[00m exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep. Development of the \u001b[48;2;173;216;230;38;2;0;0;0mobstructive \u001b[48;2;173;216;230;38;2;0;0;0msleep apnea\u001b[00m\u001b[00m syndrome must be considered a possible side effect of \u001b[48;2;173;216;230;38;2;0;0;0mandrogen\u001b[00m therapy.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "androgen ; androgens @CHEMICAL@ obstructive sleep apnea syndrome ; syndrome of obstructive sleep apnea ; obstructive sleep apnea @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "androgen ; androgens @CHEMICAL@ obstructive sleep apnea ; sleep apnea @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of captopril on pre-existing and \u001b[48;2;173;216;230;38;2;0;0;0maminonucleoside\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m in spontaneously hypertensive rats. \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m is a side effect of captopril treatment in hypertensive patients. The possibility of reproducing the same renal abnormality with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive \u001b[48;2;173;216;230;38;2;0;0;0mproteinuria\u001b[00m invoked by puromycin \u001b[48;2;173;216;230;38;2;0;0;0maminonucleoside\u001b[00m in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption. However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "aminonucleoside ; puromycin aminonucleoside @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "aminonucleoside @CHEMICAL@ proteinuria @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Epileptogenic properties of \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m and their clinical interpretation. Three cases of EEG changes induced by single exposure to \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m anesthesia are reported. In one patient, \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m administered during a donor nephrectomy resulted in unexpected \u001b[48;2;173;216;230;38;2;0;0;0mpartial motor \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m\u001b[00m. Until the cause of the \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m was correctly identified, the patient was inappropriately treated with anticonvulsants. Two other patients suffered from partial, complex and \u001b[48;2;173;216;230;38;2;0;0;0mgeneralized \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m\u001b[00m uncontrolled by medication. Epileptic foci delineated and activated by \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m were surgically ablated and the patients are now \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m-free. Previous exposures to \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m have to be disclosed to avoid mistakes in clinical interpretation of the EEG. On the other hand, \u001b[48;2;173;216;230;38;2;0;0;0menflurane\u001b[00m may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "enflurane @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "enflurane @CHEMICAL@ partial motor seizures @DISEASE@ @CID@ enflurane @CHEMICAL@ generalized seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Enhanced stimulus-induced neurotransmitter overflow in \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mhypertensive\u001b[00m rats is not mediated by prejunctional beta-adrenoceptor activation. The present study examines the effect of 6-day \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m-treated rats. Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only. However, \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m treatment resulted in the incorporation of \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m into renal catecholamine stores such that approximately 40% of the catecholamine present was \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m while the norepinephrine content was reduced by a similar degree. Total tissue catecholamine content of the kidney on a molar basis was unchanged. Stimulus-induced fractional overflow of neurotransmitter from the \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m-treated kidneys was approximately twice normal and consisted of both norepinephrine and \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m in proportions similar to those found in the kidney. This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade. Propranolol had no effect on stimulus-induced overflow in either group. Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m-treated group. In conclusion, chronic \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m treatment results in enhanced fractional neurotransmitter overflow. However, neither alterations in prejunctional beta-adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration. Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after \u001b[48;2;173;216;230;38;2;0;0;0mepinephrine\u001b[00m treatment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "epinephrine @CHEMICAL@ hypertensive @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "epinephrine @CHEMICAL@ hypertensive ; hypertension @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Ocular manifestations of juvenile rheumatoid arthritis. We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years. Thirty-six of the 210 patients (17.2%) developed iridocyclitis. Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis. However, 30% of the patients developed uveitis after 16 years of age. Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry. Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases. Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used \u001b[48;2;173;216;230;38;2;0;0;0mchloroquine\u001b[00m or \u001b[48;2;173;216;230;38;2;0;0;0mhydroxychloroquine\u001b[00m in 173 of 210 cases and found only one case of \u001b[48;2;173;216;230;38;2;0;0;0mchorioretinopathy\u001b[00m attributable to these drugs. Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular \u001b[48;2;173;216;230;38;2;0;0;0mcataracts\u001b[00m was found. Typical \u001b[48;2;173;216;230;38;2;0;0;0mkeratoconjunctivitis sicca\u001b[00m developed in three of the uveitis cases. This association with uveitis and JRA was not noted previously. Surgical treatment of \u001b[48;2;173;216;230;38;2;0;0;0mcataracts\u001b[00m, band keratopathy, and glaucoma achieved uniformly discouraging results.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hydroxychloroquine @CHEMICAL@ chorioretinopathy @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "chloroquine @CHEMICAL@ cataracts @DISEASE@ @CID@ chloroquine @CHEMICAL@ chorioretinopathy @DISEASE@ @CID@ hydroxychloroquine @CHEMICAL@ keratoconjunctivitis sicca @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mwater intoxication\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m administration during saline-induced abortion. Four cases of \u001b[48;2;173;216;230;38;2;0;0;0mwater intoxication\u001b[00m in connection with \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m administration during saline-induced abortions are described. The mechanism of \u001b[48;2;173;216;230;38;2;0;0;0mwater intoxication\u001b[00m is discussed in regard to these cases. \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of \u001b[48;2;173;216;230;38;2;0;0;0mwater intoxication\u001b[00m and instructed to watch the diuresis and report such early signs of the syndrome as \u001b[48;2;173;216;230;38;2;0;0;0masthenia\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mmuscular irritability\u001b[00m, or \u001b[48;2;173;216;230;38;2;0;0;0mheadaches\u001b[00m. The \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions. The urinary output should be monitored and the \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m administration discontinued and the serum electrolytes checked if the urinary output decreases. The \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m should not be administered in excess of 36 hours. If the patient has not aborted by then the \u001b[48;2;173;216;230;38;2;0;0;0moxytocin\u001b[00m should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oxytocin @CHEMICAL@ water intoxication @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oxytocin @CHEMICAL@ water intoxication ; water intoxication syndrome @DISEASE@ @CID@ oxytocin @CHEMICAL@ asthenia @DISEASE@ @CID@ oxytocin @CHEMICAL@ muscular irritability @DISEASE@ @CID@ oxytocin @CHEMICAL@ headaches @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(\"Entities of expected output colored \\033[48;2;144;238;144;38;2;0;0;0mgreen\\033[00m, of predicted \\033[48;2;173;216;230;38;2;0;0;0mblue\\033[00m\\n\")\n",
    "for row in dataframe[dataframe[\"match\"]==False].iterrows():\n",
    "    try:\n",
    "        rels_expected=extract_relation_triples(row[1][\"expected output\"], config[\"ner_labels\"], config[\"re_labels\"], True)\n",
    "        rels_predicted=extract_relation_triples(row[1][\"predicted output\"], config[\"ner_labels\"], config[\"re_labels\"], True)\n",
    "    except ValueError:\n",
    "        continue\n",
    "    \n",
    "    msg.info(\"input text\")\n",
    "    print(highlight_entities(row[1][\"input\"], rels_expected, rels_predicted))\n",
    "    msg.good(\"Expected output:\")\n",
    "    print(row[1][\"expected output\"])\n",
    "    msg.info(\"Actual output:\")\n",
    "    print(row[1][\"predicted output\"])\n",
    "    print(\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f1470779-494a-41f5-a227-0f05cfeaabc1",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "llm_gen_re",
   "language": "python",
   "name": "llm_gen_re"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
